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A major problem in head and neck cancer management is the high rate of loco-regional 
recurrence following surgery and post-operative radiotherapy. Tumour cells that remain 
in the surgical margins are the likely source for this recurrence. Gene-mediated 
approaches, that take advantage of the genetic profile of these tumours, have the 
potential to eliminate these remaining cells. The high frequency of p53 mutation in 
head and neck cancers makes this gene a good candidate for therapy. The majority of 
residual cancer models used for treatment investigations are established subcutaneously 
in immunodeficient hosts. However, residual cancer models in muscle of 
immunocompetent hosts would more closely mimic the clinical scenario. 
In vitro studies established the suitability of the p53 mutated PDVC57 cell line for 
adenoviral-p53-mediated tumour destruction. PDVC57 cells showed 70% transduction 
efficiency. Polymerase chain reaction, Western blotting and immunocytochemistry 
confirmed the expression of the p53 transgene. Western blot analysis demonstrated 
increases in p21 WAFl, MDM2 and BAX proteins following Ad5CMV-p53 transduction. 
A significant reduction in PDVC57 number was observed following transduction of 625 
vp/cell Ad5CMV-p53. The TUNEL assay and acridine orange/ethidium bromide 
incorporation suggested apoptotic death in 50010 and 70% of PDVC57 cells 48 hours 
after transduction with 2500 vp/cell Ad5CMV-p53 respectively. 
A new model of residual cancer was established by implanting 1 x 105 PDVC57 cells 
into the muscle of syngeneic immunocompetent hosts, and its reproducibility 
demonstrated. The reduction in tumour area following cisplatin treatment demonstrated 
the potential of this model for examining treatment efficacy. However, infection with 5 
x 1010 vp Ad5CMV-p53 failed to destroy tumour in the muscle, likely due to the 
insufficient expression of the transgene. In comparison, Ad5CMV-p53 infection of a 
PDVC57 derived subcutaneous model of residual cancer, eliminated tumour in 4/6 
cases. These studies highlight the requirement for improved gene delivery strategies for 
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Chapter 1: Introduction 
1.1 Cancer Biology 
Chapter 1 - Introduction 
Carcinogenesis is a multi-step process of vast complexity. Six major areas of 
biology are thought to be essential for malignant growth. These are self-sufficiency 
in growth signals; insensitivity to growth-inhibitory (anti-growth) signals; evasion of 
apoptosis; limitless replicative potential; sustained angiogenesis; and tissue invasion 
and metastasis. 
Growth signals are required for the normal cell to actively proliferate. Signalling 
molecules include soluble growth factors, extracellular matrix components and cell-
to-cell adhesion molecules. Tumour cells are capable of generating many of their 
own growth signals, and show reduced dependence on stimulation from their normal 
tissue microenvironment. The soluble growth factors commonly elicit their effects 
by binding to membrane receptors that are then activated to initiate intracellular 
signalling. When activated, most of the receptors have tyrosine kinase activity, 
which results in phosphorylation of cytoplasmic proteins on tyrosine residues 
(Cooper et ai, 1984). Examples of receptors with tyrosine kinase activity include 
the epidermal growth factor (EGF), which is frequently over-expressed in squamous 
cell carcinoma of the head and neck (SCCHN, Grandis et ai, 1996), transforming 
growth factor-a (TGF-a), platelet-derived growth factor (PDGF), fibroblast growth 
factors (FGF) and the insulin-like growth factors (ILGF). 
Cellular qUiescence and tissue homeostasis are controlled by multiple anti-
proliferative signals, which either block proliferation by forcing cells into GO 
quiescent cell cycle arrest, or into a permanent post-mitotic state. Disruption of the 
retinoblastoma (RB) pathway, which is essential for progression through the G 1 
phase of the cell cycle, liberates the E2F transcription factor rendering cells 
insensitive to anti-growth factors and allowing progression through the cell cycle 
(Chellappan et ai, 1991; Bartek et aI, 1999). 
Genetic alterations shown to contribute to cancer development include the gain-of-
function mutations of proto-oncogenes such as RAS, MYC and ABL, along with the 
25 
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loss-of-function mutations of the tumour suppressor genes such as the RB and p53 
genes (Collins et aI, 1997). 
Expansion of tumour cell populations relies not just on the proliferation rate of the 
cell, but also on the rate of cell death. The acquired resistance towards apoptosis is a 
hallmark of most, if not all, tumours. This resistance to apoptosis in cancer cells can 
be attributed to a variety of strategies. The most obvious and commonly occurring 
loss of regulation of apoptosis occurs when the p53 tumour suppressor gene is 
mutated. This results in the absence of a key component in DNA damage detection 
(Gusterson et aI, 1991). 
The proliferative life span of normal mammalian cells is limited by intrinsic 
controls, which desensitise the cell cycle machinery to extrinsic stimulation after a 
given number of cell divisions. One mechanism involved in this process of cellular 
senescence, is the progressive erosion of chromosome telomeres, which occurs with 
each round of DNA replication (reviewed by Wynford-Thomas, 1999 and Schar, 
2001). Both the p53 and RB/p16INK4a pathways are normally involved in this growth 
inhibition (Wynford-Thomas, 1999; reviewed by Hanahan et ai, 2000). To avoid 
mortality, a tumour needs to escape multiple proliferative barriers, which is made 
possible as a result of genetic mutations affecting these pathways. To prevent 
telomere erosion and hence cell senescence, malignant cells are able to up-regulate 
telomerase enzyme, which adds hexanucleuotide repeats onto the ends of telomeric 
DNA (Riou et ai, 2002). 
Mammalian cells require oxygen and nutrients for their survival so are therefore 
located within 100 to 200 ~m of blood vessels, which represents the diffusion limit 
for oxygen (Thomlinson and Gray, 1955). Without the capability to recruit new 
blood vessels via the process of angiogenesis, tumours cannot grow beyond a critical 
size or metastasise to other organs. A balance between pro- and anti-angiogenic 
molecules usually tightly regulates this process. Tumours are able to shift this 
balance in favour of pro-angiogenic factors, and turn on the 'angiogenic switch'. 
Carmeliet et ai, 2000 discuss some of the signals that trigger angiogenesis, which 
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include low p02, low pH, hypoglycaemia, the pressure generated by proliferating 
cells, and genetic mutations resulting in the activation of oncogenes (for example 
RAS) or the deletion of tumour suppressor genes (for example p53 and Von Hippel-
Lindau (VHL» that control the production of angiogenesis regulators. Angiogenesis 
consists of dissolution of the basement membrane, migration, and proliferation of 
endothelial cells, canalisation, branching and fonnation of vascular loops, and 
fonnation of the basement membrane (Yancopoulos et ai, 2000; Carmeliet et ai, 
2000). 
A further characteristic of successful malignant cells is the capability to invade other 
tissues and metastasise to other areas of the body. Metastasis is the major cause of 
cancer related deaths (Sporn, 1996). Several classes of genes are altered in cells 
possessing invasive or metastatic capabilities, including cell-cell adhesion molecules 
(CAMs) and integrins, which link cells to extracellular matrix substrates (Hanahan 
et ai, 2000). Matrix metalloproteinases (MMPs) act to degrade the extracellular 
matrix, and have been implicated in the invasion and metastasis of SCCHN. 
Overexpression of multiple MMPs and the downregulation of tissue inhibitors of 
matrix metalloproteinases (TIMPs) is characteristic of SCCHN, and analysis of 
MMP-9 in particular, might be useful for evaluating the malignant potential 10 
individual cases (O-Charoenrat et ai, 2001). 
1.2 Squamous Cell Carcinoma of the Head and Neck: Incidence, Etiology, 
Treatment and Recurrence 
Squamous cell carcinoma (SeC) represents about 90% of all head and neck cancers 
and is the sixth commonest human malignancy worldwide (Zarbo and Crissman, 
1988). An estimated 900,000 new cases occurred worldwide in 1995 (parkin et ai, 
1993). In England and Wales, the overall incidence is stable at 5000 cases/year 
(14/105 of the male and 5.5/105 of the female population) but within the head and 
neck sites, tumours of the larynx and oral cavity are increasing (reviewed by 
Jefferies et ai, 1999). 
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The main etiological factors involved in the onset of SCCHN are tobacco smoking 
and alcohol consumption (Mashberg et ai, 1993). In India and the Far East the 
practice of chewing a quid of betel (consisting of betel nut, tobacco and lime) is a 
major etiological factor involved in the development of SCCHN. Other possible 
risk factors include poor nutrition (nitrosamine consumption), occupations (exposure 
to asbestos, wood dust, coal products, organic chemicals, cement or rubber), viral 
infection (human papilloma virus (HPV» and poor dental hygiene (Muscat and 
Wynder, 1992; reviewed by Gaur et ai, 1997). There is now also increasing 
epidemiological evidence, that a family history of head and neck cancer is a risk 
factor for this disease (reviewed by Jefferies et ai, 2001; reviewed by Prime et ai, 
2001). 
The mainstay of treatment for SCCHN is surgery with post-operative radiotherapy 
when the tumour is large or has spread to involve two or more lymph nodes in the 
neck, or sometimes radiotherapy alone may be used. However, despite advances in 
surgical techniques, new chemotherapeutic agents and the introduction of different 
ways of delivering radiotherapy, survival of patients with head and neck cancer has 
not significantly improved over the past 30 years (reviewed by Ganly et ai, 2000) 
The major cause for concern in this treatment failure is the lack of sensitivity of 
conventional histopathological techniques in detecting tumour free surgical margins 
or field cancerisation. Recent studies using molecular diagnostics reveal that 
undetected deposits of tumour frequently remain at the operative site declared 
tumour-free by histopathology, and that this minimal residual disease (MRD), may 
result in loco-regional recurrence a short time after primary intervention. In view of 
this, most surgeons aim for a minimum of I-cm clearance when resecting these 
cancers, but the microscopic distance is often much less than this. Another problem 
is that patients with advanced stage III or IV disease, which represents two thirds of 
patients presenting with head and neck cancer, show loco-regional recurrence in 10-
60% of cases (Choksi et ai, 1988; Leemans et ai, 1994) and distant metastatic 
disease in 15-25% of cases (Lee mans et ai, 1993). Although loco-regional control 
has improved during the last decades, S-year survival rates have not changed 
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significantly, due to a higher frequency of distant metastases (reviewed by van 
Houten et ai, 2000). Distant metastases are most frequent in the lung followed by 
bone, liver, skin and brain. Reported 5-year survival rates vary from 38 to 60% 
(reviewed by Hanna et ai, 2001). 
Slaughter and colleagues (1953) proposed the concept of field cancerisation, which 
suggests that, the whole of the upper aerodigestive tract is exposed to the damaging 
effects of environmental agents such that tumours may develop at multiple sites. 
The field cancerisation hypothesis predicts that second or multiple primary tumours 
occur as independent genetic events (reviewed by Jefferies et ai, 1999). 
The usual treatment for recurrent SCCHN is salvage surgery or chemotherapy 
(commonly usmg agents such as methotrexate, cisplatin (cis-
diamminodichloroplatinum, cis-DDP), bleomycin, cyclophosphamide or vinblastine, 
either alone or in combination), since a second schedule of radiotherapy is not 
always possible. However, lack of tumour specificity remains a major problem with 
chemotherapy in that they attack normal and dividing cells and produce side effects 
which often prevents the delivery of dosages of drugs required to eliminate tumours 
(Hong and Clayman, 2000). Whilst chemotherapy shows a relatively high response 
rate, this is rarely sustained on a long-term basis. There is thus an urgent need to 
develop other ways of eliminating residual cancer to improve long-term survival. 
Ideally this would involve treating MRD early when the tumour burden is low. 
1.3 Detection of Minimal Residual Disease and Metastasis in Squamous Cell 
Carcinoma of the Head and Neck 
Improved detection and eradication of MRD, to reduce local and distant relapse, is 
one of the major challenges in the management of SCCHN. These residual tumour 
cells may grow and be the source of cells for local and regional recurrences, and 
distant metastases. Classical diagnostic methods such as radiology and 
histopathology have limited sensitivities for tumour cell detection, and molecular 
diagnostics may also miss cancer cells if they are not present in the sample analysed. 
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Molecular techniques are however, worth evaluating to improve the detection of 
MRD. This is particularly important in head and neck cancer, because residual 
tumour cells and field cancerisation are believed to play a crucial role in the 
relatively high recurrence rates observed in these patients. 
There are at least three areas where detection of small SCCHN deposits is of clinical 
importance: (a) the assessment of the status of surgical margins, (b) the detection of 
micrometastases in lymph nodes, and (c) the detection of micro metastases elsewhere 
as assessed by bone marrow and blood sample analysis. Molecular markers for the 
detection of cancer cells in clinical samples, can either exploit unique changes in 
tumour biology to enable tumour specific detection, or else detect tissue specific 
changes that are homogeneously expressed in the tumours, but not in the clinical 
sample of analysis (van Houten et ai, 2000). 
At present two main methods are used to detect MRD, one based on antigen-
antibody interaction and the other based on amplified nucleic acids. The most 
commonly used nucleic acid markers are mutations or alterations in tumour 
deoxyribonucleic acid (DNA, tumour-specific markers) or differentially expressed 
messenger ribonucleic acid (mRNA, tissue-specific markers, reviewed by van 
Houten et ai, 2000). 
Mutated p53 has been used successfully as a marker to detect tumour cells in various 
tissues such as tumour resection margins, lymph nodes, urine and saliva (reviewed 
by van Houten et ai, 2000). Brennan et ai, 1995 reported that, molecular detection of 
residual cancer using p53 mutations, as the marker in a plaque hybridisation assay 
was superior to histopathology in detecting SCCHN cells in surgical margins. 
Brennan et ai, 1995 used molecular techniques to determine whether infiltrating 
tumour cells harbouring the same p53 gene mutation as in the primary tumour could 
be detected in histopathologically negative surgical margins and cervical lymph 
nodes of patients with SCCHN. Among specimens initially believed to be negative 
after examination by light microscopy, a substantial percentage contained p53 
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mutations specific to the primary tumour. Thirteen of 25 cases showed molecular 
positive p53 mutation in the margins pronounced tumour-free by light microscopy. 
Five of these 13 (38%) went on to display local recurrence, compared to none of the 
12 cases with negative margins after the application of the molecular assay (Brennan 
et aI, 1995). 
In a subsequent study using a modified p53 plaque assay Partridge et aI, 2000, 
showed that 13 of 18 (72%) of primary tumours examined harboured a p53 gene 
mutation, and 6 of these cases demonstrated residual tumour cells, harbouring the 
same p53 mutations, at the surgical margins declared tumour-free after conventional 
light microscopy. Even though all patients in the study received adjuvant 
radiotherapy, six cases with tumour positive surgical margins, by molecular 
analysis, had biopsy proven recurrence of their carcinoma at the site of the primary 
tumour or in the neck, highlighting the need for new treatments if cure rates are to 
be improved. Of these six cases with p53 mutated tumour cells in the surgical 
margin, 5 had MRD present in the muscle and mucosal surgical margins. All 
patients with local recurrence died of the disease within 8-22 months. Four of the 5 
cases with tumour-positive muscle margins developed local recurrence with one 
case developing both regional and distant metastases. 
It is well known that the status of the lymph nodes in the neck is one of the most 
important prognostic factors in head and neck cancer. The presence of lymph node 
metastasis in the neck reduces the expected survival by 50% (van Dongen et aI, 
1996). Therefore, the accurate clinical and pathological assessment of the status of 
the lymph nodes is an essential aspect in the staging of head and neck cancer. Plaque 
assays can be used to examine the p53 mutational status of the lymph nodes. 
At present, the limitation of p53 mutation-based detection of rare tumour cells in 
SCCHN patients is that p53 mutations are not present in all head and neck cancers. 
In addition the plaque assay is time consuming and cumbersome, and not suitable 
for automation. 
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Recent advances in the field of molecular genetics have provided extremely 
sensitive reverse-transcriptase polymerase chain reaction (RT-PCR) methods that 
enable the sensitive detection of tumour cells through the amplification of tumour-
specific or tumour-associated (marker) nucleotide sequences in DNA or ribonucleic 
acid (RNA). Polymerase chain reaction (PCR) -based techniques maybe more 
sensitive in identifYing cancer cells than immunocytochemistry (ICC) techniques. 
One of the most difficult samples to analyse for MRD is blood or bone marrow 
because the number of tumour cells in relation to the number of white blood cells is 
extremely low. Immunocytochemistry or RT -PCR methods have been reported for 
the detection of SCCHN cells at these sites (partridge et aI, 2000; van Houten et aI, 
2000). A considerable number of molecular markers for the detection of SCCHN 
tumour cells in bone marrow and blood of SCCHN patients have been explored, at 
present, E48 antigen expression seems one of the most promising. The expression of 
the E48 antigen appears to be restricted to normal squamous and transitional 
epithelia and their malignant counterparts. A detection ability of one tumour cell in 
107 nucleated blood cells is claimed by PCR-based E48 analysis (Brakenhoff et aI, 
1999). 
In a study reported by van Houten et aI, 2000 individual disseminated epithelial cells 
were detected using R T -PCR for the E48 antigen in the bone marrow aspirates of 41 
of 108 SCCHN patients (37%). Tumour cells were detected in 26.3% of stage I 
patients, whereas in stage IV disease almost twice as many patients presented with 
tumour cells in the bone marrow. The presence of epithelial cells at the time of 
primary treatment appeared to indicate a significantly higher risk for development of 
local or distant tumour recurrences. Furthermore, these studies revealed that 
patients presenting with bone marrow tumour cells showed a significantly shorter 
disease-free interval than those without. 
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1.4 p53 Tumour Suppressor Gene Structure and Function 
The humanp53 gene encompasses 16 to 20 kb of cellular DNA located on the short 
arm of chromosome 17 at position 17p 13.1 (McBride et ai, 1986; Miller et ai, 1986). 
This gene encodes a 393-amino acid (11 exon) nuclear phosphoprotein involved in 
the regulation of cell proliferation (- 53 kd in molecular weight, Soussi et ai, 1990). 
Lane and Crawford (1979) first identified p53 as a cellular protein, because it 
formed a tight complex with the simian virus 40 large T antigen (SV 40-T). The p53 
nuclear protein consists of at least three domains including: a transactivation domain 
at the amino (NH2) terminus (codons 20-42), involved in the transcriptional 
functions of p53; the mid-region with a sequence-specific DNA binding domain 
(codons 100-293) and the carboxy (COOH) terminus with a nuclear localisation 
domain (codons 316-325) and an oligomerisation domain at codons 319-360 
(Greenblatt et ai, 1994). Additionally, the COOH terminus of the p53 protein has 
functions in the recognition of DNA damage (Bakalkin et ai, 1994), negative 
regulation of p53 binding to promoter sequences, the transcription of p53-
transactivated genes (Horikoshi et ai, 1995) and the induction ofapoptosis (Wang et 
ai, 1996a). In the mid-region, four of the five evolutionary conserved domains are 
found (Pavletich et ai, 1993). 
The p53 protein is found in very low quantities in normal cells, but large quantities 
of p53 can be detected in transformed cells in culture, as well as in human tumours 
by mc (Hollstein et ai, 1991). As the normal p53 protein has a very short half life 
(6-20 minutes), it is often inferred that the detection of the p53 protein is 
synonymous with mutation because the mutant form has a half-life of up to 6 hours, 
probably due to stabilisation of the protein (Levine et ai, 1991). However, caution 
should be used in the interpretation of IRC positive staining as being synonymous 
with p53 gene mutation. Of critical importance is the consideration of the other 
mechanisms that underlie stabilisation of the p53 protein, such as changes in mouse 
double minute-2 (MOM2, Momand et ai, 1992) or p19 alternative reading frame 
(ARF, Kamijo et ai, 1998) protein levels. 
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P53 has been termed the "guardian of the genome"(Lane, 1992), since it has a key 
role in controlling cell proliferation by causing cell cycle arrest and apoptosis 
through induction of p53 responsive genes (Figure 1.1). When DNA is damaged 
wildtype p53 protein accumulates in the tumour cells and switches off the 
replication process in order that the repair system has time to act. If the cell 
succeeds in repairing the damage then p53 releases it into the replication cycle, 
otherwise p53 triggers apoptosis. Cells that lack functional p53 fail to undergo cell 
cycle arrest or apoptosis, resulting in continued proliferation in the face of genetic 
damage, subsequent genetic instability, and tumour progression (Lane, 1992; 
Amundson et ai, 1998; Vogt Siognov and Haupt, 1999). Wildtype p53 protein 
prevents tumour formation and initiates apoptosis when introduced into cancer cells, 
whereas mutant pS3 protein does not (Baker et ai, 1990; Shaw et ai, 1992; Clayman 
et ai, 1995). The functions of the wildtype p53 gene in cell cycle arrest and 
apoptosis make it potentially ideal for replacement gene therapy in malignant 
diseases (Chen et ai, 1990). 
1.5 Comparison of the Mouse and Human p53 Gene Sequence 
The p53 gene has been highly conserved during evolution. In cross-species 
comparisons, the p53 protein shows five highly conserved regions, which are 
regarded as essential to the function of p53 . Both mouse and human genomes 
contain a single copy of a functional p53 gene, being located on chromosome 11 and 
the short arm of chromosome 17 respectively. The human and mouse p53 genes 
have been cloned, and show a remarkably similarity. Both genes contain 11 exons 
interrupted by 10 introns. Although the introns differ in length, they interrupt the 
exons at precisely homologous positions (reviewed by Soussi et ai, 1990). These 
authors also report an 81 % homology between the mouse and human protein 
sequence. 
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Figure 1.1: The induction of p53 responsive genes involved in ceU cycle arrest 
and apoptosis. Protein kinases are responsible for the stabilisation of p53 following 
DNA damage, whilst the inhibition of MDM2 by p 14ARF is the mechanism for p53 
stabilisation used following oncogene exposure. Stabilisation of p53 inhibits its 
binding with MDM2, leading to an increase in p53 level, and the subsequent up-
regulation of p53 responsive genes involved in either cell cycle arrest or apoptosis. 
Bcl-2-Associated protein X (BAX); Death Receptor 5 (DR5); Fibroblast Associated 
(FAS); Growth Arrest and DNA Damage inducible protein (GADD45) . 
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1.6 Activation, Stabilisation, Localisation, and Degradation of p53 
The p53 tumour suppressor gene encodes a short-lived transcription factor, which is 
stabilised in response to a variety of stresses. Activation of p53 in response to 
cellular stress such as DNA damage (caused by y-irradiation, ultraviolet (UV) 
exposure, or chemical agents such as cis-DDP, Kastan et ai, 1991), hypoxia 
(Graeber et ai, 1996), heat shock and activated oncogenes (reviewed by Vogel stein 
et ai, 2000) all result in an increase in p53 expression (Figure 1.1). In unstressed 
cells, p53 is predominantly nuelear in the G 1 phase of the cell cycle and is largely 
cytoplasmic during the Sand G2 phases, consistent with its role as a mediator of G 1 
cell cycle checkpoints (Shaulsky et ai, 1990). In response to stress, however, p53 is 
stabilised and retained in the nucleus where it induces expression of genes involved 
in cell cycle arrest or apoptosis. The ability to retain p53 in the nucleus is critical for 
a cell to mount a p53-mediated stress response (Stommel et ai, 1999). 
Post-translational modifications of p53 by phosphorylation and acetylation have 
been implicated in its stability and transcriptional activation (Ashcroft et ai, 1999). 
Many different kinase families phosphorylate p53. These include DNA-dependent 
protein kinase (DNA-PK) in the presence of DNA strand breaks; Ataxia-
telangiectasia mutated (ATM) kinase, in response to ionising radiation, but not 
ultraviolet radiation; Ataxia-telangiectasia related (ATR) kinase and caesin kinase II, 
in response to a wide range of chemotherapeutic drugs and protein kinase inhibitors; 
Mitogen-activated serine-threonine-specific protein kinase (MAP kinase); Cyelin-
dependent kinases (CDKs); and Signalling lymphocyte-activation molecule 
associated protein (SAP) kinases (Figure 1.1; reviewed by Amundson et ai, 1998; 
reviewed by Vogel stein et ai, 2000). 
One of the most effective proteins involved in the regulation of p53 protein stability 
is MDM2. Phosphorylation of p53 inhibits the binding of MDM2 to p53, leading to 
an increase in p53 level, lengthening of the protein half-life, nuclear localisation, 
and transactivation activity (Shieh et ai, 1997; Unger et ai, 1999). The selective 
down-regulation of MDM2 expression also helps mediate this process (Vousden, 
2000). 
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In unstressed cells the MDM2 gene encodes a nuclear phosphoprotein that inhibits 
p53-mediated transactivation and promotes the ubiquitin-ligase-dependent 
degradation ofp53 (Freedman et ai, 1998). This ubiquitin-ligase degradation ofp53 
occurs within the cytoplasm of the cell, as a result of the export of p53 from the 
nucleus to the cytoplasm by MDM2 (Strommel et ai, 1999). Furthermore, 
transcriptional activation of the MDM2 gene is induced by p53 (Barak et ai, 1993), 
therefore, MDM2 has been proposed to regulate p53 by a negative feedback loop 
mechanism, which keeps p53 levels low during normal growth and development 
(WU et ai, 1993). 
Other cellular proteins that have been shown to playa direct role in regulating p53 
stability and transcriptional activity include p14ARF, c-jun N-terminus kinase (INK) 
and cyclic adenosine monophosphate (cAMP) response element (CRE) protein 
binding protein (CBP)/p300 (reviewed by Buschmann et ai, 2000). Of particular 
interest has been the discovery that several oncogenes (MYC, RAS, E2Fl, E1A) can 
induce stabilisation of p53 by enlisting the activity of pI4ARF, a protein that 
functions by binding directly to MDM2, inhibiting the ubiquitination of p53 and 
allowing accumulation of p53 in the nucleus (Figure 1.1; reviewed by Evan and 
Littlewood 1998; Vousden, 2000). 
The INK4a-ARF locus on chromosome 9p21 encodes two distinct tumour 
suppressors, p 16 INK4a and the ARF protein (p 14ARF in humans, p 19ARF in the mouse, 
Quelle et ai, 1995). Whereas p 16INK4a restricts cell growth through preventing 
phosphorylation of the RB protein (Serrano et ai, 1993; Sherr and Roberts, 1995), 
p14ARF acts to stabilise p53 by inhibiting the action of MDM2 (Tao and Levine, 
1999). P14ARF binds directly to MDM2, preventing it from targeting p53 for 
degradation, and additionally prevents MDM2 from shuttling p53 from the nucleus 
to the cytoplasm where degradation occurs (Figure 2; reviewed by Lobrum et ai, 
2000). The mechanism of MDM2-mediated regulation by p 14ARF involves 
intracellular compartmentalisation. P14ARF stabilises p53 by sequestering MDM2 
from the cytosol and confining it to the nucleus, mainly in the nucleolus (reviewed 
by Esteller et ai, 2001). 
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A further mechanism that leads to the inactivation of p53 is its location within the 
cytoplasm. P53 is a transcription factor, therefore, only the p53 protein that is 
transferred into the nucleus can act as a negative regulator of cell proliferation. The 
sequestering of the p53 protein into the cell cytoplasm therefore prevents its acting 
as a tumour suppressor. This cytoplasmic sequestering of p53 has been observed in 
a number of human tumours, and is thought to result from a profound resistance to 
MDM2 mediated degradation (Zaika et ai, 1999). Cytoplasmic sequestration of p53 
in tumour cells is associated with poor long-term patient survival and may be an 
important mechanism of tumourigenesis in the substantial fraction of tumours that 
do not have mutated p53 (Sun et ai, 1992). 
Other mechanisms that cause the inactivation of p53 transcriptional activity include 
p53 mutations, chromosomal deletions or the binding to viral oncoproteins (T 
antigen of SV40, EIB protein of adenovirus, HPV E6), which prevents appropriate 
action following DNA damage, allowing replication to proceed (Chang et ai, 1995). 
The E6 protein of oncogenic HPV s has been shown to bind to wildtype p5 3, 
shortening its half-life and inactivating its function via ubiquitin-dependent 
degradation of the p53 (Scheffner et ai, 1990; Mietz et ai, 1992). 
1. 7 Tbe Role of p53 in tbe Cell Cycle 
One of the major functional roles of p53 lies in the regulation of the cell cycle, with 
studies implicatingp53 as a checkpoint control factor at the GIIS and the G2 phases. 
Growth arrest at these stages is often to enable repair of damaged DNA prior to 
replication. A number of p53 target genes have been identified, that are involved in 
the cell cycle, these include p2lWAFIICIPl (wildtype p53-activated fragment-l 
(WAFl), cyelin-dependent kinase-interacting protein 1 (CIPI), EI-Deiry et aI, 1993) 
and l4-3-3u (Hermeking et ai, 1997). P21 WAF lICIP I inhibits CDKs and induces a 
GIIS block (Harper et aI, 1993), whilst 14-3-30 inhibits CDC25C and induces a 
block at the G21M phase of the cell cycle (Peng et ai, 1997). 
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1.7.1 The Role of p53 in G 1 Cell Cycle Arrest 
Following DNA damage, p53 undergoes post-translational modifications, including 
phosphorylation and acetylation, resulting in its stabilisation and activation as a 
transcription factor. One effect of this increase in p53, is the up-regulation of the 
downstream p21WAFIICIPJ gene, which mediates a Gl cell cycle arrest by inhibiting 
the action ofCDKs. The role of these kinases is to phosphorylate the RB product. In 
its non- or hypophosphorylated state, RB prevents progression from G 1 to S phase 
through its interaction with members of the E2F transcription factor family. This 
pRB-E2F complex blocks the transcriptional activation by E2F, of genes required 
for this cell cycle phase transition (Chellappan et aI, 1991). Cyclin Dl: CDK4 
regulates transition through the early G 1 phase of the cell cyele by phosphorylation 
ofpRB, which results in the release of transcription factor E2F from pRB (Askew et 
aI, 1991). Free E2F mediates transcription ofE2F-dependent genes, ineluding DNA 
polymerase, thymidine kinase, and dihydrofolate reductase (DHFR; Figure 1.2). 
Cyelin Dl: CDK4 kinase activity is specifically inhibited by the CDK inhibitor 
(CKI) p16INK4a (Sherr and Roberts, 1995), whereas the CKI p21WAFlICIPl binds to all 
of the cyelin CDKs (Askew et aI, 1991; Johnson et ai, 1993). Cyclin Dl 
overexpression results in an increase in p21 W AFlICIPl expression. P21 W AFlICIPl 
expression can occur as a result of both p53-dependent and independent pathways 
(Levine, 1997). At low concentrations, p21 WAF lICIP 1 promotes the assembly of an 
active cyelin D: CDK4 complex, whereas it inhibits its activity at higher 
concentrations (reviewed by Martin et ai, 1999). The CKI p27KlPl also binds to all 
of the CDKs but inhibits cyelin D: CDK4 activity much less efficiently than cyelin 
A: CDK2 kinase activity (Blain et aI, 1997). The CKIs can be divided into two 
families of genes, the p21 family consists of p21WAFJICIPJ, p27 KIPJ and p57 KIP2 
which are general inhibitors of the GlIS CDKs, and the INK4 family whose 
members p16INK4a, p15INK4b, pl~K4c and pl~K4d are specific inhibitors of cyelin 
D lICDK4 or CDK6 complexes (reviewed by Schreiber et aI, 1999). 
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G lIS Ce]ill<=>Cyclie 
lProgression 
Figure 1.2: G1-S Cell Cycle. p53 regulates the cell cycle by transcriptionally 
inducing genes that control the cell cycle. For normal Gl-S progression to occur 
CDK4 complexes with cyclin Dl, resulting in the phosphorylation of RB. In this 
phosphorylated state, RB can no longer bind to transcription factors such as E2F, 
resulting in expression of E2F -target genes required for the transition from G 1 to S 
phase. Activated p53 causes a G 1 cell-cycle arrest by increasing the transcription of 
the CKI p2l WAFlICIPl . P2l WAF lICIP 1 blocks CDK4 activity and thereby inhibits entry 
into S phase. 
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1.7.2 The Role ofp53 in G2 Cell Cycle Arrest 
More recently, p53 has been implicated in the G2IM checkpoint. p53 directs the 
transcriptional induction of the p21WAFJICIPJ and 14-3-3cr genes. During the normal 
cell cycle, negative regulation of Cyelin B-CDC2 prevents premature mitotic entry 
prior to the completion of S phase (Shapiro et ai, 1999). CDC2 is negatively 
regulated by phosphorylation on threonine-14 and tyrosine-IS. The de-
phosphorylation of CDC2, which is necessary for entry into mitosis, is controlled by 
CDC2SC, a dual-specificity phosphatase that is, in tum, regulated by cell cycle-
dependent phosphorylation events (Peng et ai, 1997). After exposure to damage-
induced double-strand DNA breaks, the ATM kinase is activated. As a result, the 
CHK2 protein is phosphorylated, and a related kinase, CHKl, is also modified. 
Activation of CHIO and CHK2 results in phosphorylation of CDC2SC, which 
promotes the binding of CDC25C to 14-3-3 proteins. Thus bound, CDC25C is 
sequestered into the cytoplasm, unable to dephosphorylate and activate Cyclin B-
CDC2. With CDC2's inhibitory phosphorylation intact, cells undergo G2 arrest 
(Weinert, 1997; Shapiro et ai, 1999; Figure 1.3). p21 WAFlfCIPl prevents any CDC2 
that enters the nucleus from becoming activated. Without the p53-mediated 
induction of p21WAFJICIPJ and 14-3-30; inhibition of Cyelin B-CDC2 is not 
maintained following DNA damage, and cells are capable of entering mitosis (Bunz 
et ai, 1998; Chan et ai, 1999). 
The p53-regulated protein GADD45 has also been implicated in G2 arrest, by also 
inhibiting the activity of the Cyelin B l/CDC2 complex, probably by the direct 
interaction with the CDC2 (Wang et ai, 1999). 
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G2",M eellaCycle 
Progression 
Figure 1.3: G2-M Cell Cycle. Activated p53 may contribute to a G2 arrest by 
increasing the transcription of 14-3-3-0. 14-3-3-0 sequesters the CDC25C 
phosphatase in the cytoplasm preventing it from entering the nucleus and activating 
CDC2, the CDK that promotes G21M transition. P indicates phosphorylation. 
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1.8 Apoptosis in Development and Maintenance 
Apoptosis is a cellular process of self-directed suicide in the presence of 
supernumeracy, misplaced or damaged cells (Meier et ai, 2000). It plays a key role 
in embryonic development, maintaining normal tissue homeostasis, cytotoxic 
immunological reactions, and at the end of the life span of differentiated cells (Kerr 
et ai, 1972; reviewed by Gorczyca et ai, 1993). During development numerous 
structures are formed only later to be removed by apoptosis (Meier et al, 2000). The 
critical role of apoptosis in development is evident throughout vertebrate life and, 
consequently, dysfunction's in apoptosis manifests not only in developmental 
abnormalities but also in a wide variety of adult pathologies, such as acquired 
immunodeficiency syndrome (AIDS) and cancer (Williams et ai, 1991; Ameisen et 
ai, 1995). The interest in apoptosis in oncology stems from the observation that, at 
least in some tumours, malignancy may be associated with loss of the ability of the 
cell to undergo spontaneous apoptosis rather than with increasing cell proliferation 
rates. The conservation of apoptotic machinery through evolution has provided a 
wealth of experimental systems with which to study, understand and, eventually, 
manipulate this fundamental biological process (Meier et aI, 2000). 
1.9 Cellular Appearance of Apoptosis and Necrosis 
Apoptotic cell death is triggered by a range of stimuli including intracellular cues 
such as DNA damage (caused by ionising radiation and a variety of anti-tumour 
drugs), heat shock and osmotic stress, and extracellular cues including growth factor 
withdrawal, matrix detachment, and direct cytokine-mediated killing (Sellers et ai, 
1999). However, the level and longevity of the insult, rather than the nature of the 
insult itself, usually determine whether apoptotic or necrotic cell death is triggered, 
with high levels resulting in necrosis and lower levels in apoptosis (Lennon et ai, 
1991). The time to onset of apoptosis after a lethal stimulus is variable but the 
changes are rapid (a few minutes duration, Bellamy et aI, 1995). Late stages of 
apoptotic cell death are morphologically highly distinctive and easily distinguishable 
from both viable and necrotic cells via light microscopy. Ideally most cell death 
detection assays should be coupled with direct morphological evaluation of the cell 
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population under study to define with certainty the mode of cell death that is 
occurring (McGahon et ai, 1995). 
During apoptosis co-ordinated morphological and biochemical changes occur within 
the nucleus, cytoplasm, organelles, and plasma membrane (Figure 1.4). The nucleus 
condenses and chromatin marginates to form dense granular caps under the intact 
nuclear membrane (Bellamy et ai, 1995). Molecular characterisation of chromatin 
reveals an ordered degradation of the DNA by endogenous nuclease, first into large 
fragments of 30-50 kilobases, and finally into nucleosomal fragments of 180-200 
base pairs (Wyllie et ai, 1980). However, cleavage of chromatin to nucleosomal 
fragments does not occur in all cell types and can be inhibited without blocking the 
other changes ofapoptosis (Walker et ai, 1993; Jacobson et ai, 1994). Mitochondrial 
DNA is not fragmented in apoptosis, indicating that DNA fragmentation is a specific 
nuclear event. The cells round-up, dissociates from its neighbours, and shrinks 
dramatically, apparently due to voiding of water and ions with consequent 
compaction of the organelles and an increase in cell density. The cell surface starts 
to bleb violently. Around this time the nucleus starts to break up into several 
membrane-bound fragments. The cell itself then splits into multiple membrane 
bound 'apoptotic bodies', some of which contain nuclear fragments (Wyllie et ai, 
1984). In tissues, apoptotic cells and their smaller fragments, apoptotic bodies, are 
rapidly taken up by neighbouring cells and are degraded within lysosomes, without 
eliciting an inflammatory reaction (Bellamy et ai, 1995). Recognition and 
engulfment of apoptotic cells by phagocytes occurs before membrane integrity is 
undermined and protects the surrounding tissues or cells from the damaging effects 
of released intracellular contents (McGahon et ai, 1995). The speed of apoptosis and 
the rapidity of clearance of apoptotic bodies in vivo (a few hours at most) mean that 
the identification of only a few apoptotic bodies in a tissue section can represent a 
considerable degree of cumulative cell loss (Wyllie et ai, 1999). 
In comparison, necrotic cell death tends to occur after exposure to extreme variance 
of physiological conditions such as hyperthermia and hypoxia, which may result in 
damage to the plasma membrane (McGahon et ai, 1995). Necrosis occurs due to the 
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lack of capability of the damaged cell to maintain homeostasis. This results in an 
influx of water and extracellular ions, causing the entire cell to swell. The 
mitochondria and other intracellular organelles also swell and rupture (reviewed by 
Chandrasoma et ai, 1991). Lysosomal enzymes digest the plasma membrane causing 
cell lysis, and release of cytoplasmic components into the extracellular fluid (Figure 
1.4). One of the first changes detectable by light microscopy in necrotic cells is the 
homogenous and deeply acidophillic cytoplasm, this stains pink with the acidic stain 
eosin. Necrotic cell death in vivo is often associated with extensive tissue damage, 
and consequently an intense inflammatory response (Van Furth et ai, 1988). 
Different cells show different morphologic changes after they undergo necrosis, 
reflecting variations in cell composition, speed of necrosis, and type of injury. 
Coagulative necrosis typically occurs in solid organs as a result of deficient blood 
supply and anoxia. Ghost outlines of dead cells with coagulated cytoplasm and 
absent nuclei are apparent for several days following the onset of necrosis (reviewed 
by Chandrasoma et ai, 1991). Liquefactive necrosis occurs when lysosomal 
enzymes released by the necrotic cells cause rapid liquefaction, resulting in a fluid~ 
filled cavity often surrounded by inflammatory cells (reviewed by Chandrasoma et 
ai, 1991). These changes are typically observed between 1 and 5 days after the 
onset of necrosis. Necrosis occurs commonly in solid tumours, frequently observed 
at distances greater than 150-200 J..lm away from blood vessels. This can often be 
seen in tumour nodules as viable cells surrounding a vascular network, with an area 
of central necrosis (reviewed by Tannock et ai, 1992). 
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Necrosis 
mitochondrial changes 
chromatin pattern conserved 
normal reversIble swelling irreversible swelling disintegration 
ApoptoSIS 
mitochondrial structure preserved i".ct~ ~ 
~ CIf ,~: O~C® 
nuclear changes apoptotic bodies 
normal condensation (cell blebbing) fragmentation secondary necrosis 
Figure 1.4: Morphological Characteristics Distinguishing Necrosis from 
Apoptosis. www.roche-applied-science.com (apoptotic manual). 
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1.10 Apoptotic Pathways 
The process of apoptosis is complex and continuously changing in relation to new 
gene involvement and the interactions of various genes in this pathway. Two central 
pathways are involved in the process of apoptotic cell death, a receptor-mediated 
and a mitochondrial pathway resulting in caspase activation (reviewed by Sellers et 
ai, 1999; reviewed by Gottlieb, 2000). Apoptosis is regulated by interplay of a 
variety of gene products that can either act as inducers or inhibitors of this process. 
A central regulator of apoptotic susceptibility is the tumour suppressor gene p53. 
However, p53-independent apoptotic pathways have also been reported. One 
example is the tumour necrosis factor ligand, which can bind cell-surface DRs to 
activate caspases and cause apoptotic cell death in p53 null cells (Yoshida et ai, 
1996). 
1.10.1 The Role ofp53 in Receptor-Mediated Apoptosis 
Potential transcriptional targets of p53 that may contribute to apoptosis are the cell-
surface DRs. These are cell surface receptors that transmit apoptotic signals when 
initiated by specific "death ligands". These receptors can activate death caspases 
within seconds of ligand binding, causing an apoptotic demise of the cell within 
hours (Ashkenazi and Dixit, 1998). Death receptors belong to the tumour necrosis 
factor receptor (TNFR) gene superfamily, which is defined by similar, cysteine-rich 
extracellular domains (Smith et ai, 1994). The DR's contain in addition a 
homologous cytoplasmic sequence termed the "death domain" (DD, Tartaglia et ai, 
1993). 
P53 activates an important DR, FAS (also called CD95 or Apo-l), that plays an 
important role in the regulation and function of the immune response. 
F AS/CD951 Apo-l is induced by p53 in response to DNA damage, and plays a 
significant role in the apoptosis of the malignant cell induced by anti-cancer drugs 
(Owen-Schaub et ai, 1995). p53 responsive elements have been identified in the FAS 
gene. In addition, p53 may facilitate the transport of FAS from the golgi to the 
membrane. F AS is essential for T-cell killing in response to anti-cancer drugs, and 
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for MYC-mediated apoptosis. Both responses are p53-dependent, hence linking 
F AS with the apoptotic pathway of p53 (reviewed by Ashkenazi and Dixit, 1998). 
The ligands that activate these receptors are structurally related molecules that 
belong to the TNF gene superfamily. FAS ligand (FASL, also called CD95L) binds 
to F AS. It has been suggested that each F ASL trimer bind three F AS molecules 
(Smith et ai, 1994). Since DDs have a propensity to associate with one another, 
F AS ligation leads to clustering of the receptors' DD (reviewed by Ashkenazi and 
Dixit, 1998). The Fas-associated death domain protein (FADD, also called MORTl) 
is a cytosolic protein also containing DDs, it interacts exclusively with 
F AS/CD951 APO-1, inducing apoptosis when over-expressed (Johnson Webb et ai, 
1997). FADD also contains a "death effector domain" (DED) that binds to caspase-
8 (also called F ADD-like interleukin-I-beta converting enzyme (FLICE), or MACH, 
Boldin et aI, 1996). Caspases are cysteine proteases that cleave proteins at aspartic 
acid residues contained within a tetrapeptide recognition motif Caspase activity is 
regulated by adaptor molecules that promote or inhibit caspase activation (Figure 
1.5a). Activators (such as the adaptor protein F ADD) promote the formation of a 
death-inducing signalling complex. Their actions are opposed by multiple inhibitor 
proteins (inhibitor of apoptosis proteins, lAPs) that block activation of both effector 
and initiator caspases (Sellers et aI, 1999). The activated caspase-8 (or 10) then 
activates downstream effector caspases such as caspase-9, or cleaves procaspase 3, 
committing the cell to apoptosis (Green, 2000). 
Another member of the TNFR family, KILLERlDR5, is also induced by p53, in 
response to genotoxic stress (Wu et ai, 1997). Similarly to CD95, interaction of 
DR5 with its ligand, tumour necrosis factor-related apoptosis-inducing ligand 
(TRAIL), activates the cytoplasmic DD ofDR5, which in turn activates the caspase 
cascade culminating in apoptosis (MacFarlane et aI, 1997; Walczak et ai, 1997, 
Figure 1.5b). TRAIL belongs to the TNF family, and is a type II transmembrane 
protein whose extracellular region forms a soluble molecule on cleavage (Pitti et aI, 
1996). Both membrane-bound TRAIL and soluble TRAIL rapidly induce apoptosis 
in a wide variety of transformed cell lines via interaction with the DRs DR41TRAIL-
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R1 and DR5ffRAlL-R2 (Pan et ai, 1997; Walczak et ai, 1997). TRAIL is expressed 
constitutively in many normal tissues, however, TRAIL appears to induce apoptotic 
cell death only in tumourigenic or transformed cells and not in normal cells 
(Ashenazi et ai, 1999). 
1.10.2 The Role of p53 in the Mitochondrial Pathway of Apoptosis 
Earlier stages in the induction of apoptosis are associated with mitochondrial 
changes. The B-Cell Lymphoma/leukaemia-2 (BCL-2) family of proteins is a key 
player in this form of apoptosis (Tsujimoto et ai, 1985). This large family of 
proteins can be broadly divided into three groups. The anti-apoptotic members such 
as BCL-2, BCL-XL, BCL-W, Myeloid Cell Leukaemia sequence 1 (MCL-I), Al 
(BFL-1) and BOO, all exert anti-cell death activity and share sequence homology, 
particularly within four regions, BCL-2 homology (BH) I through BH 4, although 
some members lack an apparent BH4 domain. The pro-apoptotic members such as 
BAX, BCL-2 AntagonistIKiller (BAK), BCL-XLIBCL-2 Associated Death 
promoter (BAD) and BCL-2 related Ovarian Killer (BOK), share sequence 
homology in BH1, Bill and BH3 but not in BH4, although significant homology at 
BH4 has been identified in some members. The BH3 only proteins, are pro-
apoptotic proteins which include BCL-2 Interacting Killer (BIK), BH3 Interacting 
domain Death agonist (BID), BCL-2 Interacting Mediator of cell death (BIM), 
Harakiri (HRK), BIK-Like Killer protein (BLK), NOXA, PUMA and BCL-
2/adenovirus E1B-19kD Interacting Protein-3 (BNIP3), BNIP-3-Like (BNIP3L), 
share sequence homology only in BH3 (reviewed by Tsujimoto et ai, 2000). 
One p53 target gene linking p53 to such mitochondrial events is BAX. BAX is a pro-
apoptotic member of the Bcl-2 family of apoptotic regulators, located in the cytosol 
of healthy cells (Fadeel et ai, 1999). Interestingly, the anti-apoptotic gene BCL-2, 
which is normally located in the outer membrane of the mitochondria (Krajewski et 
ai, 1993), counteracts the effect of BAX on apoptosis. BCL-2 is transcriptionally 
repressed by wildtype p53 (Miyashita et ai, 1994), whilst BAX is directly induced by 
it (Zhan el ai, 1994). Thus, p53-induced apoptosis may result from shifting the 
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BAXlBCL-2 balance in favour of programmed death (reviewed by Johnson Webb et 
aI, 1997; reviewed by Amundson et aI, 1998). However, studies have found that 
BAX which is downstream of p53 can induce apoptosis in both p53 wildtype and 
p53-null tumour cells both in vitro and in vivo (Kagawa et aI, 2000). In response to 
apoptotic stimuli, BAX translocates from the cytoplasm to the mitochondria, where 
it oligomerises, facilitating permeabilisation of the mitochondrial membrane by 
inducing the formation of ion-permeable pores (Wolter et ai, 1997). This 
translocation-oligomerisation-permeabilisation reaction is inhibited by anti-
apoptotic members of the BCL-2 family and is stimulated by pro-apoptotic BH3-
only members of the BCL-2 family, for example BID (Boya et aI, 2001). The 
backbone of the permeability transition pore complex (PTPC) of the outer/inner 
mitochondrial membrane is constituted by two proteins, namely the voltage-
dependent anion channel (VDAC) in the outer membrane, and the adenine 
nucleotide translocator (ANT) in the inner membrane. Both VDAC and ANT have 
been reported to physically and functionally interact with BAX, BAK and BCL-2 
(reviewed by Gottlieb, 2000; reviewed by Tsujimoto et aI, 2000; reviewed by Boya 
et aI, 2001). This permeabilisation of the mitochondrial membrane allows the 
release of cytochrome c and apoptosis-inducing factor (AIF; reviewed by Boya et aI, 
2001). In a variety of different apoptosis-inducing conditions, AIF translocates 
through the outer mitochondrial membrane to the cytosol and to the nucleus. 
Apoptosis inducing factor induces nuclear chromatin condensation as well as large 
scale (- 50kb) DNA fragmentation. In contrast to cytochrome c, AIF acts in a 
caspase-independent fashion. Recombinant AIF suffices to cause three hallmarks of 
apoptosis, namely the dissipation of the mitochondrial transmembrane potential and 
the release of cytochrome c, the condensation of nuclear chromatin, and the 
exposure of phosphatidylserine on the plasma membrane surface. These alterations 
are rapid (30-120 minutes, Daugas et aI, 2000). The release of cytochrome c to the 
cytosol results in its association with another key factor, the apoptosis protease-
activating factor (APAF-l). Apoptosis protease activating factor-l binds 
cytochrome c, dATP or ATP and forms a large (-700 kDa) multimeric complex, 
termed the apoptosome, which also includes molecules of caspase 9 and 3. Caspase 
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9 is activated when bound to AP AF -1 where it processes caspase 3 to its active form 
(Zou et ai, 1997; Chinnaiyan, 1999). 
The caspases are modulated by another set of proteins, the lAPs. One of these, the 
X-linked Inhibitor of Apoptosis Protein (XIAP), binds to and inhibits the proteinase 
activity of caspase-9, and thereby can block apoptotic processes at this point 
(Deveraux et ai, 1998). It may also bind to and inhibit caspase-3 . A protein with a 
dual name of second mitochondria-derived activator of caspases (SMAC) and direct 
inhibitor of apoptosis protein binding protein with low pI (DIABLO) is released 
from the mitochondria along with cytochrome c during apoptosis, promoting 
caspase activation by associating with the AP AF-I apoptosome and inhibiting XIAP 
(Figure 1.6, Du et ai, 2000; Verhagen et ai, 2000). Different pro-apoptotic members 
playa major role in initiating cytochrome c release in certain settings of apoptosis: 
BID is implicated in F AS-mediated apoptosis, BAX in DNA damage-induced 
apoptosis and BAD in lymphokine deprivation induced cell death in certain cells 
(Tsujimoto et ai, 2000). 
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Figure 1.5: Receptor Mediated Apoptosis. a) Apoptosis signalling by FAS. FASL 
binds to and activates CD95IFAS/APOl. Receptor trimerization and activation leads 
to the recruitment of F ADD that can recruit and activate procaspase 8. b) Apoptosis 
signalling by DR4 and DR5. TRAIL/AP02L binds to and activates DR4 and DR5, 
resulting in activation of caspases and apoptotic cell death. From 
www.rndsystems.com. 
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Figure 1.6: Mitochondrial Pathway of Apoptosis. Early apoptotic changes are 
seen at the mitochondria. These include a shifting in the BAXlBCL-2 balance in 
favour of programmed death. BAX is targeted to the mitochondria where it 
promotes apoptosis by facilitating the release of AIF and cytochrome c from the 
mitochondria, which in turn triggers a cascade of caspase activation. From 
www.mdsystems.com. 
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1.11 p53 Gene Mutations in Squamous Cell Carcinoma of the Head and Neck 
The most frequently mutated gene in SCCHN is the p53 tumour suppressor gene, 
which is mutated in between 30-75% of tumours (Bartek et ai, 1991; EI-Naggar et 
ai, 1995; Liloglou et ai, 1997). Approximately 98% of all p53 mutations in SCCHN 
are found within exons 5-8 (Greenblatt et ai, 1994; Hussain and Harris, 1998.). P53 
mutational hotspots within exons 5-8 of SCCHN patient samples have been located 
at codons 175, 238-248 and 273-282 (Thierry Soussi's p53 database 
(www.p53.curie.fr.Figure1.7}.Thirty-five percent of non-invasive lesions and 75% 
of invasive carcinomas harbour p53 mutations, with the majority of mutations 
located in exons 5-7 for the non-invasive lesions, and exon 5-8 for the invasive 
carcinomas (EI-Naggar et ai, 1995). 
The activity of the p53 protein is extremely sensitive to the conformation of the 
protein. The p53 gene is inactivated in a high percentage of cancers, mostly through 
missense mutations in one allele, that cause single amino acid residue changes in the 
DNA binding domain of the protein, often rendering the protein non-functional, and 
allowing the detection of high concentrations of the protein in these cells (Levine, 
1997; Hussain and Harris, 1998; de Vries et ai, 2002). 
P53 missense mutations can cause both a loss of tumour suppressor function and a 
gain of oncogenic function by changing the repertoire of genes whose expression is 
controlled by this transcription factor (Dittmer et ai, 1993). A deletion within the 
p53 gene frequently results in no p53 protein at all. Tumour derived p53 mutants are 
usually transcriptionally inactive, but some mutants retain the ability to transactivate 
a subset of p53 target genes (Monti et ai, 2002). p53 point mutations can lead to 
either overexpression of mutant p53 protein or a non-functional protein (reviewed 
by Levine, 1997). In addition, a mutation that inserts or deletes a single base or more 
will change the reading frame for the entire subsequent sequence. A change of this 
sort is called a frame-shift, because the sequence of the new reading frame is 
completely different from the old one, so the entire amino acid sequence of the 
protein is altered beyond the site of mutation. Thus, the function of the protein is 
likely to be lost completely, or no protein will be present at all. 
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A mutation that completely eliminates gene function, usually because the gene has 
been deleted, is called a null mutation. When a mutation fails to affect the 
phenotype, it is always possible that this is because it is leaky - enough active 
product is made to fulfil its function, even though the activity is quantitatively 
reduced or qualitatively different from the wildtype. Mutations that impede gene 
function (but do not necessarily abolish it entirely) are also called loss-of-function 
mutations. A loss-of-function mutation is recessive (Lewin, 1994). Sometimes a 
mutation has the opposite effect and causes a protein to acquire a new action; such a 
change is called a gain-of-function mutation. A gain-of-function mutation is 
dominant (Lewin, 1994). p53 functions as a tetrameric transcription factor. Mutant 
p53 can hetero-oligomerize with the wildtype, inhibiting its function in a dominant 
negative fashion (Roemer, 1999). Dominance depends on the ratio of the proteins as 
well as on the position of the mutated amino acid residue. Mutations that alter the 
tertiary structure can give rise to proteins capable of forcing upon wildtype p53 a 
non-wildtype conformation, and hetero-tetrameric complexes with altered 
conformation are impaired for DNA binding (Roemer, 1999). In addition to 
dominance, mutant p53 can exert oncogenic functions independently of the 
inactivation of wildtype p53. Such gain-of-function manifests itself in the 
enhancement oftumourigenicity, of metastatic potential, and of survival and therapy 
resistance of wild type p53-null tumour cells. 
The presence of a p53 gene mutation maybe associated with a poor clinical outcome 
for SCCHN cancer patients (Field et ai, 1993). The expression of mutated p53 
seems to be an early event in the multistage process of head and neck carcinogenesis 
(Shin et ai, 1994). The expression of mutated p53 maybe widespread in the oral 
mucosa, as explained by the field cancerisation hypothesis, predisposing SCCHN 
patients to development of recurrence or a second tumour (Burns et ai, 1994; Gallo 
et ai, 1995). Molecular assessment of surgical margins for p53 mutations have 
shown that if the margins are positive for the genetic alteration found in the tumour 
there is an increased risk of local recurrence (Brennan et ai, 1995; Partridge et ai, 
2000). This finding was supported by Shin et ai, 1996 who found that a higher level 
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of mutant p53 expression correlated with an increased likelihood of early recurrence 
and! or second primary tumours. 
The mutational pattern in SCCHN may also be influenced by exogenous 
carcinogens, such as mutagens in cigarette smoke, for example benzo(a)pyrene. 
These preferentially induce transversions (guanine (G): cytosine (C) - thymine (T): 
adenine (A» . The spectrum of p53 mutations is wider in cigarette smokers, who 
also drink alcohol. P53 mutations in non-smokers and non-drinkers predominate at 
cytosine phosphate guanosine dinucleotides (CpG) sites, which are suggested as 
endogenous mutational 'hotspots' (Boyle et 01, 1993; Liloglou et 01, 1997). Alcohol 
has been suggested to cause mucosal injury, increasing the absorption of the 
mutagenic toxins present in cigarette smoke (reviewed in Brennan et 01, 1995a). In 
addition, alcohol may cause carcinogenesis directly by inducing microsomal 
enzymes involved in the metabolism of carcinogenesis, or by contributing to 
nutritional deficiencies, or by introducing carcinogenic impurities a frequent 
contaminant of alcoholic beverages (reviewed by Brennan et 01, 1995a). 
1.12 The p53 Gene Family 
The p53 tumour suppressor gene has centre stage in the processes of cell cycle 
regulation and apoptosis. However, with the recent discovery of two new p53 gene 
family members, p73 (Kaghad et 01, 1997) and p63 (also known as p5J, p40, KET, 
or p73L; Yang et 01, 1998; Osada et aI, 1998), which show striking sequence 
homology to p53, it is unclear if p53 will still keep this pivotal position in these 
essential pathways. The sequence identity between the three genes reaches 63% in 
the DNA binding domains, 29% in the transactivation domain and 38% in the 
oligomerisation domain (De Laurenzi et 01, 2000). However, p63 and p73 are more 
closely related to one another than either is to p53 (Kaelin, 1999). 
Kaghad and co-workers identified the p73 gene on chromosome Ip36, a region that 
is frequently deleted in a variety of human cancers (Kaghad et 01, 1997). However, 
studies so far show that this gene is rarely mutated in human cancer. P73u and p73j3 
56 
Chapter 1 • Introduction 
proteins are present in mammalian cells. Both p73a and p73f3 can, at least when 
over-expressed, activate transcription from p53-responsive promoters and induce 
apoptosis in cells irrespective of their p53 status. In fact, p73 can induce apoptosis in 
the absence of p53 via a physical interaction with c-ABL (reviewed by De Laurenzi 
et aI, 2000). DNA-damaging agents activate p73, as is the case for p53 . E2Fl 
activates p53 indirectly, via p14ARF. However, results indicate that E2FI regulates 
p73 levels directly, through its recognition and transactivation of the TP73 promoter, 
driving cells into apoptosis (Soengas et aI, 2000). Both p53 and p73 are able to 
transactivate the promoters of some common genes, including p2JWAFJ , BAX, 
MDM2, cyclin-G, GADD45, and the insulin growth factor binding protein (IGFBP-
3) (reviewed by Levrero et aI, 1999). Binding to MDM2 is seen with both p53 and 
p73, although MDM2 does not target p73 for degradation (Wang et aI, 2001). 
Additionally, in contrast to p53, p73 is not bound or degraded by SV40 T antigen, 
adenoviral EIB 55 kD protein, or HPV E6. Indeed p73, but not p53, can induce 
apoptosis in E6-transformed cells (reviewed by Kaelin, 1999). 
P63 maps to chromosome 3q27-8, and has been demonstrated to be essential for 
limb and skin formation during development (Yang et aI, 1998; Osada et aI, 1998). 
P63 like p73 can bind to p53 DNA-binding sites in vitro and can activate 
transcription from p53-responsive promoters in vivo. In addition, p63 can induce 
apoptosis inp53-defective tumour cells (Yang et aI, 1998; Osada et ai, 1998). The 
tumour-derived p63 missense mutations retained their ability to transactivate the 
MDM2 and/or the BAX promoter but not the p2 JWAFI promoter (Kato et aI, 1999). 
Mutations in p63 although detectable are rare (reviewed by Kaelin, 1999). 
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Figure 1.7: P53 Mutational Hotspots in Head and Neck Cancers. Approximately 
98% of all p53 mutations in SCCHN are found within exons 5-8, between codons 
100 and 350. From www.p53.curie.fr. 
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1.13 Prediction of Radiotherapy and Chemotherapy Responses in Cancer 
The prediction of radio- and chemo-therapy response is a critical step to determine 
the treatment strategy and reduce potential patient suffering. Adverse side affects 
associated with chemotherapy, include systemic toxicity due to lack of specificity, 
rapid drug metabolism, and both intrinsic and acquired drug resistance (Johnstone et 
ai, 2002). The adverse symptoms following radiotherapy is dependent on the site 
and size of the treatment area, as well as the dose of radiotherapy used. Radiation 
causes damage to normal tissue, with most side effects the result of damage to the 
microvasculature (Williams, 1990). A significant number of patients with SCCHN 
have tumours, which are resistant to radio- and chemo-therapy, a major factor in the 
high rate of recurrence observed for this type of malignancy (Pirollo et ai, 1997). 
The sensitisation of these tumours to radio- and chemotherapy, resulting in a 
decrease in the amount of treatment necessary to be effective, would be of immense 
benefit to the patient. 
Genetic alterations in tumours are likely to be largely responsible for the differing 
responses following therapeutic intervention. Many studies have focused on 
determining the effects of p53 mutation on the response of cancer cells to 
therapeutic agents. The results have been conflicting, with some studies indicating 
enhanced sensitivity and others indicating increased resistance to the same 
compounds. The theory that loss of function of the p53 gene results in increased 
resistance to anticancer agents and radiotherapy is understandable because p53 
protein mediates Gl arrest allowing for DNA repair, and induces the apoptotic 
pathway in cases with incorrect repair. Mutations in p53 or in the p53 pathway can 
produce resistance to many agents (reviewed by Johnstone et ai, 2002). However, 
p53 status is not a universal predictor of treatment response, in part because not all 
drugs require p53 for their apoptotic function (Lowe et ai, 1993; Herr and Debatin, 
2001), and in some settings p53 loss can enhance drug-induced cell death (Wahl et 
ai, 1996; Bunz et ai, 1999). Responses observed in tumours treated with 
radiotherapy and/or chemotherapy are complex, and the alteration of a single gene is 
unlikely to be able to fully explain all responses. 
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Mutations or altered expresslon of the BCL-2 family proteins have also been 
recognised as important factors involved in determining the sensitivity of tumours to 
radio- and chemotherapy. The anti-apoptotic factors BCL-2 and BCL-XL and the 
pro-apoptotic factor BAX have been investigated as possible prognostic indicators 
of radio- and chemo- sensitivity in tumours. 
In a study by Gallo et ai, 1996 BCL-2 protein expression was associated with less 
responsive and more aggressive tumours in early SCCHN, treated with radiotherapy. 
In addition, the SCCHN tumours expressing BCL-2 positivity showed a higher risk 
of recurrence and a poorer survival. In contrast, Homma et ai, 1999 reported that 
BCL-2 positivity predicts for a better loco regional control in SCCHN patients 
treated with concurrent chemoradiotherapy. This group observed no significant 
association between BAX or p53 expression and clinical outcome. Wilson et ai, 
1996 also reported that BCL-2 positivity in head and neck tumours correlated with 
improved local control and survival in comparison with non-expressing tumours, 
following continuous hyperfractionated accelerated radiation treatment (CHART). 
The majority (74%) of SCC tumours of the larynx examined by IRC in a study by 
Trask et ai, 2002 reported high levels of BCL-XL expression. However, it was the 
tumours with reduced expression of BCL-XL, which were associated with a 
complete response following chemotherapy. This group also reported that 15% of 
the SCC of the larynx samples analysed showed high levels of BCL-2, with 
approximately three-quarters of these tumours showing complete response following 
chemotherapy. In addition, 81% of the samples also showed high expression of the 
pro-apoptotic factor BAX, however, the tumours with reduced expression were 
associated with complete response to chemotherapy. Others contradict this, with 
reports that high BAX expression correlates with favourable prognosis in SCC of the 
oesophagus following post-operative chemoradiotherapy, however, the prognostic 
significance of BAX in patients receiving no adjuvant therapy was minimal 
(lkeguchi et ai, 2001). 
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1.13.1 Effect of Exogenous p53 Introduction on Radiotherapy and 
Chemotherapy 
The restoration of wildtype p53 function in tumour cells has been performed to 
determine if any enhancement in the effects of conventional cancer therapies or 
reductions in recurrence rate are achievable following combination therapy. A large 
literature on the combinational efficacy of p53 introduction with standard 
chemotherapy or radiotherapy schedules has reported contradictory responses. 
When SCC lines were infected with Ad-p53, and treated with cis-DDP, doxorubicin, 
5-FU, methotrexate, or etoposide, cell proliferation was reported to be inhibited 
more effectively than following chemotherapy alone (Gumani et ai, 1999). These 
authors also reported that the combination of Ad-p53 and 5-flurouracil (5-FU) 
resulted in greater anti-tumour activity within a S.C. SCC murine model, than when 
either agent was used alone. Fujiwara et ai, 1994 reported on an effective 
combination therapy for p53-negative lung tumours, using adenoviral delivery of the 
wildtype p53 gene in combination with cis-DDP. This group demonstrated enhanced 
treatment efficacy of preclinical S.c. tumour nodules over either treatment alone, 
with combination therapy resulting in partial tumour regression, and tumour size 
being statistically significantly smaller than those in any other treatment group. 
However, the presence of some conflicting reports, indicate that the relationship 
between p53 and chemoresistance may have a tissue or cell type-specific 
component, due to varying genetic backgrounds. Kimura et ai, 1997 investigated the 
in vitro sensitivity of different kinds of anticancer agents including cis-DDP, 
etoposide, 5-FU and paclitaxel on pancreatic carcinoma cells, and found that the 
chemosensitivity was not modulated by the expression of wildtype p53 gene. Kemp 
et ai, 200 I in an in vivo study of p53 induction and apoptosis in response to radio-
and chemotherapy, reported a striking variation in responses between different 
tumour types. Lymphomas showed high rates of p53 dependent apoptosis, whilst 
tumours of the skin, lung and liver showed little or no apoptosis. 
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Apoptosis is also considered to be a major molecular mechanism of radiation-
induced cell killing. Overexpression of apoptotic suppressing genes or down-
regulation of pro-apoptotic genes can potentially render tumour cells radioresistant 
(Hanna et af, 2001). Restoration of the wildtype p53 protein activity in a radiation 
resistant SCCHN cell line, possessing a mutated p53 gene, resulted in both growth 
inhibition and a reduction in the radiation resistance level of the cell line (Pirollo et 
af, 1997). Badie et af, 2000 also investigated the consequences of wildtype p53 
gene transfer on the cell cycle and radiosensitivity of a SCCHN cell line (SCC97) 
harbouring a p53 mutation. They concluded that when wildtype p53 was transferred 
into the SCC97 cells immediately after irradiation, a prolonged G2 arrest was 
observed in the majority of cells (80%), 48 hours after treatment, followed by 
massive apoptotic cell death. In addition, the G21M transition proteins cyclin A2 and 
cyclin B 1 were observed to decrease dramatically following p53 introduction and 
irradiation, as cells arrived in G2. These observations were not caused by viral 
infection or y-irradiation alone (Badie et af, 2000). 
1.14 Mechanisms of Action of the Chemotherapeutic Agents Cisplatin and 5-
Fluorouracil 
Apoptosis plays a major role in both the cytotoxicity induced by chemotherapeutic 
agents, and following radiotherapy (Lowe et af, 1993; Rupnow et af, 1998). It may 
be triggered by two major intracellular signalling cascades, the mitochondrial 
pathway and the death receptor pathway, both leading to caspase activation and 
cleavage of specific cellular substrates (Gadducci et af, 2002). A large number of 
proteins are involved in the initiation, regulation or inhibition of apoptotic death, and 
considerable cross talk between the mitochondrial and death receptor pathways is 
evident (reviewed by Johnstone et af, 2002). P53 plays a major role in apoptosis, 
and is capable of co-ordinating this process at multiple levels via several 
mechanisms (section 1.10). However, p53 is not the only activator of the apoptotic 
pathway, as is clear from studies showing that cells with p53 mutation may still die 
by apoptosis following chemotherapeutic intervention. The p53 family genes p63 
and p73 are both capable of inducing apoptosis and may be activated in the absence 
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ofp53 (section l.12). Members of the BCL-2 family of proteins can also be directly 
phosphorylated, for example BCL-2 in phosphorylated by MAP kinases; BAK and 
BAX can be activated directly following interaction with BID; whilst NOXA, 
PUMA, BAD and BIM can bind to the anti-apoptotic proteins BCL-2 and BCL-XL 
resulting in the activation ofBAX and BAK (reviewed by Johnstone et ai, 2002). In 
addition, Tsuji et ai, 2002 have demonstrated a p53-independent pathway of 
apoptosis by pI4ARF, which is insensitive to inhibition by MDM2. 
Cisplatin is one of the most widely prescribed anti-cancer agents, and has been 
found to be the most effective drug in the treatment of solid tumours including 
epithelial ovarian carcinoma and SCCHN (Aebi et ai, 1997). Reports state that 
cisplatin exerts its cytotoxicity by inducing apoptosis (Barry et ai, 1990), and that it 
can kill cells at any phase in the cell cycle, although there is now much evidence that 
it may be most effective in Gl of the cell cycle (reviewed by Donaldson et ai, 1994). 
The cytotoxicity of cis-DDP is via the formation of inter-and intra-strand cross-links 
in DNA, as a result of free platinum entering into the cells (Kim et ai, 2002). These 
alterations in DNA structure prevent replication and thus activates cellular repair 
mechanisms, which are thought to be the cause of eventual cell death, via apoptosis 
(reviewed by Aebi et ai, 1997). Kim et ai, 2002 provide evidence that cis-DDP 
mediated apoptosis is via a receptor signalling pathway, that is mediated by F AS 
with the subsequent activation of caspase 3 within the caspase cascade. 
Alternatively, the initiation of cytochrome c release from the mitochondria by the 
activation of pro-apoptotic BID is implicated in F AS-mediated apoptosis (Tsujimoto 
et ai, 2000). 
The F AS receptor and its ligand are expressed in many tissue and tumour types. The 
receptor is activated by binding to its ligand, resulting in the induction of apoptosis 
(reviewed by Murphy et ai, 1999). Inflammation is one factor that has been 
demonstrated to up-regulate FAS ligand expression (Waku et ai, 2000). 
The chemotherapeutic agent 5-FU is an anti-metabolite that can also induce cell 
death in a p53-dependent manner (Bunz et ai, 1999). The antitumour effect of 5-FU 
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can be exerted by the formation of ternary complexes with thymidylate synthase, 5-
10-methylene-tetrahydrofolate and fluorodeoxyuridine monophosphate, thereby 
inhibiting DNA synthesis, leading to cell death (Kim et aI, 2002). Reports have 
commented that p53-dependent p21WAF1 induction and cell cycle arrest occur at 
sublethal doses of chemotherapy, whereas at lethal doses of chemotherapy apoptotic 
death is observed, consistent with models proposing a relationship between the level 
of DNA damage versus survival or death (Wu and EI-Deiry, 1996). 5-FU has been 
reported to initiate a non-receptor-mediated pathway of apoptosis, by activating 
BAX and the subsequent mitochondrial pathway and caspase cascade (Kim et ai, 
2002; Tong et aI, 2002). 
1.15 Mechanism of Cell Death following Ultraviolet Light Exposure 
Studies investigating the apoptotic pathway activated following UV exposure have 
mainly highlighted the role of c-jun N-terminus kinase (JNK). The activation of 
JNK is thought to regulate apoptosis in a cell type and signal-specific manner 
(Hochedlinger et aI, 2002). In the stress activated JNK pathway, a wide range of 
stimuli, including UV light and osmotic shock, result in activation of the mitogen-
activated protein (MAP) kinase kinases, MKK4 and MKK7, which phosphorylate 
JNK (Basu and Kolesnick et aI, 1998). 
Apoptosis via the JNK pathway is probably caused through the phosphorylation of 
proteins regulating transcription or cell proliferation, as well as by direct or indirect 
activation of the caspase cascade. Recently it has been demonstrated that interaction 
between DAXX and F AS/CD95 can lead to apoptosis via the JNK pathway 
(Reviewed by Baker and Reddy, 1998). In addition, Tournier et ai, 2000 report that 
UV -induced apoptosis is mediated through mitochondrial cytochrome c release, 
influenced by pro-apoptotic signal transduction through the JNK pathway. 
Alternatively, JNK has been suggested to be able to signal apoptosis through the 
direct inactivation of BCL-2 (Maundrell et ai, 1997). In contrast to the above 
findings, Chouinard et ai, 2002 reported that UV induced a marked and persistent 
activation ofp38 MAP kinase pathway, whereas JNK was less activated. 
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1.16 Further Genetic Alterations Associated with Squamous Cell Carcinoma of 
the Head and Neck 
Cancer is a disease associated with powerful changes in the genome. Carcinogenesis 
is a complex multi-step process, involving genetic instability in a variety of 
biological pathways, with the degree of alterations differing within and between 
tumour types. The expression or inactivation of certain oncogenes and/or tumour 
suppressor genes associated with either the cell cycle or apoptotic pathways are 
frequently altered in SCCHN, along with the expression levels of growth factors, 
angiogenic regulators, and proteins involved in invasive and metastatic pathways of 
tumour progression. The major alterations in genetic mechanisms, in addition to 
p53, associated with the development of SCCHN are discussed below. 
1.16.1 Alterations in Cell Cycle Regulatory Genes in Squamous Cell Carcinoma 
of the Head and Neck 
The dysregulation of the molecular events governing cell cycle control is emerging 
as a major component of oral carcinogenesis. eye/in Dl, p16lNK4A, p27K1PJ and RB 
genes play a critical role in the regulation of the G I-S transition of the cell cycle as 
discussed in section 1.7.1. Human SCCHN show a high frequency of inactivation of 
at least one regulatory component of the RB cell-cycle pathway. In a study by 
Okami et ai, 1999 ninety-one percent of primary SCCHN contained at least one 
alteration in the p16lNK4A/cye/in DIIRB pathway. 
An inverse relation between the expression of p16INK4A and RB has been noted in 
many tumours (Busatto et ai, 1998). Pande et ai, 1998 studied the p 16INK4A/ pRB 
pathway in oral tumourigenesis, and reported that pRB was undetectable in 
approximately 65% of oral squamous cell carcinomas and pre-malignant lesions 
probably as a result of inactivation of the RB gene. Accumulation of p16INK4A 
protein was observed in nearly all the pRB negative cases. Another member of the 
RB family, RB2/p130 has been shown to be down-regulated in oral SCC, correlating 
with tumour grading and with poor patient outcome (Paggi et aI, 2001). 
High frequencies of somatic homozygous deletions and mutations affect p16lNK4A in 
SCCHN. Gene silencing ofpJ6lNK4A by methylation is also a common mechanism 
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of gene inactivation in SCCHN (Reed et ai, 1996). It is thought that loss of 9p, the 
chromosomal location ofpJ6INK4A is an early event in the development ofSCCHN 
(Lai and EI-Nagger, 1999; Shahnavaz et ai, 2001). 
Overexpression of cyelin DJ, a Gl cell cyele regulator, is often found in many 
different tumour types, with amplification of the l1q13 region, where the cyc1in DJ 
gene is located reported in as many as 71% ofSCCHN (Arber et ai, 1999; reviewed 
by Martin et ai, 1999). Cyelin D 1 amplification has been observed to frequently 
coexist with the loss of p 16INK4A, suggesting an additional role for this amplification 
in SCCHN (Okami et ai, 1999). Cyelin Dl has been reported to be a late event in the 
development of oral malignant disease (Schoelch et ai, 1999). The overexpression of 
this protein is often associated with a poor prognosis or recurrence (Michalides et ai, 
1995). 
The p2rJP1 gene is a CKI, which regulates progression from the Gl to the S phase 
of the cell cyele by binding to, and inhibiting the activity of a broad range of cyelin-
CDK complexes required for entry into S phase. A study of oral carcinomas and pre-
cancer found that p27KIPl was significantly reduced both in oral dysplasias and 
carcinomas compared with that in normal epithelial controls (Kudo et ai, 2000). In 
addition, there was a significant reduction in p27K1P1 protein expression between 
low- and high-grade dysplasias, suggesting that changes in p27K1P1 expression may 
be an early event in oral carcinogenesis (Kuo et ai, 2002). In a study by Venkatesan 
et ai, 1999 low levels of p27KIPl expression correlated significantly with 
unfavourable treatment response, shorter overall survival, and shorter disease-free 
survival. In addition, Fujieda et ai, 1999 found that the incidence of spontaneous 
apoptosis is significantly influenced by expression of p27KIPI in oral and 
oropharyngeal SCC, suggesting that regulation of cell cycle progression by p27K1P1 
enhances induction of apoptosis in cancer cells. Studies also showed that this is 
through elevation of BAX expression, which is located, comparatively downstream 
in the apoptotic pathway. Fujieda et ai, 1999 showed that ectopic over-expression of 
p27KIPl in cancer cells induces apoptosis and perhaps slows down the progression of 
oral and oropharyngeal Sec. 
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1.16.2 Alterations in Apoptotic Regulatory Genes in Squamous Cell Carcinoma 
of the Head and Neck 
In addition to mechanisms, which increase cell growth and proliferation, the 
inhibition of cell death by apoptosis is an important pathway in the development of 
cancers. The inhibition of apoptosis is a frequent and important event in the 
pathogenesis of SCCHN. In addition to the major role of p53 mutation in the 
inhibition of apoptosis, approximately 70% of SCCHN tumours demonstrate up-
regulation ofBCL-2 and BCL-XL, potent negative regulators of apoptosis (Pena et 
ai, 1999). The proportion of SCCHN samples in which BCL-2 can be seen by 
immunochemical staining is between 50% and 75%, although others have detected 
expression of this protein only rarely (Scoelch et ai, 1999a; reviewed by Gibson et 
ai, 2000). When present, it is generally more prevalent in the poorly differentiated 
tumours. In normal oral mucosa, BCL-2 is not detectable, or is expressed only 
occasionally in the basal cells (Jordan et ai, 1996). 
As discussed in section 1.13 members of the BCL-2 family have been analysed to 
predict radio- and chemo-sensitivity in tumours. Salo et ai, 1997 reported that 
SCCHN cell lines that over-expressed BCL-2 were often radioresistance. In some 
tissues, such as those of the thyroid gland, stomach, breast and colon, 
overexpression of BCL-2 protein has been associated with better tumour 
differentiation, early stage disease, and partly with a more favourable clinical 
outcome. In contrast, reports on carcinomas of the urinary bladder, prostate, 
gallbladder, and head and neck suggest that overexpression of BCL-2 is linked to 
high histology grade, tumour progression, and/or poor prognosis (reviewed by 
Jackel et ai, 1999). Pena et ai, 1999 contradict these observations, with their data 
suggesting that expression of BCL-2, but not BCL-XL, was correlated with 
improved disease specific survival. Patients whose tumours demonstrate BCL-2 
positivity, even with Iocoregionally advanced disease, appear to have a higher 
likelihood of cure, following aggressive combined modality therapy, and may 
therefore be treated successfully with less toxic therapy. 
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Other members of the BCL-2 family have been investigated for their role in the 
development of SCCHN. Schoelch et ai, 1999a reported that apoptosis-associated 
proteins are altered in variable patterns in both premalignant and malignant SCCHN 
tumours. Both BCL-X and BAK were evident in premalignant, and especially 
malignant lesions. BCL-XL has been demonstrated to effectively inhibit the pro-
apoptotic function of BAK. In addition, BCL-X was expressed in all stages of 
SCCHN disease progression, and correlated with BAK expression. BCL-2, BAX 
and MDM2 were found to be occasionally expressed in oral premalignant lesions 
and oral SCCs, suggesting dysregulation of normal apoptotic function (Schoelch et 
ai, 1999a). 
1.16.3 Alterations in Oncogene Expression in Squamous Cell Carcinoma of the 
Bead and Neck 
It is believed that activating mutations in the RAS genes contribute to the formation 
of some 30% of human malignancies (Bos, 1989). The RAS genes encode four 21 
kDa proteins, called p21ras or RAS (B-, N-, KA-, and KB-RAS). These proto-
oncogenes are involved in signal transduction pathways, where the binding of 
guanosine triphosphate (GTP) promotes cell proliferation. The GTPase activity of 
RAS then inhibits the biological event induced. In cancer, mutation of the RAS gene 
results in the inhibition of GTPase activity, and the continual stimulation of cell 
growth, and inhibition of apoptosis (Fahraeus et ai, 1999). RAS mutations have been 
infrequently identified in the Western World whereas RAS over-expression has been 
a common finding and may be associated with the early development of head and 
neck cancer (Kiaris et ai, 1995). McDonald et ai, 1994 performed IHC analysis on 
SCCHN tissue samples to detect expression of H-RAS, K-RAS and N-RAS. They 
reported that 15/22 (68%) stained positive for H-RAS, 10/22 (45%) for K-RAS and 
7/22 (32%) for N-RAS. However, this group discusses how the overexpression of 
members of the ras gene family may be an important event in the later stages of 
SCCHN tumourigenesis. 
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The C-MYC oncogene is involved in the control of differentiation and proliferation. 
In human tumours, the overexpression of C-MYC is commonly seen as a result of 
gene amplification or chromosome translocation. Decreased expression of C-MYC 
blocks proliferation, whilst overexpression results in undifferentiated cells and 
continual proliferation (Minden et ai, 1992). Amanullah et ai, 2002 observed that 
deregulated expression of C-MYC in normal and leukaemic myeloid cells blocked 
differentiation, and concomitantly induced p53-independent apoptosis via the 
F AS/CD95 pathway. In a study to establish the frequency of MYC amplification in 
SCCHN, Rodrigo et ai, 1996 reported that 6/59 (11%) of samples showed 
amplification, frequently associated with advanced primary tumours, suggesting that 
MYC amplification is a late event in the tumourigenesis of SCCHN. This 
overexpression of C-MYC has been reported to be correlated with a poor prognosis 
for SCCHN patients (Field, 1992). 
1.16.4 Alterations in Factors Regulating Tumour Invasion, Metastasis and 
Angiogenesis in Squamous Cell Carcinoma of the Head and Neck. 
The process of angiogenesis is required by tumours to allow growth beyond a 
critical size, and metastasis to other organs. Squamous carcinomas of the head and 
neck are highly invasive and show a high frequency of locoregional metastasis 
(Leemans et ai, 1994). 
Vascular endothelial growth factor (VEGF) is a potent factor involved m 
angiogenesis. Tumour hypoxia and oncogenes up-regulate VEGF levels III 
neoplastic cells (Shweiki et ai, 1992), with up-regulation being correlated with an 
increased risk of metastasis (Weidner, 1995). Up-regulation ofVEGF-A and VEGF-
C are common occurrences in SCCHN and appear to play a vital role in the 
metastatic process of this disease (O-Charoenrat et ai, 2001 a). 
Members of the epidermal growth factor receptor (EGFR) family are frequently 
over-expressed in SCCHN tumours. Transforming growth factor-a. and EGFR are 
up- regulated early in the development of SCCHN (Grandis and Tweardy, 1993). 
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Aberrant expression of tyrosine kinases such as c-erbB-2 and c-erbB-3 as well as 
EGFR contributes to the progression of SCCHN. Amongst these, EGFR appears to 
be the dominant component controlling the invasive and angiogenic phenotype in 
SCCHN via up-regulation of multiple MMPs and VEGFs (O-Charoenrat et ai, 
2002). 
The MMPs are involved in tumour invasion, being capable of disintegrating the 
basement membrane, which is a main characteristic of tumour invasion. Matrix 
metalloproteinases -2, -3, -7, -8, -9, -10, -11 and -13 have been shown to be highly 
expressed in SCCHN (O-Charoenrat et ai, 2000; Kuropkat et ai, 2002; O-Charoenrat 
et ai, 2002). 
1.17 Neo-Angiogenesis 
As discussed in section 1.1 an essential element of malignant growth is 
angiogenesis, since the diffusion limit of oxygen dictates that viable cells need to be 
located within 100-200 ~m of a blood vessel. For tumours to grow, an appropriate 
rate of blood vessel formation in relation to the rate of neoplastic cellular 
proliferation is required, otherwise, tumour necrosis and eventual calcification result 
(reviewed by Claudio et ai, 2001). This process is regulated by a balance between 
pro-and anti-angiogenic molecules, and is derailed in various diseases, especially 
cancer (Carmeliet and Jain, 2000). Factors that trigger the angiogenesis include 
metabolic stress (low p02, low pH or hypoglycaemia), mechanical stress (pressure 
generated by proliferating cells), immune/inflammatory response, and genetic 
mutations (activation of oncogenes or deletion of tumour suppressor genes that 
control production of angiogenic regulators, reviewed by Carmeliet and Jain, 2000). 
A range of factors must be initiated in a complementary and co-ordinated fashion in 
order for the formation of a well-functioning blood vessel. In normal tissue, 
endogenous angiogenic inhibitors such as platelet factor 4, thrombospondin (TSP-I), 
brain-specific angiogenesis inhibitor (BAIl), angiostatin, and endostatin 
constitutively suppress angiogenesis. However, as cells undergo malignant 
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transformation, angiogenic mitogens, which include basic fibroblast growth factor 
(bFGF), VEGF, the angiopoietins (ANG-l), the ephrins and PDGF, become 
dominant, which causes the aberrant angiogenesis (Hanahan and Folkman, 1996). 
VEGF plays a central role in tumour angiogenesis, as it is required to initiate the 
formation of immature vessels. However, on its own it forms leaky, immature and 
unstable vessels (Yancopoulos et ai, 2000). Increased VEGF expression seems to 
correlate with p53 status, especially for p53 mutations. Linderholm et ai, 2001 
reported that the highest VEGF values were detected in tumours withp53 insertions, 
deletions, and stop codon mutations. This might indicate that angiogenesis, at least 
in part, is regulated by p53 function. A lack of adequate blood supply leads to 
tumour hypoxia and probably accounts for tumour cell apoptosis and the up-
regulation of VEGF and VEGFR. Nishizaki et al 1999 demonstrated that wildtype 
p53 gene transfer down-regulated the increased amount ofVEGF expression and up-
regulated the angiogenic inhibitor BAIl expression in mutant p53-expressing human 
non small cell lung carcinoma (NSCLC) cells. These changes caused the inhibition 
of in vivo tumour angiogenesis. Wildtype p53 protein has been shown, in cell lines, 
to suppress angiogenesis via regulation of the angiogenic inhibitor TSP-1 expression 
and to down-regulate the promoter activity of the pro-angiogenic factor VEGF in a 
dose-dependent manner (Linderholm et ai, 2001). 
1.18 The Tumour Vasculature 
Tumour vessels are structurally and functionally abnormal. Analysis by electron 
microscopy shows that in contrast to normal vessels, tumour vasculature in general 
is highly disorganised, vessels are tortuous and dilated, with uneven diameter, 
excessive branching and shunts. In addition, some vessels have an incomplete 
basement membrane and an abnormal pericyte coat. Other abnormalities include 
unusually avid binding and uptake of cationic liposomes, and expression of 
integrins, growth factors, and receptors that differ from those of normal vessels 
(reviewed by Hashizume et ai, 2000). This may be due to an imbalance of 
angiogenic regulators, such as VEGF and angiopoietins. In terms of their 
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ultrastructure, tumour walls have numerous 'openings' (endothelial fenestrae, 
vesicles and transcellular holes), widened inter-endothelial junctions, and a 
discontinuous or absent basement membrane. In addition, the endothelial cells are 
abnormal in shape, growing on top of each other and projecting into the lumen. 
These defects make tumour vessels leaky. However, there is tremendous 
heterogeneity in leakiness between different tumour types, over space and time and 
in response to treatment (reviewed by Carmeliet and Jain, 2000). Tumours are 
shown to have a characteristic pore cut-off size, the majority ranging between 380 
and 780 nm (Hobbs et ai, 1998). Tumour blood flow is chaotic and variable and 
leads to hypoxic and acidic regions in tumours, which acts as a potential barrier to 
the effective delivery of blood-borne agents (Jain, 1998). The movement of 
molecules and particles depends on their size, charge and configuration, and the 
physico-chemical properties of the interstitium. Viral and non-viral particles and 
liposomes due to their relatively large size may have trouble-penetrating tissue. 
Therefore, quantitative measurements of parameters characterising transport of 
molecules, particles and cells of different size, charge and configuration in different 
tumour types growing in various host organs are urgently needed. 
The search for specific markers of angiogenic vessels has identified certain 
molecules, for example the a.vJ33 integrin, and the ED-B domain of fibronectin as 
possible candidates, although these are not always ideal (Tarli et ai, 1999). Carson-
Walter et ai, 2001 report on the identification of tumour endothelial markers 
(TEMS) which display elevated expression during tumour angiogenesis. TEM1, 
TEM5 and TEM8 elevated expression on tumour endothelium in humans and mice 
makes these genes attractive markers for studying angiogenesis, along with their 
potential for targeting in anti-angiogenic therapies. 
1.19 Tumour Hypoxia 
Solid tumours require neovascularization and increased glycolysis for growth. 
Evidence supporting this statement includes the observations that clonal expansion 
of cancer cells depends on enhanced glucose transport and glycolysis (reviewed by 
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Zhong et ai, 1999), and that tumours cannot grow beyond a few mm3 without 
angiogenesis because of limited diffusion of 02, glucose, and other nutrients 
(Hanahan and Folkman, 1996). Squamous cell carcinomas of the head and neck 
tumours have been reported to be relatively hypoxic (Gatenby et ai, 1988; Evans et 
ai, 2000). This hypoxic characteristic of SCCHN could potentially be exploited to 
increase tumour-specific killing. 
Hypoxia occurs early in tumour development and provides a major selection 
pressure for mutations that provide a survival advantage under hypoxic conditions 
(Aebersold et ai, 2001). Brown, 1999 discusses how hypoxia selects for mutated 
p53, predisposing tumours to a more malignant phenotype. In many cancers, the 
degree of vascularisation is inversely correlated with patient survival. In addition, 
the probability of invasion, metastasis, and death has been reported to be positively 
correlated with the degree of intra-tumoural hypoxia (Hockel et ai, 1996). 
Brown and Giaccia, 1998 discussed how tumour hypoxia is associated with 
resistance to chemotherapy, immunotherapy, and radiotherapy. A number of reports 
have demonstrated a relationship between the p02 of SCCHN tumours and 
metastases and the response to radiotherapy (Nordsmark et ai, 1996; Brizel et ai, 
1997). In cancers, hypoxic regions are resistant to chemo- or radiation therapy yet 
also harbours zones of enhanced apoptosis (Elson et aI, 2000). The biological effects 
of radiation and chemotherapy are influenced by oxygen. Sensitivity to radiation is 
approximately three-fold lower in severely hypoxic cells, compared to those in 
normoxic conditions (Brown, 1999a). However, in a solid tumour in vivo, a number 
of factors associated either directly or indirectly with tumour hypoxia contribute to 
resistance to anticancer drugs (Brown, 1999a). It is important to note that 
specifically killing the hypoxic cells in tumours has greater therapeutic potential 
than oxygenating the cells, since this removes only the cells resistant to radiation or 
chemotherapy thereby producing complementary cytotoxicity (Brown, 1999). 
Hypoxia alters the activity of selected transcriptional factors including the hypoxia 
inducible factor (HIF-l), JNK and p53 (Elson et aI, 2000). Hypoxia is a 
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physiological modulator of p53 and uses p53 to mediate apoptosis. Increased 
apoptosis in response to hypoxia has been demonstrated to lead to the selection of a 
clonal population of cells with inactive or mutant p53 protein, resulting in a more 
malignant phenotype (Alarcon et ai, 1999; Koong et ai, 2000). The mechanism by 
which hypoxia induces p53 protein levels involves both the disruption of MDM2-
mediated nuclear export and the concurrent inhibition of E6IE6AP-mediated 
degradation (Alarcon et ai, 1999). The normal p53 protein can also stimulate the 
expression of genes that prevent angiogenesis. Cells in which p53 is inactivated by 
mutation would therefore, be more likely to recruit new blood vessels, providing a 
critical growth advantage at a late point in tumour development. Wildtype p53 may 
also decrease tumour cell growth by reducing the expression of the angiogenic factor 
VEGF, or by increasing the expression of an anti-angiogenic factor, resulting in 
reduced neovascularisation in vivo. Any rise in circulating angiogenesis inhibitors 
might also inhibit the growth of remote metastases. Hypoxia is known to stimulate 
angiogenesis and it may be that angiogenic tumours are hypoxic (West et ai, 2001). 
1.19.1 Therapeutic Approaches that take Advantage of the Hypoxic Nature of 
Tumours 
Many groups are investigating therapeutic approaches that utilise the hypoxic nature 
of tumours. Targeting some of the specific hypoxia-induced proteins such HIF-l, or 
using hypoxia to obtain tumour-specific gene expression for gene therapy are two 
such strategies (Brown, 1999). HIF-la is a transcription factor that plays a critical 
role in regulating genes involved in erythropoiesis, oxygen homeostasis and 
angiogenesis. HIF-la is the specific and oxygen-regulated subunit of HIF-I. It 
accumulates during hypoxia because of inhibition of its proteolytic degradation 
through the ubiquitin proteasome pathway. HIF-la protein is ubiquitinated and 
degraded in normoxia but stabilised in hypoxia. Recent evidence indicates that both 
the VHL tumour suppressor protein and p53 have been shown to bind HIF-la and 
may contribute to its degradation under normoxic conditions, by recruiting ubiquitin 
ligases such as Cullin homolog-l (CUL-l) or MDM2, respectively. Hypoxia induces 
a post-translational modification in HIF-la that affects its binding to VHL (Elson et 
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ai, 2000; Yu et ai, 2001; Will am et ai, 2002). Increased HIF-J activity leads to 
transcription of a large number of genes, the protein products of which, either 
mcrease oxygen availability or mediate metabolic adaptation to reduce oxygen 
tension. Included among these are erythropoietin, glucose transporters, glycolytic 
pathway enzymes, VEGF, heme oxygenase, and inducible nitric oxide synthase 
(Wiesener et ai, 2001; Aebersold et ai, 2001). HIF-l-regulated genes contain a 
hypoxia response element (HRE), a cis-acting transcriptional-regulatory element 
that includes one or more binding sites for HIF-l (Semenza, 2000). HIF-la may 
play an important role in human cancer progression (Zhong et ai, 1999), since its 
expression has been correlated with aberrant p53 accumulation and ce)) 
proliferation. 
The use of hypoxic cytotoxins in therapy could be exploited in preclinical SCCHN 
models. The recent development of new drugs that are non-toxic until they are 
activated in the hypoxic cell provides new options for therapy. Constructs containing 
HREs can be induced under hypoxic conditions to produce prodrug-activating 
enzyme systems with a differential toxicity against hypoxic cells. For example, the 
HREs and the prodrug activation system, cytochrome P450 reductase, have been 
used to activate the bioreductively-activated prodrug tirapazamine (Waxman et ai, 
1999). Using this system, IDF-l in hypoxic cells can bind to the HRE in a vector 
and activate the expression ofP450 (Griffiths et ai, 2000). Production of cytochrome 
P450 enzyme activates the prodrug cyclophosphamide (which can be given orally 
and has good activity against head and neck cancer, Brockstein et ai, 1999) and 
converts it to its active metabolite, 4-hydroxy-cyclophosphamide. As the active 
metabolite can diffuse through cell membranes and is intra-cellularly converted to 
phosphoramide mustard it thereby causes damage to DNA. This active metabolite 
diffuses readily, aiding in the very significant bystander effect seen with this 
particular gene directed enzyme prodrug therapy GDEPT approach (Waxman et ai, 
1999; Griffiths et ai, 2000). 
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1.20 Gene Therapy for Head and Neck Cancer 
Gene therapy has the potential to revolutionise medicine, since the transfer of vital 
genes into cells with absent or malfunctioning gene products, can be used to 
alleviate the pathogenesis or cure a variety of diseases, rather than merely treating 
the symptoms. In recent years, advances in the field of molecular biology have 
resulted in the identification of therapeutic gene products for a wide range of 
diseases, including cancer, AIDS, cystic fibrosis, Parkinson's disease and 
Alzheimer's disease. By far the largest area of research involving gene therapy is in 
cancer, perhaps due to the vastly improved understanding of its genetic basis. A 
variety of genes controlling molecular processes in cancer can be potentially utilised 
in gene therapy protocols. These can be broadly divided into those that (a) suppress 
the expression of an oncogene; (b) restore a defective tumour suppressor gene; ( c) 
enhance immune surveillance; (d) activate pro-drugs into active agents (GDEPT). 
These therapies bring about a range of outcomes including in principal, arrest of: 
tumour growth; angiogenesis; invasion; and/or metastasis (Ganly et ai, 2000). 
When treating head and neck cancer, direct gene transfer to minimal residual 
carcinoma may not be technically difficult. When the primary tumour is removed, 
the surrounding tissue that may harbour residual tumour is readily accessible for 
molecular therapy. Direct injection of the molecular therapeutic into the surgical 
resection bed and resection margins may prevent loco-regional recurrence. 
Alternatively, direct tumour injection with gene therapy agents could be used in 
cases of loco-regional recurrence, such as into the lymph nodes of the neck. 
Although patients can potentially benefit from local-regional therapy, systemic 
antitumoural efficacy may have a much greater impact on overall cancer-related 
mortality, by targeting distant metastatic disease (Ganly et ai, 2000; Heise et ai, 
2000). 
As discussed in section 1.16 of the introduction a range of genetic alterations have 
been associated with SCCHN, and many of these could be candidates for gene 
therapy approaches. However, the restoration of normal p53 gene function appears 
to be the most obvious and promising approach since one or both copies of this gene 
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is deleted or mutated in approximately 60010 of head and neck cancers. Additionally, 
it is also the most commonly mutated gene in human cancers generally. The 
correction of the mutated p53 gene is usually sufficient to cause apoptosis, with no 
adverse effect on normal cells (Liu et aI, 1994~ Overholt et aI, 1997). 
The primary factor hampering the wide-spread application of gene therapy to human 
disease is the limitations in the efficiency of gene delivery and the levels of gene 
expression achieved, to be able to induce complete tumour regression or restore 
genetic health. However, as these obstacles are overcome, we expect that gene 
therapy will become a standard part of the practice of oncology. Its initial uses are 
likely however, to be in combination with pre-existing clinical regimens such as 
chemotherapy and radiotherapy (O'Malley et ai, 1996; Vile et ai, 2000). 
1.21 Vector Delivery Systems 
No single vector can provide all the positive features required for the many 
applications of gene therapy. The choice of vector systems for delivery and 
expression of genes into cells depends on a number of factors. A brief account of 
the main advantages and disadvantages, of the most commonly used vector systems 
are given here. 
1.21.1 Non-Viral Vectors 
The simplest approach to non-viral delivery systems is direct gene transfer with 
naked plasmid DNA. The main advantages of this technique lie in its simplicity, 
both in generating the DNA and its safe administration. Theoretically there are no 
limitations for the size of the insertion, since plasmids can carry up to 35 kb of 
insert. In addition, since they have no viral coat associated with them, naked DNA 
is generally not subject to neutral ising antibody reactions (Restifo et ai, 2000). 
Hence, repeated administration of DNA is possible. The majority of studies using 
naked DNA has been devoted to restoring gene function in skeletal muscle, to 
correct muscle disorders such as muscular dystrophy, where genes have been shown 
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to be expressed for more than two months (Wolff et ai, 1990). However, studies 
into this form of gene transfer have included tumours, various epithelia or 
endothelia, and organs such as the liver, heart, or brain (Mir et ai, 1999). However, 
the major disadvantage in this approach is that gene expression is low in comparison 
with some viral vector delivery systems. 
Several approaches have been developed to enhance the efficiency of gene transfer 
via naked DNA including use of a gene gun and electroporation (Aihara et ai, 1998; 
Mir et ai, 1999). These physical methods allow DNA to directly penetrate the cell 
membrane, by the temporary opening of pores in the membrane, and to bypass the 
enzymatic degradation caused by endosome/lysosome (Aihara et ai, 1998; Mir et ai, 
1999). The gene gun approach allows DNA to reach the nucleus directly (Li and 
Huang, 2000). 
Although gene expression can be achieved by direct intra-tissue injection of naked 
DNA, other routes of administration such as intravenous (iv), generally require the 
use of a delivery vector. Among the non-viral vehicles, cationic lipids, and 
polymer-based systems have been the most extensively studied (Chillon et ai, 1998; 
Mortimer et ai, 1999). This vector delivery system takes advantage of the fact that 
cells often take up compounds that are enclosed by lipid preparations that somehow 
mimic the cell membrane. Cationic lipidlDNA complexes have been used in several 
clinical trials for the treatment of cancer and cystic fibrosis (reviewed by Alton et ai, 
1997; reviewed by Scheule, 1998; reviewed by Li and Huang, 2000), with data 
indicating that local delivery at relatively low doses were safe. However, a 
drawback of this system of delivery includes its relatively short duration of gene 
expression (Li and Huang, 2000), although in certain areas such as oncology this 
may be all that is required. Additionally, experiments have highlighted the 
discrepancy between in vitro and in vivo transfection conditions, hence, optimisation 
is needed for each differing clinical situation (Li and Huang, 2000). 
Oligonucleotide based therapy works on the principle of targeting episomal or 
chromosomal gene mutations for correction by mismatch repair. This involves the 
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delivery into diseased cells of a chimeric RNA: DNA oligonucleotide. This 
molecule is designed to align perfectly with a specified genome target, with the 
exception of a single base pair mismatch. This mismatch is recognised by the 
endogenous DNA repair system, resulting in the alteration of the DNA sequence of 
the target gene, correcting the mutation (Li and Huang, 2000). Igoucheva et ai, 
2001 reported that gene correction required an optimal length of nucleotides, with 
homology in at least 45 of the nucleotides. In addition, gene correction using 
antisense oligonucleotides showed a 1000-fold higher correction frequency than 
when sense oligonucleotides were used. This could be explained by the strand 
separation during transcription, which causes opening of the chromatin allowing 
increased accessibility to the non-transcribed strand, while the transcribed strand 
may be occupied by the RNA polymerase and accessory proteins (Igoucheva et ai, 
2001). The oligonucleotide can fonn complexes with cationic lipids and can also 
include a targeted ligand specific for a particular tumour cell associated molecule to 
make the vector tissue specific (Miller et ai, 1995). It is possible to infuse high 
doses of oligonucleotides without significant side effects. However, the current 
drawback of oligonucleotides is a short half-life and the high cost of these reagents, 
although they might be practical for limited local use. 
1.21.2 Viral Vectors 
Many viruses can be adapted for use as vectors for gene therapy. Currently, the 
retrovirus, adenovirus (Ad) and herpes simplex viruses (HSV) are the most 
commonly studied viral vector systems. However, there is also much interest in the 
delivery roles of the lentiviral family, the adeno-associated viruses (AA V), and the 
replication competent adenoviruses. To date, our studies have taken advantage of 
the features of the adenovirus vector system, and more detailed analysis of its 
characteristics are given in section 1.21.2.1. 
The retroviral vectors are widely used in gene therapy studies, probably due to its 
ability for }ong-tenn, stable gene expression, possibly as a result of its integration 
into the host cells chromosome. Such permanent integration into the target cell 
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genome may be an advantage for treating diseases that require long-term expression, 
although this may not be necessary to eliminate tumour cells. Retroviruses have a 
low immunogenic profile, since they do not transfer virus-derived coding sequences 
to the target cell. Another plus point is the large cloning capacity available 
(approximately 10 kb, Trono, 2000). A theoretic drawback of retroviruses is that the 
virus-coded genome integrates randomly into the host. Another major theoretical 
limitation of retroviruses is their ability to integrate only into actively dividing cells. 
Further only relatively low viral titres can be produced, when compared to 
adenovirus (Douar et ai, 1997). Most research on recombinant retroviral vectors for 
gene therapy has focused on the small RNA molony murine leukaemia virus 
(MoML V, Miller et ai, 1995). The virus has a small RNA genome consisting of 
three open reading frames, designated gag, pol and envelope, together with a 
packaging sequence (psi, \jI). These are flanked at each end by long terminal repeats 
(LTR) which act as promoters for the genes down-stream, and are used by the virus 
to integrate its genome into the chromosomes of infected cells (Miller et aI, 1995). 
The herpes viruses are large enveloped viruses containing double stranded DNA 
genomes Glorioso et ai, 1995). The herpes simplex virus 1 (HSV -1) is the most 
studied member of this family of viruses. A significant proportion of the population 
carry HSV since it is associated with the common cold sore. This may be an 
excellent vector for transfer of genetic material to the oral mucosa, since the virus 
infects these tissues as a natural target. The viruses can carry large inserts and can 
infect non-replicating cells (Glorioso et ai, 1995). A major approach in the 
production of HSV vectors is the use of amplicons. Amplicons are bacterially 
produced plasmids containing col El ori (an Escherishia coli origin of replication), 
OriS (the HSV-l origin of replication), HSV-l packaging sequence, the transgene 
under control of an immediate-early promoter and a selectable marker (Federoff et 
ai, 1992). The amplicon is transfected into a cell line containing a helper virus (a 
temperature sensitive mutant) which provides all the missing structural and 
regulatory genes in trans. Both the helper and amp Ii con containing viral particles 
are delivered to the recipient. 
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The main therapeutic approach using HSV vectors, is the transduction into tumour 
cells of a 'suicide' gene, namely the thymidine kinase (tk) gene. In the presence of 
thymidine kinase, ganciclovir (GCV) is phosphorylated to a toxic nucleotide 
analogue, which inhibits DNA replication (Izquierdo et aI, 1996). Rapidly dividing 
cells were more effectively killed than slowly dividing cells (reviewed by Esandi et 
aI, 1997). One extremely useful component of this approach is the finding that non-
transduced cells can also be killed in a process termed the 'bystander effect'. Toxic 
GCV metabolites transferred through gap junctions linking neighbouring cells has 
been proposed as one possible mechanism of bystander killing (Fick et ai, 1995; 
Chen et aI, 1995; Ishii-Morita et aI, 1997). A further advantage of this approach is 
the option of limiting the treatment with GCV, and thereby reducing the toxic 
activity in the cells. 
The lentiviral family includes the human-, feline- and simian-immunodeficiency 
viruses (HIV, FIV, and SIV respectively), along with the equine infectious anaemia 
virus (EIAV, Miller et aI, 1995; Crystal, 1999; Trono, 2000). These viruses possess 
most of the characteristics of the oncoretroviruses, showing long-term stable gene 
expression, and the absence of inflammatory or vector specific immune responses. 
In addition these viruses can replicate in non-mitotic cells (Trono, 2000). 
Gene therapy studies using AA V have expanded rapidly of late. These single 
stranded DNA parvovirus vectors provide long-term gene expression, integrating 
stably into the long arm of chromosome 19 (Kotin et ai, 1992). They have the 
potential ability to infect non-dividing cells, and show no immune response to vector 
transduced cells and little patient toxicity (Kaplitt et aI, 1994). In addition, recent 
advances in production techniques have improved titre levels of this virus (reviewed 
by Monahan et ai, 2000). The viral genome is extremely small, having only two 
open reading frames, rep and cap, together with another essential sequence 
designated /ip. The genome has three promoters and is flanked by repeat sequences. 
However, these viruses require a helper virus, usually an adenovirus or herpes virus, 
for lytic replication of the AA V genome. This carries the risk of helper virus 
contamination within final recombinant AA V stocks (Qazilbash et ai, 1997). A 
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potential problem associated with AA V is the small packaging capacity «5-kb). 
Predicted beneficial niches for AA V vectors include, areas where long-term 
expression of secreted proteins is required; in certain quiescent tissues such as the 
brain and the muscle; and in tissues that cannot tolerate even minor amounts of 
inflammation (reviewed by Monahan et ai, 2000). 
Replication-competent VIruses have the advantages that even if transduction 
efficiency is initially low, amplification occurs with subsequent cycles of infection 
and lytic destruction of cells. Several viruses that only replicate in tumour cells have 
been developed, and take advantage of the difference between normal and tumour 
cells to destroy tumour tissue. For example, a strain of adenovirus deleted for the 
EIB-55 kD gene, d11520 (ONYX-015, also known as CI-1042) has been developed 
for the treatment of tumours lacking p53 function. The EIB-region of the 
adenovirus vector is responsible for binding and inactivating p53 (Barker and Berk, 
1987). It was therefore hypothesised that an adenovirus lacking EIB, 55kD gene 
expression might be severely limited in its replication capability in normal cells 
(Heise et ai, 1997). In contrast, cancer cells lacking functional p53 would be 
expected to be sensitive to viral replication and subsequent cytolysis (Bischoff et ai, 
1996; Heise et ai, 1997). However, recent studies have questioned the specificity of 
the ONYX-OI5 vector for p53 mutated cells, with multiple groups demonstrating in 
vitro that ONYX-OIS can lyse tumour cells having a wildtype or mutant p53 status 
(reviewed by Rogulski et ai, 2000). Rogulski et ai, 2000 offers an explanation for 
these findings as the use of heterogeneous cell lines in these experiments, with 
diverse genetic backgrounds, so factors other than the p53 status could be involved 
in the outcome. 
Similarly, the EIA adenoviral protein inhibits the tumour suppressor pRB, which is 
frequently lost during tumourigenesis. Adenoviral vectors deleted of the E 1 A-
region have been shown to demonstrate significantly greater potency than EIA-
containing adenoviral vectors, both in vitro and in vivo (reviewed by Heise and Kim, 
2000). 
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1.21.2.1 Adenovirus Vectors 
Human adenoviruses comprise a family of at least 47 different serotypes. They are 
associated with a variety of clinical conditions, the most frequent of which is the 
common cold. Around 5-10% of patients with respiratory disease shows evidence of 
adenovirus infection (Searle and Mautner, 1998). 
Adenoviruses are medium sized (90 nm diameter) non-enveloped double-stranded 
linear DNA viruses, the genome of which is approximately 36 kb, consists of a 
unique sequence flanked at each end by a single copy of an inverted terminal repeat 
(ITR). These sequences are essential for virus replication and therefore, must be 
conserved in any vector. Deletion of the E3 region, which is involved in evading the 
host immune system, can be replaced with approximately 4 kb of foreign DNA, with 
the additional removal of the EI and E4 regions, up to 8 kb of foreign DNA can be 
inserted. Vectors with additional viral genes removed have been made in order to 
address the problem of an inflammatory response. E2A-deficient vectors which do 
not express the DNA binding protein (DBP) essential for DNA replication appear to 
be substantially less immunogenic and show improved transgene persistence and 
decreased inflammatory response in animal models. These vectors have to be 
produced in cells that provide the missing E2 proteins in trans (Searle and Mautner, 
1998). This is also the case with the El region of the adenovirus, which is essential 
for replication, therefore viruses deleted of this region are propagated and packaged 
by growth in cells expressing the E 1 gene. The standard complementing cell line is 
the human embryonic kidney cell line 293, which possesses the El gene, and thus is 
capable of producing a replication-defective viral particle (O'Malley and Ledley, 
1993, Figure 1.8). In most cases the smaller the genome the more stable the 
construct. In general, adenovirus infection is lytic, so infection of a cell is followed 
by productive replication and generation of many new virions. The effects of the 
shutting down of the host cell metabolism and the accumulation of thousands of new 
virions results in lysis and death of the infected cell, with release of the viral 
particles. The lytic cycle is divided into two phases, early and late, with the onset of 
DNA replication being defined as the beginning of the late phase (Madeley and 
Peiris, 1992). 
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The most cited advantages of adenovirus vectors are the high efficiency of gene 
transfer as compared with other presently available viral systems, the ability to 
infect non-dividing cells, and the established general safety in preclinical and early 
clinical investigations, both intratumourally and intravenously (reviewed by Breau 
and Clayman, 1996; Heise et ai, 2000). Earlier studies were carried out on the basis 
of infectious units (plaque-forming units, p.fu.), but it is now standard to dose on 
the basis of viral particles (vp; Kim, 2001). Initial experience with adenovirus in 
other human clinical trials has demonstrated that a high dose of adenovirus is 
associated with transient fever (Clayman et aI, 1998), and doses of 1013 vp on 
occasions resulted in liver dysfunction and hypotension, requiring supplemental 
oxygen (reviewed by Blackwell et ai, 1999). 
The recombinant adenovirus also remains as a non-replicating extrachromosomal 
entity and therefore has little chance to activate a dormant oncogene or interrupt a 
tumour suppressor gene, the stable expression of the recombinant gene in transduced 
cells is likely to be transient for this reason. To date, there has been no evidence of 
insertional mutgenesis in connection with the adenovirus-mediated gene delivery (Li 
et ai, 1999). In addition adenoviruses can be produced at very high titre (1013 vp/ml, 
Kim, 2001). The respiratory and gastro-intestinal epithelia are a natural target of the 
adenovirus, making it an ideal vector for head and neck cancers (Zhang et ai, 1995). 
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Figure 1.8: Production of Recombinant Adenovirus. The genome of the virus is 
approximately 36 kb. Removal of the El, E3 and E4 regions allows for up to 8 kb 
insertion of foreign DNA. Production of recombinant adenovirus can take place in 
complementary cell lines expressing El genes (Adapted from www.qbi.com). 
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1.21.2.2 Adenoviral Cell Entry 
Expression of a transgene delivered by an adenoviral vector involves several steps of 
vector-host cell interaction. This includes attachment of the vector to the host cells, 
internalisation of the vector by the host cells, entry of the vector into the nucleus, 
transcription of the transgene, translation and modification of the transgene product, 
and the product's translocation to a proper subcellular compartment, as well as 
stability of the transgene products once inside the target cells (reviewed by Pearson 
et ai, 1999). 
The Ad5-based vector has been the predominant vehicle for adenovirus gene therapy 
strategies. The ability of adenovirus to infect host cells is dependent upon the 
presence of an appropriate cellular receptor. For the majority of the adenovirus 
serotypes this receptor is the coxsackie and adenovirus receptor (CAR). Unusually, 
for viruses from different families, both adenovirus and the coxsackie virus compete 
for this receptor. CAR is a transmembrane glycoprotein of 46-kDa, which is 
expressed in a wide range of human and murine cell types (Tomko et ai, 1997; 
Bewley et ai, 1999). Initially the viral fiber protein attaches to CAR on the surface 
of the host cell. The virion then gains entrance into the cell through the interaction 
of the argine-glycine-aspartate tripeptide motif (or RGD in single-letter code) in the 
penton base, with the avJ33 and avJ35 integrins on the host cell surface (reviewed by 
Pearson et ai, 1999; Figure 1.9). While integrins avJ33 and avJ35 both promote 
adenovirus intemalisation into cells via receptor mediated endocytosis, integrin 
avf35 selectively facilitates adenovirus-mediated membrane permeabilisation and 
endosome rupture (Wickham et ai, 1993; Greber et ai, 1997). 
The acidic pH that the VIruS encounters m the endosome may trigger a 
conformational change that releases the virus into the cytoplasm and allows the 
adenovirus capsid to travel to the nucleus (Greber et ai, 1993; Wickham et ai, 1994). 
The cytoplasm however, imposes a diffusional barrier to the virus. Within the 
eukaryotic cytoplasm, organelles, solutes, and a complex lattice-like mesh of 
microtubule (MT), actin, and intermediate filament networks effectively restrict free 
diffusion of molecules larger than 500 kD (>50nm diameter, reviewed by 
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Suomalaien et ai, 1999; reviewed by Izaurralde et ai, 1999). The adenovirus at ~ 90 
nm diameter is therefore, not expected to travel freely through the cytoplasm, but to 
engage with some form of active transport. This has been reported to be achieved by 
an association of adenovirus with MT and dyneinldynactin, with the viral DNA 
remaining wrapped by the capsid until arrival at the nuclear membrane (reviewed by 
Suomalaien et ai, 1999). Many viruses depend upon nuclear host factors for 
genome replication, thus, at some stage the viral genome must enter the nucleus. 
The nuclear import of viral genomes requires the docking to the nuclear pore 
complex (NPC) prior to this transport. All viruses make use of the exposure of some 
sort of nuclear localisation signal (NLS) to achieve this (Izaurralde et ai, 1999). 
Nucleocytoplasmic transport occurs via the central aqueous channel of the NPC, 
which has a diameter of approximately 25 nm. Hence, adenovirus must undergo a 
final disassembly reaction prior to genome injection into the nucleoplasm (Cullen, 
2001). 
Various studies have shown that the levels of integrins and CAR in target cells seem 
to correlate with the transduction efficiencies of adenovirus vectors in those cells. In 
SCCHN cell lines, Blackwell et ai, 1999 showed by flow cytometry using an anti-
CAR antibody, that 31% of SCC-25 cells were positive for CAR expression, 17% in 
FaDu cells, and 9% in SCC-4 cells. In another study, a range of 3000-10,000 CAR 
receptors/cell were reported to be presence on the KB human oral epidermoid 
carcinoma cell line. In comparison, the adenovirus infection-resistant cell line Nlli 
3T3, presented with less than 100 receptors/cell (reviewed by Walters et ai, 1999). 
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Hexon 
Figure 1.9: Diagrammatic Representation of an Adenovirus. The viral fiber 
protein attaches to CAR on the surface of the host cell. The virion then gains 
entrance into the cell through the interaction of the RGD tripeptide motif in the 
penton base, with the avj33 and avj35 integrins on the host cell surface. From www. 
Q-Biogene.com. 
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1.22 The Effect of Gene Silencing on Transgene Expression 
The problem of inadequate and specific gene delivery, and gene expression levels is 
a significant challenge to the effectiveness of gene therapy. However, the frequency 
of gene silencing may pose another obstacle to overcome. Cells display a strong 
protective mechanism to preserve the structure of their genomes and to oppose the 
expression of abnormal or foreign transcription units. Many cases are known in 
which a transferred gene undergoes a brief period of expression followed by a 
decline to undetectable levels without the loss of the expression construct. This is 
commonly caused by the triggering of transcriptional silencing of the inserted 
sequences, usually via mechanisms that involve methylation of DNA within 
regulatory regions (Bestor, 2000). Gene silencing mechanisms are diverse and 
efficient and are likely to represent a barrier to many forms of gene therapy. 
The best-studied DNA modification that correlates with epigenetic gene silencing is 
methylation of cytosine residues in CpG sequences. Most of the methyl groups are 
found in cytosine-guanine (C-G) 'doublets', and, in fact, the majority of the C-G 
sequences are methylated. The methylated gene is inactive, but the non-methylated 
gene is active. The general rule is that methylation prevents gene expression and 
demethylation is required for expression. The presence of CpG-rich islands in the 5' 
regions of some genes is connected with the effect of methylation on gene 
expression. For the majority of transcriptionally active and potentially active genes 
in normal cells, these CpG islands are maintained in a fully unmethylated state. 
Human DNA has low frequencies of CpG dinucleotides except in regions of very 
high G/C contents. These CpG rich islands have an average G/C content of ~ 60%, 
compared with the 40% average in bulk DNA. In several cases, CpG-rich islands 
begin just upstream of a promoter and extend downstream into the transcribed 
region before petering out. Methylation of a CpG island at a promoter usually 
prevents expression of the gene (Lewin, 1994; Bestor, 2000; Tycko, 2000). 
CpG methylation has recently been linked to an even more general mechanism of 
epigenetic silencing, histone deacetylation. Acetylation of the lysine residues at the 
N-terminus of the histone proteins removes positive charges, thereby reducing the 
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affinity between histones and DNA. This makes RNA polymerase and transcription 
factors easier to access the promoter region. Therefore, in most cases, histone 
acetylation enhances transcription whilst histone deacetylation represses 
transcription (Tycko, 2000). 
1.23 Bystander Effect of Gene Transfer 
The "bystander effect" describes the event occurring when cancer cells that have 
received a specific therapy are able to bring about growth inhibition in untreated 
cells. The best known example of the bystander effect in human malignancy is 
displayed in the HSV -tk gene therapy. Transfected cells are killed by the addition of 
a prodrug ganciclovir, along with neighbouring untransfected cells. These adjoining 
bystander cells receive the toxic phosphorylated GCV through gap junctional 
intercellular communication (GflC) channels that connect them with adjacent HSV-
tk expressing cells (Fick et ai, 1995). 
Although apoptosis-inducing molecular therapies, such as those resulting in 
overexpression of the wildtype p53 tumour suppressor, are not toxin based, growth-
inhibitory signals may, nonetheless, be communicated to bystander cells from 
apoptotic cells through a variety of mechanisms. Frank et ai, 1998 has demonstrated 
that wildtype p53 over-expressing TUB8 SCCHN cells can bring about growth 
inhibition in non-transduced cells in vitro. This requires intercellular contact 
between wildtype p53 transduced and non-transduced (bystander) cell populations. 
Several mechanisms to explain the apparent bystander effect between apoptotic 
(wildtype p53 transduced) and non-transduced cell populations have been proposed. 
These include the influence of dead cells on the neighbouring cells due to 
phagocytosis, and the ability of wildtype p53 to inhibit the expression of proteins 
such as TSP and other vascular endothelial derived growth factors involved in the 
process of angiogenesis, thus inhibiting tumour growth (Freeman et ai, 1993; 
Dameron et ai, 1994). 
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Bystander effects can also be due to the induction of specific cytotoxic T-
lymphocytes (CTL), neutrophils or other non-specific immune responses against the 
infected tumour cells (Chen and Carbone, 1997; Waku et ai, 2000). Frank et ai, 
1998, suggests that the bystander effect of wildtype transduced cells on 
untransfected cells might be explained by receptor-ligand signalling (such as 
CD951F AS ligand), bystander cell endocytosis of apoptotic vesicles from transduced 
cells, or mechanisms whereby "apoptotic signals" from wildtype p53 transduced 
cells are communicated to non-transduced bystander cells via GllC between the two 
cell populations. The loss of GllC activity is a common (although not universal) 
phenotype in human malignancy. It is theorised that the loss of GllC in cancer cells 
allows them to escape the potential growth-regulatory controls of adjoining cancer 
cells and normal tissues (Yamasaki, 1990; Holder et aI, 1993). 
Nishizaki et ai, 1999 reported how tumour that contained wildtype-p53 transduced 
cells formed less blood vessels than non-transduced tumours, suggesting that 
inhibiting angiogenesis by the wildtype p53 gene transfer elicits the bystander 
effects. This anti-angiogenic property of p53 gene therapy was found to be 
mediated by the altered expression of the angiogenic inducer VEGF and the 
angiogenic inhibitor BAl-!. These results suggest that wildtype p53 gene transfer 
can attenuate tumour-cell-induced neo-vascularisation in vivo and suppress the 
growth of neighbouring tumour cells. 
Wildtype p53 transduction has also been reported to potently inhibit the production 
of MMP-I and MMP-13 (Ala-aho et ai, 2002). Matrix metalloproteinases play an 
important role in tumour cell invasion and metastasis, therefore the inhibition of 
MMP-1 and MMP-13, provide evidence for an additional mechanism for p53-
elicited suppression of tumour growth in vivo. 
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1.24 Murine Models of Squamous Cell Carcinoma of the Head and Neck 
Preclinical models are an essential step in the establishment of new treatment 
efficacy, safety and schedule, prior to a possible human clinical trial. The most 
appropriate animal models are those that closely mimic the biological behaviour of 
the human disease under study. However, care should be taken not to directly 
correlate the results seen in these models with those anticipated in a patient study. A 
number of murine models have been established to study new treatment regimes for 
SCCHN. The majority are subcutaneous (S.c.) models in immunodeficient nude or 
severe combined immunodeficient (SCID) mice (Clayman et ai, 1995; Clayman et 
ai, 1996; Bi et ai, 1997; Rocco et ai, 1998). 
Immunodeficient animals offer the advantage of allowing the growth of human 
tumours, since no, or a limited immune response is stimulated against these human 
cells. This is not possible in immunocompetent animals. An alternative is to grow 
mouse tumours in syngeneic immunocompetent animals, allowing full investigation 
of the effect of the immune response, on the treatment efficacy in the absence of 
variables introduced by genetic difference among individual animals. 
It is now well established that certain human tumour types (e.g. carcinomas and 
malignant melanomas) are easily adaptable for growth in nude mice or rats, whereas 
many others (leukaemia's, breast and prostate cancers) grow poorly, if at all in such 
recipients (Manzotti et ai, 1993). Tumours that do take, and grow well in nude 
rodents are often the more aggressive ones (Mitchell et ai, 1997). Immunodeficient 
nude mice lack a thymus resulting in a deficiency of T -cells and cell-mediated 
immunity, however, there are still some residual elements of the host immune 
system, including T - and B- lymphocytes, natural killer (NK) cells and 
macrophages. SCID mice lack both T - and B-lymphocytes, but not NK cells or 
macrophages. The main advantages of using SCID mice rather than nude mice are 
the better tumour growth, and the greater speed with which metastases form 
(Mitchell et ai, 1997). 
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The route by which tumour cells are implanted into the rodent is important. The 
S.C. route is popular because it is easy and causes little trauma to the animal 
however, it does not mimic the original anatomical site of most of the tumours 
studied. In studies in which cancer cells were injected S.c., the resulting tumours, 
despite being derived from malignant tissues, sometimes behaved more like benign 
tumours, becoming encapsulated and often failing to metastasise (O'Malley et ai, 
1997). Further, cells implanted S.c. often change their phenotype (Mitchell et ai, 
1997). These S.c. implants grow in a confined, rounded pattern and lack notable 
invasion of surrounding tissues and aggressive metastatic activity. Cancer patients 
have aggressive carcinomas that locally invade and metastasise, hence, this lack of 
invasive behaviour in established animal tumour models may limit the applicability 
of new cancer therapies or treatment strategies (Manzotti et ai, 1993; Mitchell et ai, 
1997; O'Malley et ai, 1997; Kerbel, 1999). 
Endogenously arising metastasis in the mouse is a surprisingly infrequent event 
compared to that associated with human cancer (McClatchey, 1999). Indeed, the 
microenvironment of the S.c. area is quite different from that of the organ from 
which the tumour is developed. It has been suggested that the nature of the 
microenvironment explain the altered response of experimental tumours to drug 
therapy (Mitchell et ai, 1997). Kerbel et ai, 1999 supports this criticism of S.c. 
grown tumours. The positive responses of such tumours to certain anti-cancer drugs 
or therapies have been questioned, and at least in some cases it has been shown that 
orthotopic ally transplanted tumours do not necessarily recapitulate the 'encouraging' 
responses of their ectopically grown counterparts. 
An alternative is to use the orthotopic approach, in which cancer cells are implanted 
into the same organ as their site of origin. O'Malley's group described such an 
orthotopic SCCHN model developed in both immunodeficient (Simon et ai, 1998) 
and immunocompetent animals (O'MaUey et ai, 1997), which showed initial loco-
regional tumour invasion, direct extension into the neck, cervical metastases, and 
pulmonary metastases. To create this model cells were inoculated in the superficial 
S.c. soft tissue that overlies the floor-of-mouth structures, which include mylohyoid 
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and geniohyoid musculature. However, a drawback of this model was the rapid 
tumour growth and identification of pulmonary metastases at or near the time of 
designated experimental end-points. This limits its use in experiments directed at 
developing new therapies for the prevention or treatment of distant metastases. 
However, this model has benefits for studying the efficacy of cancer vaccines and 
gene therapy, which may be altered by muscle and bone invasion, tumour proximity 
to critical vascular and nerve structures, or the presence of regional or distant 
metastases (O'Malley et ai, 1997). This SCCHN floor-of the-mouth model in 
immunocompetent mice has been used to study the efficacy of gene therapy 
approaches, such as the combination therapy of adenovirus-mediated transfer of the 
genes for HSV -tk and murine U,-2. Animals receiving either tk alone or tk + U,-2 
demonstrated significant tumour regression compared to U,-2 alone or control vector 
treated mice (O'Malley et ai, 1996). 
Clayman et aI, 1995, developed a model of minimal residual SCCHN which he 
claimed mimicked the post-surgical environment of head and neck cancer patients 
with advanced disease. For these experiments tumour cells were implanted S.c. into 
nude mice. After 2 days exogenous wildtype human p53 was introduced via an 
adenoviral vector, with the aim of preventing the establishment of tumour nodules. 
Untreated tumours developed into nodules, whilst Ad-p53 treated tumour sites 
showed no gross appearance of tumour nodule development. 
1.25 Gene Therapy Clinical Trials 
Gene therapy clinical trials have been on the whole disappointing, with the blame 
lying most frequently on the inadequate levels of gene expression in the targeted 
cells, to result in any clear clinical benefit. On the positive side however, the 
majority of clinical trials using the adenovirus vector have reported only relatively 
minor side effects. 
An adenovirus deleted for the EIB-55 kD gene, d11520 (ONYX-OI5) has been 
developed for the treatment of tumours lackingp53 function. Since the EIB-55 kD 
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gene product is responsible for p53-binding and inactivation, it was hypothesised 
that the deletion mutant would be unable to inactivate p53 in normal cells and would 
thus be unable to replicate efficiently (Heise and Kim, 2000). In contrast, cancer 
cells lacking functional p53 would be expected to be sensitive to viral replication 
and subsequent cytolysis. D11520 (ONYX-OI5), was the first such genetically 
engineered agent to be tested in humans. Over 200 cancer patients have been treated 
to date on over 10 clinical trials (phases I-III). 
D11520 has been studied in more than 90 patients with head and neck cancer. 
Patients with SCCHN commonly possess tumours displaying p53 abnormalities. In 
addition, these tumours are usually readily accessible, even in an outpatient setting, 
for direct injection and biopsy. D1l520 was injected directly into the tumour masses 
and adjacent normal tissue, to target the microscopic tumour deposits frequently 
present beyond the palpable edges of these tumours. On completion of phase I and II 
testing, results showed biological proof-of-concept for the replication-selective 
adenovirus approach. Most SCCHN biopsies showed some virus-induced 
cytopathic effects and in some cases tumour necrosis. Normal tissue adjacent to the 
injected tumour masses showed no significant toxicity (Kim et ai, 1998; Heise and 
Kim, 2000). The single agent efficacy of dlI520 was however limited, with response 
rate (~50% shrinkage at a single point in time) only 13%. 
In order to mcrease the potency of dlI520, treatment was combined with 
conventional chemotherapy (intravenous (i.v.) cis-DDP and 5-FU) in a phase II 
SCCHN study. Response rates were superior to historical controls treated with 
chemotherapy alone. Potential synergy was demonstrated with dlI520 and 
chemotherapy in two tumour types that supported viral replication (head and neck, 
colorectal), but not in a tumour type that was resistant to viral replication 
(pancreatic). Thirty-seven patients were treated and 19 responded (51%), comparing 
favourably with response rates to chemotherapy alone in previous trials (30-40010 
generally). The d11520 injected tumours were significantly more likely to respond 
and less likely to progress than were non-injected tumours (Heise and Kim, 2000; 
Kim, 2001). 
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Kirn, 2001 reported that the virus was generally well tolerated at doses of up to 2 X 
1012 vp by intratumoural, intraperitoneal (i.p.), hepatic arterial and i.v. 
administration. No maximally tolerated doses were identified by any route of 
administration. Fever, chills and asthenia following intravascular injection were 
more common and more severe than after intratumoural injections. Viral replication 
was tumour-selective, and was documented after administration by all routes, but 
was generally transient « 10 days). Acute inflammatory cytokines (especially 
interleukins-l and --6, IL-l and IL-6) increased within 3 h following intra-arterial 
infusion. Neutralising antibodies increased in patients, regardless of dose, route or 
tumour type. Neutralising antibodies did not block antitumoural activity in head and 
neck cancer trials of intratumoural injection. However, viral replication/shedding 
into the blood was inhibited by neutralising antibodies, with intra-arterial virus being 
more sensitive to antibody inhibition than intratumourally injected virus. 
Non-replicating adenoviral vector-mediated p53 gene therapy for cancer is currently 
undergoing phase IIII clinical trials. The drug used in these clinical trials (p53 Ad; 
ACN53; SCH58500) consists of replication-deficient, type 5 adenovirus vector 
expressing human wildtype p53 under the control of the cytomelagovirus (CMV) 
promoter. Results from early clinical trials using p53 gene therapy by itself support 
optimism for the future of this therapeutic approach (Gurnani et aI, 1999). 
However, it is likely that treatments will incorporate an arm comparing traditional 
chemotherapy against chemotherapy combined with p53 gene therapy. In ongoing 
phase I clinical trials, various chemotherapy drugs are being tested in combination 
with Ad-p53 by the i.p. and intra-hepatic artery routes of administration. The 
preliminary results of these clinical trials indicate no significant hepatic toxicity in 
humans at the maximum achievable doses of Ad-p53 (limited by the maximum 
volume patients can tolerate and the maximum virus concentration that can be 
manufactured without viral aggregation, Gurnani et aI, 1999). Phase I clinical trials 
by Clayman et aI, 1998 also assessed the efficacy of Ad-p53 gene transfer. Patients 
studied had loco-regionally-recurrent SCCHN, which were unsuccessfully treated 
with conventional therapies. Objective anti-tumour activity was detected in several 
patients following treatment with Ad-p53 (doses up to 1012 vp). The virus was 
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detected in the blood and urine of these patients but was asymptomatic, suggesting 
that systemic or regional treatment may be tolerable. 
Although the above clinical trials have generally indicated that these modified 
adenoviral vectors are relatively safe, a major set back has hit the field of gene 
therapy, with the death of a volunteer. Jesse Gelsinger was enrolled in a trial to treat 
a disease that occurs when a gene on the X chromosome is missing or defective, 
producing too little of a liver enzyme, ornithine transcarbamylase (OTC), 
responsible for removing ammonia from the blood (Marshall, 2000). The adenovirus 
vector was chosen because of its rapid gene expression (within 24 hours) as 
compared to other vectors which can take 3 to 6 weeks to begin working. Relying on 
results from mouse studies, this group had expected to see adenovirus concentrated 
in the liver. Instead a post-mortem revealed the vector was everywhere, as CAR is 
much more abundantly expressed in mouse livers than in human livers (Marshall, 
2000). This suggests that rodent models might be misleading for predicting 
patients' response to gene therapy. Jesse Gelsinger died from a massive immune 
response to the adenovirus vector itself High and sustained levels of IL-6 were 
found in his blood, resulting in a systemic inflammation, flooding of his lungs with 
fluid, and causing acute respiratory failure and death. Vectorologists have long 
known that adenovirus triggers an immune response, but for gene therapy trials 
some of the adenoviral genes are removed, in an attempt to reduce its 
immunogenicity. For the OTC trial, an adenovirus with Eland E4 genes deleted 
was used. 
In a cystic fibrosis trial, an Eland E3 deleted adenovirus, was given safely in repeat 
doses (reviewed by Marshall, 2000). Some scientists have also attempted to create 
fully gutless vectors by removing all viral genes and replacing them with substitutes. 
However, these vectors are difficult to produce at high concentrations, and require 
helper viruses to replicate, which are hard to eliminate, causing contamination. 
However, since empty capsids appear to be immunogenic this problem is likely to be 
hard to eliminate completely (Marshall, 2000). 
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1.26 Aims of this Study 
More than half of all SCCHN-related deaths is due to local failure of disease control. 
This has been explained by the presence of undetectable tumour deposits (MRD) 
remaining in the body at the surgical margins, or due to further evolution of 
dysplastic foci within the field of cancerisation. Head and neck tumours occur at 
reasonably accessible sites, making these patients good candidates for direct gene 
transfer, of appropriate gene sequences, into the surgical resection to eliminate these 
remaining malignant cells. 
The p53 gene is a good candidate for gene therapy for SCCHN since one or both 
copies of the p53 gene is deleted or mutated in approximately 60% of head and neck 
cancers. Clinical studies using a p53 molecular diagnostic to examine conventional 
"clear" surgical margins revealed that occult tumour was detected in both muscle 
and mucosal margins, with tumour in the muscle margins responsible for a high 
percentage oflocal recurrence, and ultimately patient death (Partridge et ai, 2000). 
Preclinical models ofMRD in the S.C. tissue of immunodeficient hosts have shown 
that replacement of the wildtype p53 gene is successful in eliminating tumour. 
However, transduction of nests of tumour in the dense muscle tissue, may not be 
straightforward. In addition, s.c. models have been frequently shown to be over 
encouraging, with results not replicated in other sites (Kerbel et ai, 1999). To make 
progress in this area we aim to devise a rodent model of MRD in the muscle of 
immunocompetent hosts. The new model will be developed with a squamous cell 
line harbouring a p53 mutation, which allows the efficacy of protocols to restore the 
function of this sequence to be tested. 
Initial in vitro experiments are aimed at determining the suitability of the squamous 
cell line PDVC57, for use in p53 gene transfer procedures. Analysis of transduction 
efficiency, transgene expression at the mRNA and protein levels, and mechanisms 
of cell death will be established. Particular emphasis on the degree of apoptotic cell 
death or growth arrest will be investigated, to provide a better understanding of the 
role ofthe p53 transgene in any treatment efficacy. 
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Preliminary in vivo experiments will establish the capability of the selected 
squamous cell line to grow and invade in muscle. In addition, the reproducibility of 
developing multiple tumour nests of similar size throughout the muscle will be 
determined. 
Adenoviral vectors carrying the p53 gene (Ad5CMV-p53), the marker genes ~­
galactosidase (Ad-~gal) or luciferase (Ad-Luc), and a control "empty" vector (Ad-
PolyA) will be used to assess the feasibility of this therapeutic approach to destroy 
MRD within the muscle. Since athymic mice lack a functional immune system, 
studies in nude mice do not address key issues pertaining to use of recombinant 
adenoviruses in human clinical trials. The new model will be developed in 
immunocompetent hosts, in order to determine the effects of the immune response to 
the recombinant adenoviruses and to establish the safety and efficacy of these 
vectors in gene therapy of cancer. 
Determination of the efficacy of p53 gene transfer delivered by adenovirus on the 
tumour nests established within the muscle will be analysed. The optimal vector 
delivery schedule will be established, first by testing direct intra-tumoural 
administration in this model. In addition, the capability of an established 
chemotherapeutic agent (cisplatin), commonly used in conventional treatment 
schedules for SCCHN to cause tumour cell death, will be studied in the model of 
MRD in the muscle. If both these treatments are successful, the effect of this form 
of gene transfer will be evaluated in combination with chemotherapy. 
If direct gene transfer to tumour bearing muscles is unsuccessful, other routes of 
gene delivery will be explored. Systemic gene transfer will enable the evaluation of 
the effectiveness of delivery of gene transfer via the vasculature, not only at the site 
of the primary tumour or MRD, but also on distant metastases. Although patients 
can potentially benefit from local-regional therapy, systemic anti-tumoural efficacy 
could have a much greater impact on overall cancer-related mortality, by targeting 
outgrowth of tumour foci at distant sites. 
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One characteristic of squamous cancers that can also be exploited, in addition to p53 
mediated gene therapy, is to increase tumour-specific killing by taking advantage of 
the fact that head and neck tumours are relatively hypoxic. In head and neck 
carcinomas, hypoxia correlates with a lower probability of disease-free survival 
(Koong et ai, 2000). Therefore, it is planned to further characterise the nature of the 
PDVC57 tumour models with regard to the degree of hypoxia. Hypoxia is a 
common feature of SCCHN, triggering angiogenesis, and a more malignant 
phenotype (Gatenby et ai, 1988; Brown, 1999). The determination of the presence 
or absence of hypoxia within the tumour will enable the planning of other 
potentially viable treatment strategies that can target hypoxic cells for killing. 
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Chapter 2- Materials & Methods 
2.1 Cell Lines and Culture Conditions 
The PDVC57 cell line was established from a tumour arising after S.c. injection of 
the PDV cell line (Fusenig et ai, 1978) into a C57B1I6 mouse (Quintanilla et ai 
1991). The PDV cell line was originally derived by transforming keratinocytes in 
vitro with dimethylbenz[a]anthracene (DMBA). This SCC line carries a p53 
mutation, an ATG (Met) to GTG (Val) change at codon 231, which is presumed to 
have arisen during subsequent culture in vitro (Bums et ai, 1991). 
The CarB cell line is syngeneic for NIH mice and has wildtype p53 (Diaz-Guerra et 
ai, 1992). 
The SCC25 cell line is derived from a SCCHN, which has a two base pair deletion in 
codon 209 and loss of heterozygosity (LOH) in the other allele ofp53 (Gumani et ai, 
1999). 
The SCC97 cell line is derived from a SCCHN. It has a p53 point mutation 
(transversion T -A) at the second base of the fifth intron, which inactivates the 
normal splicing donor site. This results in a 46 bp deletion in the coding sequence in 
exon 5 and a frame-shift, leading to a truncated unstable p53 (Badie et ai, 2000) . 
The HN5 cell line is derived from a SCCHN. It contains a p53 mutation, an amino 
acid substitution within exon 7 which converts cysteine to serine (codon 238, TGT 
to AGT; Gusterson et ai, 1991). 
UMSCC22A is derived from a primary tumour of the hypopharynx (Kim et ai, 
1996) and carries wildtype p53. 
The p53 gene mutations in the cell lines used in this all reside within the DNA-
binding domain. The effect of these changes on protein function depends on the site 
of mutation and the nature of the amino acid replacement. 
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2.1.1 Materials 
Complete Culture Medium: 
Dulbecco Modified Eagle Medium (DMEM) with 25mM HEPES buffer (Invitrogen 
Life Technologies - 41965-039) 
Foetal Bovine Serum (FBS) (Invitrogen Life Technologies - 10108-165) 
100 Units/ml Penicillin and 100 mg/ml Streptomycin (Invitrogen Life Technologies 
- 15140-114) 
6 cm2, 10 cm2 or 150cm2 tissue culture plates/flasks (Coming - 402/0448/06) 
Trypsin (Invitrogen Life Technologies - 25050-22) 
Versene (Invitrogen Life Technologies - 15040-074) 
2.1.2 Methodology 
PDVC57, CarB, HN5, SCC25 and UMSCC22A cell lines were grown in DMEM 
supplemented with 10% FBS, and 1 % penicillin and streptomycin (complete culture 
medium). The SCC97 cell line was cultured under the same conditions, but with 
17% FBS. All cell lines were adherent. Cells were split when 80% confluent by 
washing in versene, followed by the addition of a versene:trypsin mix at a ratio of 
1:4. After incubation for 10 minutes at 37°C, detachment was established 
microscopically and the trypsin neutralised with the addition of medium containing 
FBS. The cell suspension was centrifuged at 100G for 5 minutes, the supernatant 
carefully discarded and the cell pellet resuspended in complete culture medium. 
Viable and dead cells were discriminated by differential staining. The most 
frequently used dye is trypan blue. Cells with disturbed plasma membrane 
permeability stain blue (indicating dead cells), whist undamaged (viable) cells 
appear translucent. After addition of trypan blue, cell number and viability were 
determined by counting cells in a haemocytometer with a standard light microscope. 
Cells were plated at various concentrations depending upon the experiment to be 
carried out, usually ranging from 0.5-10 x 105 cells per IOcm2 plate. For cell 
maintenance PDVC57 cells were split at a ratio of 1:6 to 1: 10 every 3 days, and the 
other cell lines at a ratio of 1:2- 1:5. 
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2.2 Recombinant Adenovirus 
Adenoviral vectors were provided by Introgen Therapeutics Inc, Houston Texas. 
The replication-deficient recombinant p53 adenovirus (Ad5CMV-p53) contains the 
human CMV promoter, wildtype human p53 cDNA, and the SV40 polyadenylation 
signal in a mini gene cassette inserted into the E I-deleted region of modified Ad5. 
An adenoviral vector containing the same cassette but without the p53 cDNA (Ad-
PolyA) acted as a control, "empty" vector. The recombinant adenovirus that carries 
an Escherichia coli J3-galactosidase marker gene (LacZ), Ad-J3-gal, and the 
adenovirus containing the luciferase gene, Ad-Luc, were used to determine 
transduction efficiencies of the cell lines used. 
Introgen Therapeutics Inc, Houston Texas, provided the viral titres, which were 
determined by plaque assays. Early studies were performed on the basis of p.fu. but 
it is now standard to dose on the basis of vp. Therefore, for ease of comparison all 
p.fu. doses are converted to vp within this thesis (vp: p.fu. ratio for adenoviral 
vectors used in this study are 25: 1). 
2.3 Recombinant Adenovirus Infection 
2.3.1 Principle of Methodology 
As discussed in the introduction (section 1.21.2.2) expressIOn of a transgene 
delivered by an adenoviral vector, involves several steps of vector-host cell 
interaction. Initially the vector needs to be able to attach to the target cell, and gain 
entry. The adenovirus vector then needs to reach the nucleus of the host cell, where 
transgene transcription and translation can take place. For proper transgene function 
to occur the transgene product also requires to be in the correct subcellular location, 
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All supplied by Introgen Therapeutics Inc, Houston Texas. 
DMEM containing 2% FBS (no antibiotics) 
2.3.3 Methodology 
Cells were plated in either 6 cm2 or 10 cm2 cell culture plates at the desired 
concentration (ranging from 0.5-10 x 105/plate), and incubated for 24 hours at 37°C 
with 5% CO2. Culture medium was removed and the cell monolayers washed once 
with phosphate buffered saline (PBS). Various concentrations of adenoviral vector 
(usually 2500 vp/cell, equivalent to 100 multiplicity of infection (MOl)) were made 
up in DMEM. Two mls of the virus containing medium was added to each 6 cm2 
plate (4 mls to 10 cm2 plates) and cells allowed to incubate for 4 hours, where-upon 
2 mls of complete medium was added to each 6 cm2 plate (6 mls to 10 cm2 plates). 
Cells were incubated at 37°C. 
2.4 Cell Growth Assay 
2.4.1 Principle of Methodology 
The effect of infection with the four adenoviral vectors Ad5CMV-p53, Ad-PolyA, 
Ad-B-gal and Ad-Lue, treatment with cisplatin, exposure to UV radiation or mock 
infection with PBS, on cell growth was examined for each cell line. Viable and dead 
cells were discriminated by trypan blue staining. The dead stained and viable 
unstained cells were counted in a haemocytometer with a standard light microscope. 
Variation in viable cell numbers were determined daily over a week period to 
establish the effect of the various treatments on cell growth rate. 
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Ad5CMV-p53 (156, 312,625,1250,2500 vp/cell) 
Ad-Poly A 2500 vp/cell 
Ad-~-gal 2500 vp/cell 
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PDVC57, CarB, SCC25, and HN5 cells were plated at a concentration of 2 x 105 
cells per 10 cm2 culture dish for 24 hours before treatment. Cells were infected with 
a range of concentrations of Ad5CMV-p53 (156, 312, 625, 1250, 2500 vp/cell), or 
with 2500 vp/cell of either Ad-~-gal or Ad-PolyA, as previously described (section 
2.3). 
Agents known to cause cell death in a wide range of cell types were included as 
positive controls. Cells were exposed to either 2 minutes UV light (at 302 nm, as 
commonly used for viewing ethidium bromide stained DNA gels) or 20Jlglml 
cisplatin. DMEM containing 2% FBS was used for mock infections. All treatments 
were set up in triplicate. After harvesting with trypsin, cell numbers were counted 
three times using a haemocytometer under a light microscope, and the average cell 
number obtained. Viability of cells was determined by the addition of try pan blue to 
the cell suspension. Counting of cell numbers was repeated daily, up to day 7 after 
treatment. The average cell numbers were plotted against time in culture after 
treatment, and standard error of the mean data (SEM) shown. 
2.5 Detection of Reporter Gene Expression 
2.5.1 Principles of Reporter Gene Assays 
Reporter assays are used to assess the transduction efficiency of a given vector 
system, by expression of the reporter transgene. The reporter gene must be 
composed of a promoter containing an element recognised by the transcription factor 
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in question as well as a gene which expresses a protein whose activity or presence in 
the cell is easily detectable. Therefore, when the transcription factor and the reporter 
are expressed in a cell, if the transcription factor is able to activate the promoter of 
the reporter gene, the reporter gene activity will be detectable. Criteria essential for a 
reliable reporter gene include its absence or easy detection in the host, along with a 
simple, rapid, sensitive and cost-effective detection system. A broad linear range is 
desirable so that both large and small changes in expression may be detected. 
A frequently used marker for determining transfection efficiency is f3-gal, a bacterial 
enzyme, which participates, in the bacterial metabolism of carbohydrates. X-gal (5-
bromo-4-chloro-3-indolyl-f3-galactopyranoside) is a chromogenic substrate for f3-D-
galactosidase, producing a blue-black water insoluble coloured product (Couffinhal 
et ai, 1997). 
2.5.2 Materials 
Fixing solution: 
2% (v/v) Formaldehyde 
0.2% (v/v) Glutaraldehyde 
Made up in Phosphate Buffered Saline (PBS) 
Staining Buffer: 
5 rnM Potassium Ferricyanide (Sigma-Aldrich, Poole - P-3667) 
5 rnM Potassium Ferrocyanide (Sigma-Aldrich, Poole - P-3289) 
2 rnM Magnesium Chloride 
10% (v/v) Dimethyl Sulfoxide (DMSO; Sigma: D-8779) 
Made up in PBS 
X-gal Solution: 
1 mg/ml 5-Bromo-4-chloro-3-indoyl-f3-D-galactopyranoside (X-gal) (Transgenomic 
Cheshire UK - 070306) 
DMSO 
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2.5.3 Methodology 
2.5.3.1 J3-galactosidase Reporter Gene Staining of Cells 
The method followed was as stated by Harris et ai, 1996. Briefly, cell lines were 
plated in triplicate at a final concentration of 1 x 105 cells per 6 cm2 plate, and 
allowed to incubate for 24 hours at 37°C with 5% CO2. Culture medium was 
removed and cells washed once with PBS. The Ad-J3-gal was made up in DMEM 
containing 2% FBS, at a range of concentrations (0, 625, 1250, 2500 and 5000 
vp/cell, equivalent to 0, 25, 50, 100 and 200 MOl respectively). Two mls of virus 
containing medium was added to each 6 cm2 plate and allowed to incubate for 4 
hours, where-upon 2 mls of complete medium was added to each plate. Cells were 
then incubated for 24 hours at 37°C. X-gal staining solution was prepared by 
mixing the 1 mg/ml X-gal solution with 99 parts of the staining solution. Cells were 
fixed briefly (approximately 10 minutes) in the glutaraldehyde: formaldehyde fixing 
solution, washed briefly in PBS and then stained in the X-gal staining solution for 
between 15 minutes to 24 hours at 37°C. Cells were then washed in PBS and 
analysed under a light microscope to determine the transduction efficiency per vp of 
adenovirus administered. This was performed by counting at least 200 cells/plate in 
random fields and determining the percentage of positively stained blue cells. 
Triplicate plates per cell line and vp concentration were counted and the average 
reported. Control plates were as above with the addition of Ad-PolyA instead of Ad-
J3-gal. 
2.5.3.2 J3-Galactosidase Reporter Gene Staining of Tissue Sections 
Subcutaneous tumour nodules and tumour-bearing muscle was infected with Ad-J3-
gal or Ad-PolyA as described in section 2.22. Whole tumour-bearing muscles and 
s.c. tumour nodules were excised at 24 and 48 hours post-viral infection. Tissues 
were either freshly frozen in ornithine carbamyl transferase (OCT), in iso-pentane 
over liquid nitrogen, or fixed in glutaraldehyde: formaldehyde fixing solution, 
followed by standard processing and paraffin embedding. 
Three-5 J..l frozen and paraffin embedded tissue sections were prepared. Paraffin 
sections were deparaffinized in xylene and rehydrated through graded alcohol's to 
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tap water. Tissue sections were fixed briefly (approximately 10 minutes) in the 
glutaraldehyde: formaldehyde fixing solution, washed briefly in PBS and then 
stained in the X-gal staining solution for up to 24 hours at 37°C. After incubation 
for 24 hours, tissue section were washed and counterstained in haematoxylin and 
eosin, dehydrated through graded alcohol's, cleared in xylene and sections mounted 
in DPX. The transduction efficiencies were determined under light microscopy, by 
determining percentage cross-sectional area of positive blue cell staining in overall 
tumour cross-sectional area with the aid of a Leica image analysis system. Ranges 
of sections throughout the S.C tumour nodule or tumour-bearing muscle were 
analysed, with the average transduction efficiency determined. 
2.6 Polymerase Chain Reaction 
2.6.1 Principle of Methodology 
Transgene integration was confirmed by PCR, a technique for the in vitro 
amplification of selected DNA sequences. The PCR method was devised and named 
by Mullis and colleagues at the Cetus Corporation (Mullis et ai, 1987). Two short 
oligonucleotide primers (usually 18-30 bases long) complementary to the opposite 
strands of the regions of the DNA required for amplification must be known. These 
primers are used to anneal to the heat denatured DNA template, one to each strand. 
DNA polymerase carries out the synthesis of a complementary strand of DNA in the 
5' to 3' direction using a single-stranded template, but starting from a double 
stranded region. This is the primer extension reaction. 
The requirements of the reaction are simple: deoxynucleotides to provide both the 
energy and nucleosides for the synthesis of DNA, DNA polymerase, primer, 
template, and butTer containing magnesium. The deoxynucleotides and primers are 
present in large excess, so the synthesis step can be repeated by heating the newly 
synthesised DNA to separate the strands and cooling to allow the primers to anneal 
to their complementary sequences. The heating and cooling cycles can be repeated 
and DNA will continue to accumulate exponentially, the number of cycles required 
for optimum amplification varies depending on the amount of starting material and 
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the efficiency of each amplification step. Generally, 25 to 35 cycles are sufficient. A 
final incubation step at the extension temperature (usually at 72°C) results in fully 
double-stranded molecules from all nascent products. With a slight modification, the 
technique can also be used to study RNA. Reverse transcriptase (RT) is used to 
make a complementary single-stranded DNA (cDNA) copy of a messenger RNA 
(mRNA) prior to performing the PCR. The product of a PCR should be a fragment 
or fragments of DNA of defined length. The simplest way to check this is to load a 
fraction of the reaction product and appropriate molecular-weight markers onto an 
agarose gel containing ethidium bromide. The product is readily visible under UV 
transillumination. 
Using nested PCR or nested RT-PCR the sensitivity and specificity of both DNA 
and RNA amplification is considerably improved. The process utilises two 
consecutive PCRs, each involving 25 cycles of amplification. The first PCR 
contains an external pair of primers, while the second contains two nested primers 
that are internal to the first primer pair, or one of the first primers and a single nested 
primer. The fragment produced by the first reaction is used as a template for the 
second PCR. The result is effectively 50 cycles of amplification of the fragment 
flanked by the nested primer pair. 
2.6.2 Materials 
10 x RT-buffer: 
600 mM Potassium Chloride (KCI) 
30 mM Magnesium Chloride (MgCh) 
500 mM tris[hydroxymethyl] amino methane hydrochloride (Tris-HCI) 
10 x Deoxynucleotide Triphosphates (dNTP): 
2 mM Deoxyribonucleotide adenine triphosphate (dATP) (Roche Diagnostics -
1298350(10)) 
2 mM Deoxyribonucleotide cytosine triphosphate (dCTP) (Roche Diagnostics -
1298364(10)) 
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2 mM Deoxyribonucleotide guanine triphosphate (dGTP) (Roche Diagnostics -
1298372(10)) 
2 mM Deoxyribonucleotide thymine triphosphate (dTTP) (Roche Diagnostics -
1298399(10)) 
Primers: 
25 pmol sense primer (CMV2: 5' GGT GCA TTG GAA CGC GGA TT 3') 
25 pmol anti-sense primer (R3: 5' CAA ATC ATC CAT TGC TTG GGA 3') 
25 pmol nested anti-sense primer (RN3 : 5' GGG GAC AGA ACG TTG TTT TC 3') 
25 pmol sense primer (GAPDHl: 5' ACGGATTTGGTCGTATTGGG 3') 




50 mM Tris-HCI 
100 mM Dithiothreitol (DTT) (promega, P 117 A 93 71706L) 
RNasin Ribonuclease inhibitor (promega N2511) 
Avian Myeloblastosis Virus (AMV)-Reverse Transcriptase (Promega M510A 
9162609) 
Amplitaq DNA Polymerase (Perkin Elmer N808-0060) 
Water (RNase and amplimer-free) 
RNA sample (DNase treated) 
cDNA samples 
2.6.3 Methodology 
2.6.3.1 Reverse Transcription 
PDVC57 and CarB cells were infected with either 2500 vp/cell of Ad5CMV-p53, 
Ad-PolyA and Ad-J3-gal for varying time intervals (2 hours, 4 hours or 8 hours). 
Total RNA was isolated from these infected cell lines using RNA STAT-60 
(Biogenesis, UK) and treated with deoxyribonuclease (DNase-I) to eliminate 
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contaminating DNA and residual viral particles. ART master mix was prepared 
with the following quantities of reagents per reaction sample: 
1 III lOx R T -buffer 
1 III 10mMDTT 
5 III lOx dNTP 
0.5 III R3 anti-sense primer 
0.025 III RNasin ribonuclease inhibitor 
0.05 III AMV-RT enzyme 
All reagents should be stored on ice at all times. Each RNA sample at a 
concentration of I 1lg/1l1 was heated to 65°C immediately prior to use to break 
connecting bonds. TWO-Ill of RNA was added to the RT-master mix. A negative 
control was prepared by the addition of 2 III of water to the R T master mix instead 
of RNA. Reverse transcription was performed at 22°C for 10 minutes then 42°C for 
between 20 minutes and 2 hours. Samples were either frozen (-20°C) or PCR was 
performed on the cDNA. 
2.6.3.2 Primary peR Amplification 
PCR was performed with specific primers in volumes of 50 Ill/sample reaction. A 
PCR master mix was prepared with the following quantities of reagents per reaction 
sample: 
5 III lOx PCR-buffer 
2.5 III lOx dNTP 
I III sense primer CMV2 
I III anti-sense primer R3 
35 .3 III water 
0.2 III Amplitaq 
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Five-~l of each cDNA was added to 45 ~l of the PCR master mix. A negative 
control was included in each run by adding 5~1 of water to the reaction mix instead 
of cDNA. A drop of mineral oil was added to each sample to avoid evaporation. 
The amplification reaction involved an initial denaturation at 92°C for 4 minutes, 
followed by 35 cycles of denaturation at 92°C for 1 minute, annealing at 58°C for 1 
minute, and extension at 72°C for 1 minute. Samples were stored at 4°C. PCR 
products were resolved on a 1 % agarose gel and visualised by ethidium bromide 
staining. A primary product size of 312bp was detected. Samples were also 
prepared using the glyceraldehyde-3- phosphate dehydrogenase (GAPDH) primers, 
which acted as an internal control for sample loading. 
2.6.3.3 Nested peR Amplification 
To improve sensitivity, a second round ofPCR was carried out with a nested primer. 
The procedure was identical to the primary PCR amplification, with the following 
exceptions. The RN3 nested anti-sense primer was used instead of the R3 primer in 
the PCR master mix, and the addition of 5 ~l of the primary PCR product was used 
in place of the initial cDNA samples. After another 35 cycles of amplification, the 
nested PCR products were visualised on an agarose gel as before, and a slightly 
smaller (274 bp) product detected. 
2.7 SDS-PAGE (Polyacrylamide Gel Electrophoresis) for Proteins 
2.7.1 Principle of Methodology 
In the presence of protease inhibitors, which prevent protein degradation, proteins 
are exposed to a buffer containing lauryl sulfate sodium dodecylsulfate sodium salt 
(SDS), and a reducing agent such as p-mercapto-ethanol, which breaks protein 
disulphide bridges. These reagents, in combination with heat, result in protein 
denaturation. The denatured proteins bind SDS so that they are completely covered 
by the detergent. This gives the proteins a net negative charge, so that when they are 
run in a polyacrylamide gel, they migrate towards the anode. The amount of SDS 
that binds a protein is dependent on the size of the polypeptide, but independent of 
the amino acid sequence. Therefore, once the protein is denatured, the migration of 
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the protein in a SDS-polyacrylamide gel is dependent on the size of the protein. 
Thus it is possible to estimate the size of a protein by using known proteins as 
markers. 
The percentage of the gels can be varied depending on the size of the protein being 
analysed. For SDS-PAGE 6-15% gels are generally used. The proteins are 
separated according to size by sieving, smaller proteins migrate faster than larger 
proteins. The gel is composed of chains of polymerized acrylamide cross-linked by 
bis-acrylamide. Ammonium persulfate (APS) is used as a source of free radicals to 
drive the acrylamide polymerization reaction whilst N, N, N', N' -
tetramethylethylenediamine (TEMED) accelerates this reaction by catalysing the 
formation of free radicals from APS (Sambrook et ai, 1989). 
2.7.2 Sample Preparation for SDS-PAGE 
2.7.2.1 Materials 
Laemmli Sample buffer stock: 
62 mM Tris base (2-amino-2- (hydroxymethyl) propane-I , 3, -diol (tris» pH 6.8 
10% (v/v) Glycerol 
2% (w/v) SDS 
5% (v/v) f3-mercaptoethanol (Sigma-Aldrich, Poole - M-3148) 
Made up with deionised water (dH20). 
Working Laemmli Sample buffer solution: 
To 1 ml of Laemmli Sample buffer stock (Laemmli, 1970), the protease inhibitors, 
aprotinin (at a final concentration of 1 Ilg/ml), leupeptin (at a final concentration of 
1 Ilg/ml), and phenylmethylsulfonyl fluoride (PMSF) (at a final concentration of 
100 Ilg/ml) were added. 
2.7.2.2 Methodology 
The PDVC57, CarB and SCC25 cell lines, were infected with 2500 vp/cell of 
Ad5CMV-p53, or Ad-PolyA, or mock infected with PBS. After varying incubation 
intervals (4, 8, 16, 24, 48, 72 and 96 hours) the medium was removed from the 
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plates and the cells were then washed and trypsinized. The cells were pelleted by 
centrifugation at 100 G (5 minutes), supernatant discarded and pellet resuspended in 
PBS. The cells were washed and centrifuged twice in PBS, and drained well . Each 
cell pellet containing approximately 106 cells was incubated in 400 JlI of ice-cold 
working Laemmli sample buffer. DNA was physically sheared by passing the cell 
lysate through a 25 gauge needle (Becton-Dickinson, 304434), followed by 
sonication for approximately 30 seconds. The samples were then boiled for 5 
minutes, centrifuged to pellet debris, and the lysate collected into a fresh tube. 
Samples were stored at -80°C until required. The protein concentration was then 
assessed using the Bradford assay. 
2.7.3 Bradford Assay 
2.7.3.1 Principle of Methodology 
Bradford assays (Bradford, 1976) were used to determine the amount of protein in a 
sample. When the Bradford reagent reacts with protein a change in the colour of the 
reagent occurs, from red to blue. This change in colour can be measured with a 
spectrophotometer and compared to a standard curve in which known concentrations 
of a protein are reacted with reagent. Thus, the amount of protein in the unknown 
sample can be interpolated. 
2.7.3.2 Materials 
Bradford reagent: 
50 mg Coomassie Brilliant Blue G-250 (Sigma-Aldrich, Poole - B-0770) 
25ml Ethanol 
50 ml 85% (w/v) Ortho-Phosphoric Acid (Sigma-Aldrich, Poole - P-6560) 
500 ml de-ionised water (dH20) 
Filtered and stored in the dark. 
Bovine Serum Albumin (BSA) standards: 
Stocks of 0, 100, 200, 400, 600, 800 and 1000 Jlglml BSA (Sigma-Aldrich, Poole-
A-7906) in water were prepared. 
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2.7.3.3 Methodology 
100 !J.I of the standards were mixed with 3 !J.I of Laemmli sample buffer (section 
2.7.2.1). In separate tubes, 3 !J.I of the samples were mixed with 100 !J.I of water. To 
each sample 4.5 mls of Bradford reagent were added. The absorbance at 595-nm 
wavelength was read after 2 minutes incubation time. The protein concentration in 
the unknown samples was determined from the calibration obtained with the 
standards. All determinations were performed in duplicate. 
2.7.4 Western Blotting-Running a Polyacrylamide Gel and Transfer of Protein 
to a Nitrocellulose Membrane 
2.7.4.1 Materials 
1 X Electrophoresis running buffer: 
25mM Tris base 
250 mM Glycine 
0.1 % (w/v) SDS 
Make up to 1 litre with dH20 and adjust pH to 8.2 with HCI acid. 
SDS gel-loading solution: 
50 mM Tris.CI (pH6.8) 
10% (v/v) Glycerol 
2% (w/v) SDS 
10% (v/v) l3-mercaptoethanol 
0.1 % (w/v) Bromophenol blue 
Made up to 1 litre with dH20 . 
1 X transfer buffer: 
48 mM Tris base 
39 mM Glycine 
20% (v/v) Methanol 
3.75 ml ofa 10% (w/v) SDS 
Made up to 1 litre with dH20. 
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30%10.8% (w/v) Acrylamide/bis-acrylamide 29: 1 ratio (ScotLab, SL-9208) 
TEMED 
Kaleidoscope Prestained Protein Standards (BioRad, 161-0324) 
2.7.4.2 Methodology 
The gel-casting apparatus was set up according to the manufacturer's instructions 
(Protean IIxi system, BioRad 165-181). Stacking gels and 10 or 15% resolving 
polyacrylamide gels were prepared according to Sambrook et at (1989), see Tables 
2.1 and 2.2 for recipes (7.5% resolving gels for proteins ranging from 36-94 kD; 
10% resolving gels for proteins ranging from 16-68 kD; and 15% resolving gels for 
proteins ranging from 12-43 kD). Once the resolving gel had been poured, the 
surface of the gel was flattened by adding 200 ~l of water to the top of the gel. The 
gel was allowed to set and the water was removed by soaking it up with filter paper. 
The gel combs were placed at the top of the gel and the stacking gel was added. 
When the stacking gel had set, the combs were removed, the gels were fitted into the 
electrophoresis apparatus and the upper and lower chambers of the PAGE tank were 
filled with Ix running buffer. 
The samples were prepared by adding 30 ~l of the Ix SDS-gel loading solution to 
each sample, followed by heating to 100 DC for 5 minutes, to ensure denaturation of 
the protein samples. These were then loaded onto the gel using a 1 00 ~l Hamilton 
syringe (Sigma-Aldrich, Poole - ZIO 948-7), along with the pre-stained protein 
standard (see Appendix I for molecular weights of marker proteins). The lid was 
then secured and the leads connected to the power supply. Gels were generally run 
at 60 V until the tracking dye reached the end of the separating gel (usually 
overnight for large gels). 
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On completion of electrophoresis the gel was removed and the proteins in the gel 
were transferred to a 0.45 J..lm pore nitrocellulose membrane (Amersham Pharmacia 
Biotech, Buckinghamshire, UK RPN 303E). This was achieved using the Trans-
Blot® SD Semi-Dry Electrophoretic Transfer Cell apparatus (BioRad, 170-3940). 
Blotting was performed with plate electrodes in a horizontal configuration. The gel, 
nitrocellulose membrane and filter paper were soaked in Ix transfer buffer for 15-30 
minutes to equilibrate the gels, prior to transfer. The gel and nitrocellulose 
membrane was then sandwiched between sheets of the buffer-soaked filter paper. 
The plate electrodes, separated only by the filter paper stack, provided high field 
strength (V/cm) across the gel, and very efficient, rapid transfers. Large gels were 
transferred for 30 minutes to 1 hour at 15-25 V. 
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SDS- Polyacrylamide Gel Recipes: 
Table 2.1: Solutions for Preparing 5% Stacking Gels for SDS-PAGE 
Solutions Volume (mls) 
H2O 17 
30% Acrylamide mix 4.25 
1.0 M Tris (pH 6.8) 3.125 
10% SDS 0.25 
10% APS 0.25 
TEMED 0.025 
Table 2.2: Solutions for Preparing Resolving Gels for SDS-PAGE 
Solutions Volume (mls) of solutions added for final gel 
concentration of: 
10% 15% 
H2O 39.6 23 
30% Acrylamide mix 33.4 50 
1.5 M Tris (pH 8.8) 25 25 
10% SDS 1 1 
10% APS 1 1 
TEMED 0.04 0.04 
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2.7.5 Checking the Presence of Protein and its Transfer Efficiency 
2.7.5.1 Materials 
Ponceau S stain: 
2% (w/v) Ponceau S stain (3-hydroxy-4-[2-sulfo-4-( 4-sulfo-phenylazo) phenylazo-
2,7-naphthalenedisulfonic acid sodium salt) (Sigma-Aldrich, Poole UK P-3504) 
30% (w/v) Trichloroacetic acid (Sigma T -9159) 
Made up with dH20. 
Coomassie Brilliant blue stain: 
0.25% (w/v) Coomassie Brilliant Blue R-250 (Sigma B-7920) 
45% (v/v) Methanol 
44.75% (v/v) water 
10% (v/v) Acetic acid 
Coomassie Brilliant blue destain: 
45% (v/v) Methanol 
45% (v/v) water 
10% (v/v) Acetic acid 
2.7.5.2 Methodology 
Polypeptides separated by SDS-polyacrylamide gels can be detected by staining the 
gel with Coomassie blue by incubating the gel in the stain on a rocking table for 4 
hours. Excess stain was removed by incubating the gel in Coomassie destaining 
solution for 24 hours on a gentle rocking table. Thorough destaining of the gel 
allows for the detection of very little amounts of protein. To check the transfer 
efficiency of the proteins from the gel to the nitrocellulose membrane, Ponceau S 
staining can be performed. The nitrocellulose membrane was covered in Ponceau S 
stain for 5-10 minutes, with gently agitation. Excess stain was rinsed off with water. 
Any protein present stains pink, which also allows for clear detection of the 
molecular weight standards. Thorough but gently rinsing in PBS-Tween (PBST) 
removes the stain completely, without any interference with the subsequent 
immunological probing. 
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The nitrocellulose blot should be incubated in blocking buffer containing milk 
powder or BSA. The blocking buffer binds non-specifically to the areas in the 
nitrocellulose membrane to which no protein has bound. The blocking buffer may 
also bind non-specific epitopes from the proteins transferred to the membrane. This 
blocking step is performed so that when the filters are exposed to the antibodies, 
these bind minimally to the naked nitrocellulose membrane and non-specific 
epitopes. The first antibody should bind to the protein of interest. The secondary 
antibody (usually conjugated to horseradish peroxidase (HRP) or alkaline 
phosphatase (AP)), binds to the first through epitopes that are specific to the animal 
in which the primary antibody was raised. 
2.7.6.2 Materials 
lXPBS: 
PBS tablets (Sigma-Aldrich, Poole UK - P4417) one tablet dissolved in 200 ml of 
dH20 yields a 0.01 M sodium and potassium phosphate buffer, pH 7.4, containing 
0.0027 M potassium chloride and 0.137 M sodium chloride. 
PBST (phosphate-Buffered Saline-Tween 20) 
0.05% (v/v) Polyoxyethylenesorbitan monolaurate - Tween 20 (Sigma-Aldrich, 
Poole - P-5927), in 1 x PBS 
Blocking Buffer: 
3% (w/v) BSA (Sigma-Aldrich,Poole - A-7906), in 1 x PBS 
Antibodies: 
Primary antibodies (see section 2.8, Table 2.3) 
Sheep anti-mouse biotinylated antibody (Amersham Life Science RPN-IOOI) 
Rabbit anti-goat biotinylated antibody (Dako E0466) 
Streptavidin-biotinylated horseradish peroxidase (Amersham RPN-I 051) 
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2.7.6.3 Methodology 
The blot was incubated for 1-2 hours in blocking butTer on a rocking table. The 
blocking buffer was then removed and the blot washed three times in PBST, for 10 
minutes/wash. The nitrocellulose blot was then incubated in the primary antibody 
for 1-2 hours. Antibodies were diluted in PBST (section 2.8, Table 2.3 for individual 
antibody details). The blot was then rinsed three times in PBST, as before. 
Following this the blot was incubated in the secondary antibody, a sheep anti-mouse 
biotinylated antibody for all the monoclonal antibodies used and a rabbit anti-goat 
biotinylated antibody for the polyclonal antibody, for 30 minutes to 1 hour. These 
were diluted 1 in 200 in PBS with 10% human serum. The blot was rinsed again 
three times in PBST. At this point the tertiary layer, streptavidin-biotinylated 
horseradish peroxidase diluted 1 in 100, is applied to the blot and incubated for 30 
minutes to 1 hour. A further three rinses in PBST were followed by a longer wash 
of 20 minutes to 1 hour. Detection of the protein was carried out by either the 
addition of a substrate system (for example 3,3' -diaminobenzidine 
tetrahydrochloride (DAB) for HRP based detection) as described in manufacturer 
protocol, or the enhanced chemiluminescent (ECL) method was performed. 
2.7.7 Western Blotting Detection- the Enhanced Chemiluminescence System 
2.7.7.1 Principle of Methodology 
Chemiluminescence is more sensitive than colourimetric methods. Luminol (5-
amino-2, 3-dihydrophthalazine-l, 4-dione) is a hydrazide whose oxidation results in 
the production of light (prichard et ai, 1968). Horseradish peroxidase catalyses 
hydrogen peroxide (H202) into H20 and 02, providing the oxygen for the oxidation 
of luminol. The reaction was carried out in a basic buffer, which provides the 
reaction with the necessary OH ions. Hydroxyl radicals are produced during the 
reaction, and addition of radical scavengers such as coumaric acid, enhances light 
emission (Thorpe et ai, 1986). 
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2.7.7.2 Materials 
ECL kits can be purchased from a range of suppliers, however, a home made version 
was used in these experiments. 
ECL Buffer: 
100 mM Tris-HCL (pH 8.5) store at 4°C 
Caumaric acid: 
90 mM p-Coumaric acid (4-hydroxycinnamic acid; Sigma C-9008) 
Made-up in DMSO and stored at -20°C 
Luminal: 
250 mM Luminol 
Made-up in DMSO and stored at -20°C 
2.7.7.3 Methodology 
Ten ml ofECL buffer was mixed with 50 ~lluminol, 25 ~l coumaric acid and 3 ~l 
v/v H20 2 immediately prior to use. The nitrocellulose blot was removed from the 
PBST washing buffer and gently drained. Blots were then placed on a flat surface 
and incubated in the mixed ECL solution, for 1 minute in subdued light. Following 
incubation excess ECL solution was gently drained from the blots. Subsequently the 
filter blots were placed between sheets of plastic (saran) wrap and air bubbles 
removed, prior to exposure to photographic film. Films were processed and 
visualised. Generally 20 to 60 seconds exposure of the blots to photographic film 
was adequate, although re-exposure of the same blot can be carried out if necessary, 




2.8 Antibody Details 
Table 2.3: Antibodies used for Protein Detection via Western Blot Analysis 
Protein Antibody Antibody Species Amino acids detected 
Detected Clone Type Reactivity 
p53 DO-l Mouse Human only Amino acid residues 11-
monoclon 25 ofwt and mutant p53 
allgG2a of human origin 
p53 PAb248 Mouse Mouse only Amino acid residues 23-
monoclon 47 ofwt and mutant p53 
allgG of mouse origin 
p21 WAtl 65 Mouse Human, mouse, Recognise amino acid 
monoclon rat residues 90-109 of human 
allgG11C origin. 
MDM2 2AIO Mouse Mouse, human. Recognise amino acid 
monoclon residues 294-330. 
allgG2a 
'----- .- .. - --
- - -
Molecular Concentration 


































Table 2.3: Antibodies used for Protein Detection via Western Blot Analysis, continued 
Protein Antibody Antibody Species Amino acids Molecular 
Detected Clone Isotype Reactivity detected weight 
(kDa) 
BAX 5B7/A2 Mouse Mouse, Recognise amino 21 
monoclonal rat acid residues 8-16 of 
IgGl mouse Bax 
Actin AC-40 Mouse Wide Recognises epitope 42 
monoclonal variety of located on the C-
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2.9 Immunohistochemical (mC) and Immunocytochemical (ICC) Detection of 
p53 
2.9.1 Principle of Methodology 
Immunohistochemical and ICC are techniques for identifying tissue or cellular 
antigens respectively, by means of antigen-antibody interactions. The indirect 
method of antigen detection was applied, due to its superior sensitivity over that of 
the direct method. Briefly, an unconjugated primary antibody is allowed to bind to 
the antigen in the tissue or cellular sample. A second conjugated antibody raised in 
another animal host and specific for the animal and immunoglobulin class of the 
primary antibody is then allowed to bind to the primary antibody. The complex 
formed can be visualised with an appropriate chromogenic substrate. The avidin-
biotin complex (ABC) method is one such indirect approach. This method relies on 
the strong affinity of avidin for biotin. A similar molecule, steptavidin is now more 
widely used due to its reduced non-specific binding as compared with avidin. A 
high number of biotin molecules can be attached to a single antibody, making it a 
useful secondary antibody. In the ABC method a complex of avidin or streptavidin 
and biotinylated tracer, which contains free avidin binding sites, is applied to the 
biotinylated secondary antibody. Detection with an appropriate chromogen 
substrate follows . Using the Vector® Mouse On Mouse (M.O.M.TM) 
immunodetection kit allows the use of mouse monoclonal antibodies on mouse 
tissue, without the usual problem of high background. This kit utilises a novel 
blocking agent and special detection methodology to significantly reduce 
background staining. 
2.9.2 Materials 
Unconjugated primary antibody: 
p53 (DO-I; Santa-Cruz Biotechnology sc-126) 
Vector@ Mo.M ™ Immunodetection kit-Peroxidase (Vector Laboratories, PK-
2200): 
M.O.MTM Mouse IgG blocking reagent (2 drops of stock solution diluted in 2.5 ml 
PBS) 
126 
Chapter 2 - Materials and Methods 
M.O.MTM protein concentrate (add 600 f.ll of stock solution to 7.5 ml PBS to make 
M.O.M.TM diluent) 
M.O.MTM biotinylated anti-mouse IgG reagent (add 10 f.ll of stock solution to 2.5 ml 
ofM.O.M. diluent prepared above) 
VECT AST AIN® &lite ABC reagents (add 2 drops of reagent A to 2.5 mls of PBS, 
and mix. Then add 2 drops of reagent B to this and mix. Allow to stand for 30 
minutes prior to use). 
Citrate buffer: 
12 mM tri-sodium citrate (BDH 10242) to 1 litre of distilled water, adjust pH to 6.0. 
3% (v/v) Hydrogen Peroxide in tap water 
0.3% (v/v) Hydrogen Peroxide in 0.3% (v/v) normal horse serum in PBS 
AvidinlBiotin blocking kit (Vector Laboratories, SP-200 1) 
DAB substrate 
2.9.3 Methodology 
2.9.3.1 Cell Sample Preparation 
1 x 105 PDVC57 cells were grown on sterile coverslips in 6 cm2 culture dishes. 
Twenty-four hours after plating, the cells were transduced with either Ad5CMV-p53 
or Ad-Poly A (2500vp/cell) as previously described. Negative controls were also 
included, by mock infecting with PBS. Cells were exposed to these various 
conditions for either 6, 24 or 48 hours. Harvesting of cells took place at these 
various time points by removal of culture medium, washing with PBS and fixing for 
10 minutes in 1: 1 (v/v) acetone: methanol (ice-cold). The fix was removed and cells 
allowed to air-dry prior to ICC, or alternatively stored at -20°C. Fixed monolayers 
were incubated in 0.3% (v/v) hydrogen peroxide in 0.3% (v/v) normal horse serum 
in PBS for 5 minutes. The Vector ® M.O.WM immunodetection kit-peroxidase was 
used on all sample preparations as described in the manufacturer protocol, and 
briefly outlined in section 2.9.3 .3 with the exclusion of the avidin/biotin-blocking 
step. 
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2.9.3.2 Tissue Sample Preparation 
Subcutaneous tumour nodules and tumour-bearing muscles were infected with 
Ad5CMV-p53 or Ad-PolyA as described in section 2.22. Biopsies were either 
freshly frozen in OCT, in iso-pentane over liquid nitrogen, or fixed in 3.7% formalin 
followed by standard processing and paraffin embedding. Five 11 tissue sections 
were prepared. Frozen tissue was fixed for 10 minutes in 1: 1 (v/v) acetone: methanol 
(ice-cold). Paraffin sections were deparaffinized in xylene and rehydrated through 
graded alcohol's (100%; 95%, 7(010) to tap water. Antigen unmasking was 
performed on these sections by microwaving in a citrate buffer for 10 minutes on a 
medium power setting. Samples were allowed to cool to room temperature. 
Incubating in 3% (v/v) hydrogen peroxide for 5 minutes blocked endogenous 
peroxidase activity. Fixed frozen tissue sections were incubated in a weaker 0.3% 
v/v hydrogen peroxide solution, in 0.3% (v/v) normal horse serum in PBS for 5 
minutes. The M.O.MTM immunodetection kit staining procedure (section 2.9.3.3) 
was then followed . 
2.9.3.3 M.O.MTM Immunodetection Kit General Staining Procedure 
Samples were washed twice in PBS for 2 minutes, followed by the blocking of 
avidin/biotin using the Vector blocking kit. This involved a 15 minute incubation in 
avidin D blocking solution, followed by a brief wash in PBS and then 15 minutes 
incubation with the biotin blocking solution. Samples were then incubated for 1 
hour in the diluted M.O.MTM Mouse IgG Blocking reagent. Samples were again 
washed twice in PBS for 2 minutes. Samples were incubated in M.O.MTM diluent 
for 5 minutes, then excess diluent removed. The p53 (DO-I) primary antibody was 
diluted 1 in 100 with the M.O.M.TM diluent, and sections incubated for 30 minutes. 
Two x 2 minute washing in PBS were followed by a 10 minute incubation of 
samples with the diluted M.O.M.TM biotinylated anti-mouse IgG reagent. Two 
further washes of 2 minutes in PBS were carried out prior to incubation in 
VETASTAlN® &lite ABC reagent. VECTASTAlN® &lite ABC reagent prepared as 
in section 2.9.2, was added to the sections for 5 minutes. Two 5-minute washes in 
PBS were followed with incubation in DAB substrate solution for 2-10 minutes. 
Sections were counterstained with haematoxylin. 
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2.10 Detection of Apoptosis by DNA Laddering 
2.10.1 Principle of Methodology 
Chapter 2 - Materials and Methods 
Several methods have been described to identify apoptotic cells, and it is advisable 
to use a couple, along with direct morphological evaluation of the cells to validate 
experimental findings. One method used to detect apoptosis in this investigation 
was by the appearance of a typical "DNA ladder" when samples were run on an 
agarose gel during electrophoresis. This laddering results from the endonucleolytic 
cleavage of nuclear DNA, resulting in fragments of DNA. Nucleosomal excision is 
caused by endonuclease-mediated digestion of the exposed DNA linker regions 
between nucleosomes in chromatin. Since the 180-200 base pairs of DNA around a 
histone core are conformationally protected from digestion, this endonuclease-
mediated nucleosome excision is observable as a DNA ladder (with multimers of 
approximately 180-200 bp) in agarose gels (Oberhammer et ai, 1993). 
2.10.2 Materials 
Tris-borate (TEE) buffer (5 J) 
0.45 M Tris base 
0.45M Boric acid 
2% (v/v) of 0.5 M Ethylenediamine tetraacetic acid (EDT A) (pH 8.0) 
Made up to 1 litre with dH20 
2% w/v agarose ( electrophoresis grade) made up in 1 x TBE 
DNA samples 
2.10.3 Methodology 
1 x 106 PDVC57 or CarB cells per 10 cm2 culture dish were transduced with one of 
the following: Ad5CMV-p53; Ad-f3-gal; Ad-PolyA, (2500vp/cell) as previously 
described. Positive controls were 2 minutes UV light exposure or 20 J..lg/ml 
cisplatin. Untreated controls were also included. Cells were exposed to these 
various conditions for varying time periods (16; 20; 24; 40; 44; 48; 64; 68; 72 
hours) . Harvesting of cells took place at these various time points by removal and 
centrifugation of the supernatant. Two mls ofDNA-Stat-60 (Biogenesis, Poole) was 
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added to each culture plate and cells were lyzed by passing several times through a 
pipette, this was then mixed with the pelleted cell debris from the supernatant, and 
stored in cryovials at -80°C. 
DNA was prepared from samples with DNA-Stat-60 as outlined in the 
manufacturers information sheets (Biogenesis, Poole). Briefly, cell lysates are 
defrosted and 0.2 ml of chloroform added per I-ml sample volume, after vigorous 
shaking for approximately 15 seconds, and 2-3 minute incubation at room 
temperature, samples were centrifuged at 12,000 G for 15 minutes at 4°C. This 
centrifugation results in two distinct layers, a lower organic phase and an upper 
aqueous phase. DNA remains in the aqueous phase whereas RNA and proteins are 
in the interface and the organic phase. The top aqueous layer is transferred to a fresh 
tube and mixed with 0.5 mls of isopropanol. After 5-10 minute incubation at room 
temperature, samples were centrifuged at 12,000 G for 10 minutes at 4°C. The 
DNA precipitate forms a small clear to white pellet at the bottom of the tube. 
Supernatant was removed and the DNA pellet washed in 75% ethanol by vortexing 
and subsequent centrifugation at 7,500 G for 5 minutes at 4°C. The washed DNA 
pellet was briefly air-dried and then allowed to dissolve in water. The concentration 
of each DNA sample is determined by spectrophotometry at 260nm and 280nm 
wavelengths. 51lg of each DNA sample, along with a molecular weight marker 
(Appendix II) was loaded onto a 2% agarose gel containing 101lg/ml ethidium 
bromide, and allowed to run for approximately 3 hours at 100 volts. Evidence of 
DNA laddering is visualised by examination of the gel under UV light. 
2.11 Detection of Apoptosis by the Terminal Deoxynucleotidyl Transferase 
(Tdt) -Mediated dUTP Nick-End Labelling (TUNEL) Assay 
2.11.1 Principle of Methodology 
Apoptosis can be detected at the cellular level and quantified by TUNEL assay. 
This is achieved by the enzymatic in situ labelling of apoptosis induced DNA strand 
breaks. Labelling the free 3' -OH termini with modified nucleotides in an enzymatic 
reaction can identify these strand breaks. Terminal deoxynucleotidyl transferase 
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(TdT) is used in this procedure to catalyse the polymerization of nucleotides to free 
3' -OH DNA ends in a template-independent manner. The incorporation of 
fluorescein is detected by anti-fluorescein antibody Fab fragments from sheep, 
conjugated with alkaline phosphatase. After substrate reaction, stained cells can be 
analyzed under light microscope. The TUNEL reaction is considered to be a more 
sensitive and faster method than the template-dependent nick translation. In 
addition, it has been shown that, in early stages, apoptotic cells were preferentially 
labelled by the TUNEL reaction (Chapman et ai, 1999). 
2.11.2 Materials 
In Situ Cell Death Detection Kit, AP (Boehringer-Mannheim, 1684809): 
Enzyme solution: Terminal deoxynucleotidyl transferase in storage buffer 
Label solution: Nucleotide mixture in reaction buffer 
Converter-AP: anti-fluorescein antibody, Fab fragments raised in sheep, conjugated 
with alkaline phosphatase 
PBS 
4% w/v Paraformaldehyde in PBS, pH 7.4 
0.1% v/v Triton X-100 (in 0.1 % w/v sodium citrate) 
Proteinase K solution (20 J..I.glml in 10 mM Tris/HCI, pH 7.4) 
Chromogenic substrate (Fast Red) 
Cell-tak (Collaborative Biomedical Products, Bedford MA, 40241) 5 J..I.glcm2 diluted 
into a final volume of 50J..l.I O.lM Sodium carbonate buffer (pH 8.0) 
2.11.3 Methodology 
2.11.3.1 Cell Sample Preparation 
5 x 105 PDVC57 cells were transduced with one of Ad5CMV-p53; Ad-j3-gal; Ad-
PolyA; or Ad-Luc, at 2500 vp/cell, as described previously. Positive controls were 
either 2 minutes exposure to UV light or 20 J..I.glml cisplatin. Untreated controls 
were also included. Triplicate plates of cells per treatment condition were exposed to 
these various conditions for varying time periods (16; 20; 24; 40; 44; 48; 64; 68; 72 
hours). Harvesting of cells took place at the various time points by two methods. 
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The ftrst involved collecting the cells floating in the culture medium, by 
centrifugation at 100 G for 5 minutes. The cellular pellet was washed once with 
PBS, and after centrifugation the pellet was resuspended in approximately 200 III 
PBS. The resuspended cells were then spread onto a cell-tak coated microscope 
slide, and allowed to air dry. The adherent cells were grown upon coverslips within 
6-cm2 cell culture dishes, and were harvested by washing in PBS, followed by air-
drying. Coverslips and microscope slides were ftxed in 4% paraformaldehyde for 30 
minutes at room temperature prior to TUNEL staining (section 2.11 .3.3). 
2.11.3.2 Tissue sample Preparation 
Additionally, S.c. tumour nodules and tumour-bearing muscles were infected with 
either Ad5CMV-p53, Ad-l3-gal, Ad-Luc or Ad-PolyA as described in section 2.22. 
Biopsies were freshly frozen in OCT, in iso-pentane over liquid nitrogen, or ftxed in 
3.7% formalin followed by standard processing and paraffin embedding. Five 11 
tissue sections were prepared. Frozen tissue was ftxed for 20 minutes in 4% 
paraformaldehyde, followed by washing for 30 minutes in PBS, prior to TUNEL 
staining. Paraffin sections were dewaxed and rehydrated through graded alcohol 
solutions to distilled water. Sections were incubated in a proteinase K solution for 
30 minutes at 37°C, prior to TUNEL staining (section 2.11.3.3). 
2.11.3.3 In Situ Cell Death Detection (TUNEL Staining) 
The detection of apoptotic cells was performed according to the manufacturer's 
protocol. Briefly, cells or tissue were permeabilized for 2 minutes at 4°C (in 0.1 % 
Triton X-I 00 made up in a 0.1 % sodium citrate solution), on completion of ftxation. 
After rinsing in PBS, 50 III of TUNEL reaction mixture (made by mixing 450 III of 
Label solution and 50 III of enzyme solution) was added to each sample. The 
TUNEL reaction mixture is prepared immediately prior to use and stored on ice. In 
addition negative controls were set up, by the incubation of sample preparations in 
50 III of the Label solution without the presence of the enzyme solution. Positive 
controls were also included, by incubating the ftxed and permeabilized cells with 
DNase 1 (1 mg/ml) for 10 minutes at room temperature, followed by the addition of 
the TUNEL reaction mixture as for the test samples. All samples were incubated in 
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either the TUNEL reaction mixture or the Label solution for 1 hour in a humidified 
chamber at 37°C. Samples were washed three times in PBS, and subsequently 
incubated at 37 °C for 30 minutes in 50 III of the converter-AP solution. Samples 
were again rinsed three times in PBS, followed by incubation with a suitable 
substrate (Fast Red) for approximately 10-20 minutes. Cells or tissue sections were 
counterstained with Light Green and mounted in an aqueous mount ant. Slides were 
analyzed by light microscopy. 
The evaluation of TUNEL staining of PDVC57 cells was performed by counting 
200 cells each from triplicate plates per treatment condition, from both cells found 
floating in the medium and the adherent cell population, with percent apoptosis 
calculated. The evaluation of TUNEL staining in tissue sections was performed by 
counting 5000 tumour cells at random in 10 different fields at high power, to 
determine the percentage of TUNEL positive cells (Ravi et ai, 1999). Multiple 
sections throughout the tissue samples were analysed. 
2.12 Detection of Apoptosis by Acridine OrangelEthidium Bromide Uptake 
2.12.1 Principle of Methodology 
This protocol enables the differentiation of viable, necrotic, early apoptotic and late 
apoptotic cells, due to the differing uptake of two fluorescent DNA binding dyes, 
acridine orange and ethidium bromide. Acridine orange intercalates into DNA, 
giving it a green appearance. This dye also binds to RNA but because it cannot 
intercalate, the RNA stains red-orange. Ethidium bromide is only taken up by non-
viable cells. This dye also intercalates with DNA, making it appear orange, but only 
binds weakly to RNA, which may appear slightly red (McGahon et ai, 1995). In 
summary, viable cells with intact membranes will have a uniform green colour in 
their nuclei . Early apoptotic cells whose membranes are still intact but have started 
to fragment their DNA will still have green nuclei since ethidium bromide cannot 
enter the cell, but chromatin condensation will become visible as bright green 
patches in the nuclei. Late apoptotic cells, where membrane bleb bing starts to 
occur, will allow the entry of ethidium bromide. These cells will have bright orange 
133 
Chapter 2 - Materials and Methods 
areas of condensed chromatin in the nucleus, which distinguishes them from 
necrotic cells, which have a uniform orange colour (McGahon et ai, 1995). 
2.12.2 Materials 
100 !J,glml Acridine orange (Sigma, A-6014) in PBS 
100 !J,glml Ethidium bromide (Sigma, E-87 51) in PB S 
2.12.3 Methodology 
PDVC57, CarB, SCC25 or HN5 cells were plated at a concentration of 5 x 105 cells 
per 10-cm2 culture dish, 24 hours before treatment. Cells were infected with either 
2500 vp/cell Ad5CMV-p53 or Ad-PolyA, as previously described. Positive controls 
were 2 minutes exposure to UV light or inclusion of 20 !J,glml cisplatin in the 
medium. Culture medium was used for mock infections. Triplicate dishes of each 
treatment were set-up. Cells were harvested at various time points after treatment 
(24, 48 and 72 hours). The culture medium containing floating cells was removed 
but kept, adherent cells were washed, and trypsinized as previously described. Both 
floating and trypsinised cells were centrifuged at 100 G for 5 minutes, and cell 
pellets gently mixed with a 1: 1 (v/v) of the two dyes acridine orange and ethidium 
bromide (100 !J,glml). 1!J,1 of dye mix was added to every 25 !J,l of cell suspension. 
Dye uptake is almost instantaneous. 10!J,1 of cell suspension was smeared onto a 
clean microscope slide and cells examined under a 40 x objective with a filter 
combination suitable for reading fluorescein. A minimum of 200 cells were counted 
per slide and the number of cells noted that were viable, necrotic, in early apoptosis 
or in late apoptosis. The percentage of cells in each of these four groups was then 
determined. 
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2.13 Cell Cycle Analysis by Flow Cytometry 
2.13.1 Principle of Methodology 
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A flow cytometer measures and records intensities of light either scattered or emitted 
from a cell, when stained with an appropriate fluorochrome (Steen, 1990). One 
facility available via the flow cytometer is the detennination of cellular DNA 
content, in studies of cell kinetics. A single-cell suspension is prepared and cells are 
stained with a fluorescent dye, where the binding is proportional to DNA content. 
Cells are then directed in single file through a laser beam to excite the DNA-specific 
dye, and the fluorescence emission is collected and displayed as a fluorescence 
distribution. The technique allows enumeration of cells containing different 
quantities of fluorescent dye, and thus different amounts of DNA. 
Several fluorescent dyes have been used to stain DNA, including ethidium bromide, 
propidium iodide, acridine orange, mithramycin, and Hoechst 33342. Most dyes 
require fixation of cells to allow access of dye to the DNA. The application of flow 
cytometry to studies of cell proliferation requires analysis of a fluorescent DNA 
distribution to provide estimates of the proportion of cells with 2N DNA content 
(i.e., Gl and most non-proliferating cells), 4N DNA content (G2 and mitotic cells) 
and intermediate DNA content (S-phase cells). Cells with lower DNA staining than 
that of G 1 cells (the so-called "sub-G 1 peaks", "AO" cells) have been considered 
apoptotic (Gorczyca et aI, 1993). A major disadvantage of this technique is its 
inability to discriminate apoptotic cells from necrotic cells. 
Propidium iodide is a fluorescent nucleic acid dye. Binding of propidium iodide to 
double-stranded nucleic acids occurs through intercalation between base pairs with 
no preference to purine or pyrimidine base pairs. Propidium iodide does not bind to 
single-stranded nucleic acids. Propidium iodide binds specifically and 
stoichiometrically to double-stranded nucleic acid, allowing fluorescent intensity 
(above 630 nm) to be used as an indicator of cellular DNA content. RNA is also 
labelled by these dyes, emphasising the need to incubate the suspensions with 
ribonuclease to ensure selective DNA staining. 
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2.13.2 Materials 
18 J..Lg/ml Propidium iodide 
8 J..Lg/ml Rnase A 
Made-up in 1 mlofPBS. 
80% Ethanol in water (-20°C) 
2.13.3 Methodology 
Chapter 2 - Materials and Methods 
PDVC57 and CarB cells were plated at a concentration of 2 x 105 cells per lO-cm2 
culture dish for 24 hours before adenoviral infection. Cells were infected with 2500 
vp/cell of Ad5CMV-p53; Ad-f3-gal; or Ad-PolyA, as previously described. Positive 
controls were exposure to UV light for 1-2 minutes or addition of 10-20 J..Lglml 
cisplatin to the medium. Culture medium was used for mock infections. All 
experiments were set-up in duplicate. Cells were harvested at various time points 
after treatment (6, 24 and 48 hours). The cells were washed in PBS, and trypsinized 
as previously described. After centrifugation at 100 G for 5 minutes, the cells were 
washed and centrifuged again in PBS. The cells were then fixed in 80% ethanol 
whilst vortexing. Samples were then kept at 4°C for at least 1 hour, or up to several 
days. Prior to flow cytometric analysis, cells were briefly centrifuged and 
resuspended in 1 ml of PBS containing RNase A (8 J..Lg/ml) and propidium iodide (18 
J..Lg/ml) . An approximate cell concentration of 1 x 106 cells/ml is required for 
analysis. Samples were stored in the dark at 4°C prior to analysis. A Becton 
Dickinson fluorescence-activated cell sorter (F ACS; F ACScan, Heidelberg, 
Germany) was used to count 10,000 cells per sample, and a histogram of DNA 
content against cell number was plotted using CELLQuest software. The DNA 
signal (red fluorescence) can be collected in FL2. Propidium iodides red 
fluorescence signals must be collected on a linear scale. Gating of the cells allowed 
the percentage in each phase of the cell cycle to be determined. 
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In Vivo Experiments 
2.14 Animals 
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Six to eight week-old female C57B1I6 mice and athymic nude (nulnu) mice were 
obtained from Harlan Ltd (Oxford, UK). The Local Ethical Committee for animal 
welfare and the King's College Local Committee for research involving 
manipulation of recombinant DNA approved all experiments. 
2.15 Establishment of Subcutaneous Tumours 
Groups of CS7B1I6 and/or nude mice were anaesthetised with 2-S% halothane in 
oxygen. Using an 100 III Hamilton syringe 1 x 106 of freshly trypsinized PDVCS7 
cells in SO III PBS were injected slowly into the S.c. tissues of the dorsal flanks of 
these mice (Clayman et ai, 1995a; Bi et aI, 1997; Rocco et aI, 1998). Two S.c. 
tumour nodules were created on the anterior and posterior flanks of one side of each 
rodent. Animals were observed daily for tumour growth, sacrificed on day 20-25 
and tumours excised for histopathological examination. 
Subcutaneous tumours were also established in nude mice following injection of 1 x 
106-8 x106 SCC97 cells. 
2.16 Establishment of Subcutaneous Model of Minimal Residual Cancer 
Groups of mice (CS7Bl/6) were anaesthetised with 2-S% halothane in oxygen and a 
S.c. pocket developed by sharp dissection in the right anterior and posterior dorsal 
flanks. These flaps were elevated and Ix 106 of freshly trypsinized PDVCS7 cells 
introduced into each of these S.c. pockets in 50 III of PBS, to create two tumour 
sites (Clayman et aI, 1995). The flaps were sealed with horizontal mattress sutures. 
Therapeutic agents were introduced into these pockets two days post tumour -cell 
inoculation, when tumour cell proliferation was mimicking the clinical scenario 
when tiny deposits of residual tumour persists at the operative site. 
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2.17 Establishment of the Muscle Model of Minimal Residual Cancer 
PDVC57 cells at various concentrations (104, 105, 5 X 105 or 106) were implanted 
under 2-5% halothane anaesthesia in oxygen into the gastrocnemius or the rectus 
femoris muscle, of groups of C57BV6 mice (Appendix III). The gastrocnemius and 
rectus femoris muscles of the leg were chosen due to the ease of identification, good 
size and relatively superficial location allowing for minimal manipulation during 
experimentation. 
Following exposure of the muscle via a skin incision and blunt dissection the freshly 
trypsinised cells were introduced in 30-100111 of PBS using a gas-tight syringe 
(Hamilton, Carnforth, UK), and a short, 30 gauge needle. The tumour cells were 
injected with 5 parallel passes of the needle, aiming to inject into the centre of the 
muscle and into each of the four quadrants, upper, lower, left and right, to produce 
multiple nests of tumour, along the length of the muscle. The tumour cells were 
released slowly as the needle was drawn back along the muscle. The skin was closed 
with interrupted sutures. 
2.18 Tissue Fixation 
Following establishment of the tumour models, or after the vanous treatment 
schedules, tissues were excised and prepared for histological analysis. Tissues were 
either snap-frozen in OCT in isopentane over liquid nitrogen, and stored at -80°C, or 
fixed in a range of fixatives to suit the method of examination selected, prior to 
standard processing and paraffin embedding. A 3.7% formaldehyde fixative was 
used for general histological examination, p53 IHC and TUNEL staining of tissues. 
A 2% (v/v) formaldehyde: 0.2% (v/v) glutaraldehyde mix in PBS was used to fix 
tissue required for X-gal staining. 
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2.19 Histological Examination of the Muscle Model of Minimal Residual Cancer 
To assess the pattern of tumour growth in the muscle and the development of nests 
of tumour throughout the muscle length, mice were sacrificed at varying times (2-7 
days). The muscle was re-exposed and removed for histological examination. 
In the majority of cases, the entire muscle was embedded and 5 ~ cross sections cut 
every 400 ~, to allow evaluation of tumour nest number and cross-sectional area. 
However, in some cases longitudinal sections were examined to determine how far 
nests of tumour ran through the muscle. Tumour nest numbers were counted 
microscopically at all levels of the muscle, with tumour cross-sectional area 
measured at the central level for consistency. Initially the area of the tumour nests 
was estimated as the product of the two greatest perpendicular dimensions at right 
angles, multiplied by n14. However, the majority of area measurements were 
determined using a Leica Q500 IW image analysis system (Cambridge) with Qwin 
image processing and analysis software. Tumour area measurements included tissue 
comprising of at least 80% tumour cells, as well as any irregular extensions of 
tumour into the surrounding muscle, when at least five nuclei could be detected in 
each column of invading tumour cells. In addition, any cystic cavities within the 
tumour were measured as part of the tumour area. 
2.19.1 Data Analysis of the Muscle Model of Minimal Residual Cancer 
The total cross-sectional area, and the average cross-sectional area, of the tumour 
nests developing at the midpoint of the gastrocnemius or rectus femoriS muscle, as 
determined by section level number, at a specified time-point, were investigated as 
possible outcome measures. 
The total cross-sectional area of the tumour nests was calculated by summating the 
area of the individual nests developing at the muscle midpoint. The average area was 
determined by summating the individual tumour nests cross-sectional area and 
dividing by the number of nests forming at the midpoint. 
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The cross-sectional area of each tumour nest was also examined in sections 400 11 
either side of the midpoint to determine the reliability of using just a single section 
for analysis. The mid-point was chosen in order to provide a simple and reproducible 
methodology which is not influenced by ad-hoc examination of the data. Estimates 
of the variation in cross-sectional area of individual tumour nests within the same 
mouse, and between mice, were derived using analysis of variance (ANOV A). 
2.20 Molecular Therapy Schedules 
Groups of mice were re-anaesthetised with 2-5% halothane in oxygen. To establish 
the efficacy of gene transfer in each of the three murine models (as described in 
sections 2.17,2.18 and 2.19) 4-40 x 1010 vp of Ad5CMV-p53, Ad-J3-gal, Ad-PolyA, 
or Ad-Luc in 50 III PBS (equivalent to 2-20 x 109 p.f.u.) or PBS alone, was 
administered to the tumour bearing animals. Treatments consisted of either singular 
administration of virus, or a maximum of three treatments given every other day for 
three days. Animals were sacrifice 24 and 48 hours post final-infection, to allow for 
protein detection of p53 by IRC (as described in section 2.9), detection of the J3-gal 
marker gene via X-gal staining (as described in section 2.5), or detection of 
apoptosis by TUNEL staining (as described in section 2.11). 
Alternatively, animals were sacrificed at later time points (post- 48 hours) and tissue 
examined for viral treatment effects, after haematoxylin and eosin staining. 
2.20.1 Evaluation of Molecular Therapy using the Subcutaneous Tumour 
Model 
Typically after 3 weeks, two tumour nodules of 5-1 Omm diameter were present on 
the dorsal anterior and posterior flanks of each rodent. In order for direct comparison 
of treated and untreated tumour nodules, one of the two S. C. tumour nodules was 
injected with Ad5CMV-p53, whilst the other received PBS or Ad-PolyA, and acted 
as the untreated control. Injection of adenovirus or PBS into the tumour nodules was 
performed by one of two methods: administration by multiple passes at different 
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levels in one plane, injecting as the needle was withdrawn, followed by a second 
series of passes in a plane at right-angles to this was one choice, alternatively, 
adenovirus or PBS was injected at random at different levels in multiple planes. 
For determination of trans gene (p53 or ~-gal) protein expression, by pS3 mc or X-
gal staining respectively (as described in sections 2.9 and 2.S), or examination of 
apoptosis by TUNEL staining (as described in section 2.11) S.c. tumour nodules 
were treated once with S x 1010 vp of AdSCMV-p53 or Ad-~-gal in a final volume of 
SO III PBS. Following anaesthesia with 2-S% halothane in oxygen, tumour nodules 
were removed (24 and 48 hours post-infection). 
Alternatively, tumours were treated with S x 1010 vp of AdSCMV -p53 or Ad-~-gal 
in SOIlI of PBS, on days 20 and 22 post tumour cell inoculation, and rodents 
sacrificed three days later (day 2S). 
2.20.2 Evaluation of Molecular Therapy using the Subcutaneous Model of 
Minimal Residual Cancer 
Two days after PDVCS7 cells were implanted into the dorsal flanks, groups of 
rodents were re-anaesthetised and the S.c. flaps re-opened. One site received S x 
1010 vp of AdSCMV-p53 in SO III of PBS with the other site acting as an untreated 
control, receiving S x 1010 vp Ad-PolyA. A needle was used to deposit the virus into 
the S.c. pocket, where it dispersed readily into the surrounding tissues. The area 
was closed with sutures after 2-3 minutes. Animals were observed daily and 
sacrificed on either day 2 (48 hours) or 3 weeks (6 weeks) following the molecular 
intervention. 
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2.20.3 Evaluation of Molecular Therapy using the Muscle Model of Minimal 
Residual Cancer 
After injection ofPDVC57 cells into the gastrocnemius and rectus femoris muscles, 
animals were re-anaesthetised and 5 x 1010 vp of either AdSCMV-p53, Ad-PolyA, 
Ad-j3-gal, Ad-Luc in SO J ..t.l of PBS, or PBS alone was delivered to each tumour-
bearing muscle. Typically, the virus was injected on days 4, 6 and 8 following 
implantation of the tumour cells by a series of injections in one plane, followed by 
further injections in a plane at right angles to this. Alternatively, virus was injected 
at random, at different levels in multiple planes, or a single puncture hole in the 
muscle fascia was made, and the needle moved to make multiple injections in the 
muscle without removing it from the fascia. Mice were sacrificed 3 or 7 days after 
the final treatment (day 11 or IS) and the treated muscles prepared for embedding. 
Tissue sections were examined after haematoxylin and eosin staining, and tumour 
area developing after AdSCMV-p53 or Ad-PolyA treatments compared. In some 
experiments, the various viruses were administered only once with biopsies taken at 
24 and 48 hours post-viral infection. 
2.21 Chemotherapy Schedules 
To establish the most appropriate dosing concentration and time schedule of selected 
chemotherapeutic agents used to treat squamous tumours in both the S.C. model and 
muscle model of minimal residual cancer (sections 2.17 and 2.19), cisplatin (David 
Bull Laboratories 1881A Warwick, UK - stock 50 mg/SO ml), or 5-FU (David Bull 
Laboratories 2669A - stock 2S0 mg/l0 ml) were administered into the peritoneal 
cavity of tumour bearing C57B1I6 or nude (nu/nu) mice. 
A dose of 3-10 mg/kg cisplatin (60-200 III of stock) and 50 mg/kg 5-FU (40 III of 
stock) was used based on results of previous studies (Gurnani et ai, 1999). Cisplatin 
was administered either daily or every other day, with a total range of 2-5 
treatments. 5-FU was administered either every other day, for a maximum of S 
days, or once weekly for 2 weeks. 
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Rodents with residual cancer in the muscle were treated with chemotherapeutic 
agents 3 days post tumour cell inoculation. Treatment of rodents bearing S.c. 
tumours commenced 3-25 days after tumour cell inoculation. Mice were sacrificed 
1-7 days after the final treatment, and muscles or S.c. tumours removed, fixed and 
prepared for paraffin embedding. Tissue sections were examined after haematoxylin 
and eosin staining. Tissue sections were also analysed for apoptotic cells using 
TUNEL in some experiments (as described in section 2.11). 
Tumour nest cross-sectional areas were measured at the midpoint of the muscle 
minimal residual cancer model, after cisplatin treatment and compared to the nest 
areas developing for untreated controls. The two sample (un-related) t-test was 
performed to establish if significant differences in total tumour nest cross-sectional 
area was achieved. 
2.22 Establishment of a Model of Squamous Cell Carcinoma of the Head and 
Neck in the Floor of the Mouth 
To establish whether PDVC57 cells could invade and metastasise, 1 x 106 cells were 
injected into the floor of the mouth. Mice were anaesthetised with 2-5% halothane 
in oxygen and the PDVC57 cells introduced in 50 J...lI of PBS into the S.c. tissue of 
the floor of the mouth. The mouth was inspected weekly (for 12 weeks) for evidence 
of tumour growth, but no intra-oral tumours were apparent clinically. Rodents were 
sacrificed at this time and biopsies of the jaw, regional lymph nodes, liver, and lungs 
taken for paraffin embedding. Tissue sections were examined for evidence of 
metastasis. The jawbones were decalcified in 18% ethylene-diamine tetra-acetic acid 
at 4°C for 24 hours, embedded in paraffin wax and 5J...l sections prepared and stained 
with haematoxylin and eosin for microscopic examination. 
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Chapter 3- mRNA and Protein Expression 
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3.1 Detection of Reporter Gene Expression In Vitro 
Transduction efficiency is frequently evaluated using the reporter gene LacZ that 
encodes for the (3-galactosidase protein. Gene expression is inferred from (3-gal 
enzymatic activity upon exposure of infected cells or tissue to the substrate X-gal. 
To determine the adenoviral transduction efficiency of each cell line, cells were 
infected for 24 hours with Ad-(3-gal, followed by histochemical staining with X-gal. 
Transduction efficiency was assessed following infection with different 
concentrations of virus, by counting the number of blue cells after X-gal staining. A 
minimum of 200 cells was counted per plate, with the mean taken from triplicate 
sample counts per vp/cell of adenovirus tested. The percentage of positive staining 
cells was determined from the mean counts. 
It is important to include positive and negative controls for the reporter gene 
detection assays. Positive controls are usually previously tested samples known to 
contain reporter activity. This ensures that interpretations of results due to 
experimental errors are not unduly made. Negative results may arise for a number of 
reasons, including unsuccessful transduction by the vector, lack of transgene 
activation, or errors in the detection assay. Additionally, promoter background 
activity in the cell lines tested should be checked, by carrying out X-gal 
histochemistry on the untreated cell lines and Ad-PolyA infected control cells. 
Cellular transduction varies enormously between cell types, resulting in a range of 
transgene expression levels, which potentially result in a dose-dependent response to 
the gene insert. The transduction efficiency may also vary between plates of the 
same cell type affecting the interpretation of a result. To try to keep this to a 
minimum, experimental conditions were kept as close to identical as possible at all 
times, and triplicate samples were set up for each varying treatment. The capability 
of high transduction efficiency in the p53 mutated murine PDVC57 cell line in vitro 
was one of the key factors in assessing the suitability of this line for setting up in 
vivo models, in immunocompetent and immunodeficient hosts. 
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The number of infected cells increased as the number of virus particles increased 
(625, 1250, 2500, 5000 vp/cell), for all cell lines tested (Figure 3.2). Infection of all 
cell lines with Ad-PolyA was performed as a negative control, and after X-gal 
staining no positive cell staining was detected in any samples. 
Cell numbers were found to be critical for transduction efficiency. Cells were 
required to be approximately 50% confluent on the day of infection for highest 
transduction rates. For example, when PDVC57 cells were seeded at a concentration 
of 1 x 105 cells per 6 cm2 plate, and infected with 1250 vp/cell of Ad-J3-gal, 24 hours 
later, X-gal staining resulted in a mean of 63% positive (blue) cell staining. In 
comparison, when PDVC57 cells were seeded at 5 x 105 cells per 6 cm2 plate, and 
infected with 1250 vp/cell Ad-J3-gal, X-gal staining resulted in a mean of 45% 
positive cell staining. This pattern was also evident at 2500 vp/cell, where cells at 
the 1 x 105 concentration, showed 69% positive X-gal staining, compared with 50% 
when cells were at 5 x 105. Therefore, cells were ideally infected when 
approximately 50% confluent. 
Additionally it is recommended that reduced serum levels be added to medium 
containing no antibiotics to improve transduction efficiency. However, additional 
serum should be provided approximately 4 hours post-transduction, to ensure that 
cells are not deprived of nutrients, which could result in cells exiting into GO cell 
cycle quiescence. The transition between GO quiescence and early G 1 is regulated 
by growth-stimulatory and growth-inhibitory factors present in the extracellular 
environment, the up-regulation of the D-type cyclins in the presence of growth 
factors, helps mediate early G 1 progression. 
The importance of harvesting cells pnor to confluency is to prevent contact 
inhibition, which results in cell cycle arrest in early G 1 phase of the cell cycle. 
Several studies have reported the accumulation ofp27, a CDK-2 inhibitor, in contact 
inhibited cells (Davis et ai, 2001). Therefore, serum deprivation and contact 
inhibition should be avoided in the majority of experiments used in this study, since 
these factors may affect the expression of cell cycle proteins, interfering with the 
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interpretation of the transgene effect. This could potentially affect the post-
translational modifications required for p53 activity. Additionally, the distribution of 
the cell population within the cell cycle is disrupted when cells are confluent, which 
could delay or prevent entry into apoptosis (Davis et ai, 2001). Therefore, reporter 
gene, cell growth, mRNA and protein expression, and all apoptotic and cell cycle 
analysis assays were performed on cells harvested before reaching confluence, to 
minimise these outcomes. 
PDVC57 cells infected with a single dose of 1250, 2500 and 5000 vp/cell 
(equivalent to 50, 100 and 200 MOl) of Ad-~-gal exhibited good levels of transgene 
expression, ranging from 63- 74% positive cell staining (Figures 3.1 and 3.2). The 
UMSCC22A cell line also showed good transduction efficiency, with 70-98% 
positive X-gal staining after infection at 1250-5000 vp/cell Ad-~-gal (Figure 3.2). 
The HN5 cell line expressed this transgene activity in approximately 50% of the 
cells after transduction with 5000 vp/cell, with 36% of the cells showing X-gal 
positive staining at 2500 vp/cell (Figure 3.2). 
The SCC97 cell line expressed transgene activity in approximately 34% of the cells 
after transduction with 5000 vp/cell, with only 25% of the cells showed X-gal 
positive staining at 2500 vp/cell (Figure 3.2). 
The CarB and SCC25 cell lines showed fairly poor transduction levels after Ad-~­
gal infection, and X-gal staining. At 5000 vp/CarB cell, approximately 17% of the 
cells showed positive X-gal staining, with only 8% of the cells staining blue at 2500 
vp/cell . The SCC25 cells had only 5% positive X-gal staining at 5000 vp/cell, and 
3% at 2500 vp/cell (Figure 3.2). 
Couffinhal et ai, 1997, reported that histochemical staining methods report not 
whether the gene product is present or absent, but where it is active, and hence, 
vastly underestimates gene expression as compared to using an anti-~-galactosidase 
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antibody. This group also report on how different experiment conditions such as 
fixatives used, time of incubation, and temperature of staining all effect the level of 
X-gal staining seen. Additionally, X-gal staining requires a threshold level of 
enzymatic activity to recognise successful gene transfer, with high numbers of l3-gal 
copies (500-2000) necessary to transform the chromogenic substrate. We found that 
the best X-gal staining was achieved after fixing cells or tissues in a 2% (v/v) 
formaldehyde: 0.2% (v/v) glutaraldehyde mix in PBS, at 37°C for up to 24 hours. 
Since antibody staining is independent of factors governing enzyme activity 
(including copy number content of the cell) this more sensitive indicator of 
successful transduction might prove to be a better method for future experiments. 
Adenoviruses use CARs on the host cells to gain entry into the cell . The level of 
CAR expression varies considerably between different cell types and consequently a 
deficiency in this native adenovirus receptor results in cells being refractory to 
adenovirus infection. Therefore, if this critical step of adenoviral binding to the host 
cell is variable, then gene uptake, protein expression and hence therapeutic response 
will all be compromised. Various studies have shown that cells that show high 
adenoviral transduction efficiency have numerous CAR/cell (3000-10,000), with a 
high percentage of the cells containing these receptors (Blackwell et ai, 1999 and 
Walters et ai, 1999). Daqing et ai, 1999 used a monoclonal antibody RmcB that 
recognizes the CAR protein to determine receptor density among SCCHN cell lines. 
Significant variation in CAR density was found. 
In the majority of transduction experiments, cells susceptible to adenoviral vector 
entry are expected to be transduced at high levels at vp of between 1000-S000/cell 
(equivalent to 50-200 MOl). In the cell lines investigated in this study, the PDVC57 
and UMSCC22A showed high transduction efficiency within this range of vp/cell. It 
should be noted that since cells are commonly plated a day prior to transduction, the 
vp/cell is not completely accurate. This is generally adequate, however 
determination of the actual cell number on the day of infection may be necessary to 
be able to calculate the correct vp. 
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The levels of the integrins av~3 and av~5 on the host cell surface are also key to the 
internalisation of the adenoviral vector into the host cell. Therefore, poor 
transduction efficiency as determined by ~-galactosidase activity could be the result 
of limited internalisation of the adenovirus, and hence the subsequent expression of 
the transgene. 
Studies have shown that high concentrations of adenovirus regardless of the 
transgene can cause apoptosis and cell cycle arrest (Brand et ai, 1999). One 
explanation for this phenomenon may be the activation of NF-KB by the empty 
adenoviral vector, resulting in an inflammatory response (Clesham et ai, 1998). 
With this in mind a balance between the desire for high levels of transgene 
expression, and the effects of high doses of adenoviral vector should be considered. 
We therefore, subsequently used the various adenoviral vectors at 2500 vp/cell in 
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Figure 3.1: Reporter Gene Expression In Vitro. PDVC57 cells (1 x 105 
cells/plate) were infected with a range of concentrations of Ad-~-gal (625, 1250, 
2500 and 5000 vp/cell), or with Ad-PolyA. After X-gal staining, cells were 
examined under light microscopy to determine the transduction efficiency as 
determined by the percentage of positive blue cell staining. a) Ad-~-gal or Ad-
PolyA infected PDVC57 cells after X-gal staining. b) PDVC57 cells examined 
under light microscopy, after infection with 1250 vp/cell Ad-~-gal, followed by X-
gal staining. 
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Transduction efficiency at variOtti Ad-(3-gaI concentrations for a 
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Figure 3.2: Reporter Gene Transduction Efficiency following Various 
Concentrations of Ad-f3-Gal in a Range ofSCCHN Cell Lines. PDVC57, SCC97, 
UMSCC22A, SCC25, HN5 and CarB cells at 50% confluency, were infected with a 
range of concentrations of Ad-f3-gal (0, 625, 1250, 2500 and 5000 vp/cell) . After X-
gal staining, 200 cells per plate were examined under light microscopy to determine 
the percentage expressing the transgene, as determined by counting blue cells. Data 
represents mean percentage from triplicate plates of each cell at each vp of 
adenovirus tested +/ - the SEM. 
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3.2 Expression of Exogenous p53 mRNA in Adenovirus-Infected Cells 
Reverse transcriptase-PCR was performed to determine the expression of the 
transgene at the mRN A level. Nested R T -PCR was carried out to improve the 
sensitivity and specificity of the amplification, using primers for the CMV promoter 
and part of the p53 gene located in exon 3. The murine cell lines PDVC57 and CarB 
were infected with 2500 vp/cell of adenovirus carrying the human wildtype p53 
gene (Ad5CMV-p53), beta-galactosidase marker gene (Ad-p-gal), or the empty 
vector (Ad-Poly A). Two, 4, 8 and 12 hours post-infection, cells were harvested and 
total RNA isolated. 
A 274 bp CMV/p53 mRNA fragment was detected after nested PCR amplification 
in PDVC57 cells transduced with Ad5CMV-p53 2, 4 and 8 hours post-infection. 
Fragments of 274 bp were also detected in CarB cells transduced with Ad5CMV-
p53 in the same fashion, 2, 4 and 8 hours post-infection. This indicates that wildtype 
p53 mRNA was efficiently expressed from the viral vector. No transgene mRNA 
expression was detected in the untreated, Ad-p-gal or Ad-PolyA infected cells 
(Figure 3.3a). GAPDH acted as an internal control for sample loading (Figure 3.3b), 
with all samples showing similar band intensity. 
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Figure 3.3: a) Nested RT -PCR to Detect Expression of Exogenous p53 mRNA in 
Adenovirus-Infected Cells. RT-PCR was perfonned on PDVC57 and CarB cells infected 
with 2500 vp/cell Ad5CMV-p53, or Ad-PolyA. Primary amplification (Lanes 2-9) of cDNA results 
in a 312 bp band, with nested amplification (Lanes 10-18) resulting in a 274 bp band, in the 
Ad5CMV-p53 infected cell lines, but not the Ad-Poly A infected. b) GAPDH acted as an internal 
control for sample loading, with a band detected at 538 bp. 
Lane 1 and 19: q>X174 RF DNA/Hae III Fragments ladder 
Lanes 2-9 = Primary PCR products (312 bp size) CMV2 and R3 Primers 
Lane 2: CarB cells infected with 2.5 x 103 vp/cell Ad-PolyA for 2 hours 
Lane 3-5: CarB cells infected with 2.5 x 103 vp/cell Ad5CMV-p53 for 2, 4 and 8 hours respectively 
Lane 6: PDVC57B cells infected with 2.5 x 103 vp/cell Ad-PolyA for 2 hours 
Lane 7-9: PDVC57B cells infected with 2.5 x 103 vp/cell Ad5CMV-p53 for 2,4 and 8 hours 
respectively 
Lanes 10-18 = Nested PCR products (274 bp size) CMV2 and RN3 Primers 
Lane 10: CarB cells infected with 2.5 x 103 vp/cell Ad-PolyA for 2 hours 
Lane 11-13: CarB cells infected with 2.5 x 103 vp/cell Ad5CMV-p53 for 2,4 and 8 hours 
respectively 
Lane 14: PDVC57B cells infected with 2.5 x 103 vp/cell Ad-PolyA for 2 hours 
Lane 15-17: PDVC57B cells infected with 2.5 x 103 vp/cell Ad5CMV-p53 for 2, 4 and 8 hours 
respectively 
Lane 18: CarB cells infected with 2.5 x 103 vp/cell Ad-PolyA for 2 hours 
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3.3 Western Blot Analysis 
Western blot analysis allows the identification of a particular protein, if expressed in 
a tissue sample or cell line on the basis of its size. Thus it is possible to estimate the 
size of a protein by using known proteins as markers. It is important to determine 
that both the protein lysate and the antibodies used in Western blot procedures are 
reliable. All cell samples analysed in this study reacted with at least one antibody, 
indicating that the sample preparation was adequate to provide suitable material for 
Western blot analysis. Bradford assays (Bradford, 1976) were used to determine the 
amount of protein in a sample, to enable the loading of similar protein 
concentrations from the total cell lysate for each sample. It is also important to 
check for good polypeptide separation on SDS-polyacrylamide gels by staining with 
Coomassie blue, which allows the detection of small quantities of protein. In 
addition, transfer efficiency of the proteins from the gel to the nitrocellulose 
membrane can be checked by staining with Ponceau S. Actin which is constitutively 
expressed in many species is often detected to check for even sample loading 
allowing confirmation that the conditions used were within the linear range. All 
these methods were performed during Western blot analysis in these studies to 
reduce misinterpretation of results. Detection of a specific protein on the 
nitrocellulose was performed either by coulorimetric or chemiluminescence 
methods, the latter being more sensitive. Western blot however, does not provide 
accurate determination of quantities of protein present, allowing only the arbitrary 
indication of differences in levels between the various samples within the same blot. 
The use of a scanning densitometer can be utilised to measure the relative amounts 
within specific bands. 
Care should be taken when analysing Western blot protein expression data, many 
antibodies cannot distinguish between wildtype and mutant proteins, since these 
generally migrate at the same speed as each other. If the mutation results in a 
change in the size of a protein, this may be detectable if the antibody binding epitope 
of the protein is not affected. In addition, many proteins are normally expressed at 
low levels, making them difficult to detect. Therefore, if a sample does not show 
expression of a particular protein it cannot be automatically inferred why. 
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Explanations include the inadequate regulation of the protein, a mutation causing 
loss of expression, or a truncated destabilised protein, along with inadequate 
quantities of protein sample loaded onto the gel. When analysing the consequences 
of gene transfer on the protein expression levels of the transgene itself, as well as its 
upstream and downstream transcriptional targets, other factors should be considered 
when analysing the levels of expression. Particular consideration should be 
attributed to the variation in transgene expression levels occurring in the cell lines, 
and whether the levels expressed are sufficient for detection, and also whether the 
protein is able to cause the up-regulation of its targets. As discussed in the 
introduction (section 1.22) gene silencing could also be an explanation for the 
absence or altered effect of a particular protein by the triggering of transcriptional 
silencing of the inserted sequences. The best-studied DNA modification that 
correlates with epigenetic gene silencing is methylation of cytosine residues in CpG 
sequences. The genetic sequencing of the genes encoding these proteins, would 
enable the confirmation of the status of the protein regarding wildtype or mutated 
form, and may aid the understanding of the molecular mechanism for the increase or 
decrease in protein level. It should always be kept in mind that detection of protein 
expression by Western blotting does not necessarily imply that the protein is active. 
3.3.1 Expression of Endogenous p53 Protein, Detected by Western Blotting 
The endogenous mutated murine p53 protein was recognised by Ab-248 in both 
parental PDVC57 and PDVC57 cells infected with 2500vp/cell Ad5CMV-p53 (after 
24 hours infection) as a band at 53 kDa. The murine CarB cells (p53 wildtype) and 
human cell line SCC25 (p53 mutated) did not show any detectable p53 protein 
(Figure 3.4b). The absence of measurable p53 protein in the CarB line is likely to be 
the result of its wildtype p53 expression, which is normally kept at low levels in the 
cell . The lack of measurable p53 protein in the human SCC25 cell line being due to 
the specificity of the Ab-248 antibody for murine p53 only. 
The p53 protein is normally found in very low quantities in cells, but large quantities 
of p53 can be detected in malignant cells in culture, as well as in human tumours. 
Higher levels of p53 expression are often observed in cells possessing mutant rather 
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than wildtype p53 protein, because the mutant protein has a longer half-life altering 
expression from 6-20 minutes for normal up to 6 hours, probably due to stabilisation 
of the protein. It is therefore, often inferred that the detection of the p53 protein by 
Western or ICC is synonymous with mutation. This was apparent in these studies 
with the wildtype p53 CarB samples expressing as expected undetectable levels of 
p53 (Figure 3.4b). In comparison endogenous p53 was detected in the mutated 
PDVC57 (Figure 3.4b), and HN5 cell lines (Figure 3.4a). However, mutation ofp53 
does not always result in its stabilisation and high expression of the protein, as 
observed with the SCC97 and SCC25 cell lines (data not shown). 
3.3.2 Expression of Exogenous p53 Protein in Adenovirus-Infected Cells, 
Detected by Western Blotting 
Western blot analysis was performed to confirm that the transgene was translated in 
the host cells to the protein product. The expression of the exogenous human p53 
protein in Ad5CMV-p53 infected PDVC57 cells were determined using the mouse 
anti-human p53 monoclonal antibody DO-I . A 53 kDa band corresponding to p53, 
recognised by DO-I , was observed in cellular extracts isolated from PDVC57 cells 
infected with Ad5CMV-p53 , but was not seen in untreated cells or after infection 
with Ad-PolyA (Figure 3.4a). pS3 protein levels in the AdSCMV-p53 infected 
PDVC57 were low 6 hours post-infection, with higher levels detected by 16 hours 
and sustained at 72 hours post-infection. 
The cellular extracts prepared from untreated murine CarB cells, human SCC97 and 
human SCC2S cells were not recognised by the DO-I antibody (data not shown), 
however, the untreated human HNS cells displayed good pS3 protein levels (Figure 
3.4a). These results were reproducible in repeated experiments, with representative 
data from one experiment presented. The lack of detectable pS3 protein in the 
SCC25 and SCC97 cell extracts was in agreement with previous studies on these 
lines (Gurnani et ai, 1999; Badie et ai, 2000), and probably due to the fact that the 
mutations in p53 resulted in either a complete loss of function of the protein, a 
truncated unstable protein, or no protein at all. The murine CarB cell line, which 
expresses wildtype p53, also showed no measurable expression with the anti-human 
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p53 antibody (data not shown). This is because the antibody is specific to the 
human p53 protein, and should not pick up mouse p53 protein. 
The amount of p53 protein in cells is determined mainly by the rate at which it is 
degraded, rather than the rate at which it is made. This high level of p53 detected in 
p53 mutated cells may be the result of its inability to bind to the MDM2 protein, 
whose function is to shuttle p53 into the cytoplasm for degradation via the ubiquitin-
proteasome pathway (Ashcroft et ai, 2000). In cells harbouring wildtype p53, the 
binding of p53 to MDM2 lowers the concentration of p53 and reduces transcription 
of the MDM2 gene, closing the feedback loop and allowing p53 levels to rise again. 
The amplification of the MDM2 gene in the genome is a possible cause of 
inactivation of p53, due to its property of stimulating the degradation of p53 
(Vogelstein et ai, 2000). 
Other factors within the p53-MDM2 pathway can also affect the expression of p53. 
The deletion of the plc;ARF gene, can inactivate p53 expression by failing to inhibit 
MDM2, and thereby keeping p53 degradation under control (Esteller et ai, 2001). A 
further mechanism that leads to the inactivation of p53 is its location within the 
cytoplasm, as discussed in section 3.4. This cytoplasmic sequestering of is thought 
to result from a profound resistance to MDM2 mediated degradation (Moll et ai, 
1996). This reciprocal regulation between MDM2 and p53 proteins makes it 
important to compare p53 expression, p53 mutation results and MDM2 expression. 
In addition, the high levels of p53 in a sample could also be due to the 
overexpression of the wildtype p53 protein, as is the case following Ad5CMV-p53 
infection of the cells in these experiments. The wildtype p53 protein was rapidly 
expressed in the PDVC57 cells after infection since it was detectable by Western 
blotting 6 hours after infection (and possibly earlier, since this was the first time 
point tested) and was maximal in cells after 16 h. Since a human p53 specific 
antibody was used to detect the exogenous human p53 transgene in a murine cell 
line, the expression can be confirm as that being carried by the adenoviral vector, 
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Figure 3.4: Western Blot Probing for p53 following Infection of Cell Lines with 
Ad5CMV-p53. Protein extracts from the untreated murine cell lines PDVC57 and 
CarB, and the untreated human cell lines SCC25 and HN5, were run on a 10% 
polyacrylamide gel, along with Ad5CMV-p53 infected PDVC57 cells at various 
time points (6, 16,24 and 72 hours). Fifiy-Ilg of the total protein extract was run per 
lane, and the blot probed with a) DOl anti-human p53 at a concentration of 0.1 
Ilg/ml; b) Ab-248 anti-murine p53 at a concentration of 1.0 Ilg/ml. Actin was used as 
a sample loading control to conflrm that the conditions used were within the linear 
range. 
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3.3.3 Expression of Endogenous p21 WAFt Protein 
p21 WAFI is a downstream target of p53. Up-regulation of p53 results in the up-
regulation ofthe p21 W AFI protein, which functions to induce G 1 cell-cycle arrest. To 
detennine whether infection of PDVC57 cells with Ad5CMV -p53 yields a 
functional p53 protein, changes in p21 WAFI protein levels were investigated by 
Western blot analysis, using the anti-p21 W AFI antibody clone 65 . 
A 21 kDa band corresponding to p21 WAFI , recognised by clone 65, was observed in 
cellular extracts isolated from PDVC57 cells infected with Ad5CMV -p53, 6-24 
hours post-infection (Figure 3.5). p21 WAFI was also detected in untreated PDVC57 
cell extracts (Figure 3.5). However, no p21 WAFI was detected in the untreated CarB, 
HN5, SCC25 and SCC97 extracts (data not shown). The levels of p21 WAFI in 
Ad5CMV-p53 infected PDVC57 extracts were substantially higher than that seen in 
the uninfected sample at all time points tested (Figure 3.5). These results were 
reproducible in repeated experiments, with representative data from one experiment 
presented. 
It has previously been reported that the basal level of p21 W AFI is very low to 
undetectable in p53 deleted cell lines (Qazilbash et ai, 1997; Kagawa et ai, 1997). 
This could be a reason for why we did not detect p21 WAFI bands in the SCC25, HN5 
and SCC97 p53 mutated cell lines. 
Kagawa et ai, 1997 also reported an up-regulation in expression of p21 W AFI after 
infection of H1299 (homozygously deleted p53) human lung cancer cells after 
infection with AdCMV-p53. In a study by Katayose et ai, 1995, the rise in p21 WAFI 
protein expression after infection with Ad-p53, varied between endogenous p53 
mutated and endogenous wildtype p53 cell lines, with the latter showing much lower 
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Figure 3.5: Western Blot Probing for p21wAFl. Fifty-Ilg of the total protein extract 
from PDVC57 cells infected with 2500 vp/cell Ad5CMV-p53, 6, 16 and 24 hours 
post infection, and untreated PDVC57 were run on a 15% polyacrylamide gel. The 
blot was probed with the anti-p21 WAF I clone 65 at 2.0 Ilg/ml. Actin was used as a 
sample loading control to confIrm that the conditions used were within the linear 
range. 
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3.3.4 Expression of Endogenous MDM2 Protein 
MDM2 regulates p53 by a negative feedback loop mechanism as the MDM2 nuclear 
phosphoprotein inhibits p53-mediated transactivation and promotes its degradation. 
However, transcriptional activation of the MDM2 gene is induced by p53. These 
processes keep p53 levels low during normal growth and development. To 
determine whether infection of PDVC57 cells with Ad5CMV-p53 resulted in 
changes in the MDM2 protein levels, cell extracts were analysed by Western blot, 
using the anti-MDM2 antibody clone 2AIO. 
A 90 kDa band corresponding to MDM2, recognised by clone 2AI0, was observed 
in cellular extracts prepared from Ad5CMV-p53 infected PDVC57 cells, 6-24 hours 
post-infection, and in the untreated cells (Figure 3.6). The MDM2 protein levels in 
untreated PDVC57 cells were low, but rose 6-24 hours following Ad5CMV-p53 
infection. Cell extracts prepared from untreated SCC25, SCC97, HN5 and CarB cell 
lines were also analysed by Western blot with the anti-MDM2 antibody. Weak 
positive bands at 90 kDa were present in all samples (data not shown). These results 
were reproducible in repeated experiments, with representative data from one 
experiment presented (Figure 3.6). 
Wildtype p53 induces MDM2 expression by recognising a response element situated 
downstream of the first exon of the oncogene (Barak et ai, 1993). The function of 
MDM2 in the binding and ubiquitin-proteasome degradation of p53 in the cytoplasm 
has been widely reported. 
The MDM2 gene product was originally detected in a complex with the tumour 
suppressor p53 (Momand et ai, 1992). Overexpression of MDM2 gene has been 
found in many cancer cells, and human cancers, containing wildtype p53, leading to 
the hypothesis that MDM2 displays oncogenic functions by inactivating p53 (Wu et 
ai, 1993). Later studies revealed alterations in expression of both p53 and MDM2 
genes suggesting that abnormal expression of the two genes may confer an additive 
effect on cell growth (Brown et ai, 1998). The overexpression of MDM2 has been 
shown to induce tumourigenesis. The loss of p 19ARF function by aberrant 
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methylation seems to be a central factor behind the observed abnormalities of altered 
expression ofMDM2 in a wide variety of human tumours (Esteller et ai, 2001). 
At least five to seven MDM2-related polypeptides have been found . Two of these 
five, p90, the full length protein and p58, which harbours a deletion at the C-
terminus, are capable of binding p53 . In most studies p90 is the MDM2 form found 
to be over-expressed (Brown et ai, 1998). Agarwal et ai, 1999, studied the 
expression levels of MDM2 protein in premalignant and malignant SCCHN. They 
observed overexpression of MDM2 in 72% of SCCHN and 52% of premalignant 
lesions, suggesting that altered MDM2 expression is an early event in the 
pathogenesis of oral neoplasia. Katayose et ai, 1995 reported that basal levels of 
MDM2 protein were not detectable in cells that were null for p53 or contained 
mutant p53, although endogenous MDM2 protein bands of approximately 90 kDa 
and 57 kDa were readily detected in all cells expressing wildtype p53. They went 
on to report that following exposure to Ad-p53 there was a marked increase in the 
levels of high and low molecular weight MDM2 proteins in all cell lines examined. 
Haupt et ai, 1996, reported on a cell type-specific inhibition of p53-mediated 
apoptosis by MDM2. The overexpression of MDM2 resulted in effective protection 
from apoptosis, in H1299 cells, but not in HeLa cells. This is probably caused by 
differing alterations in other genetic components of the pathway. 
When the PDVC57 cells were infected with Ad5CMV-p53 an increase in the levels 
ofMDM2 (90 kDa) was apparent 6-24 hours later, in agreement with the findings of 
Katayose et ai, 1995, mentioned above. This overexpression of MDM2 after 
Ad5CMV-p53 transduction did not prevent apoptosis in the PDVC57 cells, implying 
that other genetic factors might be dominant in this pathway. The role of MDM2 in 
shuttling p53 from the nucleus to the cytoplasm for degradation is probably active, 


























































Figure 3.6: Western Blot Probing for MDM2 protein. Fifty-flg ofthe total protein 
extract from PDVC57 infected with 2500 vp/cell Ad5CMV-p53, 6, 16 and 24 hours 
post infection, and untreated PDVC57 cells were run on a 7.5% polyacrylamide gel. 
The blot was probed with the anti-MDM2 clone 2AIO at 1.0 flg/ml. Actin was used 
as a sample loading control to conflrm that the conditions used were within the 
linear range. 
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3.3.5 Expression of Endogenous BAX Protein 
P53-induced apoptosis may result from shifting of the ratio of BAXlBCL-2 in 
favour of programmed cell death. BCL-2 is transcriptionally repressed by wildtype 
p53, whilst BAX is induced by it. To determine whether infection of PDVC57 cells 
with Ad5CMV-p53 resulted in a functional p53 protein, changes in BAX protein 
levels were investigated by Western blot analysis, using the anti-BAX antibody 
clone SB7/A2. A 21 kDa band corresponding to the BAX protein, recognised by 
clone 5B7/A2, was observed in cellular extracts isolated from PDVC57 cells, 
infected with Ad5CMV-p53 after 6 and 24 hours, but was not present at 48 hours 
post-infection (Figure 3.7). BAX protein was not detected in parental untreated 
PDVC57 (Figure 3.7), and SCC97 cell extracts (data not shown). These results were 
reproducible in repeated experiments, with representative data from one experiment 
presented (Figure 3.7). 
The detection of increased BAX expression in the PDVC57 cell line infected with 
Ad5CMV-p53 at time points preceding onset of apoptosis, is consistent with the 
hypothesis that BAX accelerates or induces programmed cell death in these cells. 
The magnitude of BAX protein induction that we observed in PDVC57 cells after 
infection with Ad5CMV-p53 is comparable to what has been reported in previous 
studies of cells undergoing apoptosis after wildtype p53 expression (Frederick et ai, 
1999). This induction of the pro-apoptotic mediator BAX occurred at time points 
prior to the observation of changes in cell morphology indicative of terminal 
apoptosis. The time points of increased BAX protein expression correlated well with 
the time points of apoptotic cell death detection via TUNEL (section 4.5) and 
acridine orange/ethidium bromide dye incorporation (section 4.6). 
In a study on the levels of BAX expression in SCCHN, moderate to marked BAX 
expression was reported in 63% of SCCHN tumours, and of these the strongest 
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Figure 3.7: Western Blot Probing for BAX Protein. Fifty-~g of the total protein 
extract from PDVC57 infected with 2500 vp/cell Ad5CMV-p53, 6, 24 and 48 hours 
post infection, and untreated PDVC57 were run on a 15% polyacrylamide gel. The 
blot was probed with the anti-BAX clone 5B7/A2 at 0.6 ~g/ml. Actin was used as a 
sample loading control to confIrm that the conditions used were within the linear 
range. 
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3.4 Expression of Exogenous p53 Protein in Adenovirus-Infected PDVC57 Cells 
by Immunocytochemistry 
Immunocytochemistry with the human anti-p53-specific antibody DO-l revealed 
that infection of PDVC57 cells with Ad5CMV -p53 at 2500 vp/cell resulted in 
cytoplasmic and nuclear expression of the p53 transgene in approximately 70% of 
the cells, after 6 hours, but not after infection with Ad-PolyA or Ad-l3-gal (Figure 
3.8a). However, by 24 and 48 hours post infection the majority of positive staining 
was in the nucleus with only a small percentage of cells showing cytoplasmic 
staining. Some cells showed the morphological characteristics of apoptosis at this 
stage, as typified by Figure 3.8b. 
Immunocytochemical and IHC detection of exogenous wildtype p53 protein enables 
the establishment of both the presence of p53 as well as its location. Endogenous 
wildtype p53 within normal cells is at low to undetectable levels in the nucleus, 
however, high levels of p53 have been detected in tumour tissue and cell lines, as a 
result of p53 mutation causing stabilisation of the protein (Field et ai, 1991; 
Nylander et ai, 1995). However, in this investigation, the wildtype p53 protein was 
detected using a human anti-p53 specific antibody, as a result of the high expression 
levels ofthe wildtype humanp53 transgene following Ad5CMV-p53 infection. 
The presence of positive p53 protein staining in the cytoplasm of the PDVC57 cells 
6 hours following Ad5CMV-p53 infection caused initial concern, since p53 is 
inactivated within the cytoplasm. p53 is a transcription factor, therefore, only the 
p53 protein that is transferred into the nucleus can act as a negative regulator of cell 
proliferation. The sequestering of the p53 protein into the cell cytoplasm therefore 
prevents its acting as a tumour suppressor (Chang et ai, 1995). This cytoplasmic 
sequestering of p53 has been observed in a number of human tumours, and is 
thought to result from a profound resistance to MDM2 mediated degradation via the 
ubiquitin-proteasome pathway (Zaika et ai, 1999). Within the discussion on Western 
blot analysis (section 3.3), it was reported that following Ad5CMV-p53 infection, 
the induction of high levels ofMDM2 were observed. Overexpression ofMDM2 is 
commonly seen in sarcomas and brain tumours, and can result in the degradation of 
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p53, which takes place in the cytoplasm (Zaika et ai, 1999). The p19ARF protein is 
capable of binding directly to MDM2, preventing it from targeting p53 for 
degradation, therefore the deletion of the plcj1RF gene results in the failure to inhibit 
MDM2 and keep p53 degradation under control (Vogel stein et ai, 2000). However, 
Western blot analysis of the PDVC57 cell line, established the up-regulation of 
p19ARF following Ad5CMV-p53 infection, indicating that this part of the p53-
MDM2_pI9ARF pathway is functional (data not shown). 
However, by 24 and 48 hours post-Ad5CMV -p53 infection the majority of the 
human p53 protein was located in the nucleus of the cells, indicating that the 
translocation of the transgene product to the correct subcellular compartment occurs 
after 6 hours but before or at 24 hours post-infection. This coincides well with the 
Western blot analysis data (section 3.3), which showed expression of exogenous p53 
protein at 6-72 hours post Ad5CMV -p53 infection. In addition, the up-regulation of 
p21 WAF\ MDM2 and BAX proteins following Ad5CMV-p53 infection is indicative 
of a transcriptionally active p53 protein, which must reside in the nucleus to be able 
to achieve these actions. 
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a) 100 f.lm 
b) 
Figure 3.8: Exogenous p53 Protein Expression by Immunocytochemistry. 
Immunocytochemistry was performed on PDVC57 cells either infected with 
Ad5CMV-p53 or Ad-PolyA. The human p53 specific, DO-l antibody was used to 
detect the human p53 transgene in the murine cell line (indicated by brown staining), 
using the mouse on mouse vector-stain system. a) Indicates PDVC57 cells infected 
with Ad5CMV-p53, harvested 6 hours post-infection; b) indicates PDVC57 cells 
infected with Ad5CMV-p53, harvested 24 hours post-infection. 
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4.1 Effect of Exogenous Adenovirus Vector and the p53 Gene or f3-galactosidase 
Inserts on Cell Growth In Vitro 
The effect of adenovirus exposure on PDVC57 and CarB cells were investigated to 
determined the suitability of these lines for future in vivo work. Cells were seeded at 
a density of 2 x 105 cells per 10 cm2 plates, 24 hours prior to treatment. Triplicate 
plates were prepared for each treatment schedule, to control for minor variation due 
to the plating of slightly different number of cells. Viable cells were counted daily 
for five days, by trypan blue exclusion. The mean cell number from counting 
triplicate plates following infection was plotted against the number of days post-
infection. Growth assays were reproducible in repeated experiments, with 
representative data from one experiment presented (Figure 4.1). Cell monolayers 
were analysed by light microscopy prior to cell trypsinisation, to assess the degree of 
cell death by looking for the extent of floating cells, cells rounded up but still 
attached to the cell plate, and healthy cells, and to provide a rough indication of the 
cell number to be counted. 
Cell doubling times were similar for both the PDVC57 and CarB cell lines, with 
numbers of cells doubling roughly every 24 hours. The control cells ceased to grow 
or showed slower cell growth after 4-5 days, which may have been because of their 
confluency and exhaustion of nutrients in the cell medium. Medium was changed at 
day 3 to try and counteract nutrient exhaustion, especially where cells were 
proliferating for the length of the experiment. 
The number of viable cells remaining following infection of adenovirus showed that 
infection had differing effects on cell proliferation in the two murine cell lines 
PDVC57 and CarB. When the CarB cell line, possessing wildtype p53, was infected 
with 2500 vp/cell Ad5CMV-p53, Ad-PolyA or Ad-p-gal, viable cell numbers 
remained similar to that of the untreated cell line (Figure 4.1b). 
In comparison, when the PDVC57 cell line, possessing a mutated p53, was infected 
with 2500 vp/cell Ad5CMV-p53, Ad-PolyA or Ad-f3-gal, differences were apparent 
in viable cell numbers (Figure 4.1a). Infection with 2500 vp/cell Ad5CMV-p53 
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resulted in approximately 75% growth inhibition measured at days 2 and 3 post-
infection, when compared to the control untreated cells. The percentage cell growth 
inhibition rose to approximately 95% of that of the untreated PDVC57 cells, 4 and 5 
days post-infection. Changes in viable cell number were statistically significant 
between untreated and Ad5CMV-p53 infected cells (2500 vp/cell) at day 2 through 
to 5 as derived by the t-test (Table 4.1). Forty-eight hours after infection with 
Ad5CMV-p53, examination of cell mono layers by light microscopy showed that 
approximately 50% of the PDVC57 cell population, were either floating in the 
culture medium or showing a rounded-up appearance, with the remaining proportion 
of cells viable. 
The effect of Ad-~-gal and Ad-PolyA infection at 2500 vp/cell on PDVC57 cell 
growth was initially similar to that of the untreated cells, showing no statistically 
significant differences in the viable cell numbers at days 2 and 3 post-infection. 
However, by 4 days post-infection, the percentage cell growth inhibition for the Ad-
PolyA infected PDVC57 cells was approximately 30% when compared to the 
untreated cells, and approximately 50% for Ad-~-gal infected cells. This was also 
the case at day 5 post-infection, with percentage cell growth inhibition of Ad-~-gal 
and Ad-PolyA approximately 50% as compared to the untreated PDVC57 cells. 
These differences in cell number between untreated and Ad-~-gal or Ad-PolyA 
infected cells was significantly different at day 4 and 5 post-treatment as shown in 
Table 4.l. 
Although infection of PDVC57 cells with 2500 vp/cell Ad-~-gal and Ad-PolyA at 
days 4 and 5 showed 30-50% cell growth inhibition when compared to the untreated 
cells, infection with 2500 vp/cell Ad5CMV-p53 always showed a greater percentage 
of cell growth inhibition than these other two vectors. The differences in PDVC57 
cell numbers post-Ad5CMV-p53 infection were significantly lower than after Ad-~­
gal or Ad-PolyA infection as determined by the t-test from day 2-5 post-infection 
(Table 4.1). The two control vectors, Ad-PolyA and Ad-~-gal both had a toxic effect 
on the PDVC57 cells, showing a reduction in cell numbers as compared to the PBS 
treated cells, however, the Ad5CMV-p53 infected PDVC57 cells showed 
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significantly greater reduction in cell number. This implies that the adenoviral 
vector backbone itself has a moderate toxic effect on cell growth regardless of the 
transgene insert, as discussed in section 7.8. However, the wildtype p53 transgene 
was capable of causing additional reductions in cell number, as a result of cell killing 
over and above that of the non-specific control adenovirus vector effects. 
PDVC57 cells were also infected with Ad5CMV-p53 over a range of vp/cell (156, 
312, 625, 1250 and 2500) to determine whether the same amount of cell growth 
inhibition occurred following infection with less infectious particles (Figure 4.1c). 
Approximately 50% cell growth inhibition when compared to the results for 
untreated PDVC57 cells, was present 3 days after infection with all of the different 
concentrations of virus. This increased by day 4, with infection of PDVC57 cells 
with 156 vp/cell Ad5CMV-p53 showing 57% growth inhibition when compared to 
untreated cells, 312 vp/cell, 68%; 625 vp/cell, 84%; 1250 vp/cell 88% and 2500 
vp/cell 95% respectively. 
This was maintained at day 5, with infection of PDVC57 cells with 156 vp/cell 
Ad5CMV-p53 showing 70% growth inhibition as compared to untreated cells, 312 
vp/cell, 64%; 625 vp/cell, 83%; 1250 vp/cell 90% and 2500 vp/cell 95% 
respectively. These reductions in cell numbers after infection with the range of 
vp/cells of Ad5CMV-p53, were all significantly different to the untreated PDVC57 
cell number from days 3-5 post-infection (Table 4.1). 
Therefore the overall observations were that the growth of PDVC57 cells was 
significantly reduced when transduced with Ad5CMV -p53 in vitro, as compared to 
mock-infected cells or those infected with Ad-~-gal or Ad-PolyA (Figure 4.1a). 
Ad5CMV-p53 was capable of significantly reducing PDVC57 cell number at all the 
vp/cell range tested (156.25, 312, 625, 1250 and 2500 vp/cell respectively, Figure 
4.1c) when compared to the PBS treated cells. Analysis of the cell culture plates 
prior to trypsinisation and cell counting showed many cells either floating in the 
culture medium, or showing a rounded up appearance on the culture dish. Hence the 
reduction in cell number was attributed to the death of a large proportion of the cells. 
172 
Chapter 4 - Results and Interpretation 
However, viable cells were still present on the culture dishes 5 days after infection 
with Ad5CMV-p53, although cell numbers remained practically static over this time 
course. Explanations for these remaining cells could be that they represent 
uninfected PDVC57 cells; cells that had been growth arrested, so numbers remain 
static; or as a result of a slowing in cell proliferation. Slowing of growth rate has 
been observed previously, and reported to be associated with over-expression of 
wildtype p53 protein and induction of p21 W AFl (Qazilbash et ai, 1997). 
Bougeret et ai, 2000, have also reported that mutated p53 cells were more sensitive 
to Ad-p53 than wildtype p53 cells. This group suggests that this may be the result 
of overexpression of p53 inhibitors in tumours expressing wildtype p53, which leads 
to inactivation of both the endogenous p53 and the reintroduced exogenous p53. 
However, from experiments on transduction efficiency using the marker gene J3-gal 
followed by X-gal staining, the CarB cells were found to be much less susceptible to 
adenoviral infection than the PDVC57 cells when compared over a range of vp/cell 
concentrations (Figure 3.2). Ideally, experiments should be carried out using 
concentrations of adenovirus to obtain similar levels of transgene expression in all 
the cell lines tested. Hence, the inability of Ad5CMV -p53 infection of CarB cells to 
reduce cell numbers might be explained by the low level of transgene expression in 
these lines. However, the PDVC57 cell lines were still able to cause significant 
growth reduction after infection with 156.25 vp/cell of Ad5CMV -p53, when only a 
relatively low percentage of the cells were transduced. This suggests that a 
bystander effect of cell killing occur, to enable a large proportion of untransduced 
cells to be killed as well as those effectively transduced by the Ad5CMV-p53 vector. 
Frank et ai, 1998 has demonstrated that wildtype p53 over-expressing TUl38 
SCCHN cells can bring about growth inhibition in non-transduced cells in vitro. 
This requires intercellular contact between wildtype p53 transduced and non-
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Figure 4.1c) 
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Figure 4.1: Cell Growth Curves after Adenoviral Infection. PDVC57 and CarB 
cells were infected with either Ad5CMV-p53, Ad-p-gal, or Ad-PolyA. Results show 
the mean cell number of counts, for triplicate samples, +/- the standard error of the 
mean (SEM). a) PDVC57 cells infected with 2500 vp/cell of either Ad5CMV-p53, 
Ad-/3-gal, or Ad-PolyA, or mock infected with PBS. 
b) CarB cells infected with 2500 vp/cell of either Ad5CMV-p53, Ad-p-gal, or Ad-
PolyA, or mock infected with PBS. 
c) PDVC57 cells infected with a range of concentrations of Ad5CMV-p53 (156 .25, 
312.5, 625, 1250, 2500 vp/cell) or mock infected with PBS. 
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Table 4.1: Statistical Analysis of PDVC57 Cell Numbers following Adenoviral 
Infection. Differences in cell number following various treatments were performed 
using the t-test to determine if significant differences between groups occurred. P < 
O.OOS. 




Untreated and AdSCMV-p53 (2S00 vp/cell) infected 2 11.63 
Untreated and AdSCMV -p53 (2S00 vp/cell) infected 3 21.39 
Untreated and AdSCMV -p53 (2S00 vp/cell) infected 4 66.37 
Untreated and AdSCMV-p53 (2S00 vp/cell) infected S 40.28 
Untreated and Ad-f3-gal (2S00 vp/cell) infected 4 14.0S 
Untreated and Ad-f3-gal (2S00 vp/cell) infected S 14.13 
Untreated and Ad-PolyA (2S00 vp/cell) infected 4 10.20 
Untreated and Ad-PolyA (2S00 vp/cell) infected S 6.80 
Ad-f3-gal and Ad5CMV-p53 (2S00 vp/cell) infected 2 9.70 
Ad-f3-gal and AdSCMV -p53 (2S00 vp/cell) infected 3 6.14 
Ad-f3-gal and AdSCMV -p53 (2S00 vp/cell) infected 4 23.76 
Ad-f3-gal and AdSCMV-p53 (2S00 vp/cell) infected S 20.13 
Ad-PolyA and AdSCMV-p53 (2S00 vp/cell) infected 2 S.67 
Ad-Poly A and AdSCMV -p53 (2S00 vp/cell) infected 3 S.17 
Ad-Poly A and Ad5CMV -p53 (2500 vp/cell) infected 4 30.51 
Ad-PolyA and AdSCMV-p53 (2500 vp/cell) infected 5 6.96 
Untreated and AdSCMV-p53 (1S6 vp/cell) infected 3 29.0S 
Untreated and AdSCMV -p53 (1S6 vp/cell) infected 4 30.00 
Untreated and AdSCMV-p53 (1S6 vp/cell) infected S 22.03 
Untreated and AdSCMV-p53 (312 vp/cell) infected 3 44.90 
Untreated and AdSCMV-p53 (312 vp/cell) infected 4 34.31 
Untreated and Ad5CMV-p53 (312 vp/cell) infected S 22.45 
Untreated and AdSCMV-p53 (625 vp/cell) infected 3 22.70 
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Table 4.1 continued: 




Untreated and Ad5CMV-p53 (625 vp/cell) infected 4 43 .11 
Untreated and Ad5CMV-p53 (625 vp/ceU) infected 5 29.79 
Untreated and Ad5CMV-p53 (1250 vp/cell) infected 3 25.09 
Untreated and Ad5CMV-p53 (1250 vp/cell) infected 4 33.12 
Untreated and Ad5CMV-p53 (1250 vp/cell) infected 5 32.14 
Untreated and Ad5CMV -p53 (2500 vp/cell) infected 3 20.44 
Untreated and Ad5CMV-p53 (2500 vp/cell) infected 4 51.83 
Untreated and Ad5CMV-p53 (2500 vp/cell) infected 5 38.40 
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4.2 Effect Of Cisplatin and UV Exposure on Cell Growth In Vitro 
Cisplatin and UV exert their cytotoxicity by inducing apoptosis (Aebi et ai, 1997 
and Kao et aI, 2001). Chemotherapeutics have been reported to result in cell cycle 
arrest at sublethal doses, and apoptosis at lethal doses (Wu et aI, 1996). In order to 
estimate the time points suitable for the study of the effect of cisplatin and UV 
exposure on the cell lines used in these experiments, cells were examined by light 
microscopy, after treatment with 10 or 20 Jlglml cisplatin or 1 or 2 minutes UV 
exposure, followed by counting viable cells. Examination of cells under light 
microscopy also allowed for detection of dead or dying cells by looking for cells 
floating in the culture medium, or cells showing a rounded-shrunken appearance, 
prior to detachment from the culture plate. The effect of cisplatin and UV exposure 
on PDVC57, CarB, HN5 and SCC25 cells were reproducible in repeat experiments. 
PDVC57, CarB, HN5 and SCC25 cell lines were all found to be sensitive to cell 
killing by cisplatin at the two concentrations tested (10 and 20 Jlglml respectively) as 
well as to exposure to UV irradiation for 1 and 2 minutes. The majority of cells 
were killed at these doses after 48-72 hours. 
PDVC57 cells showed greater than 50% growth inhibition as compared to untreated 
cells 48 hours post-cisplatin (20 Jlglml) or 2 minutes UV exposure (Figure 4.2). At 
72 hours (day 4) post- cisplatin or UV exposure this cell growth inhibition was 
approximately 80%. A high proportion of PDVC57 cells showed signs of cell death 
after addition of 10 or 20 Jlglml cisplatin and after 1 or 2 minutes UV exposure. 
This could first be detected at 4 hours post-treatment, with approximately 50% 
PDVC57 cell death 24 hours after exposure to UV for 2 minutes and 32 hours after 
addition of 20 Jlglml cisplatin. The majority of the PDVC57 cells were floating in 
the culture medium or showing a rounded up appearance 72 hours post-cisplatin or 
UVexposure. This was in contrast with untreated PDVC57 cells that were viable. 
CarB cells were also sensitive to UV and cisplatin treatment. However, reductions in 
cell number were detected earlier than after treatment of PDVC57 cells, with 
approximately 50% cell death detected microscopically, 18 hours after 2 minutes 
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UV exposure and 24 hours after 20 ~g/ml cisplatin. The majority of the CarB cells 
were floating in the culture medium 48 hours post UV exposure or cisplatin 
treatment. Untreated CarB cells were viable at this time point. 
It was also clear that HN5 cells were sensitive to UV exposure and cisplatin 
treatment, as determined by reduction in cell number as compared to untreated cells, 
and morphological signs of cell death microscopically. Approximately 50% of the 
cells were either floating in culture medium or had a rounded-shrunken appearance 
24 hours after both treatments with 20 ~g/ml cisplatin or exposure to UV for 2 
minutes. After 48 hours the majority of cells were floating in the medium. The 
majority of untreated HN5 cells were healthy at this time point. 
SCC25 cells were also examined for sensitivity to cisplatin and UV mediated cell 
death. Approximately 50% reduction in cell number was observed 16 hours after 2 
minutes UV exposure and 32 hours after treatment with 20 ~g/ml cisplatin. The 
majority of the SCC25 cells were floating in the culture medium 48 hours post 
cisplatin treatment or UV exposure, in contrast to untreated SCC25 cells that were 
viable. 
The length of time taken by cells to die after treatment can vary from hours to many 
days, being highly dependent upon the cell type, the toxic agent being investigated, 
as well as the expression levels of multiple drug resistance (MDR1), Bcl-2, MDM2 
or other proteins (Wu et aI, 1996). Brown and Wouters, 1999a report that wildtype 
p53 predisposes cells to a more rapid rate of cell death after DNA damage, such as 
cisplatin, particularly with normal or transformed cells, and that short term assays 
have often led to the conclusion that mutations in p53 confer resistance to genotoxic 
agents. 
The first signs of cell death could be detected microscopically in the wildtype p53 
containing CarB cell line 4 hours after cisplatin or UV exposure, in agreement with 
Brown and Wouters observations mentioned above. 
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Figure 4.2: Cell Growth Curve after Cisplatin or UV exposure. PDVC57 cells 
were exposed to UV for 2 minutes or treated with 20 Jlglml cisplatin. Data indicates 
the mean cell number counts of triplicate samples, harvested daily +/- the SEM. 
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4.3 Detection of Apoptotic Cell Death 
There are several methods of detection of apoptosis. These include those looking at 
morphological changes in the pattern of chromatin condensation, and those that 
detect DNA degradation, typical of apoptotic cell death. Despite the large number of 
methods that have been developed to analyse cell death, particularly apoptosis, the 
identification of the mode of cell death and its quantification is not always simple or 
straightforward. 
4.3.1 Apoptosis Detection Time Points 
Changes in cell morphology, including cell shrinkage and floating cells, were 
observed in cells treated with Ad5CMV-p53, and also those exposed to cisplatin or 
Uv. This induction of apoptosis was quantified 16-72 hours after transduction with 
Ad5CMV-p53. DNA fragmentation, acridine orange/ethidium bromide uptake and 
TUNEL assays were used to determine the presence of apoptosis. Results obtained 
from these methods are consistent with increases in apoptotic cell death. Apoptotic 
cell death is postulated to occur by a cascade of events that suggest temporal 
activation of upstream and downstream mediators. In this study, we observed 
overexpression of exogenous p53 protein at 6 hours, peaking at 16 hours through to 
72 hours (Figure 3.4). P21 WAFI and BAX were all up regulated by 6 hours and 
remained at peak levels at 24 hours (Figures 3.5 and 3.7 respectively) . Earlier time 
points were not investigated by Western blot, but it would be logical to think that 
exogenous p53 expression occurs at earlier time points than 6 hours, to allow for the 
up-regulation ofthe other downstream p53-mediated proteins analysed at this time. 
Detection of exogenous p53 mRNA by RT-PCR showed that the exogenous 
wildtype p53 mRNA was detectable 2 hours after transduction of PDVC57 cells 
with Ad5CMV-p53 (Figure 3.3). Thus it would be plausible for exogenous p53 
protein to be present prior to the earliest time point tested by Western blot of 6 
hours. Detection of p53 mRNA were not performed at time points earlier than 2 
hours post Ad5CMV-p53 infection, therefore, detection at this level might have 
occurred earlier also. 
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Changes in cell morphology indicative of apoptosis occurred later, between 16 and 
48 hours, as determined by TUNEL and acridine orange/ethidium bromide dye 
incorporation. Earlier time points were not investigated, although from observation 
of the AdSCMV-p53 infected PDVCS7 cells by light microscopy, rounding up and 
detachment from the culture plate could be seen from about 8 hours. These 
observations support the temporal induction of pro-apoptotic mediators after the pS3 
death signal, ultimately culminating in apoptotic cell death. 
4.4 Detection of Apoptosis by DNA Fragmentation Analysis 
A characteristic hallmark of apoptosis, is the presence of a ladder of DNA fragments 
equivalent to approximately 200 base-pairs and there multiples following agarose 
gel electrophoresis of DNA samples. This is just one of the changes observed in the 
co-ordinated morphological and biochemical events of apoptosis. As necrosis results 
in the random degradation of DNA, this test can help to distinguish between the two 
different cellular processes. 
DNA was prepared from both the adherent and detached cells 16-72 hours after 
treatment, for analyses on ethidium bromide stained agarose gels. DNA-Iaddering 
was observed on agarose gels, in DNA samples prepared from PDVC57 cells 
exposed to 20 ~glml cisplatin, after 40, 44 and 48 hours (Figure 4.3a). No DNA 
fragmentation was observed at the earlier time points examined (16, 20 and 24 
hours) or at time points after 48 hours (64, 68 and 72 hours). In addition DNA 
laddering was detected in DNA samples prepared from PDVCS7 cells 24 to 48 
hours after exposure to 2 minutes UV light (Figure 4.3b). However, no detectable 
DNA fragments were visualised following infection with AdSCMV -p53, Ad-B-gal 
or Ad-PolyA, or in the mock-infected cells at any time points between 16 and 72 
hours post-infection (Figure 4.3c). This is to be expected with the untreated and 
control vectors, since the more sensitive TUNEL and acridine orange/ethidium 
bromide techniques for apoptosis detection only found low levels of apoptosis in the 
PDVCS7 cells under these conditions. However, the absence of DNA laddering in 
the AdSCMV-p53 infected PDVCS7 cells is surprising, since high levels of 
apoptotic cell death as determined by TUNEL and acridine orange/ ethidium 
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bromide dye incorporation were reported. One explanation for the lack of apoptotic 
cell death detection is that DNA laddering shows relatively low sensitivity as 
compared to TUNEL, with the requirement of at least 1 x 106 cells to be able detect 
DNA fragmentation. In addition, DNA laddering can only establish an all or nothing 
result on the presence or absence of apoptosis in the cell population as a whole, 
rather than in individual cells. The analysis of the entirely homogenised cell 
population thus allows only the occasional and late detection of the apoptotic event. 
Fragmented DNA was also observed in CarB DNA samples prepared 16 and 20 
hours after treatment with 20 ~g/ml cisplatin and exposure to 2 minutes UV light 
(Figure 4.4). No DNA fragmentation was observed in these samples at the later time 
points tested. 
Wyllie et al (1997) has reported that cleavage of chromatin to nucleosomal 
fragments does not occur in all cell types and can be inhibited without blocking the 
other changes of apoptosis. Mitochondrial DNA is not fragmented in apoptosis, 
indicating that DNA fragmentation is a specific nuclear event. The growth of other 
tumour cell lines, for example, H358 (a human non-smaIl-cell lung cancer (NSCLC) 
cell line in which both alleles of p53 are deleted), has been reported to be inhibited 
by Ad5CMV -p53, but DNA fragmentation was not observed (Fujiwara et ai, 1994). 
Caspase-3 has been specifically implicated as the effector caspase responsible for 
cleavage of the human DNA fragmentation factor that subsequently activates the 
DNA endonuclease required for the formation of apoptotic DNA ladders (Liu et ai, 
1998). A lack of caspase-3 activation is consistent with inefficient formation of 
DNA ladders and altered apoptotic morphology (Formigli et ai, 2000). Following 
UV or cisplatin exposure of PDVC57 or CarB cells, caspase-3 activation occurs, 
resulting in DNA laddering. However, infection with Ad5CMV-p53 in these same 
two cell lines, does not seem to activate caspase-3 as determined by the lack of DNA 
laddering. Other assays for the detection of apoptosis reveal high levels of apoptotic 
cell death following Ad5CMV -p53 infection in the PDVC57 cells. Analysis of 
caspase-3 up-regulation following Ad5CMV-p53 infection would be an interesting 
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follow up in PDVC57 cells to determine whether inhibition of this part of the 
apoptotic pathway is occurring, or whether as mentioned previously the sensitivity 
of the assay system is the cause for the lack of DNA laddering. 
184 
Chapter 4 - Results and Interpretation 
a) PDVC57 cells b) PDVC57 cells c) PDVC57 cells 
treated with exposed to 2 infected with 
20 flg/ml cisplatin minutes UV light 2500 vp/cell 
Ad5CMV-p53 
40h 44h 48h 40h 44h 48h 40h 44h 48h 
Figure 4.3: Demonstration of DNA Laddering in PDVC57 Cells. PDVC57 cells 
were exposed to either a) 20 J.lg/ml cisplatin, b) 2 minutes UV, c) 2500 vp/cell 
Ad5CMV-p53, for 40 hours (Lane 1), 44 hours (Lane 2) and 48 hours (Lane 3). 
DNA was extracted from samples and 5 J.lg of each DNA sample was run per lane of 
a 1.5% agarose gel. Cisplatin or UV exposure resulted in characteristic DNA 
laddering. No laddering was detected following Ad5CMV-p53 infection. 
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b) CarB cells 
were exposed for 
2 minutes to UV 
light 
16h 20h 
Figure 4.4: Demonstration of DNA Laddering in CarB Cells. CarB cells were 
exposed to either a) 20 Ilg/ml cisplatin, b) 2 minutes UV, for 16 hours (Lane 1) and 
20 hours (Lane 2). DNA was extracted from samples and 5 Ilg of each DNA sample 
was run per lane of a 1.5 % agarose gel. Cisplatin or UV exposure resulted in 
characteristic DNA laddering. 
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4.5 Detection of Apoptosis in PDVC57 Cells by TUNEL 
The TUNEL method is based on detection of extensive DNA breakage to identify 
apoptotic cells. Apoptotic cells detected by TUNEL and alkaline phosphatase were 
visualised as cells with red stained areas in the nucleus. However, since this method 
is not specific for apoptosis, care should be taken to additionally identify the 
characteristic cell morphology of apoptosis in TUNEL stained cells. The total 
numbers of apoptotic cells included those found floating in the medium, as well as 
the adherent cells. Data represents the result of triplicate analysis of 200 cells. 
Apoptosis was detected in PDVC57 cells by TUNEL between 16 and 72 hours after 
treatment with 2500 vp/cell Ad5CMV-p53. The majority of the TUNEL positive 
PDVC57 cells were in the population that had already detached from the culture 
plate and were floating in the medium. Greater than 90% of these floating cells 
stained TUNEL positive between 16 and 72 hours post-Ad5CMV-p53 treatment 
(Figure 4.5). The floating cells represented approximately 35% of the total cell 
number at 24 hours post-Ad5CMV-p53 treatment and 50% by 48 hours. TUNEL 
staining in the adherent PDVC57 cell population was much less frequent. Twenty-
four hours after infection with Ad 5 CMV-p53, 3% of the adherent cell population 
stained for TUNEL. The number of TUNEL-positive apoptotic adherent cells 
increased to approximately 5% by 48 hours post-Ad5CMV-p53 infection. Therefore, 
when the two cell populations (floating and adherent) were combined, 34.5% of the 
cells showed TUNEL staining 24 hours after Ad5CMV-p53 infection, rising to 50%, 
48 hours after treatment. TUNEL staining at 72 hours post-treatment were sustained 
at levels similar to 48 hours treatment. 
The majority of positive TUNEL reaction was observed in the sub-set of cells that 
were floating, and collected in the culture medium. A likely explanation for this is 
the fact that a very early event in apoptotic cell death is cell detachment from its 
neighbours (Grossman, 2002). Au et ai, 1999, reported on high levels of detached 
cells after paclitaxel treatment, and observed differing aspects of apoptosis within 
the detached and attached cell subsets. Floating cells showed the full spectrum of 
apoptotic changes, whilst the attached cells showed only activation of caspase-3-like 
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proteases, but not poly-ADP-ribose-polymerase (PARP) cleavage, or DNA 
fragmentation. This could help explain the low levels of TUNEL reactivity observed 
in the attached PDVC57 cells in these studies, after Ad5CMV-p53, cisplatin, and 
UV exposure. The substantial degree of TUNEL reactive cells in the detached cell 
population is likely to be attributable to the high levels of p53 expression after 
Ad5CMV -p53 gene transfer, resulting in the up-regulation of genes involved in 
apoptotic cell death pathway. Significant induction of apoptosis as detected by 
TUNEL has been reported in many in vitro studies (Liu et ai, 1995; Spitz et ai, 
1996). 
Two-three percent TUNEL stained nuclei were detected 48 to 72 hours after 
infection with 2500 vp/cell Ad-f3-gal, Ad-PolyA or Ad-Luc. The majority of this 
TUNEL staining was from the small proportion of cells floating in the culture 
medium, with positive adherent cells very rarely detected. 
Exposure of PDVC57 cells to 20I-lg/ml cisplatin or 2 minutes UV light, resulted in 
high levels of TUNEL stained cell nuclei. Greater than 90% of the cells collected 
from the medium stained by TUNEL between 16-72 hours. Approximately 50% of 
the cell population were detached from the plate and floating in the medium 24 
hours after cisplatin or UV exposure, this rose to approximately 90% by 48 hours for 
both treatments. Therefore, the majority of cells after 48 hours cisplatin or UV 
exposure stained for TUNEL. The adherent cells showed occasional TUNEL 
staining after 16 hours cisplatin exposure, increasing to 7% after 48 hours . In 
PDVC57 cells exposed to UV, the adherent cells showed 5% TUNEL staining after 
16 hours, increasing to 9% after 48 hours . . Lower doses of cisplatin, or time ofUV 
exposure, along with the testing of TUNEL reactivity at earlier time points might 
allow the detection of apoptosis by this method in the attached cell population. 
There was only minimal detectable apoptosis (1 %) by TUNEL in untreated control 
experiments following mock-infection with PBS. 
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Figure 4.5: TUNEL Stained PDVC57 Cells 24 Hours after Ad5CMV -p53 
Infection. PDVC57 cells were infected with 2500 vp/cell Ad5CMV-p53, 24 hours 
later adherent and floating cells were harvested and subjected to TUNEL staining. 
The percentage of TUNEL positive cells showing reddy brown staining was 
determined by counting 200 cells from triplicate samples, under light microscopy. 
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4.6 Detection of Apoptosis In Vitro by the Differential Uptake of Acridine 
Orange and Ethidium Bromide 
Morphological detennination of apoptosis is essential due to the shortcomings of 
other currently available techniques. Acridine orange and ethidium bromide 
intercalates with DNA enhancing the characteristics of apoptotic cell death, making 
observation of these cells easier, under fluorescent microscopy. Both floating and 
adherent PDVC57, CarB, SCC25 and HN5 cells infected with 2500 vp/cell 
Ad5CMV-p53 or Ad-PolyA, were collected 24 and 48 hours post-treatment and 
analysed following incorporation of acridine orange and ethidium bromide. In 
addition cells exposed to 2 minutes UV light, treatment with 20 ~g/ml cisplatin or 
mock-infection, were analysed in the same manner. Figure 4.7 shows the percentage 
of these cell lines that are viable, or in early or late apoptosis. Triplicate samples per 
condition were analysed, and the mean percentage of cells in each group detennined. 
Figure 4.6 shows photomicrographs of acridine orange/ethidium bromide stained 
PDVC57 cells, 24 hours after infection with Ad5CMV-p53, and shows 
representative dye incorporation and cell morphology of viable, early apoptotic and 
late apoptotic cells. Viable cells display a uniform green nucleus. Early stages of 
apoptosis, when cells have intact membranes but DNA fragmentation has begun, 
result in cells with green nuclei since ethidium bromide cannot enter the cell, 
however, chromatin condensation is visible as bright green patches (Figure 4.6 a and 
b). Late stages of apoptosis, when membrane blebbing allows the entry of ethidium 
bromide results in bright orange areas of condensed chromatin, distinguishable from 
necrotic cells, which have a uniform orange colour (Figure 4.6 a and b). 
The data represented in Figure 4.7 illustrates that the majority of untreated and Ad-
PolyA infected cells (PDVC57, CarB, SCC25 and HN5) were viable, displaying a 
uniform green coloured nucleus. The Ad-Poly A vector however, did cause low 
levels of apoptosis, over that seen in the untreated PDVC57, CarB, SCC25 and HN5 
cells, showing that the adenoviral backbone is capable at 2500 vp/cell of initiating 
apoptosis. These levels of apoptosis caused by Ad-PolyA however, were 
substantially less than that seen after Ad5CMV -p53 infection of PDVC57 cells. 
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Hence, the exogenous p53 protein and not non-specific adenoviral processes must be 
the key to this increased apoptotic activity seen in the Ad5CMV-p53 infected cells. 
However, only slightly higher levels of apoptosis in comparison with Ad-PolyA 
infected cells were observed after Ad5CMV-p53 infection of the CarB, SCC25 and 
HN5 cells. One explanation for this is the lower transduction efficiency of these 
cells at 2500 vp/cell as compared to the PDVC57 cells. Alternatively, the differences 
could result from varying genetic backgrounds present in the cell lines. 
Exposure of the four-tested cell lines to UV or cisplatin resulted in high levels of 
apoptotic cell death. The majority of the PDVC57, CarB and SCC25 cell lines 
showed morphological and dye incorporation characteristics indicative of apoptosis 
at 24 and 48 hours post-treatment. The HN5 cell line was less sensitive to apoptotic 
cell death by UV and cisplatin exposure. Although significant apoptotic cell 
morphology was observed, approximately a fifth of the HN5 cells remained viable at 
48 hours. 
Infection of the four-tested cell lines with 2500 vp/cell Ad5CMV-p53 resulted in 
varying degrees of apoptotic cell death. This can be partially explained by the 
variability in transduction efficiency of the cell lines (see section 3. 1), and also the 
different genetic background of each cell line. The PDVC57 cells showed high 
levels of both early and late stage apoptosis, although approximately a third of the 
cells remained viable 48 hours post-infection. 
CarB was considered for use as a normal control, since it possesses a wildtype p53 
gene. However, based on results obtained from transduction experiments (section 
3.1), this line is not ideal, since it showed low transduction efficiency as compared 
to the PDVC57 cell line. As anticipated from these earlier observations, infection of 
CarB cells with 2500 vp/cell Ad5CMV-p53 resulted in the majority of cells 
remaining viable. The SCC25 and HN5 cell lines also showed only low levels of 
apoptosis following Ad5CMV-p53 infection, with the majority of cells remaining 
viable over the time period investigated. 
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The differences in levels of apoptotic cell detection between the TUNEL and 
acridine orange and ethidium bromide dye incorporation assays were probably a 
reflection of the fact that different stages of apoptosis were being measured. Since 
the detached and attached cells were combined within the analysis using acridine 
orange and ethidium bromide dye incorporation, the degree of apoptotic morphology 
detected in each of these cell subsets is unclear. 
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a) 100 11m 
b) 100 11m 
Figure 4.6: Acridine OrangelEthidium Bromide Uptake of PDVC57 Cells 
following Infection with Ad5CMV-p53. The incorporation of the DNA stains 
ethidium bromide and acridine orange into a cell enables the differentiation of 
viable, necrotic, and early and late stage apoptosis. The photomicrographs show 
PDVC57 cells that have been infected with Ad5CMV -p53 for 24 hours, followed by 
incorporation of the two dyes. Viable cells are revealed as cells with uniform green 
staining in the nucleus. Early apoptotic cells have green nuclei, but chromatin 
condensation becomes visible as bright green patches in the nuclei. Late apoptotic 
cells have bright orange areas of condensed chromatin in the nucleus. 
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Figure 4.7a) 
PDVC57 Cell Viability Status as Determined by Acridine Orange 
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Figure 4.7: Cell Viability Status as Determined by Acridine Orange and 
Ethidium Bromide Dye Incorporation. Column charts showing the mean 
percentage of a) PDVCS7; b) CarB; c) SCC2S and d) HNS cells showing viable, 
early apoptotic and late apoptotic cell morphology. Data represents the mean 
percentage of cells/viability status group following three counts of 200 cells, +/-
SEM. Cell lines received either no treatment, 2 minutes exposure to UV light, 20 
~glml cisplatin, 2500 vp/cell Ad-PolyA, or 2500 vp/cell Ad5CMV-p53. Cells were 
harvested at 24 and 48 hours post treatment and analysed under a fluorescent light 
microscope following the incorporation of acridine orange and ethidium bromide 
dyes (1: 1 v/v at 100~glml) . 
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4.7 Apoptotic Detection in Cisplatin or UV Exposed Cells 
Cisplatin and UV irradiation were capable of inducing apoptosis in the absence of 
wildtype p53 in HN5, SCC25 and PDVC57 cells. Although p53 is required for DNA 
damage-induced apoptosis in some cells, its presence is not essential in others. A 
p53-independent mechanism could be functional in these cell lines to enable 
cisplatin and UV exposure to induce apoptosis. 
It is well documented that p53-independent mechanisms of apoptosis exist. 
Alternatively, it is possible that the endogenous p53 was partially functional and 
hence cisplatin or UV exposure induced apoptosis via p53. It has been shown that 
p53 transactivation mutants, which are able to bind DNA, are able to induce 
apoptosis. Mutant p53 can lose the ability to activate some but not other promoters, 
resulting in gain-of -function activities, as discussed in more detail in section 4.2 
(Blagosklonny, 2000; van Oijen and Slootweg, 2000). It would be of interest to 
study the effects of cisplatin or UV exposure on p53 target gene expression within 
the cell lines used in these studies. This would help to determine whether the 
apoptosis is the result of p53-independent pathways, or to the p53 mutant retaining 
the ability to transactivate a subset ofp53 target genes. Since the SCC97 and SCC25 
cells showed no detectable p53 protein by Western blot analysis, it is highly likely 
that these cell lines achieved apoptotic cell death following UV or cisplatin exposure 
in a p53-independent fashion. 
UV damages DNA by forming pyrimidine dimers, resulting in somatic mutation. 
UV irradiation has also been shown to be capable of activating apoptosis via both 
p53-dependent and p53-independent pathways. As discussed in the introduction 
(section 1.15) the major apoptotic pathway induced by UV is the JNK pathway, with 
subsequent activation of the caspase cascade. In a study by Takahashi et ai, 2001 
the p53-independent induction of GADD45 after UV irradiation is discussed. The 
Oct-l regulatory element is thought to be one of the essential elements involved in 
the activation of the GADD45 promoter by UV irradiation in a p53-independent 
pathway. Another p53-independent pathway that results in apoptotic cell death 
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following UV irradiation has been described in keratinocytes, due to loss of 
attachment as a result ofintegrin-sensitivity (Gniadecki et ai, 1997). 
The cytotoxicity of cisplatin via alterations in DNA structure prevent replication and 
thus activates cellular repair mechanisms, which are thought to be the cause of 
eventual cell death, via apoptosis (Barry et ai, 1990). However, in a review by 
Gonzalez et ai, 2001 apoptotic, necrotic and a defective apoptotic cell death program 
are implemented as possible causes of cell death following cisplatin exposure, with 
the outcome dependent upon the dose and cellular status. Cell death as a result of a 
defective apoptotic program, lack some morphological and biochemical 
characteristics attributed to apoptosis. 
Contradictory reports have ansen regarding the status of p53, and the cells 
subsequent sensitivity to chemotherapeutic agents (Wahl et ai, 1996; Pirollo et ai, 
1997; Zamble et ai, 1998). In addition the relationship between the level of DNA 
damage as a result of the chemotherapeutic agent versus cell survival or death is 
commonly reported. The p53-dependent p21 WAFl induction and cell cycle arrest have 
been reported to occur at sublethal doses of chemotherapy, to allow DNA repair, 
whereas at lethal doses of chemotherapy apoptotic death occurs (Fisher, 1994; Wu et 
ai, 1996). Wu et ai, 1996 reported that DNA degradation was found following 
exposure to lethal doses of chemotherapeutic drugs regardless of the p53 status. This 
group reported that tumour cell lines containing an intact wildtype p53 pathway was 
not necessarily more sensitive to treatment by DNA-damaging chemotherapeutic 
agents as compared with cell lines containing mutant or no p53 . Our studies were in 
agreement with this, since DNA laddering was detected in both the p53 wildtype 
CarB cell line and the p53 mutated PDVC57 cell line after exposure to either 
cisplatin or uv. It is also clear from the various experiments carried out on the cell 
lines exposed to these two DNA damaging agents, that lethal doses were 
administered, resulting in apoptosis in the majority of cells by 72 hours. However, in 
other studies mutations in p53 have been shown to confer sensitivity to drugs whose 
toxicity is modulated by nucleotide excision repair, such as cisplatin. Mutant p53 
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through its inability to transactivate p21 W AFl, increases the sensitivity of 
chemotherapeutic agents by initiating apoptosis (Brown et ai, 1999a). 
Wang et ai, 1998 provide evidence that cells carrying mutations resulting in loss of 
function in the p53 gene can be killed by cisplatin via a p53-independent route with 
some similarities to replicative senescence, but not apoptosis. The shortening of the 
telomere and the inhibition of telomerase activity have been observed in cells treated 
with cisplatin (reviewed in Wang et ai, 1998). However, this is unlikely to be the 
case in the cell lines tested in this study (PDVC57, HN5, and SCC25), SInce 
apoptotic characteristics were detected via a number of assays. 
Cisplatin and UV exposure of cells resulted in DNA laddering, positive TUNEL 
staining, and apoptotic cell morphology as observed after incorporation of acridine 
orange and ethidium bromide dyes. Each of the methods used to detect and measure 
apoptosis has its own advantages and limitations. Detection of apoptosis is 
complex, therefore, a couple of methods along with the observation of cell 
morphology are important. The TUNEL assay has been used extensively to 
demonstrate apoptosis, however, it is now apparent that this method can also stain 
necrotic cells (Walker and Quirke, 2001 ; Aigner, 2002; Baima and Sticherling, 
2002). Hence, alternative methods for specifically detecting apoptotic cell death, 
such as the detection of caspase-3 activity, may be more appropriate in future 
studies. 
The PDVC57 cells (possessing a mutated p53) showed positive characteristics of 
apoptotic cell death after exposure to 20 Jlg/ml cisplatin by DNA laddering (40-48 
hours post exposure, section 4.4); TUNEL (16-72 hours after exposure, section 4.5); 
and acridine orange/ethidium bromide incorporation and cell morphology analysis 
of apoptosis (24 and 48 hours post exposure, section 4.6). The observation of no 
DNA laddering after cisplatin exposure of PDVC57 cells at time points prior to 40 
hours is surprising. This could be attributed to the fact that DNA laddering studies 
cell death in a cell population as compared to the other two assays used which study 
cell death in single cells. DNA laddering is relatively insensitive requiring at least 
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106 cells/test and does not allow for quantification of apoptosis. It could be that not 
enough cells displaying DNA fragmentation were harvested at these earlier time 
points to allow for the visualisation of a DNA ladder on an agarose gel. 
The acridine orange/ethidium bromide dye uptake followed by morphological 
examination of the individual cells allows the discrimination between early and late 
stages of apoptotic cell death. Exposure of PDVC57 cells to cisplatin resulted in a 
high percentage of cells displaying characteristics of early apoptosis 24 hours after 
exposure (63%) and a high percentage of cells displaying characteristics of late 
apoptosis 48 hours after exposure (72%). These results correspond well with the 
findings from the other apoptotic detection methods used. 
As observed in the cell proliferation assay UV exposure of PDVC57 resulted in 
earlier detection of cell death than following cisplatin exposure (section 4.1). 
Exposure of PDVC57 cells to 2 minutes UV irradiation resulted in DNA laddering 
(24-48 hours post exposure); TUNEL (16-72 hours post exposure) and acridine 
orange/ethidium bromide incorporation and cell morphology analysis of apoptosis 
(24 and 48 hours post exposure). 
Exposure of PDVC57 cells to UV resulted in approximately even distribution of 
early and late apoptotic cells after 24 and 48 hours as detected by acridine orange 
and ethidium bromide dye uptake, corresponding well with the apoptosis detection 
times seen by DNA laddering and TUNEL. 
The wildtype p53 CarB cell line was analysed for apoptotic cell death by DNA 
laddering and acridine orange/ethidium bromide dye incorporation. Apoptotic cell 
death was detected after exposure to cisplatin and UV at earlier time points than for 
the PDVC57 cells. DNA fragmentation was detected on agarose gels at 16-20 hours 
post cisplatin and UV exposure, corresponding well with the fluorochrome uptake 
assay, which showed high levels of apoptosis at 24 and 48 hours post cisplatin and 
UV exposure. 
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The SCC25 p53 mutated cell line, also showed a high level of apoptotic cell death 
following exposure to UV light or cisplatin. Acridine orange/ethidium bromide dye 
incorporation followed by cell morphology analysis revealed 94% and 89% of the 
cells were apoptotic, 24 hours after exposure to 2 minutes UV light, or 20 /lg/ml 
cisplatin respectively. These findings were sustained 48 hours post-UV or cisplatin 
exposure (Figure 4.7). 
The p53 mutated HN5 cells took longer to show high levels of apoptosis than the 
other lines investigated. Twenty-four hours after UV or cisplatin exposure, 55% and 
38% of the cells were apoptotic respectively, as determined by cell morphology 
analysis after incorporation of acridine orange and ethidium bromide. However, 48 
hours after exposure to UV or cisplatin, apoptotic cell detection was 82% and 71 % 
respectively. 
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4.8 Cell Cycle Analysis 
Cell cycle analysis as determined by flow cytometry was carried out for PDVCS7 
cells infected with 2S00vp/cell AdSCMV-p53, Ad-PolyA or Ad-~-gal . At 6, 24 and 
48 hours post-infection, cells were analyzed for DNA content by propidium iodide 
staining. Duplicate plates were analysed per treatment, with results representative of 
duplicate experiments. Ten thousand cells were counted for each sample using a 
Becton Dickinson fluorescence-activated cell sorter (F ACS). Data was collected 
using the FL2 fluorescence detection channel and displayed on a linear scale. A 
histogram of DNA content against cell number was plotted using CELLQuest 
software. 
It is essential to determine the linearity of the F ACScan during flow cytometry, in 
terms of DNA content analysis, the channel number of a G2+M peak should be 
twice that of the GO/G 1 peak. The positioning of the GO/G 1 peaks and the G2+M 
peaks provide the baseline against which other peaks were compared. If the 
instrument is unable to provide a linear response, then changes in the amount of 
DNA in a population, due to test treatments will be unable to be accurately gauged. 
Linearity was achieved in these experiments (Figure 4.8) with the GO/G 1 peak at 
approximately 300 and the G2+M peak at 600. 
The percentage of cells in each phase of the cell cycle (sub-G 1, GO/G 1, S and G2-
M) after treatment is shown, Figure 4.8. Cells with lower DNA staining than that of 
Gl cells (the so-called "sub-Gl peaks") have been considered apoptotic. However, 
making this assumption does not discriminate apoptotic cells from necrotic cells. In 
these experiments changes in cell cycle populations were the key emphasis, hence, 
cell acquisitions were gated to exclude cell debris in this analysis. Additionally, cells 
floating in the culture medium prior to harvesting were not collected for analysis. 
Therefore, this data underestimates the percentage of potentially apoptotic cells after 
the various treatments, although, the majority of treatments did result in a moderate 
increase in this population of cells. 
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4.8.1 Cell Cycle Analysis following Cisplatin and UV Exposure 
To assess the effect of cisplatin on the cell cycle distribution of PDVC57, cisplatin 
was added to the culture medium 24 hours after seeding at 2 x 105 cellslI Ocm2 dish. 
A concentration of 20 Jlg/ml cisplatin was lethal in the majority of the PDVC57 
cells, with cells showing apoptosis by 24 hours as shown from growth inhibition 
experiments (Section 4.2), TUNEL staining (Section 4.5) and examination of cells 
after acridine orange and ethidium bromide incorporation (Section 4.6). Therefore, a 
lower concentration of cisplatin, 10 Jlg/ml, was used to detect cell cycle distribution 
changes without the immediate killing of the cells. Six hours after PDVC57 cells 
were exposed to 10 Jlg/ml cisplatin, approximately 5% more cells were detected in 
the sub-G 1 phase of the cell cycle as compared to the untreated control cells. 
However, as mentioned above this is likely to underestimate the true number of cells 
in this phase, since no floating cells were collected for analysis, and cell debris were 
gated out of the F ACScan count. In addition, cisplatin shifted the number of cells in 
GO/Gl from 38% in untreated cells up to 43%, cells in S phase from 15% up to 
22%, and cells in G2+M from 35% down to 24%. These changes in cell number 
within each cell cycle phase, is only relatively small, showing a slight arrest at the 
G I-S checkpoint. After 24 hours cisplatin exposure, the majority of the cells were 
apoptotic. 
The effect ofUV exposure on the cell cycle distribution ofPDVC57 cells were also 
analysed, with the length of UV exposure reduced from 2 to 1 minute, to collect 
cells that did not die immediately. Six hours after PDVC57 cells were exposed to 
UV light for 1 minute, cell numbers shifted in GO/G 1 from 38% in untreated cells 
down to 33%, cells in S phase remained similar, and cells in G2+M from 35% up to 
38%. The changes in cell cycle distribution between the untreated and UV exposed 
cells were fairly small, with a slight shift into arrest at the G2-M checkpoint. After 
24 hours UV exposure, the majority of the cells were apoptotic. 
Previous studies have reported both Gland G2 phase cell cycle arrests as responses 
to DNA damage induced by UV in cultured cells (Pavey et ai, 2001). Gl arrest is 
generally p53-dependent, therefore, since the PDVC57 cells contain a p53 gene 
202 
Chapter 4 - Results and Interpretation 
mutation, they are unlikely to be able to transactivate p21 W AFI , which can block cells 
at this stage of the cell cycle. Chang et aI, 1999 discusses the dose-dependent 
effects of DNA-damaging agents on Gl arrest, showing important roles for both p53 
and p21 W AFI in ionising radiation-induced G 1 cell cycle arrest. Certain DNA-
damaging agents such as UV light and cisplatin will at high doses inhibit mRNA 
synthesis, and reduce the expression of p21 WAFI (reviewed in Chang et ai, 1999). 
Thus, p53 may be unable to transactivate the p21WAFJ gene because of the presence 
of transcription-blocking lesions in the p21WAFJ gene, and, thus, the ability to arrest 
the cells in G 1 should be attenuated. However, proficient transcription is also 
required for the G I-S transition by activating E2F-responding genes. Since UV light 
inhibits RNA synthesis by inducing transcription-blocking DNA lesions, the 
transactivation of the p21 WAFJ gene may not be efficient despite high-induced levels 
of p53. In a study by Tweedle et ai, 2001 mutant or null p53 cell lines, did not arrest 
strongly in G2 or Gl after irradiation, whereas p53 wildtype cell lines showed either 
G 1 arrest or no change in cell cycle distribution. 
In addition, no G2 arrest was detected in the PDVC57 cell lines following exposure 
to cisplatin or UV light, again this is likely to be the result of lethal doses being used 
and rapid apoptotic death. Cell cycle arrest and a specific cell cycle check point at 
the boundary of the G2 and M phases have been suggested to be involved in 
apoptosis induction in a variety of proliferating cells treated with cisplatin (reviewed 
by Gonzalez et ai, 2001). If cisplatin-induced cellular damage were irreparable 
during the G2 phase, controlled elimination of platinated cells via apoptosis would 
prevent the passage of these cells into mitosis (Evans et ai, 1994). Other studies 
have reported that the levels of the G2 phase proteins cyclin Bland CDC2 can be 
up-regulated following UV irradiation (Pavey et ai, 2001), and this would be an 
interesting follow up in our cells. This would help to determine if this pathway is 
functional in our cell line. It would also, be interesting to study lower doses of these 
reagents to establish whether the induction of apoptosis is dose dependent and 
whether lower doses of the damaging agent cause growth arrest instead of apoptosis 
in these cell lines. 
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4.8.2 Cell Cycle Analysis following Adenoviral Infection 
Flow cytometric analysis of untreated PDVC57, and cells infected with the empty 
adenovirus vector Ad-Poly A, showed similar cell cycle phase distribution 6 hours 
post-infection. However, after 24 hours differences occurred in cell cycle phase 
distribution, with Ad-PolyA infected cells showing a 16% decrease in cell numbers 
in GO/G 1 phase, a 5% increase in cells in the S phase, and a 4% decrease in cells in 
the G2+M phase, as compared to the untreated cells. A small increase in the sub-G 1 
cell number was observed. Similar distribution was sustained at 48 hours. This 
pattern of cell cycle phase distribution over time was also observed in the Ad-~-gal 
infected PDVC57 cells with the exception of little change in the S phase cell 
numbers (Figure 4.8). This decrease in cell number in GO/Gl phase following both 
Ad-PolyA and Ad-~-gal infection ofPDVC57 cells, could be an explanation for the 
reduction in cell numbers observed at days 4-5 following infection with these 
vectors in the growth assay experiments (section 4.1). 
Other studies may help to explain some of the changes we observed in our 
experiments, following infection with Ad-Poly A or Ad-~-gal. It is frequently 
reported that when a cell is transfected with an empty vector, the phenotype of the 
cell may be affected. Modification of cells with DNA can be seen as abuse to the 
cells similar to DNA damage, thus altering the cells behaviour. In a study carried out 
by Teramoto et ai, 1995, infection with adenovirus induced slowing of cell 
proliferation as a result of both increased apoptotic cell death and lower recruitment 
into S phase. These authors report that increasing concentrations of adenoviral 
vector is accompanied with increased apoptosis and slowing of the cell cycle of 
infected cells. Brand et ai, 1999 have shown that adenoviral vectors lacking a 
transgene result in apoptosis and cell cycle arrest, especially when used at a high vp. 
This group reported an early but reversible G21M cell cycle arrest, and suggested 
that this could be the result of a cellular emergency reaction to the adenoviral 
infection process. In addition the G21M arrest observed may at least in part be 
responsible for the severe but also reversible growth retardation upon adenoviral 
transduction. A possible explanation for the reduction in PDVC57 cell numbers 
observed in the growth assay 4-5 days following infection of Ad-Poly A or Ad-~-gal 
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could therefore be due to low levels of apoptosis and a slowing of proliferation of 
these cells. 
Infection ofPDVC57 with Ad5CMV -p53 when compared to untreated cells, showed 
increases in cell numbers within the sub-Gl (3%), S (3%) and the G2+M (3%) 
phases of the cell cycle, with a 5% reduction in cell number within the GO/G 1 cell 
cycle phase, 6 hours after infection, as compared to the untreated PDVC57 cells. By 
24 hours the sub-Gl cell number had increased to 7.39% of the cell population, and 
a small decrease in cell number within the G2+M phase (2%) was observed in 
comparison to the untreated cells. Forty-eight hours after Ad5CMV-p53 infection, 
approximately 8% fewer cells were counted in the GO/G 1 cell cycle phase, 6% less 
in the S phase, and 1 % less cells in G2+M, as compared to the untreated cells. 
When compared to time matched Ad-Poly A infected cells, which is a more thorough 
control, for the detection of the p53 transgene effects on the cell cycle, small 
changes were observed at all time points. After 6 hours infection with Ad5CMV-
p53, PDVC57 cells showed a 7% decrease in cell number in the GO/Gl cell cycle 
phase as compared to Ad-Poly A infected cells, a 2% increase in S phase cells, and a 
4% increase in G2+M cells. By 24 hours the GO/G 1 decrease seen at 6 hours had 
altered to a 15% increase, with a 6% decrease in the S phase and a 2% increase in 
G2+M cells. Forty-eight hours after infection with Ad5CMV-p53, a 8% increase in 
GO/G 1 cell number was observed as compared to time matched Ad-Poly A infected 
cells, a 6% decrease in S phase cells, and a 4% increase in G2+M phase cell number. 
Previous studies have shown a spectrum of cell cycle effects following adenoviral 
infection with the p53 transgene, as well as after cisplatin or UV exposure. The 
ability of a cell to undergo growth arrest or apoptosis seems to be dependent on the 
cell type, phase of the cell cycle, differentiation status, the presence of other 
oncogenic abnormalities and external growth and survival factors, as well as the 
level of DNA damage and p53 induced. 
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Chen et ai, 1996 discuss how the cellular level ofp53 can dictate the response taken 
by the cell, such that lower levels of p53 result in arrest whereas higher levels result 
in apoptosis. Nevertheless, DNA damage can heighten the apoptotic response to 
p53 without altering the protein level of p53 in cells. It seems likely that several p53 
activities, both transcriptionally dependent and transcriptionally independent, can 
play a role in mediating cell death. It is well established that certain cell types are 
extremely sensitive to p53-mediated apoptosis (e.g. lymphoid cells), whereas others 
typically undergo G 1 arrest and are relatively resistant to apoptosis (e.g. fibroblast 
cells, Canman and Kastan, 1998). The ability of cells to undergo p53-mediated 
apoptosis can also be greatly reduced through enhanced expression of the BCL-2 
oncoprotein and related proteins. On the other hand, loss of G 1 cell cycle 
checkpoint control, such as through inactivation of the RB tumour suppressor gene 
product or overexpression of the S-phase promoting E2F -1 transcription factor, has 
been linked to increasing the susceptibility of cells to p53-mediated apoptosis 
(Canman and Kastan, 1998). In addition, alternative possibilities that may account 
for attenuated G 1 arrest include amplification of cyclin D 1, CDK4 or CDK6 
(McKenzie et ai, 1999). A useful future investigation would be to determine the 
status of the CDK-Cyclin D l-RB pathway in the PDVC57 cells, to establish if the 
above explanations for loss of G 1 arrest is applicable to our findings. 
The observation that exogenous p53 expreSSIOn In the PDVC57 cells after 
Ad5CMV-p53 infection resulted in p21 WAFl induction as determined by Western 
blot, (Figure 3.5) suggests that a G 1 arrest should be plausible. However, the lack of 
G 1 arrest detected by F ACS after Ad5CMV -p53 infection would imply that the 
pathway downstream of p53 is non-functional. P21 WAFl functions as a CKI, in Gl 
of the cell cycle. McKenzie et ai, 1999 reported that mutations in p21WAFl could 
potentially result in persistent CDK activity, RB hyperphosphorylation, and 
progression through the cell cycle. The ability of p21 WAF l to inhibit CDK activity 
appears to depend upon the stoichiometric relationship of the number of p21 W AFI 
molecules bound to G 1 cyclin-CDK complexes (reviewed by Canman and Kastan, 
1998). The S-phase promoting E2F family of transcription factors appears to be 
critical downstream targets of p21 W AFl inhibitory activity. Deregulation of E2F 
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activity is strongly implicated as a mechanism by which abrogation of RB function 
sensitises cells to p53-mediated apoptosis. Abrogation of RB function leads to 
deregulation of cell growth and extensive p53-dependent apoptosis, linking loss of 
E2F regulation with apoptosis. Convincing evidence now suggests that p53 and 
E2F-1 can co-operate to induce apoptosis (Qin et ai, 1994). Hence, it might be the 
case within these PDVC57 cells that p21 WAF I function is impaired, is at an 
insufficient level, or its expression is unstable. If this is the case then this might 
result in deregulation of E2F activity and therefore, increase the susceptibility of 
these cells to p53-mediated apoptosis. The expression of exogenous p53 in the 
PDVC57 cells, as detected by Western blot show that very high levels of expression 
are achieved which could also contribute to the choice of apoptotic cell death over 
growth arrest. 
Experiments carried out in this research suggest that the p53 transgene is functional, 
ICC showed that the exogenous p53 was expressed in the nucleus (section 3.4). In 
addition, analysis by TUNEL staining (section 4.5) and acridine orange/ethidium 
bromide DNA staining followed by examination of cell morphology (section 4.6) 
shows the ability of p53 to induce apoptosis appears functional. 
In a study by Polyak et ai, 1996 the effect of wildtype p53 expression to cause cell 
cycle arrest or apoptosis was investigated in 12 cell lines. Of these 12, 6 underwent 
apoptosis after Ad-p53 infection, 3 growth arrested, and 3 had little effect on flow 
cytometric patterns of cell cycle distribution. This study found that the induction of 
p21 WAFI could not account for the differential response to p53 . Kagawa et ai, 1997 
however, reported that p53-mediated apoptosis is dominant over growth arrest, since 
exogenous p53 overcame p21 WAFI mediated cell cycle arrest at G1 and induced 
apoptosis. 
The decision of a cell to undergo p53-dependent GI arrest or apoptosis appears to 
depend upon the cellular context in which p53 is activated. The presence or absence 
of specific growth factors or the actual levels of p53 expressed within a cell can 
dictate which pathway is chosen. 
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Figure 4.8: Cell Cycle Analysis by Flow Cytometry. PDVC57 cells were treated 
with a range of agents, and harvested at 6, 24 or 48 hours post-treatment. Cells were 
analysed for DNA content by propidium iodide staining, followed by flow 
cytometry. The percentage of cells in each phase of the cell cycle (sub-G 1, GO/G 1, S 
and G2-M) is presented. a) Untreated PDVC57; b) 10 J..lg/ml cisplatin for 6 hours; c) 
1 minute UV exposure, harvested at 6 hours; d, e and f) 2500 vp/cell Ad5CMV-p53 
for 6, 24 and 48 hours respectively; g, h and i) 2500 vp/cell Ad-PolyA for 6, 24 and 
48 hours respectively; j , k and 1) 2500 vp/cell Ad-~-gal for 6, 24 and 48 hours 
respectively. 
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Chapter 5 - Preclinical Models in the 
Subcutaneous Tissue and Floor of the 
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5.1 Establishment of the Subcutaneous Tumour Model 
Following injection of PDVC57 cells into the flanks of syngeneic C57B1I6 hosts, 
tumour nodules (typically 7-10 mm in diameter) were apparent after 20 days. 
Subcutaneous tumour nodules developed in C57B1I6 mice after administration of 1 x 
106 PDVC57 cells in > 95% of cases. Histologically, the tumours were spindle-cell 
carcinomas with little differentiation (Figure 5.1). They were typically encapsulated 
but could invade into the surrounding tissues and muscle at later time points (>20 
days). The majority of tumours developed central necrosis (>11 days). 
The PDVC57 and SCC97 cell lines were also used to establish S.c. tumours in nude 
mice. Introduction of 1 x 106 PDVC57 cells subcutaneously resulted in 8/10 (80%) 
tumour take rate, after 15-18 days. Introduction of 1 x 106 SCC97 cells 
subcutaneously resulted in 5/8 (63%) tumour take rate, with nodules taking longer to 
grow (30-40 days) than observed for PDVC57 derived tumours. When 8 x 106 
SCC97 cells were used to establish S.c. tumours, nodules developed in 6/8 (75%) of 
animals, by day 17. Histological examination revealed large areas of central 
necrosis in these tumour nodules at time of biopsy. 
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a) 100 Jlm 
b) 100 Jlm 
Figure 5.1: Subcutaneous Tumour Nodules. Development of S.C. tumours were 
achieved by implanting 1 x 106 PDVC57 cells into the S.c. tissue of C57B1I6 or 
nude (nu/nu) rodents. a) Shows a S.C. tumour nodule 21 days after PDVC57 tumour 
cell implantation. b) Shows the PDVC57 cells grow to form spindle cell carcinomas 
with little differentiation in the S.c. tissue. 
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5.2 Treatment of Subcutaneous Tumours with Cisplatin 
Most solid human tumours have relatively low growth fractions, therefore care 
should be taken when considering treatment efficacy in in vivo models. Many 
cytotoxic anti-cancer drugs target rapidly dividing cells, hence highly proliferating 
tumour models tend to show exaggerated responses to these agents (Kerbel, 1999). 
Subcutaneous tumours created in immuno-competent and -deficient hosts were 
treated with 3, 5 or 10 mg/kg cisplatin i.p., either daily or every other day, with a 
total of 2-5 treatments, in line with similar experiments. The dose and frequency of 
treatments were slowly increased since limited evidence of gross tumour nodule 
reduction was observed. However, examination of tumour morphology (Figure 
5. 2a) and TUNEL staining of tissue sections (section 5.7) revealed the presence of 
dead and dying cells following all treatment schedules. Homogenous pale pink 
cytoplasm and absence of cell nuclear were observed in haematoxylin and eosin 
stained tissue sections, following cisplatin treatment. Increasing doses of cisplatin 
did not result in significantly greater tumour cell death. In addition, large variations 
in the degree of cell death detected were observed between tumour nodules treated 
with the same dosing schedules. 
5.3 Treatment of Subcutaneous Tumours with 5-Fluorouracil 
Subcutaneous tumours created in immuno-competent and -deficient hosts were 
treated by i.p. injections with 50 mg/kg 5-FU. Initially treatment were administered 
once weekly for 2 weeks, but limited histological evidence of tumour cell death 
along with no evidence of gross tumour nodule reduction was observed. Treatment 
schedules were therefore altered with administration of 50 mg/kg 5-FU every other 
day, for a maximum of 5 days. When compared with PBS-treated controls, the S.c. 
tumour nodules developing in rodents treated with 5-FU contained more ghost cells, 
with coagulated cytoplasm and often no nucleus (Figure 5.2b), indicative of 
coagulative necrosis. However, little evidence of an inflammatory response was 
observed in the 5-FU treated tissue as would be expected following necrotic cell 
death. 
215 
Chapter 5 - Results and Interpretation 
a) 100/lm 
b) 100/lm 
Figure 5.2: Effect of Chemotherapeutic Treatment on Subcutaneous Tumour 
Nodules. PDVC57 derived tumours were established in the S.C. tissue of 
immunocompetent C57Bl/6 rodents. Chemotherapeutic agents were administered 
into the peritoneal cavity. Tumours were excised 7 days after the fmal treatment and 
tissue sections examined for morphological evidence of cell death. . Homogenous 
pale pink cytoplasm and absence of cell nuclear were observed in haematoxylin and 
eosin stained tissue sections. a) A total of 5 daily injections of 10 mglkg cisplatin 
was administered i.p., 3 days following tumour cell inoculation. b) Three doses of 
50 mglkg 5-FU were administered i.p. every other day, commencing 6 days after 
tumour cell inoculation. 
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5.4 The Morphological Assessment of Subcutaneous Tumours following 
Molecular Therapy 
Subcutaneous tumour nodules (day 18-24 post-tumour cell inoculation) were 
injected with either 5 x 1010 vp Ad5CMV-p53, Ad-J3-gal or PBS. Treatment 
schedules involved either a single treatment with tissues taken for histological 
examination 24 and 48 hours later, or two treatments on days 20 and 22, with 
biopsies taken 72 hours after the last treatment. Tissue sections were analysed by a 
variety of methods. The Ad-J3-gal treated tumour nodules were assessed for 
transgene expression by X-gal staining (section 5.5). The Ad5CMV-p53 infected 
tissues were assessed for p53 transgene expression by mc (section 5.6). In addition 
after all treatment schedules, tissues were examined for TUNEL (section 5.7). 
Microscopic examination of the Ad5CMV -p53 treated sites revealed areas of dead 
cells, with a significant inflammatory cell infiltration. In comparison, the PBS 
treated tumours showed no such patterns of cell death, except a central area of 
necrosis (Figure 5.3). 
5.5 Detection of Reporter Gene Expression in Subcutaneous Tumour Nodules 
To evaluate whether the in vitro reporter gene expression observations translated 
into a similar in vivo response, we examined the effects of Ad-J3-gal treatment in an 
established S.C. tumour model within an immunocompetent host. No endogenous J3-
gal like activity was seen in the tumour cells, muscle, surface epithelium or 
connective tissue after mock-infection with Ad-Poly A. It is difficult to accurately 
assess the total number of tumour cells expressing J3-gal activity, since only ranges 
of sections at various levels of the tumour were examined. However, percentages of 
positive cellular expression were determined by examining samples by image 
analysis, from numerous experiments and reporting the range of expression seen. 
Following direct injection of 5 x 1010 vp Ad-J3-gal into S.c. tumour nodules, a range 
of 5-30% of the tumour cells stained positive by X-gal staining 24-48 hours post-
infection (Figure 5.4). In some cases, areas of tumour along needle tracks were 
stained whereas, in other cases, scattered blue cells were observed. Multiple tissue 
sections were examined throughout the tumour nodule. As a positive control for the 
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reporter gene detection assays, previously tested samples known to contain reporter 
activity were included in the detection experiment. On occasions small quantities of 
the adenovirus suspension was observed to ooze out of the needle puncture hole 
after administration. Therefore, skin biopsies surrounding the S.C. tumour were also 
taken after Ad-f3-gal infection of the tumour nodule and stained with X-gal, to 
determine iftransgene expression was detectable at this site. No positive blue X-gal 
staining was seen at these sites. 
Different tumour cell lines will have varying susceptibility for adenoviral vector 
uptake, resulting in a range of transduction efficiencies due to differing 
concentrations of the CAR and integrins on the tumour cells. In addition, it is 
generally observed that transgene expression within particular tumours grown within 
immunodeficient hosts is greater than when the same tumour is grown in 
immunocompetent hosts. This can be explained by the enhanced immune response 
against the adenoviral vector initiated within an immunocompetent animal. Previous 
studies in S.c. tumour models in nude mice have reported X-gal staining after 
infection with Ad-f3-gal in the range of 30-60% of the tumour cells (Clayman et ai, 
1995; Cusack et ai, 1996). Much lower transduction efficiencies have generally 
been observed when similar concentrations of Ad-f3-gal have been used to transduce 
S.c. tumours in immunocompetent animals. Li et ai, 1998 reported less than 5% of 
S.c. tumour cells expressed the f3-gal transgene after a single administration of Ad-
f3-gal when using the equivalent of 2.5 x 1010 vp of virus. The variability in vivo of 
gene expression levels, in immunocompetent and immunodeficient mice have also 
been reported after transfer of f3-gal by plasmid-liposome complexes and by 
replication-incompetent retroviruses (Lukacs et ai, 1999). 
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100 11m 
Immune cell infiltration 
Figure 5.3: Gene Therapy in an Established Subcutaneous Tumour. A 
concentration of5 x 1010 vp Ad5CMV-p53 were administered into PDVC57 derived 
S.C. tumour on day 20 and 22 post tumour cell inoculation. Biopsies were taken on 
day 25, and prepared for histological analysis. A heavy immune cell infiltrate is 
present within the tumour nodule (indicated by arrow). 
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a) 100 f.lm 
b) 100 f.lm 
c) 100 f.lm 
Figure 5.4: X-gal Staining of Subcutaneous PDVC57 Tumour Nodules Arising 
in C57BV6 Immunocompetent Hosts. Treatment with 5 x 1010 vp Ad-~-gal, 21 
days after PDVC57 tumour cell implantation. Twenty-four to forty-eight hours 
later, the tumour was removed and X-gal staining carried out on both frozen and 
paraffm embedded tissue sections. The photomicrographs show a representative 
level of transgene expression. 
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5.6 Expression of Exogenous p53 Protein in Adenovirus-Infected Subcutaneous 
Tumour Nodules by Immunohistochemistry 
After establishment ofS.C. tumour nodules in C57BlI6 or nude mice, Ad5CMV-p53 
was injected into the tumour with passes of the needle in multiple planes. Tumours 
were harvested 24-72 hours later and IHC carried out using the human p53-specific 
DO-l antibody. Protein could be detected by IHe after 24 hours, in approximately 
2-10% of tumour cells from immunocompetent hosts (Figure 5.5), and 
approximately 10-20% of tumour cells in immunodeficient hosts (Figure 5.6). 
These values were slightly lower than those observed following Ad-~-gal infection 
followed by X-gal staining. This could be a result of differing sensitivities between 
the two detection systems. 
5.7 Detection of Apoptotic Cell Death In Vivo 
It is important to be aware that it can be difficult under some circumstances, 
particularly for tissues and tumours in vivo, to assess apoptosis. This is as a result of 
the dynamic nature of this process, therefore, not all of the cells destined to die by 
apoptosis may be visible at anyone time. As discussed in the introduction (section 
1. 9) apoptotic cell death, and the clearance of apoptotic bodies in vivo is rapid (a few 
hours at most, Wyllie et ai, 1999). Hence, the identification of only a few apoptotic 
bodies in a tissue section can represent a considerable degree of cumulative cell loss. 
5.7.1 Detection of Apoptosis/Necrosis by TUNEL in Subcutaneous Tumours 
Theoretically, the TUNEL reaction can detect not only apoptotic DNA, but also the 
random fragmentation of DNA by multiple endonucleases occurring in cellular 
necrosis (Gold et ai, 1995). Gorczyca et ai, 1993 discusses how TUNEL can also 
detect cells dying by necrosis, but reported that this is at least one order of 
magnitude lower, as compared with labelling of apoptotic cells. Hence, the number 
of DNA strand breaks present in cells, which die, by apoptosis is markedly higher 
than during necrosis. TUNEL has been reported to be more sensitive than most other 
methods of apoptotic detection, identifying apoptosis at early stages prior to changes 
in cell morphology. However, a positive TUNEL assay reaction should not be 
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considered as a specific marker of apoptosis, since it can also indicate necrotic cell 
death. Care should be taken to additionally identify the characteristic cell 
morphology of apoptosis in TUNEL stained cells. 
Apoptotic cells detected by TUNEL were visualised as cells with reddy brown 
bodies in the nucleus. Established S.C. tumours, infected with Ad5CMV-p53, Ad-
PolyA, Ad-B-gal or Ad-Luc, were harvested 24-72 hours post-treatment and 
prepared for TUNEL staining. An intense level of TUNEL reactive nuclei (60-80%) 
were detected in the S.C. tumour cells established in immunodeficient hosts, 24, 48 
and 72 hours after infection with 5 x 1010 vp Ad5CMV-p53 (Figure 5.7c). Levels of 
positive TUNEL reactivity following infection with 5 x 1010 vp Ad5CMV -p53 in 
S.C. tumour nodules established in immunocompetent hosts was slightly lower than 
in immunodeficient hosts (50-60%, Figure 5.7a). The ability of TUNEL to detect 
both apoptotic and necrotic cell populations probably explains in part the high 
percentage of positive TUNEL staining detected in the Ad5CMV -p5 3 infected S. C. 
tumour nodule. Minimal TUNEL staining for apoptosis (1-2%) did occur in the Ad-
Poly A, Ad-B-Gal and Ad-Luc treated tumours, however, this was much lower than 
the Ad5CMV-p53 treated tumours and was probably due to vector toxicity. It was 
also observed that the TUNEL assay labelled necrotic cells, with the areas of central 
necrosis within the tumour nodules staining strongly (Figure 5.7d). 
Cisplatin treated tumours were also examined for TUNEL staining. Cisplatin 
resulted in approximately 10-15% TUNEL positive staining at 24 hours post-
treatment, throughout the tumour (Figure 5. 7b). The lower degree of TUNEL 
positive reactivity as compared to Ad5CMV-p53 infection could be explained by an 
insignificant dose of cisplatin delivered to cause major apoptotic cell death. 
Alternatively, it could result from cisplatin causing only apoptotic cell death, with no 
necrosis, since little inflammatory cell infiltration was observed after cisplatin 
treatment when studied in immunocompetent hosts, as compared to the large 
inflammatory cell infiltration following adenoviral infection. 
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a) 100 flm 
b) 100 flm 
Figure 5.5: Exogenous p53 Protein Expression in Immunocompetent Hosts. 
Subcutaneous PDVC57 tumour nodules were established in C57B1I6 mice, and 5 x 
1010 vp of Ad5CMV-p53 administered into the S.C. tumour nodules approximately 
three weeks post tumour cell inoculation. Twenty-four to forty-eight hours post 
viral infection, S.c. tumour nodules were harvested. Immunohistochemistry with 
the human p53-specific DO-1 antibody was carried out on tissue sections at a 
concentration of 2 Jlglml. Exogenous p53 expressing cells are visualised as cells 
with brown staining. 
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100 Jlm 
Figure 5.6: Exogenous p53 Protein Expression in Immunodeficient Hosts. 
Subcutaneous PDVC57 tumour nodules were established in nu/nu nude mice, and 5 
x 1010 vp of Ad5CMV-p53 administered into the S.c . tumour nodules 
approximately three weeks post tumour cell inoculation. Twenty-four to forty-eight 
hours post viral infection, S.c. tumour nodules were harvested. 
Immunohistochemistry with the human p53-specific DO-l antibody was carried out 
on tissue sections at a concentration of 2 Jlg/ml. Exogenous p53 expressing cells are 
visualised as cells with brown staining. 
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a) 100 !lm b) 100 !lm 
c) 100 !lm d) 100 !lm 
Figure 5.7: TUNEL Staining of Subcutaneous Tumours following Adenovirus 
Infection or Cisplatin Treatment. PDVC57 derived S.c. tumours were established 
in C57BV6 or nude (nu/nu) rodents. TUNEL staining was performed according to 
the manufacturer's guidelines, on tissue sections prepared following treatment with 
a range of agents. a) S.C. tumour nodules established in C57BV6 hosts, treated with 
5 x 1010 vp Ad5CMV-p53. Tumours were harvested 24 hours post-infection. b) S.c. 
tumour nodule established in C57B1I6 hosts, treated with 5 mg/kg cisplatin on days 
23, 25, 30, 34, and 39 post-tumour cell inoculation. Tumours were harvested 24 
hours after the last cisplatin treatment. c) S.C. tumour nodule established in nu/nu 
hosts, treated with 5 x 1010 vp Ad5CMV-p53. Tumours were harvested 24 hours 
post-infection. d) Untreated S.C. tumour nodule, established in C57BV6 hosts, 
showing positive TUNEL staining in the area of central necrosis. TUNEL positive 
cells are visualised as cells with reddy brown staining in the nucleus. 
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5.8 Establishment of the Model of Minimal Residual Cancer in the 
Subcutaneous Tissue 
The model of minimal residual cancer was created as described by Clayman et al 
(1995), to mimic the clinical scenario when microscopic tumour deposits remain in 
the S.c. tissue after surgery. 1 x106 PDVC57 cells were deposited into S.c. pockets 
in the right anterior and posterior flanks of C57B1I6 mice, to enable one site to act as 
a control, whilst the other received the treatment under test. The molecular 
intervention took place 48 hours post tumour cell inoculation, before tumour nests 
had developed. 
5.9 Morphological Assessment of the Model of Minimal Residual Cancer in the 
Subcutaneous Tissue following Molecular Therapy 
Two days following tumour cell inoculation, molecular therapy with a single dose of 
5 x 1010 vp Ad5CMV-p53 into the anterior S.c. tumour pocket, resulted in the 
absence of tumour nodules 20 days later, as detected following visual inspection and 
palpation, in 6/6 mice. The posterior S.c. tumour sites of these rodents were treated 
with the same dose of Ad-Poly A, and tumours were visible in all rodents (6/6) at this 
site after 20 days. 
Histological examination of the Ad5CMV-p53 infected sites revealed a mass of 
dead cells, liquefaction and chronic inflammation, surrounded by a connective tissue 
capsule (Figure 5.8). However, viable nests of tumour were found outside of the 
encapsulated zone in 2/6 mice treated with Ad5CMV-p53. The Ad-PolyA treated 
tumours were typical spindle cell carcinomas. 
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100 11m 
Immune cell infiltrate Liquefactive necrosis 
Figure 5.8: Microscopic Appearance of the Model of Minimal Residual Cancer 
in the Subcutaneous Tissue 20 Days After Treatment with 5 x 1010 vp of 
Ad5CMV-p53. 
1 x 106 PDVC57 cells were administered into a S.C. pocket, as described by 
Clayman et ai, 1995. Forty-eight hours later, 5 x 1010 vp Ad5CMV-p53 was 
administered into the S.C. pocket. Tissue was harvested 24-48 hours post-infection 
and sections examined under light microscopy following haematoxylin and eosin 
staining. The section shows a heavy immune cell infiltrate and areas of liquefactive 
necrosis as indicated by arrows. 
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5.10 Evidence of Necrotic Cell Death in PDVC57 Derived Tumour Models 
Necrosis as a result of extreme variance in physiological conditions results in a 
number of morphological, biochemical and physiological changes, which distinguish 
cell death from apoptotic mechanisms. In vitro studies of cell death in cell lines have 
reported the presence of apoptotic and necrotic pathways, as well as aponecrosis a 
relatively newly described type of cell death with morphological and molecular 
aspects of both apoptosis and necrosis. Formigli et ai, 2000 report on how different 
types of cell death is produced depending on the intensity of the insult, with 
aponecrosis probably resulting from an incomplete execution of the apoptotic 
program. Several groups have reported on the necessity of caspases in the apoptotic 
pathway, and how the same cell death stimulus can result in either apoptotic or 
necrotic cell death, depending on the availability of activated caspase (Denecker et 
ai, 2001; Miyazaki et ai, 2001;Li and Beg, 2000). 
Necrotic cell death in vivo usually involves contiguous cells, and as discussed in the 
introduction (section 1.9) is associated with a significant inflammatory response. In 
comparison, apoptotic cell death is usually observed in scattered individual cells, 
with no inflammatory response. Necrosis may arise from: release of lytic enzymes 
by the tumour cells themselves or from invading lymphoid cells; from tumour 
necrosis factors; from vascular insufficiency in the centre of a rapidly growing 
tumour; or even from tumour cell death as a response to radiotherapy or 
chemotherapy (reviewed by Garrod, 1990). 
Examination of untreated PDVC57 derived S.C. tumours over time revealed that an 
area of central necrosis was present in the majority of nodules 11 days after tumour 
cell implantation. Central necrosis may result from an inadequate supply of oxygen 
and nutrients from the blood supply, so these areas of necrosis are normally 
observed at distances greater than 150-200 Ilm away from blood vessels (Claudio et 
ai, 2001). This is likely to be the result of rapid tumour proliferation. Belien et ai, 
1999 showed that as a result of changes in vascular and interstitial pressure, the 
blood flow pattern changes and will be diverted away from the centre of the tumour 
to a more peripheral path. This group suggests that this reduction in blood vessel 
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flow at the centre of tumours may hamper the delivery of nutrients and oxygen as 
well as drugs, which could result in necrosis. When the PDVC57 S.c. tumours were 
analysed for blood vessel location using the anti-CD31 antibody, the highest density 
of blood vessels were present at the tumour periphery or growing front of the 
tumour, making the above explanation for central necrosis likely in these studies. 
Knowledge of blood vessel characteristics within the PDVC57 tumour models could 
potentially aid planning of future experiments, such as vascular delivery, or the 
potential use of anti-angiogenic agents. The role of anti-angiogenic factors in 
inhibiting new blood vessel formation might result in stimulation of tumour necrosis. 
However, a disadvantage of using anti-CD31 antibodies to detect blood vessels in 
this investigation, lies in the inability to conclude whether these vessels are neo-
angiogenic. As discussed in the introduction (section 1.18) av(33 integrin, the ED-B 
domain of fibronectin, and TEMS have recently been identified as potentially useful 
specific markers for angiogenic vessels, and would be useful for future 
investigations. 
The high percentage ofTUNEL positive cells detected after Ad5CMV-p53 infection 
of S.C. tumours in immunocompetent hosts, along with the observation of an 
inflammatory cell infiltrate indicate that cell death is likely to result from both 
apoptotic and necrotic mechanisms. Further supporting evidence of necrotic cell 
death in these S.c. studies, is the identification of coagulative necrosis, seen as the 
ghost outlines of dead cells with coagulative cyctoplasm and absent nuclei (reviewed 
by Chandrasoma et ai, 1991), which commonly results from deficient blood supply 
and hypoxia. The wildtype p53 transgene could be responsible for this necrosis, as a 
result of its ability to stimulate genes that prevent angiogenesis, which could 
subsequently result in tissue hypoxia (Bouvet et ai, 1998; Nishizaki et ai, 1999). 
Cells in which p53 is inactivated by mutation would therefore, be more likely to 
recruit new blood vessels, providing a critical growth advantage in tumour 
development. In addition, areas of liquefactive necrosis (Figure 5.8) were observed 
(fluid-filled cavities, surrounded by inflammatory cells) after Ad5CMV-p53 
infection of S.C. minimal residual cancer models in immunocompetent hosts. 
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5.11 Establishment of a Squamous Cell Carcinoma Model in the Floor of the 
Mouth 
To thoroughly test treatment efficacy of Ad5CMV-p53 in preclinical models, it was 
planned that if this form of therapy were successful in the model of residual cancer 
in the muscle, then an intra-oral residual cancer model would also be examined. 
This would establish treatment efficacy at the clinical site of SCCHN, since muscle 
and bone invasion, tumour proximity to critical oral vascular and nerve structures, or 
the presence of regional or distant metastases may alter treatment outcome. 
PDVC57 cells administered into the floor of the mouth ofC57B1I6 mice were left to 
grow for 8-12 weeks. No gross evidence of tumour development was observed over 
this time period. The jaw, lymph nodes, lung and liver were harvested at this time 
for histological analysis. From initial implantation ofPDVC57 cells into the mucosal 
membrane of the floor of the mouth, tumour invasion was apparent after histological 
examination, within the adjacent muscle layers and invading into the mandible in the 
majority of cases. Tumour was present in 8/8 jaw specimens, with invasion into 
muscle and the bone of the jaw in 8/8 and 6/8 specimens respectively. This model 
would therefore be beneficial for investigating a range of treatment efficacy in deep 
muscle and bone structures. In addition, since this model has been established in an 
immunocompetent host, investigation of any immune mediated effects generated 
against the treatment can also be established. 
Other tissue specimens were analysed for the presence of metastasis. Lung tumour 
metastasis was detected in 118 mice (Figure 5.9), and lymph node metastasis in 118 
mice. Since metastasis was a late event in this model, tumour had reached the 
maximum size permitted before extensive metastasis had occurred, making this 
model inappropriate for investigating systemic delivery of Ad5CMV-p53 in the 
treatment of distant metastasis. A possible way to tackle this problem would be to 
dissect out the primary tumour, allowing for longer survival of the animal. This 
would prolong the chance of observing higher rates of metastasis, and potentially 
enable the use of this model for systemic gene therapy, not only at the site of the 
primary tumour or residual cancer, but also on distant metastases. 
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100 !lm 
Figure 5.9: Lung Metastasis following Tumour Implantation in the Floor of the 
Mouth. 1 x 106 PDVC57 cells were administered into the floor of the mouth of 
C57IBI 6 mice. Twelve weeks later the jaw, lymph nodes, lung and liver tissues 
were harvested for histological examination. The photomicrograph represents 
tumour that has metastasised to the lung. 
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Chapter 6 - Preclinical Model of Residual 
Cancer in the Muscle 
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6.1 Establishing a New Model of Minimal Residual Cancer in the Muscle 
To determine whether the PDVC57 cell line was capable of growing in muscle, and 
to establish how many cells were required to create tumour foci at this site, 1 x 104, 
1 X 105, 5 X 105 or 1 X 106 cells were implanted in different volumes of PBS (30-100 
JlI). Exponentially growing cells were freshly trypsinized and thoroughly mixed 
prior to injections, to minimise cell clumping. 
Initial experiments showed that the volume of cells in PBS used for implanting into 
the muscle was critical. A final volume of 30-40 JlI of cell suspension resulted in 
minimal leakage of the inoculate, when injected into the muscle. Injection of greater 
volumes (50-100 JlI) caused ballooning of the tissue and leakage of fluid from the 
needle puncture holes. 
Preliminary experiments implanting PDVC57 cells into the gastrocnemius or rectus 
femoris muscles revealed that it was possible to create nests of tumour at these sites, 
with all concentrations of cells tested. Morphological analysis of tissue sections 
revealed small viable tumour nests at days 3-7 post tumour-cell inoculation, 
observed as spindle cell carcinomas (Figure 6.1). 
6.1.1 Optimisation of the Model of Minimal Residual Cancer in the Muscle 
In subsequent experiments, whole muscles were harvested on day 4, after 
implantation of 1 x 104, Ix 105 or 1 x 106 PDVC57 tumour cells by injecting with 5 
passes of the needle, into 5 parallel regions of the muscle, aiming to produce 5 tracts 
of tumour along the length of the muscle. After paraffin embedding, cross-sectional 
sections of the tumour-bearing muscles were cut at 400 Jl intervals, and each section 
examined for the number of tumour nests developing. The number of tissue sections 
prepared at 400 Jl intervals throughout the tumour-bearing gastrocnemius or rectus 
femoris muscles were fairly standard, as would be expected from similar aged 
rodents. A range of 18 - 26 tissue section levels/gastrocnemius muscle, and a range 
of 18-27-tissue section levelslrectusfemoris muscle, was analysed (Tables 6.1a, 6.2a 
and 6.3a). Measurements of tumour nest cross-sectional area were determined at the 
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muscle midpoint, and in sections 400 J.l either side. Alternatively, in some 
experiments the tumour-bearing muscle was sectioned longitudinally, to determine 
how far nests of tumour ran through the muscle. 
6.1.2 Comparison of Tumour Nest Numbers Developing throughout the Muscle 
following Implantation of 1 x 104, 1 X 105 or 1 x 106 PDVC57 Cells 
When 1 x 104 PDVC57 cells were implanted into the muscle, with 5 needle passes, a 
range of 0-5 tumour nests were observed per semi-serial section 4 days later (Table 
6.4a). Of the 12 muscles examined, only 7.4% of the semi-serial sections showed 4 
or more tumour nests. In the majority of sections (77.8%), 0-2 nests developed 
(Table 6.1a). Following implantation of 1 x 104 PDVC57 cells into the 
gastrocnemius muscle a mean of 42.8 tumour nests developed throughout the tissue, 
fewer (mean = 30) tumour nests developing throughout the rectus femoris muscle 
(Table 6.4a). 
In comparison, a range of 0-7 tumour nests were counted per semi-serial sections 
examined following implantation of 1 x 105 PDVC57 cells into the muscle, in the 
same manner (Table 6.4a). From the 8 muscles examined, 4 or more tumour nests 
developed in 39.1 % of the semi-serial cross-sectional sections, after implantation of 
1 x 105 PDVC57 cells into the muscle, with a similar percentage (39%) of sections 
showed 0-2 tumour nests (Table 6.2a). Following implantation of 1 x 105 PDVC57 
cells into the gastrocnemius muscle a mean of 71.75 tumour nests developed 
throughout the tissue, fewer (mean = 67.25) tumour nests developed throughout the 
rectus femoris muscle (Table 6.4a). 
Implanting 1 x 106 PDVC57 cells into the muscle resulted in a range of 0-6 tumour 
nests developing per semi-serial cross-section examined, 4 days later (Table 6.4a). 
From the 8 muscles examined, fewer sections (26.1%) displayed 4 or more tumour 
nests than when 1 xl05 cells were implanted. Fifty percent of the cross-sectional 
sections analysed, following implantation of 1 x 106 cells showed 0-2 tumour nests 
developing (Table 6.3a). Following implantation of 1 x 106 PDVC57 cells into the 
gastrocnemius muscle a mean of 49.25 tumour nests developed throughout the 
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tissue, but unlike following introduction of the other two cell concentrations, more 
(mean = 60.0) tumour nests developed throughout the rectus femoris muscle (Table 
6.4a). 
An explanation for the differences in tumour nest numbers developing at each cross-
sectional area examined, is that one or more tumour nests could fail to develop, or 
two or more tumour nests could coalesce. However, analysis of the number and 
cross-sectional area of tumour nests developing at the muscle midpoint, suggest that 
fusion of nests is not a common event (section 6.2). 
A general observation was that the number of tumour nests developing at either end 
of the muscles was less than the sections analysed from the mid-region of the 
muscle. Since the muscle tapers at the ends, making the cross-sectional tissue area 
smaller, the tumour nests might coalesce, or else not all of the 5 injections of tumour 
cells may be deposited to the far ends of the muscle. In addition, since the tumour 
cells were injected along the length of the muscle, the needle puncture hole is 
located at one end of the muscle, with the possibility of tumour inoculate leaking 
from this site. 
An alternative explanation is that tumour cells may be squeezed along the tissue 
planes if the muscle contracts when the needle is withdrawn. Nevertheless, the 
multiple tumour nests that do develop in this model present the opportunity to 
rigorously test the efficacy of molecular intervention or other therapeutic approaches 
to destroy residual tumour in the muscle. 
6.1.3 Comparison of Tumour Nest Numbers Developing at the Muscle Midpoint 
following Implantation of 1 x 10\ 1 X 105 or 1 x 106 PDVC57 Cells 
The range in number of tumour nests developing at the midpoint of the muscle, was 
narrower than that for the number of nests forming throughout the tissue, for all cell 
concentrations investigated. Following implantation of 1 x 104 PDVC57 cells into 
the muscle, analysis of the midpoint tissue section revealed a range of 1-4 nests 
developing. Slightly more tumour nests were observed to developed at the midpoint 
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of the gastrocnemius as compared to the rectus femoris (mean nest number of 3.17 
and 2.67 respectively, Table 6.4b). 
Examination of the muscle midpoint section following implantation of 1 x 105 
PDVC57 cells revealed a range of 2-5 tumour nests developing. Slightly more nests 
developed at the midpoint of the gastrocnemius (mean of 3.75) than in the rectus 
femoris (mean of3.5, Table 6.4b). 
Following implantation of 1 x 106 PDVC57 cells into the muscle, analysis of the 
midpoint tissue section revealed a range of 1-4 nests developing. The mean number 
of nests developing at the midpoint tissue section of the gastrocnemius and rectus 
femoris muscles were the same, 2.75 (Table 6.4b). 
6.1.4 Analysis of Individual Tumour Nest Cross-Sectional Area at the Muscle 
Midpoint 
At the midpoint of the muscle, as determined by the median section level number, 
the cross-sectional area of each tumour nest was determined by measurement with a 
Leica image analysis system (Tables 6.1b, 6.2b and 6.3b). These data were analysed 
to determine the differences in tumour development at each cell concentration, for 
the two different muscles, gastrocnemius and rectus femoris (Table 6.4b). 
Analysis of individual tumour nest cross-sectional area at the muscle midpoint, 4 
days after establishment of the model of minimal residual cancer, by implanting 1 x 
104 PDVC57 cells, revealed that generally nest were larger in the gastrocnemius 
than in the rectus femoris muscles. The mean cross-sectional area for individual 
tumour nests at the midpoint after implantation of 1 x 104 PDVC57 cells was 0.210 
mm
2 in the gastrocnemius (range, 0.006-0.970 mm2; S.D., 0.302 mm2) and 0.064 
mm
2 in the rectus femoris (range, 0.007-0.270 mm2; S.D., 0.074 mm2 : Table 6.4b). 
Following implantation of 1 x 105 PDVC57 cells into the muscle, with analysis of 
tumour nest cross-sectional area at the midpoint 4 days later, it was again found that 
the tumour nest cross-sectional areas within the gastrocnemius muscle were larger 
236 
Chapter 6 - Results and Interpretation 
than those developing within the rectus femoris muscle. The mean cross-sectional 
area for individual tumour nests at the midpoint after implantation of 1 x 105 
PDVC57 cells was 0.194 mm2 in the gastrocnemius (range 0.050-0.470 mm2; S.D., 
0.127 mm2) and 0.139 mm2 in the rectus femoris (range, 0.030- 0.250 mm2; S.D., 
0.074 mm2: Table 6.4b). 
Tumour nest cross-sectional areas at the muscle midpoint were substantially larger 
following implantation of 1 x 106 PDVC57 cells than those seen following 
implantation of 1 x 105 and 1 x 104 cells. The mean cross-sectional area of 
individual nests in the gastrocnemius was 0.379 mm2 (range 0.100- 0.860 mm2; 
S.D., 0.289 mm2) and in the rectus femoris 0.334 mm2 (range 0.100-1.250 mm2; 
S.D., 0.324 mm2 : Table 6.4b). 
Overall observations were that with increasing cell numbers, the tumour nest cross-
sectional area measurement increased this being most apparent between the 1 xl 05 
and Ix 106 measurements. However, morphologically, the tumours developing after 
implanting 1 x 106 PDVC57 cells, frequently contained internal cysts after 4 days 
(Figure 6.1). In addition, implanting 1 x 106 tumour cells often resulted in tumour 
growing between the lateral and medial heads of the gastrocnemius muscle and out 
into the surrounding connective tissue. Implanting 1 x 105 cells resulted in a greater 
number of tumour nests developing throughout the muscle than following 
implantation of 1 x 104 and 1 x 106 cells, with approximately 40% of cross- sections 
showing 4 or more tumour nests. Implantation of 1 x 104 cells typically resulted in 
only 1 or 2 nests developing per section level, and although many viable tumour 
cells were present, tumour nest cross-sectional areas showed much variation 
between the two muscles investigated (Figure 6.1). These observations strongly 
suggest that the number of tumour cells injected to produce nests of an appropriate 
size must be established empirically for each new cell line tested. 
Prior to performing statistical analysis, the models established by implanting 1 x 105 
PDVC57 cells into the gastrocnemius or rectus femoriS muscles seem to be the most 
consistent with regard to tumour nest number, cross-sectional tumour nest area and 
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morphological characteristics. The mean number of nests at the midpoint was the 
highest, and measurements of tumour cross-sectional area and nest numbers were 
relatively similar for both the gastrocnemius and rectus femoris . Therefore, future 
experiments testing the efficacy of various treatment regimes were set up using 1 x 
105 PDVC57 cells, in either the gastrocnemius or rectus femoris . 
6.1.5 Analysis of Total Tumour Nest Cross-Sectional Area at the Muscle 
Midpoint 
The total cross-sectional tumour area measured at the midpoint can also be used to 
determine variance in the model of minimal residual cancer in the muscle following 
preclinical treatment studies. Following implantation of 1 x 104 PDVC57 cells, the 
total tumour cross-sectional area at the midpoint of 6 representative gastrocnemius 
muscles ranged from 0.190 - 0.980 mm2 (mean, 0.665 mm2; S.D., 0.332 mm2), and 
of 6 representative rectus femoris muscles ranged from 0.060 - 0.390 mm2 (mean, 
0.261 mm2; S.D., 0.209 mm2 ; Table 6.1b). 
The total cross-sectional area of tumour nests at the midpoint after implantation of 1 
x 105 PDVC57 cells ranged from 0.49 - 1.08 mm2 in 4 representative gastrocnemius 
muscles (mean, 0.700 mm2; S.D., 0.271 mm2), and ranged from 0.33 - 0.56 mm2 in 
4 representative rectus femoris muscles (mean, 0.473 mm2; S.D., 0.102 mm2; Table 
6.2b). 
When 1 x 106 PDVC57 cells were implanted into the gastrocnemius or rectus 
femoris muscle the total tumour cross-sectional area developing at the muscle 
midpoint 4 days later ranged from 0.47 - 1.33 mm2 in 4 representative 
gastrocnemius muscles (mean, 1.015 mm2; S.S., 0.400 mm2) and ranged from 0.44-
1.57 mm2 in 4 representative rectus femoris muscles (mean, 0.983 mm2; S.D., 0.622 
mm
2
; Table 6.3b). 
Overall, the mean total tumour cross-sectional area developing at the midpoint of the 
gastrocnemius and rectus femoris muscles increased as the concentration of cells 
implanted increased. 
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6.2 Coalescing Tumour Nests 
A possible problem with analysing the data on the basis of the individual tumour 
nests developing at the midpoint section of the muscle, is if one or more tumour 
nests coalesce. It would be anticipated that where tumour nests have coalesced, the 
cross-sectional area of the combined tumour mass should be greater than that of a 
single nest. The relationship between the number and cross-sectional area of the 
individual nests forming at the midpoint in the gastrocnemius or rectus femoris 
muscles are shown in Figure 6.2. These data do not show that the areas of a given 
tumour nest is related to the number observed, indicating that fusion of nests is not a 
common event. This suggests that, as long as the number of nests remains variable, 
average tumour nest area is a better outcome measure than total tumour area, since 
the latter increases when more nests are present. 
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c) 100 Jlm d) 100 Jlm 
e) 100 Jlm t) 100 Jlm 
Figure 6.1: Microscopic Appearance of the Murine Model of Minimal Residual 
Cancer in the Muscle. The model of residual cancer in the muscle was established 
using different numbers of PDVC57 cells, which were implanted into either the 
gastrocnemius or rectus femoris muscles of C57B1I6 syngeneic immunocompetent 
mice. Whole muscles were harvested on day four, and multiple sections analysed. a-




Table 6.1a: Summary of the Number of Tumour Nests Created Following Implantation of 1 x 104 PDVC57 Cells into the 
6'astrocnemius or Rectus femoris Muscles Aiming to Create 5 Tumour Nests per Section Level. Histological sections were examined 
every 400 11 along the muscle. G indicates the gastrocnemius, R the rectus femoris. The values shown in red indicate the midpoint where 
the tumour nest cross-sectional area was measured. Data for twelve representative muscles is shown (1 G-12R). 
Muscle Number of tumour nests developing in the muscle, following 5 injections along the length of the muscle and examination 
of muscle cross sections every 400 11. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 
IG 1 '> 3 2 2 2 3 4 3 4 .t 4 4 4 2 2 1 1 1 1 1 
-' 
2G 0 1 2 2 2 2 2 2 2 2 3 .'} 2 1 2 3 2 2 2 2 2 2 1 0 0 
3G 0 1 1 1 1 1 1 1 2 1 ! 1 1 2 2 1 1 1 1 1 0 1 
4G 1 1 1 1 1 1 1 1 1 1 1 2 .. 3 2 2 2 2 3 4 4 3 2 3 1 1 
5G 0 0 0 0 0 0 0 4 4 3 3 1 4 4 3 4 2 2 2 2 2 3 3 1 
6G 1 2 2 2 1 1 0 1 1 1 J 3 2 2 5 5 4 2 1 1 1 1 
7R 0 0 0 0 0 1 1 1 3 3 1 1 .) 3 3 3 3 1 1 1 1 1 1 1 
8R 0 0 0 1 1 1 1 1 1 " 1 1 1 2 2 1 1 1 1 0 0 0 
9R 0 1 3 3 3 3 4 2 3 2 3 1 1 0 0 2 2 2 
lOR 0 1 2 3 3 2 3 2 3 . ., 1 2 2 2 2 2 1 1 0 0 0 0 
11R 0 1 1 1 0 0 0 0 1 2 '> . ~ 3 2 2 2 2 2 3 2 1 0 1 
-' 
12R 0 0 0 0 0 1 4 3 2 1 .2 1 2 2 1 3 2 1 1 0 0 













Table 6.1b: Cross-Sectional Area of Individual Turnour Nests Measured at the Midpoint of the Muscle by Irnage Analysis After 
Irnplanting 1 x 104 Cells. Area is in mm2 to 3.d.p. G indicates the gastrocnemius, R the rectus femoris. Data from twelve representative 
muscles are shown (lG-12R). 
Muscle Nurnber of Section Cross-sectional area of turnour Total Mean S.D. Variance S.E.M. 
nests level nests rneasured at the rnidpoint in turnour turnour between between between 
developing rnrn2 area area per turnour turnour tumour 
at within nest in nest nest nest areas 
rnidpoint muscle at rnm2 areas areas within 
the within within the same 
midpoint the same the sarne rnuscle 
in mm2 muscle muscle 
Nest 1 Nest 2 Nest 3 Nest 4 
IG 4 11 0.030 0.100 0.030 0.030 0.190 0.048 0.035 0.001 0.020 
2G 3 12 0.170 0.130 0.060 0.360 0.120 0.056 0.003 0.039 
3G 1 11 0.970 0.970 0.970 0 0 0 
4G 4 13 0.040 0.006 0.005 0.580 0.630 0.158 0.282 0.080 0.163 
5G 4 13 0.690 0.220 0.040 0.030 0.980 0.245 0.309 0.096 0.179 
6G 3 11 0.070 0.010 0.780 0.860 0.287 0.428 0.183 0.303 
7R 3 13 0.070 0.130 0.190 0.390 0.130 0.060 0.004 0.042 
8R 2 10 0.270 0.030 0.300 0.150 0.170 0.029 0.170 
9R 3 9 0.050 0.010 0.040 0.100 0.033 0.021 0.004 0.015 
lOR 2 10 0.050 0.010 0.060 0.030 0.028 0.001 0.028 
llR 4 12 0.030 0.030 0.010 0.007 0.077 0.019 0.012 0.000 0.007 
12R 2 11 0.009 0.090 0.099 0.050 0.057 0.003 0.057 
~-














Table 6.2a: Summary of the Number of Tumour Nests Created Following Implantation of 1 x 105 PDVC57 Tumour Cells into the 
Gastrocnemius or Rectu.~femoris Muscles, Aiming to Create 5 Tumour Nests per Section Level. Histological sections were examined 
every 400 J..l along the muscle. G indicates the gastrocnemius, R the rectus femoris . The values shown in red indicate the midpoint where 
the tumour nest cross-sectional area was measured. Data from eight representative muscles are shown (1 G-8R). 
Muscle Number of tumour nests developing in the muscle following 5 injections along the length of the muscle and examination 
of muscle cross sections every 400 J..l. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 
IG 1 1 2 2 1 1 4 4 5 4 5 .;:; 4 4 4 5 5 5 3 3 5 5 5 2 
2G 1 2 3 4 4 5 4 3 2 2 1 2 .3 5 5 5 4 4 4 4 3 2 1 1 1 0 
3G 1 3 4 3 4 3 2 2 ~ 5 5 5 5 5 5 4 5 4 
4G 4 4 3 2 2 3 4 5 5 5 4 "') 3 3 4 5 1 1 0 0 0 0 0 0 
5R 1 1 1 1 2 2 4 4 4 4 4 4 ..t 4 5 5 6 5 4 3 ..., 2 2 2 1 1 .) 
6R 1 2 2 1 1 0 0 0 0 1 2 3 3 J 6 4 3 3 3 7 6 5 3 3 4 3 3 
7R 1 2 2 3 3 3 3 3 3 5 3 j 1 1 1 2 2 4 4 3 3 3 2 1 1 













Table 6.2b: Cross-Sectional Area of Individual Tumour Nests Measured at the Midpoint of the Muscle by Image Analysis After 
Implanting 1 x 105 Cells. Area is in mm2 to 3.d.p. G indicates the gastrocnemius, R the rectus femoris. Data from eight representative 
muscles are shown (lG-8R). 
Muscle Number of Section Cross-sectional area of tumour nests Total Mean S.D. Variance S.E.M. 
nests level measured at the midpoint in mm2 tumour tumour between between between 
developing area area tumour tumour tumour 
at within per nest nest nest areas 
midpoint muscle nest in areas areas within the 
at the mm2 within within same 
midpoint the the same muscle 
in mm2 same muscle 
muscle 
Nest 1 Nest 2 Nest 3 Nest 4 Nest 5 
1G 5 12 0.12 0.12 0.32 0.05 0.47 1.08 0.216 0.174 0.030 0.078 
2G 3 13 0.05 0.10 0.37 0.52 0.173 0.172 0.030 0.099 
3G 5 9 0.16 0.14 0.14 0.08 0.19 0.71 0.142 0.040 0.002 0.018 
4G 2 12 0.15 0.34 0.49 0.245 0.134 0.018 0.095 
5R 4 13 0.08 0.10 0.08 0.07 0.33 0.083 0.013 0.000 0.006 
6R 3 14 0.05 0.24 0.18 0.47 0.157 0.097 0.009 0.056 
7R 3 12 0.10 0.25 0.18 0.53 0.177 0.075 0.006 0.043 
















Table 6.3a: Summary of the Number of Tumour Nests Created Following Implantation of 1 x 106 PDVC57 Cells into the 
Gastrocnemius or Rectusfemoris Muscles, Aiming to Create 5 Tumour Nests per Section Level. Histological sections were examined 
every 400 ~l along the muscle. G indicates the gastrocnemius, R the rectus femoris. The values shown in red indicate the midpoint where 
the tumour nest cross-sectional area was measured. Data from eight representative muscles are shown (1 G-8R). 
Muscle N umber of tumour nests developing in the muscle following 5 injections along the muscle length and examination of 
muscle cross sections every 400 ~. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 
IG 0 0 3 4 3 3 1 1 1 3 -;,\ 4 3 3 4 4 3 2 2 3 1 1 
2G 1 1 1 1 2 3 3 2 2 .:. 1 4 5 5 6 6 5 4 3 3 
3G 0 0 1 1 1 2 3 4 5 4 3 ~ 4 4 4 3 3 2 3 3 3 2 2 1 1 
4G 1 1 1 1 1 1 1 1 1 1 ~ 1 1 1 1 1 1 1 1 1 1 0 
5R 0 1 1 2 2 2 3 5 6 2 , 3 4 4 4 5 4 5 3 2 0 " ~ 
6R 0 0 2 3 3 3 3 3 2 1 1 .5 2 2 2 3 3 4 2 3 1 1 0 
7R 0 0 1 2 2 3 4 5 3 ., 2 4 4 5 6 5 4 5 4 4 4 














Table 6.3b: Cross-Sectional Area of Individual Tumour Nests Measured at the Midpoint of the Muscle by Image Analysis After 
Implanting 1 x 106 Cells. Area is in mm2 to 3.d.p. G indicates the gastrocnemius, R the rectus femoris. Data from eight representative 
muscles are shown (IG-8R). 
Muscle Number of Section Cross-sectional area of tumour Total Mean S.D. Variance S.E.M. I 
nests level nests measured at the midpoint in tumour tumour between between between 
developing mm2 area area per tumour tumour tumour 
at within nest in nest areas nest areas nest areas 
midpoint muscle at mm2 within the within the within the 
the same same same 
midpoint 
in mm2 
muscle muscle muscle 
Nest 1 Nest 2 Nest 3 Nest 4 
IG 4 11 0.13 0.17 0.18 0.85 1.33 0.333 0.346 0.119 0.173 
2G 2 10 0.10 0.86 0.96 0.480 0.537 0.289 0.380 
3G 4 12 0.29 0.15 0.22 0.64 1.30 0.325 0.218 0.047 0.109 
4G 1 11 0.47 0.47 0.47 0 0 0 
5R 4 11 0.5 0.21 0.24 0.52 1.47 0.368 0.165 0.027 0.083 
6R 3 12 0.1 0.22 1.25 1.57 0.523 0.632 0.340 0.365 
7R 2 10 0.16 0.28 0.44 0.220 0.085 0.007 0.060 



















Table 6,4a: Summary of the Data Observed from Histological Examination of Tissue Sections Every 400 J.l. Throughout the Muscle 
in the Model of Minimal Residual Cancer Developed in the Gastrocnemius or Rectus femoris Muscles Following Implantation of 
Either 1 x 104, 1 X 105 or 1 x 106 PDVC57 Cells, 
G indicates the gastrocnemius, R the rectus femoris . Summary of data in Tables 6.1a, 6.2a and 6.3a. 
Cell Number Range of Total Total Mean Mean Mean Total levels Total nests Mean Mean 
number of nests number number number number number examined in examined in number of number 
implanted muscles developing of levels of nests of levels of nests of nests the G or R the G or R levels of nests 
into examined throughout examined examined examined examined examined muscles muscles examined examined 
muscles the muscle per per level per perGorR per level 
muscle muscle muscles in the G 
orR 
muscles 
1xl0· 12 0-5 270 437 22,5 1,62 36.42 G 140 G257 G 23.33 R G1.84 
R130 R 180 21.67 R 1.38 
1x105 8 0-7 192 556 24 2.90 69,5 G92 G287 G23.00 G3.12 
R 100 R269 R2S.00 R2.69 
1x10b 8 0-6 174 437 21.75 2.51 54,63 GN89 G 197 G22.25 G2,21 
















Table 6.4b: Summary of the Number and Cross-Sectional Area of Tumour Nests Developing at the Muscle Midpoint in the Model 
of Minimal Residual Cancer Developed in the Gastrocnemius or Rectus femoris Muscles Following Implantation of Either 1 x 104, 
1 X 105 or 1 x 106 PDVC57 Cells. 
G indicates the gastrocnemius, R the rectus femoris . Summary of data in Tables 6.1 b, 6.2b and 6.3b. 
Cell Mean Range of Mean Mean Range of Mean S.D. in Range of Mean S.D. in 
number number of tumour number of number of cross- cross- cross- cross- cross- cross-
nests nests nests nests sectional sectional sectional sectional sectional sectional 
developing developing developing developing areas of area of area of areas of area of area of 
at the at the in the G at in the R at individual individual individual individual individual individual 
midpoint midpoint the the tumour tumour tumour tumour tumour tumour 
midpoint midpoint nests nests nests nests nests nests 
developing developing developing developing developing developing 
in the Gin in the G in in Gin in the R in in the R in in Rin 
mm1 mm1 mm1 mm1 mm1 mm
1 
1 xlO" 2.92 1-4 3.17 2.67 0.006- 0.210 0.302 0.007 - 0.064 0.074 
0.970 0.270 
1 x 105 3.625 2-5 3.75 3.5 0.050- 0.194 0.127 0.030- 0.139 0.074 
0.470 0.250 
1 x 106 2.75 1-4 2.75 2.75 0.100- 0.379 0.289 0.100- 0.334 0.324 i 
0.860 1.250 I 
-- -- - ----- -- ---- ---
---- _ .. -
- ------
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Figure 6.2: The Relationship between the Number and Cross-Sectional Area of 
Individual Tumour Nests developing at the Muscle Midpoint. The individual 
tumour nest area developing at the muscle midpoint were measured by image 
analysis tools and plotted against the number of nest developing. Gastrocnemius (G) 
and rectus femoris (R) muscles. Eight representative examples are shown, data 
taken from Table 6.2b. 
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6.3 Statistical Analysis to Determine the Variability in the Cross-Sectional Area 
of Individual Tumour Nests Developing at the Midpoint of the Gastrocnemius 
and Rectusfemoris Muscles, Following Implantation of 1 x 104, 
1 X 105 or 1 x 106 PDVC57 Cells 
The aim of the first part of this investigation was to determine the reliability and 
reproducibility of the model of minimal residual cancer in the muscle. Using 
ANDV A, the variation in the cross-sectional areas of individual tumour nests in the 
gastrocnemius and rectus femoris muscles, 4 days after implantation of 1 x 104, 1 X 
105 or 1 x 106 PDVCS7 cells could be established. 
For a reproducible and reliable model to be established the tumour nest cross-
sectional areas within either the gastrocnemius or rectus femoris, after implantation 
of each concentration of cells, would need to belong to the same population. That is 
to say that the variability between tumour nest area within the muscle of each animal 
at a given concentration of cells is low, in addition to the variability between the 
other rodents tested at the same cell concentration. 
The varlance estimates within and between the individual tumour nest cross-
sectional areas at the midpoint of the gastrocnemius or rectus femoris muscle, along 
with the F-ratio value to determine significance are shown in Table 6.5 . For a 
significant variance in populations to be present, the between group estimate of 
variance needs to be greater than the within group estimate of variance. This data 
shows that following implantation of 1 x 104 cells, both the rectus femoris and 
gastrocnemius muscles show this trend, and hence have a F-ratio higher than 1. 
This is also seen following implantation of 1 x 105 cells, but for the rectus femoris 
muscle only. 
After implantation of 1 x 106 cells to create the muscle model, the within group 
variance estimate was determined to be larger than the between group variance 
estimate for both the rectus femoris and gastrocnemius muscles, suggesting that the 
values come from the same population. A similar pattern of estimate variation 
within and between groups of individual tumour-nest areas was established 
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following implantation of 1 x 105 cells into the gastrocnemius muscle. The F-ratios 
were therefore, below the value of 1, implying that the individual tumour nest cross-
sectional area measurements are similar within and between animals under these 
conditions. 
Table 6.5 shows the F-distribution ratios from statistical tables at the 5% 
significance level. For significance to be reached the calculated F-ratio needs to be 
greater than the value in the statistical tables, taking into account the sample sizes 
and the numbers of samples. A significant difference in cross-sectional areas of 
individual tumour nests was not reached following implantation of 1 x 104, 1 x 105 
or 1 x 106 cells into the gastrocnemius or rectus femoris muscles in any of the cases 
shown in Table 6.5, implying that all the data belongs to the same population. Thus 
tumour nests of reasonably similar size can be established when creating the model 
of minimal residual cancer in the gastrocnemius or rectus femoris muscles, of the 
same rodent and rodents in the same set up group. 
251 
Chapter 6 - Results and Interpretation 
Table 6.5: Analysis of Variance was performed to determine the variability in 
the cross-sectional area of individual tumour nests measured at the midpoint of 
the gastrocnemius and rectus femoris muscles, following implantation of 1 x 104, 
1 X 105 or 1 x 106 PDVC57 cells. 
The variance in individual tumour nest cross-sectional areas was determined for the 
gastrocnemius or rectus femoris muscle within an individual animal, and also 
between the animals in the same group. G represents the gastrocnemius muscle, R 
the rectus femoris muscle. The F ratios are indicated along with the value to be 
exceeded to reach 5% significance, all values to 3.d.p. 
Cell numbers Variance estimates of the Calculated F-Ratio from 
implanted individual tumour nest F-Ratio distribution 
cross-sectional area tables 
measured at the midpoint 
Within Between 5% 
samples samples significance 
level 
1 xl04 G 0.069 G 0.148 G 2.145 G3.025 
R 0.005 R 0.008 R 1.670 R3.326 
Ix 105 G 0.019 G 0.007 G 0.382 G 3.587 
R 0.005 R 0.006 R 1.072 R3.708 
Ix lOb G 0.135 G 0.018 G 0.133 G 4.737 
R 0.128 R 0.052 R 0.405 R 4.347 
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6.4 The Reliability of Analysing Total Tumour Nest Area at the Midpoint of the 
Muscle 
To investigate the reliability of measuring the total tumour cross-sectional area using 
a single cross-section within a given tumour-bearing muscle, the adjacent sections 
on either side of the midpoint were also analysed by ANOV A. This allows the effect 
of treatment schedules on tumour nest cross-sectional areas developing at just the 
muscle midpoint to be compared with untreated controls in future experiments. In 
addition, measurement at the muscle midpoint provides a simple and reproducible 
methodology, which is not influenced by ad-hoc examination of the data. This 
analysis could not be undertaken to assess the reliability of measuring the mean 
individual tumour nest area, as on some occasions the number of tumour nests 
differed from one section to the next. This was perceived to be one of the 
advantages of using total tumour area rather than the mean area of the nests as an 
outcome measure following therapeutic intervention. 
No significant variance in total tumour nest cross-sectional area was determined by 
ANOVA at the three tumour-bearing muscle levels examined (F = 0.354, df= 23). 
Comparison of the total cross-sectional tumour area at the midpoint and at sections 
400 11 on either side of this point revealed that histological examination of sections 
taken at the midpoint of the muscle could be considered as representative of the size 





Table 6.6: Analysis of Variance was Performed to Determine the Variability in the Total Cross-Sectional Tumour Area Measured 
at the Midpoint of the Muscles and Sections 400 J.1 on Either of this Point, Following Implantation of 1 x 105 PDVC57 Cells. This 
would determine the Reliability of Analysing a Single Midpoint Section in Further Experiments. 
a) The midpoint section of the tumour bearing muscle, b) the section 400 J.1 before the midpoint, and c) the section 400 J.1 after the 
midpoint. 
a) 
Muscle Number Section Cross-sectional area of individual tumour Total Mean S.D. Variance S.E.M. 
number of nests level nests measured at the midpoint in mm2 cross- cross- between between between 
at sectional sectional individual individual individual 
midpoint tumour tumour tumour tumour tumour 
area in area of nest areas nest areas nest areas 
the individual in the in the in the 
muscle at nests in same same same 
the mm2 muscle muscle muscle 
midpoint 
inmm2 
Nest 1 Nest 2 Nest 3 Nest 4 Nest 5 
I 5 12 0.15 0.22 0.31 0.29 0.30 1.27 0.254 0.068 0.005 0.034 
2 3 13 0.31 0.12 0.28 0.71 0.237 0.102 0.010 0.072 
3 5 9 0.10 0.09 0.20 0.10 0.10 0.59 0.118 0.046 0.002 0.023 
4 4 11 0.17 0.24 0.08 0.35 0.84 0.210 0.114 0.013 0.066 
5 4 13 0.19 0.60 0.21 0.09 1.09 0.273 0.225 0.050 0.130 
6 5 15 0.01 0.12 0.40 0.05 0.06 0.73 0.146 0.157 0.025 0.079 
7 3 12 0.08 0.13 0.33 0.58 0.193 0.132 0.018 0.094 














Table 6.6b) continued 
Muscle Number 



















Cross-sectional area of individual tumour Total 









Nest 1 Nest 2 Nest 3 Nest 4 Nest 5 
0.l5 0.19 0.39 0.24 0.26 l.23 
0.77 0.17 0.94 
0.16 0.08 0.24 
0.l7 0.25 0.08 0.36 0.86 
0.24 0.44 0.20 0.12 l.00 
0.02 0.10 0.44 0.56 
0.09 0.16 0.37 0.62 





area of nest areas 
individual in the 

























































Table 6.6c) continued 
Muscle Number 



















Cross-sectional area of individual tumour 
nests measured at the midpoint in mm2 
Nest Nest Nest Nest Nest Nest 
1 2 3 4 5 6 
0.18 0.26 0.22 0.32 
0.36 0.13 0.31 0.03 0.02 
0.12 0.08 0.26 0.10 0.08 
0.16 0.16 0.08 
0.19 0.69 0.22 0.08 
0.01 0.11 0.26 0.09 0.02 0.04 
0.08 
0.20 0.33 0.06 0.45 
Total Mean S.D. 
cross- cross- between 
sectional sectional individual 
tumour tumour tumour 
area in area of nest areas 
the individual in the 
muscle at nests in same 
the mm2 muscle 
midpoint 
in mm2 
0.98 0.245 0.060 
0.85 0.170 0.158 
0.64 0.128 0.076 
0.40 0.133 0.046 
1.18 0.295 0.270 
0.53 0.088 0.093 
0.08 
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6.5 Cisplatin Treatment of the Muscle Model of Minimal Residual Cancer 
To provide an example of the application of the present model the effect of an 
established cytotoxic drug, cisplatin was analysed. Cisplatin, a commonly used 
chemotherapeutic in the treatment of SCCHN, was initially tested by administration 
into the peritoneal cavity of tumour-bearing rodents. Doses ranged from 3-10 mg/kg 
based on results of previous studies (Gumani et ai, 1999), and were administered 
either daily or every other day, with a total of 2-5 treatments per animal. Treatment 
was initiated 3 days post tumour-cell implantation, and experiments terminated 1-7 
days after the final treatment. PBS treated controls were also included. At this time, 
whole muscles were harvested, and tissue prepared for histological examination. 
Total tumour nest cross-sectional areas at the midpoint of the muscle were 
measured. To determine if a significant difference in total tumour nest cross-
sectional area was apparent between these two treatment groups the two-sample (un-
related) t-test was performed. Since prior prediction that cisplatin would result in 
smaller nest areas, the hypotheses is one-tailed. 
Analyse was carried out on tumour-bearing muscles from animals treated with 3 
mg/kg cisplatin, administered on days 5, 7, 9 and 11 post tumour-cell inoculation, 
and sacrificed on day 14. Treatment of tumour-bearing muscles with this schedule of 
cisplatin reduced the number of tumour nests forming at the muscle midpoint (range 
1-5 in the cisplatin treated group, n = 6; range 4-5 in the PBS control group, n = 6; 
Table 6.7). When compared to PBS-treated controls, the tumour nests developing in 
rodents treated with cisplatin contained more ghost cells and showed fewer tumour 
fronds invading into the surrounding tissue, although some spidery outgrowths were 
still present. Statistically rodents treated with this cytotoxic were found to have 
significantly lower total tumour cross-sectional area, measured at the muscle 
midpoint, than the group treated with PBS (t = 5.97, df= 10, P = 0.0001; cisplatin 
mean 0.67 mm2, range 0.29 - l.35 mm2, S.D. 0.446 mm2, n = 6; PBS mean 2.25 
mm
2
, range l.70 - 2.83 mm2, S.D. 0.377 mm2, n = 6). Therefore, this method of 
analysis was capable of distinguishing differences in treatment efficacies. 
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Table 6.7: The Effect of a) Repeat Treatments with 3 mglkg Cisplatin and b) 
PBS Treatments, on the Number and Total Cross-Sectional Area of the 
Tumour Nests Developing in the Gastrocnemius Muscle. 
a) 
Sample Number Cross-sectional area of individual tumour Total 






1 2 3 4 5 
1 1 0.29 0.29 
2 5 0.25 0.18 0.37 0.24 0.31 1.35 
3 3 0.22 0.12 0.12 0.46 
4 4 0.27 0.18 0.38 0.28 1.11 
5 1 0.47 0.47 
6 2 0.18 0.16 0.34 
b) 
Sample Number Cross-sectional area of individual tumour Total 






1 2 3 4 5 
1 4 0.31 0.72 0.47 0.20 1.70 
2 5 1.15 0.62 0.47 0.16 0.42 2.82 
3 5 0.49 0.29 0.39 0.52 0.31 2.00 
4 5 0.48 0.22 0.38 0.25 1.00 2.33 
5 4 0.86 0.47 0.39 0.64 0.01 2.37 
6 5 0.39 0.59 0.48 0.33 0.47 2.26 
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6.6 Detection of Reporter Gene Expression in the Minimal Residual Cancer 
Model in the Muscle 
Four days after tumour cell implantation into the muscle of syngeneic mice, the 
muscles were re-exposed and Ad-f3-gal was injected in multiple planes into the 
tumour-bearing muscle. Twenty-four to forty-eight hours later, whole muscles were 
harvested for X-gal staining. X-gal staining of multiple semi-serial frozen sections 
taken throughout the muscle, revealed that typically <3% of the tumour cells 
expressed the transgene. Positive cell staining was frequently detected along the 
plane likely to represent the path taken by the needle used to inject the virus (Figure 
.3). One of the most successful experiments, producing high levels of expression of 
the transgene in the muscle is shown in Figure 6.3b. 
Positive X-gal staining was also detectable within a low number of the muscle fibres 
on some occasions (Figure 6.3c). Adenovirus has a low tropism for mature skeletal 
muscle. Kimura et ai, 2001, reported how a maturation-dependent loss of the 
myofiber's susceptibility to recombinant adenovirus uptake occurs, due to structural 
and biochemical changes during muscle maturation. The levels of CAR expression 
is severely down regulated during muscle maturation. The mice used to set-up the 
minimal residual tumour model within the muscle were generally 6-8 weeks old, this 
could explain the relatively low reporter gene expression that was observed within 
the muscle fibres in these studies. 
In addition S.c. tissue and skin surrounding the tumour-bearing muscle site were 
taken for X-gal staining to determine if the Ad-f3-gal vector had leaked from the 
muscle into the surrounding tissue area, where transgene expression resulted. 
Positive X-gal staining was not detected in skin or subcutaneous tissue surrounding 
the muscle after intramuscular injection. However, positive X-gal staining was 
sometimes observed in the connective tissue surrounding the muscle. 
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6.7 Expression of Exogenons p53 Protein in Adenovirus-Infected Tumours in 
the Minimal Residual Cancer Model in the Muscle 
The model of minimal residual cancer in the muscle of syngeneic mice was set up as 
previously described. Four days after tumour cell implantation, Ad5CMV-p53 was 
injected into the muscle with passes of the needle in multiple plains. Whole muscles 
were harvested between 24 and 72 hours post infection and prepared for mc with 
the human specific DO-l antibody. Protein was detected in approximately 1 % of 
tumour cells. This low level of transduction efficiency, and p53 protein expression is 
the likely cause of the poor treatment efficacy following Ad5CMV-p53 infection in 
















Figure 6.3: X-gal Staining of the Muscle Model of Minimal Residual Cancer. 
5 x 1010 vp of Ad-p-gal was administered into tumour-bearing muscles 3 days after 
PDVC57 tumour cell implantation. Twenty-four to forty-eight hours later, the 
muscle was harvested and X-gal staining carried out on both frozen and paraffm 
embedded tissue sections. a) Shows a typical level of trans gene expression seen in 
the tumour in the muscle. b) Shows a high level of transgene expression with both 
tumour cells and muscle fibres transduced. c) Shows transduction and transgene 
expression of the muscle fibres. 
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6.8 Molecular Therapy in the Muscle Model of Minimal Residual Cancer 
Molecular therapy schedules in this study were dosed on the basis of vp, as 
compared with earlier studies which used p.f.u or multiplicity of infection (MOl). 
Taking this into account the adenoviruses used in this study have a ratio of 25 vp to 
every 1 p.f.u. Since tumour cells will be proliferating whilst in the muscle, exact 
vp/cell values are hard to estimate accurately. However, since 1 x 105 cells were 
initially implanted into the muscle, and based on the in vitro findings, that 2500 
vp/cell established high transduction efficiency, and the number of PDVC57 cells 
double in number roughly every 24 hours, a dose of 5 x 1010 vp was tested. This 
provided an excess dose of virus as compared to the in vitro studies, to take into 
account the inherent difficulties arising with in vivo gene transfer. When molecular 
therapy is initiated 4 days following tumour cell implantation, an adenovirus dose of 
4 x 109 vp would represent the in vitro equivalent of a dose of 2500 vp/cell. Hence 
approximately a log scale higher dose was used in vivo. 
Treatment of tumour-bearing muscles with one to three doses of 5 x 1010 vp 
Ad5CMV-p53, Ad-j3-gal, or Ad-PolyA, commencing 2-4 days after implantation of 
1-5 x 105 PDVC57 cells into the gastrocnemius or rectus femoris muscles, failed to 
significantly reduce tumour burden at these sites. Seven days after the final 
treatment the majority of tumour nests were found to have coalesced into a single 
mass, the cross-sectional area of which was similar for the animals treated with 
Ad5CMV-p53 and those treated with the control vectors, Ad-j3-gal or Ad-PolyA 
(Figure 6.4). 
Histological assessment of sections prepared at the midpoint of the tumour-bearing 
muscles revealed that the mean cross-sectional areas were broadly similar for the 
animals treated with Ad5CMV-p53, Ad-j3-gal, and Ad-PolyA (Ad5CMV-p53 range 
2.17 - 5.78 mm2, mean 4.07, S.D., 0.73mm2; Ad-j3-gal range 2.25 - 5.53 mm2, mean 
3.81, S.D., 0.64 mm2; Ad-PolyA range 2.52 - 4.95 mm2, mean 3.45, S.D., 0.49 
mm
2). Comparison of the tumour cross-sectional area after treatment with 
Ad5CMV-p53 or Ad-PolyA showed no significant difference between the two 
groups (t = 0.90, df= 10, P = 0.391). 
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The major factor determining this poor outcome must be attributed to the very low 
transduction efficiency in this model (approximately 1-3% by X-gal staining, section 
6.6). Thus, it would appear that the major limitation of this technology at present is 
the need to transduce a high proportion of tumour cells to observe a therapeutic 
effect. Analysis of TUNEL reactivity suggests that induction of apoptosis or 
necrosis, in a portion of the tumour cells in the muscle occurred (section 6.9), 
however, the majority of the tumour cell population in the tumour-bearing muscles 
does not respond by apoptosis. In contrast to the negative results observed after 
delivery of AdSCMV-p53, treatment of rodents implanted with similar numbers of 
tumour cells with i.p. cisplatin reduced the area of the tumour nests (section 6.S). 
Combinations of AdSCMV -p53 and cisplatin treatments were not investigated, 
because of the poor response observed following AdSCMV-p53 treatment alone. 
It was often observed that following infection with AdSCMV-p53, Ad-PolyA or Ad-
f3-gal that an immune response was initiated with the tumour-bearing muscles 
infiltrated with inflammatory cells. This was not apparent in the tumour-bearing 
muscles mock infected with PBS. Immunohistochemical analysis detected the 
presence of cytotoxic T lymphocytes, neutrophils and monocytes in the tumour-
bearing muscles of AdSCMV-p53 and Ad-PolyA infected rodents. Therefore, in 
some cases immune-mediated effects might contribute to small reduction in tumour 
cell number, independent of the transgene. Thus, whereas tumour cell killing 
attributable to pS3-mediated induction of apoptosis, necrosis, and effects on 
angiogenesis probably all contribute to tumour cell destruction when efficient 
transduction of tumour cells is achieved, the results seen in adenoviral-treated 
animals over those observed in PBS-treated controls indicate that immune-mediated 
effects are also important. 
However, a single tumour nodule of dead and dying malignant cells developing in 
the connective tissue outside of the muscle mass, was observed in a rodent treated 
with AdSCMV-p53. This demonstrates that this treatment can destroy a proportion 
of the tumour cells within the nodule growing outside of the dense muscle tissue 
(Figure 6.S). 
263 
Chapter 6 - Results and Interpretation 
a) 100 !lm 
b) 100 !lm 
Figure 6.4: Molecular Therapy using the Muscle Model of Minimal Residual 
Cancer. Ad5CMV-p53 or Ad-PolyA at a concentration of 5 x 1010 vp was 
administered into the muscle ofPDVC57 tumour-bearing rodents. The virus was 
administered 4,6 and 8 day's post PDVC57 tumour-cell inoculation. Whole 
muscles were harvested for histological examination on day 15. a) Shows the Ad-
PolyA treated tumour-bearing muscle; b) shows the Ad5CMV-p53 treated tumour 
bearing muscle. 
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100 11m 
Inflammatory cell infiltrate 
Figure 6.5: Histological Appearance of a PDVC57 Tumour Nodule Developing 
on the Surface of the Muscle, Following Treatment with Ad5CMV -p53. 1 x 105 
PDVC57 cells were implanted into the gastrocnemius muscle of immunocompetent 
hosts. Ad5CMV-p53 at a concentration of5 x 1010 vp was administered into the 
tumour-bearing muscle 4,6 and 8 day's post PDVC57 tumour-cell inoculation. 
Whole muscles were harvested for histological examination on day 15. A nodule of 
PDVC57 derived tumour developing on the outer surface of the gastrocnemius 
muscle, showed an inflammatory cell infiltrate (as indicated by arrow). 
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6.9 Detection of Apoptosis by TUNEL in the Model of Minimal Residual 
Cancer in the Muscle 
Apoptotic cells detected by TUNEL were visualised as cells with red bodies in the 
nucleus. 
TUNEL staining was performed on sections from tumour-bearing muscles infected 
with Ad5CMV -p53, Ad-Poly A, Ad-f3-gal or Ad-Luc. The level of TUNEL staining 
detected was considerably lower than that observed in the S.c. tumours. Positive 
TUNEL staining was present in only a few (1-2%) of the tumour cells 24 and 48 
hours after infection with Ad5CMV-p53. TUNEL staining was also detected in the 
occasional tumour cells within the muscle after treatment with Ad-PolyA, Ad-f3-gal 
and Ad-Luc. This low level of TUNEL staining can be explained by the poor 
expression of the transgene in the muscle model of minimal residual cancer, 
resulting in inadequate levels of the wildtype p53 protein to initiate large-scale 
apoptotic cell death, and hence resulting in the continual growth of tumour nests. 
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7.1 Molecular Therapy for Residual Cancer 
The requirement for further investigation into the treatment of SCCHN was 
necessary to tackle the static survival rate and high degree of recurrence observed in 
this disease clinically. Conventional treatment strategies of surgery with post-
operative radiotherapy have not resulted in significant advances in SCCHN patient 
outcome, in spite of improvements in surgical techniques, methods of delivery of 
radiotherapy and new chemotherapeutic agents. These observations highlighted the 
need to establish new treatment strategies to deal with this problem. Since a major 
cause of treatment failure in SCCHN is the result of local-regional recurrence, often 
as a consequence of residual cancer remaining in the margins, around the site of 
surgery, a preclinical model that mimics this scenario is essential for the thorough 
testing of new treatment regimes, prior to clinical trials. 
Mutations in the p53 gene are one of the most frequent occurrences in SCCHN, and 
cancers in general, and due to p53's major role in apoptosis and cell cycle arrest, 
replacement of the wildtype p53 gene is an obvious starting point in the battIe to 
improve treatment efficacy. Potential applications for gene therapy include treatment 
of patients with histological and molecular evidence of residual cancer. It is 
anticipated that adjuvant therapies will be more effective following removal of the 
bulk of tumour. In these cases, the use of p53 as an adjunct modality injected into 
the operative site following surgery may reduce the rate of recurrence by inducing 
apoptosis in these remaining malignant cells. In addition, patients with locally 
progressive disease that is not amenable to surgery, radiotherapy, or chemotherapy, 
and cases with extensive dysplastic lesions, that frequently harbour p53 gene 
mutations, might also benefit from this gene replacement therapy. 
Approximately 26,000 publications centred on the role ofp53 are available, bringing 
insights into its functions in cancer biology, along with seemingly perplexing 
contradictions and confusion. The cell cycle checkpoint proteins that sense and 
signal DNA damage have been remarkably conserved during evolution, being found 
in organisms spanning yeast to humans (Vogel stein et ai, 2000). 
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Previous in vitro studies have demonstrated that Ad-p53 transduction of cell lines 
can have a range of outcomes on cell viability and mechanisms of cell death (Liu et 
aI, 1994; Kimura et aI, 1997; Overholt et aI, 1997), with one explanation for this 
being the differing genetic backgrounds of the cells interfering with various genetic 
pathways. It was therefore important to test the PDVC57 cell line for its suitability 
for use in setting up the new model of residual cancer in the muscle, with regard to 
its transduction efficiency and mechanism of cell death. The data presented from 
this study demonstrated that the PDVC57 cell line was susceptible to adenoviral 
infection, showing good reporter gene and p53 transgene transduction levels 
(Section 3.l and 3.4). RT-PCR and Western blotting showed the ability of 
Ad5CMV-p53 to infect the PDVC57 tumour cells and induce expression of p53 
mRNA and protein respectively (Section 3.2 and 3.3). Evidence has also been 
presented in these studies that indicates that the mechanism of cell death in vitro 
following Ad5CMV-p53 transduction ofPDVC57 cells is largely apoptotic (Section 
4.5 and 4.6). As anticipated from previous investigations on other cell lines (Harper 
et aI, 1993; Zhan et aI, 1994), transduction ofPDVC57 tumour cells with Ad5CMV-
p53 resulted in the up-regulation of p21 W AF l and BAX proteins as determined by 
Western blot analysis, proteins which are involved in cell cycle arrest and apoptosis 
respectively. 
The promising results noted in this study in vitro, suggested that Ad5CMV -p53 may 
show activity within a PDVC57 derived in vivo model, and hence the muscle model 
of residual cancer was established. 
The majority of previous preclinical studies to test the efficacy and determine the 
optimal schedule, route and dosing of new and conventional therapies have utilised 
S.c. models of SCCHN within immunodeficient hosts. These models provide an 
idea of the efficacy of gene therapy strategies in vivo, for example, infection of a 
S.c. SCCHN tumour nodules established in a nude mouse, with Ad-p53 resulted in 
at least 50% reduction in tumour mass (Clayman et aI, 1996). However, since 
undetected tumour often remains within the deep muscle margins as well as in the 
mucosal tissue, these models do not efficiently address the issues concerning these 
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conditions. It is anticipated that transduction of tumour cells in the muscle of 
immunocompetent hosts may be more difficult. Questions regarding the diffusion of 
the vector within dense muscle tissue, and the affect of the immune system on 
transgene expression levels and duration, which are lacking in the current S.c. 
immunodeficient models, are key issues necessary to stringently test the efficacy of 
treatments preclinically. 
The establishment of a new reproducible rodent model of residual cancer in the 
muscle of a syngeneic, immunocompetent host is an important step forward and will 
facilitate future preclinical studies to devise effective strategies to destroy tumour 
cells, which remain in deeper structures. The present model has been developed with 
a squamous cell line harbouring a p53 mutation, which allows the efficacy of 
protocols to restore the function of this sequence to be tested. The model was 
established so that multiple nests of tumour developed throughout the muscle, 
mimicking the clinical scenario more closely than the encapsulated S.c. tumour 
models. However, this model of residual cancer in the muscle could be easily 
adapted to enable the study of many other treatment potentials. This model can also 
be created by introducing human tumour cells into the muscle of immunodeficient 
rodents to create nests of tumour at this site, providing that the cell line selected has 
characteristics that permit growth in this tissue. This model should also be useful in 
testing the benefits of p53 mediated gene transfer in various combination approaches 
and when delivering novel treatments via different routes, and testing alternative 
schedules of administration as a way to more aggressively treat residual cancer at 
less accessible sites. 
The therapeutic effects of the expression of exogenously delivered wildtype p53 in 
cancer cells and preclinical tumour models have been examined in a wide range of 
malignancies. Growth retardation, induction of apoptosis and/or loss of 
tumourigenicity of transduced cells has been reported in many of these (Clayman et 
ai, 1995; Harris et ai, 1996; Hamada et ai, 1996). These effects are often reported in 
tumours that harbour a p53 mutation. Several mechanisms have been proposed for a 
bystander effect following Ad-p53 infection including intercellular communication 
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within the tumour via gap junctions, apoptosis, anti-angiogenesis, cytokines or other 
soluble mediators, and immunological mechanisms (discussed in section 1.23). 
However, not all studies show a therapeutic benefit, which has led to speculation 
that there is a threshold for the level of p53 protein expression to induce reversion of 
tumours phenotypes (Spitz et ai, 1996; Kimura et ai, 1997). Additionally, the tissue 
or cell type, and genetic makeup might be crucial in determining the relative 
resistance or sensitivity to p53-dependent cell death. Kimura et ai, 1997 suggest 
that the limitations of Ad-p53 gene therapy lie in the fact that not all cells are 
infected by the vector, not all infected cells result in adequate transgene expression, 
and not all cells that express the p53 transgene ultimately die. These and other 
factors may result in the eventual reestablishment of the tumour if no additional 
treatment is given. A better understanding of the molecular events leading to cell 
death in sensitive cells could facilitate development of strategies for overcoming 
resistance. 
In a preVlOUS model of minimal residual cancer in the S.c. tissue of 
immunodeficient rodents, infection with Ad-p53 prevented the establishment of 
tumours (Clayman et ai, 1995). When we created this model using the PDVC57 cell 
line in immunocompetent rodents, to enable comparison between treatments in the 
S.c. and muscle sites, differing treatment efficacies were observed. Treatment of the 
S.c. tumour model of residual cancer, with Ad5CMV-p53, showed the clinical 
absence of tumour nodules in 6/6 mice. Histological examination however, revealed 
that viable tumour was still present in 2 of the 6 cases, although a large central 
region of dead and dying cells was observable. In comparison, Ad5CMV- p53 
infection of the model of residual cancer in the muscle resulted in no significant 
tumour mass reduction. It is probable, that treatments injected directly into S.c. 
tumours can be expected to diffuse more readily at this site than when injected into 
the dense muscle bed. This means that anti-cancer agents which are found to be 
effective in destroying S.c. tumours may not necessarily eliminate remaining 
malignant cells in the muscle. These studies also suggest that the site of tumour is 
more problematic to treatment efficacy than the immune status of the host (see 
section 7.4). 
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Within these studies, the established PDVCS7 derived S.c. and residual S.c. tumour 
models showed either complete prevention of tumour establishment or large areas of 
tumour cell death following AdSCMV -p53 infection as anticipated from the results 
of earlier studies. This tumour cell death could be accounted for by a number of 
mechanisms, including via apoptosis and necrosis (since positive TUNEL staining 
was observed, section S.7.1), immune-mediated (section 7.4), anti-angiogenic or 
anti-invasive mechanisms (see sections 1.16.4; 1.17 and 1.23). It would therefore, be 
interesting to determine any changes in the levels of the angiogenic factors VEGF 
and TSP, along with the levels of the invasive/metastatic factors MMP-I and MMP-
13 before and after AdSCMV-p53 infection. 
The different degrees of cell death following AdSCMV -p53 infection of PDVCS7 
tumour cells in the S.c. model of minimal residual cancer and in an established S.c. 
nodule, is likely to be as a result of a number of factors. Firstly, infection of the S.c. 
model of minimal residual cancer is initiated 48 hours after tumour cell 
implantation, when tumour nodules are not fully established and cell numbers are 
relatively low. In addition, because of the relatively low tumour cell numbers, 
infection with S x 1010 vp of adenovirus represents a very high dose, in comparison 
to the established S.c. tumour nodules where tumour cell number will be much 
greater. It is also plausible that since nodules of tumour are not present 48 hours 
following tumour cell implantation, the subsequent delivery of adenovirus will not 
need to diffuse through tumour masses (as is the case with the established S.c. 
tumour nodules), and hence, probably allows for a greater level of transgene 
expressIOn. 
7.2 Molecular Diagnostics 
Carcinogenesis is a highly complex multi-step genetic process, and solid tumours 
inherently display cellular heterogeneity. This makes the identification of a 
molecular marker, common to all cancer cells, very difficult. Our knowledge of the 
molecular processes involved in the onset of tumourigenesis and neoplastic 
progression is continually evolving, with an ever-increasing list of etiologic factors 
identified. A major characteristic of human neoplasia is uncontrolled cell 
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proliferation, with tumour cells invariably undergoing selection to an apoptotically 
resistant phenotype. Therefore, a candidate gene that plays a principal regulatory 
role in this process is an ideal starting point. The pathways and mechanisms of 
action of each of the genes implicated in cancer progression often vary depending on 
the presence or absence of other gene mutations in the same pathway. Thus, 
therapies directed at the molecular events associated with carcinogenesis might be 
limited by an incomplete understanding of the complexity of cancer progression in 
any given tumour. 
Gene therapy holds great promise for the treatment of cancers because a variety of 
genes controlling molecular processes can be introduced, which can arrest tumour 
growth, angiogenesis, invasion, and/or metastasis. Gene therapy, for many human 
diseases must restore the function of a gene permanently. However, tumour cells 
can be destroyed, either by transient expression of genes that destroy a tumour or by 
genes that prime the immune system to attack malignant cells. 
The world of molecular diagnostics is undergoing major change because of both 
technical advances and the availability of rapidly expanding genetic databases 
generated by the study of human genomics. These resources comprise an 
extraordinary opportunity to decipher the biological association between genetic 
variants and treatment-outcome (Chanock et ai, 2002). The ability to be able to 
predict treatment outcomes on the basis of knowledge of individual genetic 
backgrounds will aid therapeutic planning. This is unlikely to be common practice 
however, until general automated assays are available that can test for multiple 
aberrations simultaneously. In a recent study, gene-expression profiles based on 
mlcroarray analysis were used to predict patient survival in early-stage lung 
adenocarcinomas (Beer et ai, 2002). A risk index based on the top 50 genes 
identified a low-risk and a high-risk index for lung adenocarcinomas, which differed 
significantly with respect to survival. The identification of genes that predict 
survival in early stage lung adenocarcinoma allows the isolation of a high-risk group 
that may benefit from adjuvant therapy. The possibility of patients receiving 
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personalised treatment based on predictions made on the genetic background of their 
disease could be available in the not too distant future. 
7.3 Choice of Vector 
Adenoviral vectors have been utilised for gene delivery in these studies since 
production of high titre levels is possible. Recombinant replication-defective 
adenoviral vectors generally provide high efficacy of gene transfer in vitro and in 
vivo that is not dependent on the replicative state of the cell. In addition these 
vectors provide the safety of transient expression, without integration of the 
transgene into the genome, with the majority of clinical trials reporting only 
relatively minor side effects. Since most human solid tumours show relatively slow 
growth patterns, the ability of adenoviral vectors to infect both dividing and non-
dividing cells is of great advantage over other vector systems, such as the retroviral 
vectors, which can infect only actively dividing cells. When the strategy of cancer 
gene therapy is to kill the infected tumour cells, then long-term transgene expression 
may not be necessary. 
The characteristic of adenoviruses of not integrating viral DNA into the host cells 
genome, results in only transient gene expression, commonly ranging from 7-42 
days (Ganly et ai, 2000). This is generally seen as adequate for a role in cancer gene 
therapy, since the use of genes that cause tumour cell death or prime the immune 
system, need not persist long-term to have therapeutic affects. However, this short-
term gene expression is unlikely to be desirable in situations where long-term gene 
expression is required, such as cystic fibrosis. Many experiments have shown a 
longer duration of transgene expressIon following gene transfer into 
immunodeficient hosts as compared with immunocompetent animals, apparently 
because of the elimination of adenovirus-infected cells in the latter by cytotoxic T 
lymphocytes (Searle and Mautner, 1998). Li et ai, 1998 used the adenovirus in an 
immunocompetent rodent model of S.C. growing kidney Renca tumour cells, and 
reported gene expression of about 7 days. 
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When the duration of ~-gal expression was followed over time in the PDVC57 
tumours infected with Ad-l3-gal, strong positive X-gal staining was detected at 24, 
48 and 72 hours. The level of marker gene expression as determined by X-gal 
staining was similar over this time period. When examined at 144 hours (day 6) no 
X-gal staining was detected, indicating that adenovirus-mediated transgene 
expression is transient, in our immunocompetent models. The length of time of p53 
transgene expression in immunocompetent hosts was similar to that seen following 
Ad-l3-gal infection. However, slightly lower quantities of p53 protein were detected 
as compared to the l3-gal protein. An explanation for this is that the IHC detection 
of p53 may be less sensitive than X-gal staining for the expression of l3-gal. Other 
factors to be considered in the length of gene expression, is the cells proliferative 
state. Highly proliferative cells are likely to show a shorter gene expression than 
differentiated cells. PDVC57 have a cell number doubling time of about 24 hours, 
indicative of a rapidly proliferating cell line. 
Optimism should remain for the use of adenoviral vectors for clinical use. The 
majority of clinical trials using the adenoviral vector have reported only relatively 
minor side effects with the exception of the death of Jesse Gelsinger, due to a 
massive immune reaction to the vector. However, most trials using the adenovirus 
to deliver therapeutic genes have been disappointing with little evidence of clinical 
benefit, often as a consequence of inadequate gene expression. One trial involving 
multiple intratumoural injections of Ad-p53 (with doses up to 1 X lOll pfu) into 
patients with incurable recurrent local or regionally metastatic SCCHN (with or 
without tumour resection) demonstrated objective anti-tumour activity in only a 
small percentage of cases. Discrepancies in the predicative capacity between 
preclinical model treatment efficacy and patient outcome could be potentially 
reduced if preclinical models with characteristics more in line with the human 
situation were employed. This could reduce costly trials prior to the thorough 
testing of new treatment schedules. 
Other clinical trials have demonstrated a potential synergy with replication-deficient 
adenoviral vectors carrying the p53 gene and chemotherapy in some tumours 
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(Gurnani et ai, 1999, see section 7.10). Combinational therapies that take advantage 
of both gene therapy along with conventional chemotherapeutic agents seem to be a 
likely stepping stone in the pathway to the routine use of gene therapy only. 
7.4 Immune Response to Adenoviral Vectors 
Approximately 90% of humans have antibodies to human adenoviruses (Ganly et ai, 
2000). This pre-existing immunity may reduce the transduction efficiency, 
especially on second or subsequent exposure to the adenoviral vector. Li et ai, 1998 
reported on multiple exposure of Ad-13-gal in an immunocompetent rodent S.c. 
tumour model, and found an increase in transgene expression following a second 
round of infection. In addition Clayman et ai, 1998 discusses studies that have 
indicated that direct intratumoural injection of adenoviral vectors into mice that have 
been previously immunised with adenovirus did not prevent efficient transgene 
expression. Tumour nodules may therefore provide a site of minimal immune 
response to adenoviral infection, in contrast to an intravenous route of delivery. 
Alternatively, gene therapy could be administered in tandem with drugs that stabilise 
the transgene protein (e.g. p53), prolonging its expression, or that induce 
immunosuppression to prevent the formation of anti-adenovirus antibodies. The 
length of time between each treatment is probably critical to the degree of immune 
response seen. However, it should be kept in mind that the immune response 
generated against adenovirus infected cells could also be beneficial in tumour gene 
therapy, for eradicating uninfected tumour cells in the vicinity of those infected. The 
finding that adenovirus can result in induction of cytotoxic T cells and a significant 
reduction in tumour size, despite a low transduction efficiency, provides optimism in 
the climate of poor in vivo gene transfer. It is therefore essential that treatment 
strategies are optimised in each case to determine if immune responses are beneficial 
or if longer transgene expression is required due to the elimination of transduced 
cells. Immunocompetence of the host is therefore critical in evaluating in vivo gene 
transfer efficiency in malignant tumours, and is key in addressing how this may alter 
therapeutic efficacy, in situations that will be clinically evident. The use of 
immunodeficient rodents suffers from the absence of T-cell responses in the host and 
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does not allow determination of any effect of host immunity on gene expression. 
The lack of immune response to a vector may spuriously enhance the extent and 
duration of any gene-mediated therapeutic effect, or fail to reveal beneficial 
immune-mediated bystander effects. 
It is well recognised that adenoviral vectors elicit both a humoural and a cellular 
immune response in syngeneic hosts (Chirmule et ai, 1999). High numbers of 
polymorphonuclear cells and cytotoxic T lymphocytes detected in the tumours 
treated with AdSCMV-p53 and Ad-PolyA, but not in tumours mock-infected with 
PBS, suggests that inflammation may participate in the efficacy of these agents in 
vivo (Zhang et ai, 1995). Evidence from the present study, also showed heavy 
infiltration of S.c. tumours and tumour-bearing muscles, treated with Ad-PolyA, 
Ad-~-gal or AdSCMV-p53 by neutrophils, monocytes and cytotoxic T lymphocytes, 
as determined by IHC. This strongly supports the notion that immune-mediated 
effects, which are independent of the transgene, are important in preventing 
outgrowth oflow numbers of tumour cells. 
At a late stage into this research a report by Fields et ai, 2001 questioned the 
suitability of using CS7BlI6 mice in immune response studies. These authors 
revealed that these mice have a unique tolerance mechanism that limits this strain as 
a model for development of preclinical studies of immune responses for i.v. 
administration of adenoviral, and possibly other vectors. Given the well-documented 
immunogenicity of the first-generation adenoviral vector, data from CS7Bl/6 mice 
may therefore grossly underestimate immunological consequences in certain gene 
therapy protocols. In C57Bl/6 mice i. v. administration of the highly immunogenic 
adenoviral vector appears less immunogenic than conventional, non-gene based 
treatment (Field et ai, 200 I). Studies by this group illustrate the difficulty of 
extrapolation of results obtained in inbred strains of mice and highlight the 
importance of studies in other animal models. 
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7.5 Vector Diffusion 
It was anticipated that diffusion of the vector might be more problematic within the 
muscle as compared to models in the S.c. tissue. Examination of reporter gene 
expression was frequently observed to be localised to areas resembling the pathway 
taken by the needle, with only limited diffusion to other areas of the tumour. Others 
previously (Yang; Wickham, 2000) have reported this pattern of gene expression. It 
was observed in these studies that reporter gene expression was improved slightly by 
making multiple random injections of the vector in multiple planes of the tumour. 
As in many gene therapy protocols for the treatment of cancer, direct intra-tumoural 
injections to deliver genes to the tumours has been relied on. These patterns and 
levels of gene transfer via direct intratumoral injection showed that this method was 
inefficient in transducing a majority of cells within the tumour. The S.c. tumour 
nodules showed a higher percentage of tumour cells expressing the reporter gene, 
than the tumour cells in the muscle model. This could be as a result of direct 
tumoural injection to the S.c. site, as compared to unknown sites within the tumour-
bearing muscle. Hence the adenoviral vector may not be located in the vicinity of 
the tumour nests within the muscle, limiting the concentration directly delivered to 
the tumour cells. 
In addition, the use of the gastrocnemius or rectus femoris skeletal muscles of the 
leg could result in the release of the virus from the muscle site during movement of 
the animals, and the contraction of the muscle fibres. X-gal staining of whole 
muscles frequently showed positive staining at the edge of muscle blocks, 
suggesting that the adenoviral vector delivery solution was not retained at the 
injection sites. Diffusion of adenoviral vectors through muscle to reach the nests of 
tumour, which lie between or invade the muscle fascicles, results in transduction of 
only a very small percentage of the malignant cells at this site. These findings 
indicate that clinically, the direct injection of adenoviral vectors into the muscle bed 
after tumour resection, with the aim of eliminating any residual cancer, is unlikely to 
be successful even though the tumour-bearing area is widely exposed at the time. 
Thus, it would appear that the major limitation of this technology at present is the 
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need to transduce a high proportion of tumour cells in the muscle to observe a 
therapeutic effect. 
Strategies that might improve vector delivery include using agents that disrupt the 
permeabilisation of the cell membrane. Detergents and proteases, have been shown 
to enhance the transduction efficiency in vivo (Kuriyama et ai, 2001; Yang). These 
or similarly acting agents would be an interesting addition prior to or at the same 
time as gene delivery in future experiments to determine whether enhanced gene 
diffusion occurs in the residual cancer in the muscle model. However, extreme 
caution would be required when using these reagents clinically, as disruption of the 
extracellular matrix, may aid metastatic tumour cell spread. 
Another possibility in the battle to improve transgene expression levels is the use of 
replication-competent adenoviruses. Currently, the most promising approaches are 
based on replication-competent agents that allow efficient tumour penetration 
because of their capacity for tissue-specific replication (Hemminki et ai, 2002). 
Replication-competent adenoviruses have the benefit of combining the anti-tumour 
properties of the viral infection with the action of the therapeutic protein. The virus 
itself is capable of lysing the infected tumour cell, and its replication results in the 
amplification of the input dose of the virus, allowing the spread and further infection 
of the adjacent tumour cells (Hermiston, 2000). In addition, adenoviral infection 
may generate an antitumoural immune response (Heise et ai, 2000). It should be 
noted however, that replication competent adenoviruses can only be studied 
efficiently in immunodeficient tumour models, since they can only effectively 
replicate in human cells (You et ai, 2000). Therefore, immune response cannot be 
studied in preclinical studies. 
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7.6 Tumour Interstitial Pressure 
When the adenoviral vector was administered into S.c. tumour nodules or into the 
muscle it was occasionally observed that small volumes of the injection fluid would 
leak back out of the puncture site. A likely explanation for this is the high pressure 
that is present within the tumours and muscle tissue. Solid tumours exhibit 
interstitial hypertension, in normal tissues, the pressure is around Omm Hg, but in 
solid tumours it is much higher. This hypertension reduces convection (pressure 
driven bulk flow) across the wall of the tumour vessels, which can reduce the 
delivery of macromolecules, and additionally it leads to steep pressure gradients 
from the tumour periphery to the surrounding host tissue. These pressures cause 
tumours to 'ooze' interstitial fluid into the surrounding tissue, thus flushing drugs 
out from the tumour (Jain, 1998). This group also describe how the central zones of 
tumours have a uniformly elevated interstitial pressure (interstitial hypertension), 
while the peripheries are surrounded by a zone of almost normal interstitial pressure 
(Jain, 1998). 
Reducing the injection volume and releasing the injection fluid slowly as the needle 
was being withdrawn from the tumour or muscle site resulted in minimal leakage. 
Volumes in the range of 30-50 ~l were optimal, allowing an adequate amount to 
administer multiple injections, but with minimal leakage. It was also observed that 
less leakage occurred if only one needle puncture hole was made into the tumour, 
with the needle position altered without removing fully, allowing injection fluid to 
be administered to various areas within the tumour. 
Subcutaneous tissue and skin surrounding the S.c. tumour nodule or the tumour-
bearing muscle site were taken for X-gal staining to determine if the Ad-f3-gal vector 
had leaked into the surrounding tissue area during administration. No X-gal positive 
staining was detected on tissue surrounding these sites. This can be explained by a 
number of scenarios. Firstly, the virus could be refractory to surface administration, 
as has been reported in previous studies (Clayman et ai, 1995a). Secondly, the layers 
of skin may have low or no CAR for the uptake of the adenoviral vector. However, 
after direct injection or i. v. administration of Ad-f3-gal, the gross appearance of this 
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site was blue by X-gal staining 24-48 hours post-infection, implying that reporter 
gene expression had occurred, and that CAR receptors were present. However, high 
power histological examination of the skin was not performed, so the actual cell 
types expressing J3-gal were not determined. 
7.7 Tumour Invasion and Metastasis 
A major characteristic of tumour biology IS the capability for invasion and 
metastasis enabling cancer cells to escape the primary tumour mass and colonise 
new areas in the body. Several classes of proteins are altered in cells possessing 
invasive or metastatic capabilities, as discussed in the introduction (section 1.1 and 
l.16.4), these include cell-cell adhesion molecules and integrins, which link cells to 
extracellular matrix substrates (reviewed by Hanahan et ai, 2000). Matrix 
metalloproteinases act to degrade the extracellular matrix, and have been implicated 
in the invasion and metastasis of SCCHN (O-Charoenrat et ai, 2001). In a clinical 
study on the patterns of invasion in SCCHN, Brown et ai, 2002 reported how the 
increased size of the primary tumour, site and depth of invasion of the tumour in the 
soft tissues were associated with an increased risk of tumour invasion of the 
mandible. These deeper tumours show a more aggressive biological behaviour, with 
an invasive pattern of disease. 
Preclinical tumour models should ideally possess invasive characteristic of 
carcinogenesis, to enable the thorough testing of treatment strategies, in conditions 
often evident in the clinical setting. It has frequently been reported that S.c. tumour 
models do not possess this invasive characteristic, instead growing in confined, 
rounded patterns. Tumour cells with the ability to invade tissue tend to be those 
with a more aggressive genotype. 
The PDVC57 cell line used in these studies showed invasive patterns of tumour 
growth in both the muscle model of residual cancer, and in the floor of the mouth 
where metastasis was also apparent. 
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7.8 Toxicity of Empty Adenoviral Vectors at High Concentrations 
Examination of both in vitro and in vivo studies following infection with the Ad-
Poly A vector revealed alterations over and above that of PBS treated cases. 
Changes observed included a reduction in PDVC57 cell number as compared with 
PBS treated cells, and induction of an inflammatory response in tumour models. 
Other studies have reported that the empty adenoviral vector is directly toxic. Zhou 
et ai, 1996 suggest that the toxicity of adenovirus vectors may be related to the 
direct effect of the vector particle or to low levels of expression of the virus after 
entry. 
Synthesis of viral DNA and expression of viral proteins may occur with vectors like 
the one used in our studies, which have been E 1 deleted, although efficient 
transcription of viral proteins requires Ela gene products (Loser et ai, 1998). 
Various explanations for the toxic effect of the empty adenoviral vector have been 
made. Several groups report that following infection with E I-deleted adenovirus the 
dying cells did not have the morphological characteristic of apoptosis, nor did they 
show degraded DNA laddering on an agarose gel (Tolletson et ai, 1996; Teodoro 
and Branton, 1997). This is also the case in our studies of cells infected with Ad-
PolyA, where no signs of DNA laddering, and only very low levels of apoptosis 
were detected by TUNEL or acridine orange and ethidium bromide incorporation 
assays. 
Toxicity in cell culture has also been reported for the E2a, E3-I1.6K and E4 gene 
products of adenovirus (Brand et ai, 1999). The E3-11.6K product, termed the 
adenovirus death protein (ADP) is only expressed in large amounts during the very 
late stages of infection (T eodoro and Branton, 1997), as expected due to its role in 
efficient lysis of adenovirus-infected cells (Tolletson et ai, 1996). E3-11.6K 
mediates the release of adenovirus progeny from infected cells. Tolletson et ai, 1996 
reported that in view of the E3-11 .6K role in lysis of adenoviral infected cells, it 
seems unlikely that cell death is the result of non-specific necrosis. A rapid, non-
inflammatory cell death would increase the chance of the released virus infecting 
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other cells. Thus this group suggest that E3-11.6K containing adenoviral vectors, 
may induce atypical apoptosis. 
In vitro studies of cell death in cell lines have reported the presence of apoptotic and 
necrotic pathways, as well as aponecrosis a relatively newly described type of cell 
death with morphological and molecular aspects of both apoptosis and necrosis. 
Formigli et ai, 2000 report on how different types of cell death is produced 
depending on the intensity of the insult, with aponecrosis probably resulting from an 
incomplete execution ofthe apoptotic program. Several groups have reported on the 
necessity of caspases in the apoptotic pathway, and how the same cell death stimulus 
can result in either apoptotic or necrotic cell death, depending on the availability of 
activated caspase (Li and Beg, 2000; Denecker et ai, 2001; Miyazaki et ai, 2001). 
Since low levels of apoptotic cell death were detected in these studies, its seems 
likely that a combination of slowing of cell proliferation, apoptosis and direct vector 
toxicity may all contribute to the in vitro effects observed following Ad-PolyA 
infection. 
Toxicity as a consequence of adenoviral gene transfer is also linked to immune 
responses against adenoviral antigens, in particular inflammatory responses. The 
ability to critically evaluate the biological role of a gene of interest using 
adenovirus-based vectors has been hampered by the development of local 
inflammation at the site of delivery. Clesham et ai, 1998 demonstrated that high 
MOl infection of vascular smooth muscle cells with a replication deficient 
adenoviral vector expressing no transgene leads to activation of the transcription 
factor NF-KB. It is possible that an immune response to adenovirus infection is 
responsible for the elevation in NF-KB level. NF-KB is efficiently induced by the 
cytokines IL-l, IL-6 and TNFu. Loser et ai, 1998 reported that in the lungs, local 
administration of EI-deleted virus at doses between 107 and 108 p.fu. resulted in 
elevated IL-6 levels in the serum. 
Many cellular stimuli result in the induction of both the tumour suppressor p53 and 
NF-KB. In contrast to activation of p53, which is associated with the induction of 
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apoptosis, stimulation of NF-KB has been shown to promote resistance to 
programmed cell death. These observations suggest that a regulatory mechanism 
must exist to integrate these opposing outcomes and co-ordinate this critical cellular 
decision making event. It has been shown that both p53 and NF-KB inhibit each 
other's ability to stimulate gene expression and that this process is controlled by the 
relative levels of each transcription factor (Webster and Perkins, 1999). 
Genes encoding cytokines, cytokine receptors, cell adhesion molecules, 
chemoattractant proteins, and growth regulators are positively regulated by NF-KB. 
These include IL-2, IL-6, IL-8, the IL-2 receptor VCAM-1, ICAM-1 TNF-a,IFN-y, 
and c-myc. Thus it appears likely that the outcome of cross talk between NF-B and 
p53 will depend on the nature of the stimuli, the growth conditions, and the cell 
type. 
7.9 Systemic Delivery of Adenoviral Vectors 
The ability to deliver vectors systemically is very exciting, firstly because it can be 
used to target metastases, since the location of these is usually unknown for 
treatment by direct approaches. In addition, direct intratumoural injections often 
result in limited transduction of tumour cells, with the vector remaining along the 
needle track with little further diffusion. Using the vasculature may provide a better 
route for reaching more of these tumour cells. Studies investigating the potential of 
systemic delivery highlight that mechanisms for good targeting of the vector, along 
with protection of the vector against degradation, sequestration or immune attack 
whilst it reaches its site of infection are necessary (Vile et ai, 2000). Additionally, 
the vector needs to be able to penetrate into the tumour from the blood stream, so 
that it can carry out its function. Little is known regarding the characteristic of pores 
within SCCHN blood vessels specifically. 
Since direct injection of adenovirus to the tumour-bearing muscle model showed 
low transgene expression, and minimal therapeutic benefits, preliminary studies to 
delivery the adenovirus systemically were performed to try and improve the levels 
of the transgene expressed. Twenty-four hours after systemic delivery of 2.5 x 109 
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vp Ad-f3-gal in10JlI volume, into the jugular vein, organs were harvested for X-gal 
staining. X-gal staining of whole organs and freshly sliced organs of approximately 
1 mm thickness was performed, to determine the gross appearance of f3-gal 
expression. X-gal staining was detected in liver, kidneys, spleen, and skin of both 
immunocompetent and immunodeficient hosts. The gross appearances of these 
organs were a prominent blue colour, but on slicing the organs, it was clear that the 
majority of this X-gal staining was at the outer edge of the organs only. On 
histological examination of 5Jl tissue sections, positive X-gal staining was detected 
in only a small proportion of the cells. 
These preliminary studies highlighted as anticipated from other studies (Xu et ai, 
1997; Blackwell et al 1999) the need for tumour specific receptor targeting by the 
adenoviral vector. The fact that many tissues express CAR allows transgene 
expression to many non-essential sites. Hence, uptake of virus by other cells in the 
body, will lower the concentration available for the target tumours, either reducing 
therapeutic effect or requiring the need for high concentration or repeat dosing of the 
adenovirus to achieve therapeutic benefit at the tumour site. Alternatively, the use 
of isolated local vessels to the area to be targeted could in theory allow for higher 
levels of adenovirus uptake prior to the substantial filtering out of adenovirus by the 
liver. These early studies however, showed that intravascular delivery was feasible, 
that the adenoviral vector was able to penetrate into a range of tissues and that 
transgene expression was achieved. These pilot intravascular studies were short 
term, with only single administration of the adenovirus performed, so no immune 
responses to repeat doses were investigated. 
Marshall, 2000 reporting on a clinical trial using the hepatic artery for delivery of 
the adenoviral vector suggest that rodent models might be misleading for gene 
therapy. Relying on results from mouse studies, they had expected to see adenovirus 
concentrated in the liver in patients. Instead a post-mortem revealed the vector was 
everywhere. Levels of CAR is much more abundant in mouse livers than in human 
livers (reviewed by Marshall, 2000). It is therefore, necessary to assess the level of 
CAR on particular cell types, from a range of species to enable these factors to be 
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taken into account when testing treatment efficacy. In our preliminary i.v. 
experiments in rodents, the liver showed f3-gal expression, after Ad-f3-gal infection 
into the jugular, followed by X-gal staining. The liver has also been reported to be a 
major filter system for cationic liposomes, which are commonly used to deliver 
plasmid DNA, limiting the effectiveness of systemic treatments (Xu et ai, 1997). 
Another possible barrier to sufficient systemic gene delivery is the disorganised 
nature of tumour vasculature, as discussed in the introduction (section 1.18). 
Tumour blood flow is chaotic and variable due to differences in tumour vessel 
diameter and pore size, this results in hypoxic regions in tumours, which acts as a 
potential barrier to the effective delivery of blood-borne agents (Jain, 1998). 
7.10 Combinational Therapies 
Other possible directions for Ad-p53 gene therapy include combination therapy with 
radiation or cytotoxic agents, as suggested by the enhanced antitumoural effects of 
combination treatments in preclinical and clinical models. Although clinical trials 
using p53 gene therapy by itself support optimism for the future of this therapeutic 
approach, many studies have incorporated combinational investigations usmg 
traditional chemotherapeutic agents along with p53 gene therapy. 
The requirement for wildtype p53 to induce apoptosis, following exposure to a 
variety of agents, including radiotherapy, has been well documented. In addition to 
eliminating cells by induction of apoptosis, transduction of tumour cells with 
wildtype p53 can also increase the sensitivity of some tumour cells to radiation or 
can restore radiosensitivity in radioresistant cell lines by restoring G 1 or G2 cell 
cycle arrest and apoptosis (Pirollo et ai, 1997). These findings suggest that 
transduction of tumour cells with wildtype p53 might increase the therapeutic 
benefit of low-dose irradiation and allow this treatment modality to be used again 
when patients present with a recurrence after radiotherapy. Tumours with p53 gene 
mutations, high levels of BCL-2, or high levels of BCL-2: BAX (factors that are 
important mediators of apoptosis) may be resistant to radiation (Aebi et aI, 1997). 
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Clinical studies usingp53-mediated approaches in combination with radiotherapy or 
chemotherapy has reported conflicting outcomes. This is probably because it is 
often impossible to separate sensitivity to a given treatment from the overall 
biological behaviour of a given tumour, due to the different genetic aberrations 
present in the various tumours. Although some experimental tumours that are 
resistant to radiotherapy harbour p53 mutations, other studies reveal that tumours 
with mutant p53 are sensitive to radiotherapy (Wilson et ai, 1995; Pirollo et ai, 
1997). Thus, unravelling the relation between genetic aberrations and chemo- and 
radiosensitivity will require in-depth study of the genetic background and 
clinicopathological features before substantive conclusions can be reached, and gene 
therapy is introduced into routine patient management. 
7.11 Tumour Hypoxia as a Potential Therapeutic Target 
To further characterise the properties of the PDVC57 tumour models, the degree of 
hypoxia was investigated. Determining the level of hypoxia in these tumour models 
would enable the decision on whether this aspect of tumour biology could be 
harnessed in treatment strategies either alone or in combination with Ad5CMV -p53 
gene transfer. Most normal tissue have an average oxygen concentration equivalent 
to a partial pressure (p02) of about 40 mmHg (Hill et ai, 1992). Some tissues in the 
body may have lower p02 levels (e.g., liver, kidney, cartilage, and brain) but most 
tumours contain a significant proportion of cells that are hypoxic. Hypoxic cells 
have been reported to be more resistant to radiation, chemotherapy and 
immunotherapy than aerobic cells (Webster et ai, 1995; Brown and Giaccia, 1998), 
so not surprisingly hypoxia correlates with a lower probability of disease-free 
survival in head and neck carcinomas (reviewed by Koong et ai, 2000). Available 
methods to determine the extent of hypoxia in tumours include using radiation 
sensitisers. Radiosensitiser work by being electron affinic compounds, a property 
they share with oxygen (Tannock, 1992). Two radiosensitisers, pimonidazole 
hydrochloride and 7-(4' -(2-nitroimidazole-l-yl)-butyl)-theophylline (NITP) were 
used in this study both functioning by binding to cells with low oxygen 
concentrations. Hypoxia was detected in a two-part protocol, basically involving 
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introduction of the radiosensitiser in vivo, followed by mc based detection of 
hypoxic regions within tissue sections. 
Both radiosensitisers were able to detect regIOns of hypoxia in both PDVC57 
derived established S.c. tumours developing In immunocompetent and 
immunodeficient hosts, in established S.C. SCC97 derived tumours developing in 
immunodeficient hosts, and within PDVC57 derived tumour nests developing in the 
muscle of immunocompetent hosts. Preliminary studies revealed that the 
pimonidazole hydrochloride radiosensitiser was a better detector of hypoxia in these 
models giving more consistent staining than NITP, which occasionally gave non-
specific staining. Areas of tumour hypoxia were more commonly detected in the 
larger S.c. tumour nodules, than in the tumour-bearing muscle model. It was 
frequently observed following pimonidazole hydrochloride based detection 
methodologies within S.C. tumour nodules, that a wave of hypoxia was present at 
the advancing edge of the tumour. This could imply that due to the high rates of 
proliferation at the advancing edge of the tumour, the demand for oxygen is 
outstripped, due to inefficient levels of neo-angiogenesis. Weidner, 1999 reported 
that apoptotic cell death could be triggered when tumour cells proliferate or 
'outgrow' their supporting vascular system. A cord or sheath of viable tumour cells 
surrounds or clings to a centrally disposed blood vessel. The sheath of viable cells 
appears to remain as thick as diffusion allows exchange of nutrients, oxygen, and 
waste products by the crowded cell population. Tumour cells that proliferate beyond 
this diffusion limit undergo necrosis, which may be caused by ischaemic hypoxia 
(Weidner, 1999). 
Isolated areas of positive hypoxic cell staining were present in a number of tumours 
developed within the muscle. Pimonidazole hydrochloride detected foci of hypoxic 
cells on rare occasions in the tumour nests within the muscle, at day 5, but more 
frequently at 10 and 15 days post tumour-cell initiation. NITP based hypoxia 
detection, was present, as foci of positive immunoreactivity at days 7 and 8 post-
tumour cell inoculation. Therefore, the two radiosensitisers used to detect tumour 
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hypoxia were fairly comparable in the time scale of positive reactivity within the 
tumour-bearing muscle model. 
Many groups are investigating therapeutic approaches that utilise the hypoxic nature 
of tumours. The use of hypoxic cytotoxins is one such therapeutic strategy that could 
be exploited in our PDVC57 model system (as discussed in section 1.19). Studies 
have established that HIF-l can bind to lIRE in a vector and activate expression of 
the transgene, cytochrome P450, in transduced cells (Waxman et ai, 1999; Griffiths 
et ai, 2000). Production of this enzyme activates the prodrug cyclophosphamide and 
converts it to its active metabolite. Hypoxia-responsive elements contain several 
transcription factor-binding sites, one of, which is essential for hypoxic activation, 
by binding the complex HIF-l. HIF-la is hypoxia-regulated via the post-
translational stabilisation and transactivation by several additional factors. 
Preliminary experiments conducted in collaboration with the team at Oxford 
BioMedica, used a lIRE regulated expression vector encoding a reporter gene, to 
transduce PDVC57 cells. The transduced PDVC57 cells were subsequently exposed 
to either normoxic (21% oxygen in 5% carbon dioxide) or hypoxic (0.1% oxygen in 
5% carbon dioxide) conditions. Transgene expression in the PDVC57 cells, as 
determined by X-gal staining, under normoxia or hypoxia were found to be similar, 
due to the high lIRE activity of this cell line in normoxic conditions. Analysis by 
Western blotting of the protein extracts from these PDVC57 transduced cells after 
exposure to normoxic and hypoxic conditions would determine the levels ofHIF-la 
and HIF-2a, and might help to explain this high level of HRE activity under 
normoxia in this cell line. HIF-la protein is normally ubiquitinated and degraded in 
normoxia, but stabilised in hypoxia. Von Hippel-Lindau tumour suppressor protein 
has been shown to bind HIF-la and may contribute to its degradation under 
normoxic conditions (reviewed by Yu et ai, 2001), therefore, it would also be 
interesting to analyse the expression of VHL in the PDVC57 cells. One explanation 
for the high lIRE activity observed in PDVC57 cells under normoxic conditions, 
could be the inactivation ofVHL. 
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In addition, the PDVC57 cells were transduced with the HRE regulated expression 
vector encoding the cytochrome P450 gene. Cytochrome P450 expression and 
activity was confirmed using a P450 biological activity assay (Griffiths et ai, 2000). 
However, subsequent administration of cyclophosphamide revealed that these cells 
were not significantly sensitive to this GDEPT mediated approach to cell killing. 
Therefore, this therapeutic strategy is unlikely to be beneficial in the PDVC57 
derived tumour models. 
7.12 Future Work 
The establishment of a reproducible model of residual cancer in the muscle of 
immunocompetent hosts is an important addition for preclinical treatment efficacy 
studies. The use of a p53 mutated cell line for creation of the model, enables 
strategies to restore the wildtype function of this gene to be investigated. However, 
this model has the ability to facilitate preclinical studies in other areas of gene 
transfer, as well as in a range of treatment strategies based on destroying tumour 
cells, which remain in deeper structures. Since the majority of tumours and cell lines 
have varying genetic backgrounds, replacement of a particular gene may show 
functionality in some tumours but not others. Therefore, it is no longer possible to 
consider that one gene will give one outcome. Investigation of transfer of 
combinations of genes may be more beneficial and an important area for future 
research. 
The present investigation highlights the need to improve delivery of the adenovirus-
vector to residual cancer in the muscle, since the low levels of transduction do not 
enable enough wildtype p53 protein expression to observe any major therapeutic 
effect. It is envisaged that improved gene transfer may occur by delivery of vectors 
in the circulation. Our preliminary studies of i.v. gene therapy indicate that the 
adenoviral vector is capable of penetrating from the blood stream into various 
tissues, where transgene expression was detected. However, specific tumour cell 
targeting is likely to be required to prevent major sequestering of the virus to the 
liver and other organs. Future challenges would be to establish the efficacy of using 
local vessels to the area of SCCHN, such as the carotid artery, for gene delivery. 
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The use of local vessels along with tumour targeted vectors could potentially retain 
the majority of the vector dose at the tumour site, and improve therapeutic efficacy. 
Targeting the vector to a tumour specific marker is likely to reduce the toxicity and 
immunogenicity, and provide increased safety for arterial administration of these 
vectors. Ligands that are commonly used for targeting include the transferrin and 
folate receptors, which are commonly expressed on tumour cell lines, and are 
elevated in SCC (Xu et ai, 1997). In addition, EGFR is frequently overexpressed in 
SCCHN making it an interesting receptor for targeting. Blackwell et ai (1999), 
reported that EGFR-targeted adenovirus enhanced infection of SCCHN cell lines. 
Further studies are warranted to establish whether administration into a local artery 
such as the carotid improves tumour cell transduction of the transgene. 
An alternative would be to tackle residual cancer in the muscle with a combination 
of therapies, without overlapping toxicities, to increase the selective and specific 
tumour cell killing. As anticipated, our findings show that different therapeutic 
agents have different effects on tumour growth at the muscle site. The positive 
treatment efficacy observed after cisplatin treatment, make this a good candidate for 
combined therapeutics with Ad5CMV-p53. However, until higher levels of p53 
transgene expression are achieved the possibility of synergistic combinational 
efficacy is unlikely. 
Considering the results obtained in vitro, where following Ad5CMV-p53 infection 
or exposure to cisplatin or UV, major apoptotic cell death was observed with no 
apparent cell cycle arrest, it would be interesting to analyse this area further. A 
better knowledge of the status of other apoptotic and cell cycle pathway members 
would help decipher the key players which may affect the decision of cells to 
undergo cell cycle arrest versus apoptosis, in this particular cell line. The effect of 
lower concentrations of Ad5CMV-p53, cisplatin or UV exposure time might enable 
the discovery of a dose-dependent mechanism of cell death in the PDVC57 cells. 
Since varying genetic backgrounds result in varying treatment outcomes, an 
important starting point would be analysis of members of the cyclin D1-RB-E2F-
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Kaleidoscope Pre-stained Protein Standards 
Protein Protein Colour Molecular Weight 
(Daltons) 
Myosin Blue 209,000 
B-galactosidase Magenta 134,000 
Bovine Serum Albumin Green 84,000 
Carbonic Anhydrase Violet 40,000 
Soybean Trypsin Inhibitor Orange 31 ,000 
Lysozyme Red 18,500 
Aprotinin Blue 7,200 
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Location of the gastrocnemius and rectus femoris muscles 
a b 
Appendix III: a) Proximal end of the right pelvic limb; view ofthe medial surface. 
The rectus femoris muscle is indicated by number 7 and the gastrocnemius muscle 
by number 14. b) Proximal end of the left pelvic limb; view of the lateral surface. 
The rectus femoris muscle is indicated by number 3 and the gastrocnemius muscle 
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